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Characterisation of Antibody populations in Renal Dialysis 
Patients: Their role in renal transplant outcome 
C.J.Taylor 
The relevance of a posi ti ve crossmatch in renal transplantation 
is controversial. Factors which may influence the relationship 
between recipient antibody sensitization and transplant outcome 
include; the antibody class and specificity, the time interval 
between the posi ti ve crossmatch and transplantation and whether 
the transplant is a first graft or a regraft. 
In highly sensitized patients the clinical relevance of a 
positive crossmatch against a particular donor is difficult to 
determine because it may be due to damaging (presumed anti-
HLA) and/or non-damaging (presumed non-HLA) antibodies. An in-
vitro assay has been developed which can reliably define the 
specificity of donor reactive antibodies even in complex 
mixtures. This technique was applied to define the 
immunoglobulin class and specificity of antibodies present in 
a series of positive crossmatch transplants. The clinical 
relevance of sensitization to HLA class I, DR, DQ and non-HLA 
was examined and a correlation sought with graft survival. The 
results showed good primary and regraft survival in the 
presence of peak positive and current positive crossmatches 
caused by IgM non-HLA antibodies. There was acceptable primary 
and regraft survival with peak positive-current negative 
crossmatches due to IgM HLA class I, but not with IgG 
antibodies. A positive B cell crossmatch caused by HLA 
antibodies was associated with good primary but poor regraft 
survival. 
These findings may be applied prospectively to select kidney 
donor and recipient pairs Who, despite a positive crossmatch, 
can be transplanted with a high probability of success. 
The target molecule of the commonest non-HLA antibody has 
remained a mystery for over 15 years. This question was 
investigated by the production and characterisation of human 
monoclonal antibodies from a renal dialysis patient by the 
generation of a mouse/human heterohybridoma. The resulting 
antibodies are of the IgM class with reaction profiles 
identical to those found in renal dialysis patients. Screening 
against panels of cells demonstrated that identical reactivity 
patterns could be generated at a different dilution for each 
MAb. This implies that the apparently different specificities 
are explained by differential target cell sensitivity. 
Reactivity profiles in fluorescence binding assays showed that 
this target cell sensitivity is dictated not by antigen density 
alone but also by antibody/antigen affinity. The results from 
enzyme treatment of target cells and from lectin inhibition 
studies show that the antibodies are polyreactive and capable 
of binding sialic acid dependent epitopes and other negatively 
charged cell surface molecules. 
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Renal transplantation is a well established method for the treatment of end 
stage renal failure. However the most common cause of graft failure remains 
immunological rejection, particularly within the first three month. after 
transplantation. The immune mechanisms involved in renal allograft 
rejection are both humoral and cellular. 
1.1 The cro ••• atch te.t 
In the mid 1960's, donor reactive antibodies in kidney transplant 
recipients were associated with a high chance of early graft failure. Thi. 
so called 'positive crossmatch' was defined by the ability of recipient 
antibodies to agglutinate donor leucocytes. Later, the complement mediated 
cytotoxicity test was introduced, in which donor specific antibody was 
identified through lysis of donor lymphocytes by recipient serum in the 
presence of rabbit complement. Preformed antibody, present at the time of 
transplantation was found to mediate 'hyperacute rejection' which may occur 
within the first 24 hours after revascularization of the graft. 
The first report of hyperacute rejection aasociated with preformed 
recipient antibodies reactive with donor lymphocyte. came from Tera.aki in 
1965 (Terasaki, Marchioro and Starz1, 1965). They noted that a kidney 
transplanted from a brother to a sister auffered immediate failure. 
Cytotoxic antibodies were demonstrated againat donor lymphocytes and the.e 
were thought to be elicited as a result of pre-transplant blood 
transfusions. They suggested the role of a croaamatch te.t, in which •• rum 
from the prospective recipient is tested with the donor cell. before 
transplantation, may be important in preventing aome early rejectiona. 
In 1966, Kiasmayer-Nielson and his co-worker a (Kiaamayer-Niel.en et al, 
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1966) also reported the existence of humoral factors associated with rapid 
rejection. In a series of 21 consecutive human kidney allografts they 
reported two instances of hyperacute rejection associated with pre-
existing humoral antibodies. Both recipients had received multiple blood 
transfusions (21 and 17 respectively) and were multigravida (5 and 3 
pregnancies respectively). The kidneys were rejected during the operation, 
with urine flow for the first 10 minutes but complete cessation after one 
hour. The transplants were described as loosing tone, becoming soft and 
flabby with a mottled appearance. The transplanted kidneys were removed on 
days 14 and 3 and both patients died shortly after. 
Histological studies revealed total cortical necrosis and thrombi in 
glomeruli and arterioles and the renal artery. There was an absence of 
interstitial cells infiltrating the graft, a characteristic of cellular 
rejection, however substantial numbers of granulocytes were found in the 
outer cortex. 
The possibility of a reaction with donor blood carried in the kidney was 
excluded as the kidneys were perfused before transplantation. Both patients 
were shown to have pregraft leucocyte antibodies which agglutinated donor 
cells to titres of 1/512. In addition IgG and IgK were eluted from kidney 
extracts following separation uaing diethylaminoethyl-cellulo.e 
chromatography. They compared the mechanism of graft de.truction to the 
Schwartzmann reaction in which antibody/antigen complexes are depo.ited in 
the vessels, causing complement activation and polymorphonuclear leucocyte 
infiltration leading to clotting and haemorrhage. 
In 1968, Terasaki reported .even caaes of hyperacute rejection in a .erie. 
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of 218 kidney transplants (Terasaki, Thrasher and Hauber, 1968). Four of 
these occurred using living related donors. Serum samples taken before 
transplantation revealed that all seven recipients were sensitized when 
tested against a panel of 10-20 random blood donors and all five patients 
tested had a positive lymphocytotoxic crossmatch against their kidney 
donor. Six patients were female with previous pregnancies and were shown 
to have cytotoxic antibodies against their husbands lymphocytes. Using the 
limited tissue typing available at that time, several of the husbands HLA 
incompatibilities were also shared with their kidney donors. The seventh 
recipient was a multiply transfused male. 
Cytotoxicity screening of the 218 recipients against a panel of cells 
showed that 23\ of males and 46\ of females had lymphocytotoxic antibodies. 
They identified blood transfusions as the priming agent for 
allostimulation, and the increased risk of sensitization in females was 
associated with previous pregnancies. They proposed that the cells 
contained in the blood transfusion, or that leaked across the placental 
barrier into the maternal blood stream during pregnancy, shared antigens 
expressed on the kidney. 
A further report by Williams and colleagues (Williams et al, 1968) 
presented a study of 132 renal transplants in which biopaies had been taken 
within one hour after revascularization. Histological evidence of 
hyperacute rejection was found in seven patients, of which only one 
functioned beyond one week. This included one out of 111 first grafts and 
five of 20 regrafts. One patient was transplanted across a blood group 
incompatibility (blood group 8 into group 0). 
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The histological features of hyperacute rejection were characterized by a 
marked degree of polymorphonuclear leucocytes accumulating in capillaries 
of glomeruli and peritubular areas. Day three biopsies showed focal 
vascular thrombosis and tubular cell necrosis with extensive fibrin 
deposition and cortical necrosis. Immunohistology of cryostat sections 
revealed IgG deposited on capillaries of the glomeruli and tubules. 
Laboratory analysis of these leucocyte antibodies demonstrated that all the 
patients were sensitized to a panel of random blood donors and that two of 
four patients tested by cytotoxicity against their transplant donora were 
positive. Agglutination tests, performed against a panel of selected cell 
linea were positive and antibody binding to graft tissue was also 
demonstrated in all cases. In two cases the antibody was shown to disappear 
24 hours after surgery, but high titrea were found 5 days post nephrectomy, 
implying that the antibodies were binding to the graft in-situ. 
The histological features of early acute rejection were characterised by 
Kincaid-Smith (Kincaid-Smith et al, 1969) in a study of 180 biopsies taken 
from 58 cadaveric transplants. They confirmed the involvement of antibody 
and complement components deposited within the graft, followed by a massive 
influx of polymorphonuclear leucocytes and platelet activation. This 
results in interstitial haemorrhage, vascular changes and thrombosis. In 
addition, the appearance of more than two polymorphs per glomeruli was 
associated with repeated rejection episodes indicating the involvement of 
antibody in acute rejection. They postulated that if the pre.ence of 
polymorphs reflected an immediate antigen-antibody reaction and subsequent 
endothelial cell damage, they may be failing to demonstrate donor reactive 
antibodies in some cases. 
5 
Finally, the interpretation of a positive crossmatch as an absolute contra-
indication to transplantation was established following a paper by Patel 
and Terasaki (Patel and Terasaki, 1969). Their concluding remarks were that 
"the ethics of transplanting kidneys without the prior knowledge of the 
crossmatch test, or across a known positive crossmatch result can 
reasonably be expected to be questioned in the face of this evidence". This 
statement clearly established a mandate to perform a prospective 
crossmatch. In a study of pretransplant sera taken from 226 recipients, 43' 
of sensitized patients (defined by cytotoxicity testing against a panel of 
lymphocytes derived from 10-40 blood donors) failed immediately. This 
compared to only 2' of patients without pregraft antibodie •• Furthermore, 
24 of 30 (80\) grafts with a direct positive crossmatch with donor 
lymphocytes failed immediately. They ascribed the 20' of succe.sful 
positive crossmatch transplants to be due to false positive reactions. 
Technical reasons such as poor cell viability and the presence of 
granulocytes in the cytotoxicity test were thought to be responsible. 
On analyzing serum samples from 681 potential recipients they identified 
a number of risk factors associated with the formation of allogenic 
antibodies and a subsequent predisposition to early graft failure. Positive 
crossmatches were three times greater with unrelated donors than related 
donors. Immediate failure was found with 23' of first grafts performed in 
women with previous pregnancies, compared to only 6' of nulliparous females 
and 6' in males. Moreover, 40' of regrafts failed immediately compared to 
only 6\ of first transplants. 
As a consequence of these findings the dogma arose that all pretransplant 
6 
donor reactive lymphocytotoxic antibodies were a barrier, precluding kidney 
transplantation. The policy of ensuring a negative lymphocytotoxic 
crossmatch became a prerequisite of transplantation. 
1.2 BLA nat.a 
The main antigenic stimulus for kidney allograft rejection and antibody 
production is the MHC (Major Histocompatibility Complex). In humans this 
is known as the HLA (Human Leucocyte Antigen) system. Evidence that HLA is 
the human MHC came from early transplants preformed using related donors. 
Graft survival was shown to correlate with the number of HLA haplotypes 
shared between the kidney donor and recipient. Two haplotype matched 
transplants had a 90% one year graft survival compared to 70% and 60% for 
one and zero haplotype matched transplants respectively. The 10% of 
transplant failures 
immunosuppression, is 
between 
thought 
HLA 
to 
identical Siblings, despite 
be due to multiple minor 
histocompatibility antigen differences. In addition, antibodies specific 
for antigens of the HLA system have been eluted from rejected kidneys after 
nephrectomy. 
The HLA system consists of ten loc i coded for on the short arm of 
chromosome six. These loci are divided into two classes of antigens based 
on biochemical and functional differences (Figure 1.2.1). 
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HLA Gene Organisation 
Human Chromosome 6 
I 
I I I I I I I I ~ J 
DP DQ DR B C E A F G H 
~ "-------------------~ 
Class II Class I 
Figure 1. 2.1 
'Classical' HLA class I antigens, (HLA-A,-B,and -C) are expr •••• d on all 
nucleated cells of the body, platelet. and sperm (Ha1im, Wong and Mittal, 
1982). They are made up of a highly polymorphic heavy chain (approximately 
44 leD molecular weight) con.i.ting of a glycoprotein with three .xtra-
cellular immunoglobulin like domains, stabilised by disulphide bonds, a 
hydrophobic transmembrane region and an intra-cellular domain. Thi. i. non-
covalently associated with the non-polymorphic molecule, beta-2-
microglobulin (12 leD) coded for on chromosome 15. Seta-2-microglobulin r. 
required for stable expression of HLA class I on the cell surface (Zij.tra 
et al, 1990). HLA class I molecules are recognised by CD8 positive T cell. 
and are associated with presentation of endogenous peptide. to cytotoxic 
T cells (Guagliardi et al, 1990; Nuchtern, Seddison and Klausner, 1990). 
The 'non-classical' loci (HLA-E,-r,-G and -8) have been recently defined 
and there is little known about their expre •• ion and phy.iological role. 
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The major HLA class II loci comprise of HLA-OR,-OQ and -OPe The 
organisation of the genes encoding the HLA class II loci are shown in 
Figure 1. 2 • 2 • 
HLA Gene Organisation 
OP DP DP OP ON 
82 A2 81 A1 A 8 
1/ 
OPw1-6 
Figure 1. 2.2 
HLA 
Class II 
DR DR DR DR DR 
82 A2 81 A 1 81 82 83 84 A 
1/ 1 
OQw1-9 DR1-18 DRw52&53 
They are non-covalently linked heterodimers consisting of an alpha chain 
(34 JeD) and a beta chain (28 JeD). Both chains have two extracellul'ar 
domains, a transmembrane region and a cytoplasmic tail. HLA cla •• II 
molecules are expressed primarily on cells of the immune system .uch .a B 
lymphocytes, monocytes, macrophages, dendritic cells and activated T cell •• 
However expression is induced on moat cell types in the presence of 
cytokines such as gamma interferon and interleukin 2. 
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The HLA-DR alpha chain (encoded by HLA-DRA) is non-polymorphic and can 
associate with either the beta chain (HLA-DRB1) encoding HLA-DRl to 18, or 
with HLA-DRB3 encoding HLA-DRwS2, or HLA-DRB4 encoding HLA-DRwS3. HLA-
DRB2 is a non-coding pseudogene. More recently an additional HLA-DRBS gene 
has been identified on the HLA-DR2 haplotype (not shown). For the HLA-DQ 
locus, both the alpha and beta chains (encoded by HLA-DQAl and HLA-DQBl 
respectively) are polymorphic. These code for the alleles HLA-DQl to 9. As 
both genes are polymorphic the possibility of cis and trans associations 
exist, therefore generating new hybrid molecules in heterozygous 
individuals. HLA-DQA2, DQB2, DOB and DNA are thought to be non-coding genes 
which are not known to be expressed at the cell surface. HLA-DPA1, encoding 
the DP alpha chain has limited polymorphism. Its product associates with 
the DP beta chain, encoded by HLA-DPB1, which is a glycoprotein carrying 
the HLA-DP alleles DPwl to 26. HLA-DPA2 and B2 are pseudogenes which are 
not transcribed and translated. 
HLA class II molecules are recognised by CD4 positive T cells and are 
thought to be involved in presenting exogenous peptide. to helper T cell. 
(Mellins et al, 1990; Nuchtern, Beddison and Klausner, 1990). 
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1.3 Blood transfusion effect 
Immunological sensitization of patients awaiting transplantation may be 
caused through three main routes: previous pregnancies; blood transfusion; 
and most commonly, rejection of a previous transplant (Opelz et al, 1981). 
In the early 1970's, studies on the degree of sensitization, defined by the 
frequency of antibodies reactive to lymphocytes derived from a random cell 
panel, correlated with poor graft survival. Also there was a lower chance 
of finding a suitable negative crossmatch donor for sensitized recipients. 
As a consequence of this, to avoid unnecessary sensitization, the policy 
of avoiding blood transfusion except when clinically essential was adopted. 
However, during this period, despite improved surgical techniques (shorter 
warm ischaemia times etc) and improved immunosuppressive regimens, most 
transplant centres noted a decline in graft survival. Surprisingly, 
superior graft survival was seen in previously transfused patients. 
The beneficial effect of pregraft blood transfusion on graft survival was 
first reported by Opelz (Opelz et al, 1973), and subsequently confirmed by 
many others (Chapman, 1990; Opelz et aI, 1979). This almost universal 
finding, of about a 20\ increase in graft survival in transfused patients 
(Opelz, 1988b) led to the policy of ensuring that all potential recipients 
were transfused prior to transplantation. The benefits of this outweighed 
the deleterious effects of sensitization and the associated dangers of 
disease transmission such as hepatitis and human immunodeficiency virus. 
The UCLA transplant registry and Collaborative Transplant Study (CTS) data 
indicated that up to five units of blood was associated with a 20' 
improvement in one year graft outcome. Greater than five units did not 
11 
consistently produce additional benefit and greater than 20 transfusions 
were associated with poorer graft survival. Enhanced graft survival was 
only demonstrable when using fresh whole blood or buffy coats. Frozen and 
stored blood failed to produce the desired effect. The requirement for 
viable leucocytes seems to be an important factor for improved graft 
survival (Chapman, 1990). 
Animal models showed that platelets, which only express class I molecules, 
may also produce enhanced graft survival without the potential deleterious 
effect of sensitization (Borleffs et al, 1983). However, human trials 
(Chapman et al, 1986b) showed that very low levels of leucocyte 
contamination (15x10') were associated with humoral sensitization (42' 
panel reactive antibodies) and that transfusion with 'pure' platelets 
(containing <5x106 leucocytes) failed to improve graft outcome, with only 
a 44\ one year graft survival. These results indicated that the use of 
platelet transfusions has not fulfilled its original promise. 
In contrast, Betuel (Betuel et al, 1985) studied 19 male patients 
transfused with only pure platelet., of whom 10 were .ubsequently 
transplanted. None of the patients were .ensitized following transfusion, 
and one year graft survival of 79\ was equivalent to control patients 
receiving blood transfusions (77\ at one year). HOwever the author. noted 
a higher incidence of rejection episodes in the platelet transfusion group 
which may become relevant with a longer follow up. Therefore the efficacy 
of platelet transfusion to improve kidney allograft survival is still open 
to debate. 
More recently, the immunosuppre.sive agent 'cyclosporine A' (CyA) has been 
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introduced. The use of CyA, either in conjunction with, or in place of 
conventional immunosuppressive therapy (azathioprine and prednisolone) is 
associated with improved graft survival (about 12-15\ at one year) when 
compared to azathioprine and prednisolone alone (Opelz, For the 
Collaborative Transplant study, 1985; Morris, 1988). The introduction of 
CyA has led some centres to question the beneficial value of pregraft blood 
transfusions on transplant survival. 
Several studies reported that they no longer found a transfusion effect 
(Kl intmalm et al, 1985 ) and consequent 1 y , f ewer centres adhere to a 
deliberate blood transfusion protocol. The UCLA registry has reported a 
steady increase of primary kidney transplants in non-transfused recipients, 
from 10\ in 1984 to 25\ in 1989 (Iwaki, Cecka and Terasaki, 1990). 
In 1987, Opelz reported the partial disappearance of enhanced graft 
survival associated with pregraft blood transfusions (Opelz, 1987a). 
However, this was independent of the use of CyA and is due to increased 
graft survival in the non-transfused group since 1984. Absence of a 
transfusion effect was also reported by Groth following the Scandinavian 
Multi Centre Cyclosporine trial (Groth, 1987). Whilst the CTS data is no 
longer able to demonstrate a beneficial transfusion effect (Opelz, 1989), 
Cats (Cats et al, 1984) still reports a 16\ improvement for transfused 
patients treated with CyA. There is now a debate whether the marginal 
benefits of transfusion outweighs their deleterious effects. 
A recent analysis of the North American data by Iwaki (Iwaki, Cecka and 
Terasaki, 1990) and Cicciarelli (Cicciarelli and Terasaki, 1988) atill 
shows enhanced graft survival following blood transfusion. Examination of 
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the UCLA transplant registry showed that this is true when the data is 
stratified for year of transplant, demonstrating the effect during the 
cyclosporin era (Iwaki, Cecka and Terasaki, 1990). The effect was strongest 
in the American black population (8-10\ enhancement), although it was also 
present in Caucasoids (4-5\ enhancement). Because of the large numbers of 
transplants recorded on the register, these relatively modest improvements 
were highly significant. However, they identified a subgroup patient., 
those transplants where the donor and recipient were HLA-DR matched, who 
gained no additional benefit from pregraft blood transfusions. In one and 
two HLA-DR antigen mismatched transplants they reported an 8\ and 10\ 
increase in graft survival respectively. 
Borleffs (Borleffs et al, 1982) demonstrated bimodal graft survival in 
rhesus monkeys given a single third party transfusion. This indicated that 
some monkeys benefited from a pregraft blood transfusion whereas others did 
not. Following this observation, J.J.van Roods' group in Leiden 
investigated which factors were important to gain enhanced graft survival 
(Van Rood and Claas, 1990). They studied almost 200 renal allograft 
recipients who had received a single blood transfusion. Enhanced graft 
survival was only found in those patients where the blood donor and 
recipient shared a single HLA-DR antigen. Patients whose blood donor shared 
no HLA-DR antigens had a graft survival similar to the non-transfused 
patients. 
These data are further supported by the use of donor specific transfusions 
(DST) in single haplotype matched live related donor transplants. Such 
transplants have a graft survival equal to HLA identical sibling donor 
transplants (Eklund et al, 1990; Salvatierra et al, 1985, Sanfilippo, 
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Thacker and Vaughn, 1990). These studies all show approximately 90' one 
year graft survival in two haplotype matched siblings and with one and zero 
haplotype matched related donor transplants receiving DST. 
Subsequent studies by Lazda and colleagues (Lazda et al, 1990) indicated 
the requirement for the blood donor and recipient to share a single HLA-
DR haplotype for improved transplant outcome following DST. In this study, 
single haplotype matched related donors and recipients who were HLA-DR 
compatible suffered more rejection episodes compared to those who shared 
only one HLA-DR allele which their donor. 
It is therefore possible that a subgroup of patients, tho.e who .hare an 
HLA-DR allele with their blood donor, benefit from preqraft blood 
transfusions. This effect may be abrogated if the recipient receive. an 
HLA-DR matched donor. 
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1.4 transplantation of highly sensitized patients 
The policy of giving deliberate pregraft blood transfuaiona and also the 
inevitable increase in the numbers of patients sensiti.ed through 
pregnancies and previous graft rejection, has led to a ri.e in the number 
of sensitised patients on most transplant waiting lists. The increa.e of 
'highly sensitised patients' (those with antibody levels reactive with 
greater than 85\ of a random cell panel) has led to the relevance of donor 
reactive antibodies as an 'absolute contra-indication to transplantation' 
to be examined in more detail. The definition of 'highly sensitized' varies 
with the transplant centre ranging from >50\ to >90\. However, persistent 
reactivity of >85\ is the criteria accepted by Eurotransplant and united 
Kingdom Transplant Service (UKTS) • A number of strategies have been 
developed in order improve the chances of finding a negatively crossmatched 
donor, or identify circumstances when a positive crossmatch can be safely 
ignored. 
1.4.1 Lymphocytotoxic autoantibodies 
Following the publication of Patel and Terasaki in 1969, most transplanta 
centres considered that all positive crossmatches would lead to acute graft 
failure. However in their report, 20," of tran.plant. performed with a 
positive crossmatch were successful. At the ttme, they attributed the.e aa 
being fal.e positives due to technical difficulties in the laboratory. 
In 1976, Cross (Cros., Greiner and Whittier, 1976) reported a .erie. of 
nine successful transplants performed in the presence of a po.itive 
crossmatch. The antibodies were found to react with the patient. own 
lymphocytes in addition to donor lymphocyte., and the.e lymphocytotoxic 
autoantibodies were not associated with graft failure. Similarly, Sta.tney 
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and Austin (Stastny and Austin, 1976) also reported successful 
transplantation in a HLA identical sibling pair. This patient had a 
positive crossmatch with the donor and also autologous lymphocytes. The 
cytotoxicity was shown to be complement dependent and reactivity was 
absorbed by autologous and donor lymphocytes, but not by platelets. These 
reports demonstrated that not all donor reactive antibodies are damaging 
to the graft, and that under some circumstances transplantation can be 
successful despite a positive crossmatch. 
This observation was soon confirmed by Reekers (Reekers et al, 1977), who 
described nine out of 132 patients with autoantibodies. Seven of the nine 
patient sera reacted with B cells only, and two were reactive with both T 
and B cells. Two patients were subsequently transplanted with a positive 
donor crossmatch, both of which were successful. 
In addition, seven such transplants were performed in highly sensitized 
patients in Oxford (Ting and Morris, 1977), of which six (86') were 
successful at three months. In this study, the autoantibodies were 
identified not only by reactivity with a panel of B lymphocytes and 
autologous B cells, but also through lack of reactivity with a panel of B 
cells derived from patients with chronic lymphatic leukaemia (eLL). Of 150 
patients on the Oxford transplant waiting list, 23 were shown to have 
lymphocytotoxic autoantibodies (Ting and Morris, 1978). Two different type. 
were described; those with reactivity against B cells alone, or against 
both T and B cells. The autoantibodies were weak or negative with CLL cell. 
which has also been confirmed by other. (Ozturk and Tera.aki, 1980). As CLL 
cells were known to express the normal complement of HLA-A,B,C and DR 
antigens on their cell surface, scr.ening again.t panels of CLL cell. 
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allowed discrimination between autoantibodies and alloantibodies. 
The predominance of autoantibody reactivity with B cells was confirmed by 
Ting and Morris (Ting and Morris, 1979) where they had performed 11 B cell 
and three T and B cell (two HLA identical) positive crossmatch transplants 
with 91% and 100% three month graft survival respectively. This compared 
to 90\ for sensitized patients transplanted with a negative crossmatch and 
72\ in non-sensitized patients. Moreover, in 15 cases the crossmatches were 
current positive, using serum taken at the time of transplantation. Of 
these, 73% were successful at three months, with no failures associated 
with hyperacute rejection. 
Additional studies (Ting and Morris, 1983) confirmed that transplants could 
be successfully carried out with positive crossmatches caused by T and B 
cell autoantibodies. Of 16 such transplants, 10 were successful, including 
five of seven with a current positive crossmatch. However a low immediate 
function rate of 25\ was noted. In this group of highly sensitized 
patients, those with mixtures of auto and alloantibodies were transplanted 
with an HLA matched donor, therefore excluding the possibility of 
sensitization to alloantigens. 
Ettenger (Ettenger, Jordan and Fine, 1983) suggested an autoregulatory 
effect of B cell autoantibodies. They found enhanced graft survival of 9o, 
at six months in ten patients with B cell autoantibodies compared to 48' 
with no antibodies. 
1.4.2 Differentiation of autoantibodies from HLA antibodies 
It is now generally accepted that transplantation can be performed safely 
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in the presence of a positive crossmatch due to lymphocytotoxic 
autoantibodies, even if they are present at the time of transplantation. 
However, in patients with a mixture of antibody populations (ie non-HLA and 
HLA antibodies), the specificity of a positive crossmatch against a 
particular donor is difficult to determine. The positive crossmatch may be 
due to damaging (presumed anti-HLA) or non-damaging (presumed non-HLA) 
antibodies and so the transplant is not usually performed. Several in-
vitro methods have been employed in an attempt to differentiate between 
autoantibodies and HLA antibodies in highly sensitized patients. 
i) optimal temperature of reactivity 
These include varying the pre-complement incubation temperature. Park 
(Park, Terasaki and Bernoco, 1977) demonstrated that B cell autoantibodies 
react more strongly at low temperatures (SOC) than at 20°C and described 
them as cold lymphocyte cytotoxins. Iwaki and his co-workers (Iwaki et al, 
1979) showed that cold B cell lymphocytotoxic autoantibodies (reactive at 
SOC), were associated with good graft survival whereas the putatively 
damaging HLA antibodies, which react more strongly at warm temperatures 
(37°C) had poor graft survival. In a series of 203 transplants they 
reported an 82\ one year graft survival with cold B cell positive 
crossmatches compared to 36\ with warm B cell or warm T and B cell poaitive 
crossmatches. This finding has alao been confirmed by others (Ayoub et al, 
1980; Posner et al, 1984), although in Posner's study the deleterious 
effect was only found with regrafta. However, other reports found no such 
effect (Coxe-Gilliland and Cross, 1981; Etheredge, Sicard and Anderson, 
1979) • 
In a subsequent publication (Iwaki et al, 1979), Iwaki confirmed hb 
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original finding in a series of 909 transplants using single haplotype 
matched related donors, first cadaver grafts and cadaver regrafts. The cold 
reactive B cell antibodies were found to be enhancing, a view also 
indicated by others (Fauchet et al, 1980). Graft survival in this group 
(68% at one year) was better than those transplants performed in patients 
with no antibodies (52\ at one year). Corroborative evidence supporting 
this finding came from Jeannet's group (Jeannet, Vassa1i and Hufschmid, 
1980) who reported 10 out of 10 six month graft survival with cold B cell 
antibodies, compared to 61\ with no antibodies, and 62\ and 50\ with warm 
B and warm T antibodies respectively. 
Exceptions to this have been noted. Deirehoi at al (Deierhoi, Ting and 
Morris, 1983) reported successful transplants in the presence of warm B 
cell crossmatches. Contrary to Parks' finding, lymphocytotoxic 
autoantibodies were shown to be reactive at 4°C, 22°C and 37°C. Of 25 
transplants performed with warm B cell crossmatches, 21 were successful. 
Reactivity of lymphocytotoxic autoantibodies at multiple temperatures was 
also reported by Ettenger (Ettenger and Robertson, 1987). Therefore this 
method was not considered reliable to distinguish damaging from non-
damaging antibodies. 
ii) Characterisation of lymphocytotoxic autoantibodies 
Lobo and colleagues (Lobo, 1981) proposed an immunoregulatory role for B 
cell autoantibodies. Using immunofluoresence technique., autoantibodies 
were shown to be 19M whereas alloantibodies ware IgG. They could be 
absorbed by autologous cells but not by red blood cell. and their 
appearance was not associated with pregnancy or blood transfusion. They 
demonstrated a correlation between the pre.ence of autoantibodies and an 
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absolute quantity of IgG in the .erum, indicating that autoantibodi •• w.r. 
modulating B cell function. Howev.r, the degree of alloimmuniz.tion 
following graft rejection was not effected. 
Lobo (Lobo, Sturgill .nd Bolton, 1984) reported .n incr •••• d incidence of 
primary non-function associated with cold re.ctiv •• ntibodie.. Biop.i •• 
taken one hour following rev.scul.riz.tion were found to cont.in IgM 
binding to kidney v.scul.r endothelium in c.pill.ries .nd .rteriol ••• 
Warming of the kidney prior to revascularization did not reduce the 
incidence of initial non-function but did reduce its severity and duration. 
The priming stimuli for, and mol.cul.r specificity ot the 
autolymphocytotoxic antibodies are largely unknown. Th.ir appearance has 
been associated with viral infection (Jeannet, Benzonana and Arni, 1981, 
Cross, Greiner and whittier, 1976, Lobo, 1981, Je.nnet, V.s •• li .nd 
Hufschmid, 1980), particularly with post-transplant Cytomegaloviru. (CMV) 
infections (Macleod et al, 1987). B.ldwin (Baldwin III .t al, 1985) 
correlated their appearance with dev.lopment of rheum.toid f.ctor following 
CMV infection, although autoantibodies do not agglutinate IgG coat.d latex. 
R.villard proposed that th.y may result from immunization with cro •• -
reacting antigens following microbial, parasitic or viral inf.ction 
(Revillard, Rivera and Robert, 1980). 
Ozturk and Terasaki (Ozturk and Teras.ki, 1979) found 1ymphocytotoxic 
autoantibodies in patients with various di •••••• , particularly .y.temic 
lupus .rythematosus (SLE, 72') and rheumatoid arthritis (RA, 68'). Th ••• 
were mainly reactive with B cells .lthough T cell reactivity wa •• 1.0 
present in 54' of SLE patients. How.v.r, lymphocytotoxic autoantibodies in 
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patients with SLE are often IgG. Their presence has also been correlated 
with lymphopenia. This may indicate that they constitute a different 
antibody population, or the same antibody having undergone immunoglobulin 
class switching. In addition, cold B cytotoxins were found in 7' of normal 
males. They were negative with monocytes, polymorphs and eLL cells. Park 
(Park, Terasaki and Bernoco, 1977) found B cell autoantibodies present in 
20' of the normal population. Their presence in normal individuals has 
been associated with increasing age but they do not appear to have clinical 
significance (Cicciarelli et al, 1980). 
The nature of the target molecule of the lymphocytotoxic autoantibodies is 
unknown. ozturk (Ozturk and Terasaki, 1979) proposed that they are specific 
for cell surface IgM, accounting for the restricted B cell reactivity and 
also their apparent immunoregulatory role associated with enhanced graft 
survival. Following this Ozturk and Terasaki (Ozturk and Terasaki, 1980) 
demonstrated that human IgM caused inhibition of cold cytotoxins to B 
cells. This was not found using IgG or human serum albumin. In control 
studies, purified IgM did not block cytotoxicity of HLA antibodies. The 
cytotoxicity was proportional to the amount of immunoglobulin on the cell 
surface of different cell types, with B cells being strong targets whereas 
T cells, null cells (non-T non-B large lymphocytes), CLL cells and 
polymorphs were negative. 
This data was supported by Takashashi (Takahashi et al, 1980) who found 
that B lymphocytes stripped of surface IgM using heterologous antisera 
(rabbit IgG anti-human-IgM) at 37°C were no longer susceptible to lysis by 
cold cytotoxins, but reactivity to HLA antibodies remained unaltered. 19K 
specificity was shown as pre-incubation of B cells with anti-human-IgG 
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failed to block autoantibody binding. In addition no effect was found using 
anti-human-IgG or -lgM at 4°C, demonstrating the requirement for the 
removal of IgM from the cell surface. 
Furthermore, using affinity chromatography, Cicciarelli (Cicciarelli et al, 
1980), demonstrated that cold B cytotoxins could be bound and eluted from 
IgM coated sepharose beads. Binding to IgG coated sepharose was weak and 
binding to HSA was completely negative. Competitive inhibition was only 
possible using purified human IgM and not with IgG nor HSA. 
Taken together, these experiments indicate IgM on the B cell surface as the 
target molecule of cold cytotoxins. The molecular specificity of 
autoantibodies reactive with T cells has not been addressed. 
iii) Autologous cell absorption 
Autoantibodies are not absorbed by platelets (stastny and Austin, 1976). 
Autologous cell absorptions using peripheral blood lymphocytes have been 
used to remove autoantibody reactivity. Sera, pre and post absorbtion have 
been used in the crossmatch test to determine the presence of auto and 
alloreactive antibodies against a particular donor. The difficulty 
encountered with this approach is the high numbers of autologous cells 
required for complete absorption of autoantibodies. Ettenger (Ettenger and 
Robertson, 1987a and b) described a protocol using a triple ab.orption 
technique which required a total of 9-15x10' autologous PBL'. to absorb 
SO~l of serum. Of 38 sera studied from highly sensitized patients, 21 (55.) 
had autoantibodies, including 11 of 13 patient. with SLE. Autologous cell 
absorptions were successful in 10 of 11 patients. Transplantation using 
related donors was performed in three patient. who had a negative 
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crossmatch following absorption and all were successful. 
The use of autologous Epstein Barr virua (EBV) transformed lymphoblaatoid 
cella lines (LCL's) has been applied to overcome the problem of high cell 
numbers required for autologous absorption. This has the advantage of 
continuous culture of large numbers of autologous B cella in-vitro, 
enabling absorption of patients autologous sera. Deirehoi (Deierhoi, Ting 
and Morris, 1984; Deierhoi, Ting and Morris, 1985) demonstrated the use of 
autologous EBV-LCL absorptions to distinguish auto and alloantibodies in 
highly sensitized patients. Similarly, Nicholls and Russ (Nicholls and 
Russ, 1989) also demonstrated specific absorption of autoantibodies using 
autologous LCL's in highly sensitized patients without depletion of 
alloantibodies. These studies used 8x10' cells par 50~1 of serum. They 
showed the usefulness of the technique for the detection of antibody 
specificities in complex sera. 
Autoantibodies are reactive with the cell line KS62 (Deierhoi, Ting and 
Morris, 1985; Deierhoi, Ting and Morris, 1984). This cell line, 
characterised as a primitive erythromyeloid leukaemia cell, does not 
express sufficient cell surface HLA to be detected by conventional 
serology. Of 940 HLA typing reagents, 10 were positive with KS62 in 
extended cytotoxicity assays. These reactions had no definable HLApattern. 
However, of 40 patients with lymphocytotoxic autoantibodies, 38 (95.) were 
positive. In highly sensitized patients without autoantibodies, 15' were 
positive. The extra reactivity may be directed towards granulocyte markers 
which are also expressed on KS62. Autoantibody positive sera absorbed with 
autologous LCL's also remove. K562 reactivity, confirming the autoantibody 
specificity. 
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1.5 The B cell cro .... tch 
The clinical relevance of a B cell positive crossmatch not cau.ed by 
autoantibodies is also controversial. One reason is that in most studie. 
the precise specificity of the B cell antibody has not been defined. 
Initial reports indicated that B cell alloantibodie. were not a •• ociated 
with poor graft outcome. Ettenger (Ettenger et al, 1977) reported 12 of 15 
transplants successful at three months, with no difference between .erum 
creatine levels in the crossmatch positive and negative groups. Similarly, 
Morris (Morris et al, 1977) reported 10 of 13 successful transplants and 
Myeburgh (Myburgh et al, 1977) found 13 of 14 were successful at between 
3 months and 3·5 years. However these early studies all assumed that the 
antibodies were alloreactive with no supporting evidence. Myeburgh (Myburgh 
and Smit, 1978) and Morris postulated that they were the same a. rat anti-
Ia (class II) antibodies which were known to cause active enhancement. 
Ting and Morris (Ting and Morris, 1977) defined alloreactive B cell 
antibodies on the basis of eLL reactivity. They reported 8 of 11 successful 
transplants in the presence of alloantibodie. a.sumed to be directed at 
donor HLA antigens. Further to this, in 1979 (Ting and Morris, 1979) they 
reported 9 of 13 (69') successful at 3 months, compared to 91' with B cell 
autoantibodies and 72\ with a negative crossmatch. 
In a retrospective study, Jeannet (Jeannet, Benzonana and Arni, 1981) found 
good graft survival associated with both weak HLA-cla •• I (11 of 13 grafts 
successful) and HLA-DR antibodies (14 of 16 grafts .uccessful). In this 
study they utilised platelet absorption, autologous crossmatch and extended 
incubation times to differentiate auto from alloreactive antibodies. They 
concluded that weak HLA-class I and HLA-class II antibodies were not 
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associated with poor graft outcome. 
The same techniques were used by d'Apice and Tait (d'Apice and Tait, 1979a 
and b), who reported improved function and enhanced graft survival with a 
positive crossmatch due to B cell alloantibodies (28 of 30 grafts 
successful compared to 15 of 48 successful with a negative crossmatch). 
They did note that the patients with positive crossmatches had received 
more blood transfusions (mean 12 units) compared to the negative group 
(mean 4 units). They hypothesized that only B cell antibodies to Ia (HLA-
DR) led to passive enhancement and were beneficial. 
However platelet absorption does not distinguish between B cell 
autoantibodies and HLA-class II antibodies and the autologous croaamatch 
on uraemic renal dialysis patients is technically difficult and unreliable. 
Therefore the results should be intarpreted with caution. 
other investigators who supported the view that B cell alloantibodies were 
not damaging included Mohanakumar (Mohanakumar et al, 1979) with 22 of 26 
transplants successful at ona year, and Coxe-Gilliland and Cross 
(Coxa-Gilliland and Cross, 1981) who reported no deleterious effect of a 
warm B cell crossmatch. Howevar Mohanakumar found a strong correlation with 
the development of post graft B call antibodies and irreversible rejection. 
Fauchet (Fauchet et al, 1980) confirmed this, with only 38' (N-15) of 
patients who developed post graft B cell antibodies successful compared to 
83' with no antibodies. Similar findinga were later reported by Martin 
(Martin et al, 1985), who found only 35' of transplants were aucceasful 
when post graft HLA class I or claas II antibodies developed. The.e 
findings appeared to contradict the report. of their non-damaginq role 
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before transplantation. 
These early publications indicated that a positive B cell crossmatch was 
not an important indicator of acute graft failure and hence many transplant 
centres do not perform the test. Other studies have drawn different 
conclusions and believe that pre-graft B cell alloantibodies are damaging 
to renal allografts. 
Dejelo and Williams (Dejelo and Williams, 1977) reported hyperacute 
rejection of a HLA-A,-B identical transplant with a positive B cell 
crossmatch thought to be directed at HLA-DR. The patient was highly 
sensitised following 51 blood transfusions and a previously failed 
transplant. Sirchia (Sirchia et al, 1979) examined the association of 
pregraft HLA-A,-B,-C and -DR antibodies (following platelet absorption) and 
graft survival. They reported 80' success at three years in patients with 
no pregraft antibodies compared to only 40\ with B cell alloantibodi.s. 
Ayoub and colleagues (Ayoub et al, 1980) drew similar conclusions and found 
a 27' one year graft survival with pregraft HLA-DR antibodies (defined by 
reactivity at 37°C and not absorbed by platelets). They concluded that IgM-
anti-lgM (auto) antibodies were enhancing whereas sensitization to HLA-
DR (with titres of >1/8) were detrimental to graft survival. 
Following their report of enhanced graft survival, d' Apice and Tait 
(d'Apice and Tait, 1980) examined the specificity of B cell antibodies in 
their series of 34 positive B cell cros.match transplants. They correlated 
T and B cell panel reactivity with HLA-DR alleles, looked at antibody 
profiles pre- and post-platelet absorption, optimal thermal reactivity and 
the segregation of reactivity with HLA haplotype_ within familie.. They 
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found twenty patients had non-HLA antibodies and 14 had HLA-DR antibodies 
(reactive at 37°C followinq platelet absorption). Of the 34 positive 
crossmatch transplants previously reported, only four were attributable to 
donor reactive HLA-DR antibodies. They concluded that most positive B cell 
crossmatches were not caused by HLA-DR antibodies. 
Further to their initial findinqs of no overall deleterious effect at three 
months, Tinq and Morris (Tinq and Morris, 1981) reported 91' one year qraft 
survival of 11 first qrafts with B cell autoantibodies compared to only 30' 
in 10 transplants without autoantibodies. In most of the failures with 
positive crossmatches, the transplants never functioned. Reqrafts also had 
poor success rates. They suqqested that not all B cell crossmatches could 
be iqnored and that B cell alloantibodies, particularly tho.e produced 
after a previous qraft failure, were damaqinq to the transplant. 
Berq (Berq and Moller, 1981) reported the hyperacute rejection of a HLA-
A, -B compatible reqraft in the presence of a donor .pecific HLA-DR 
antibody. However, in this very short communication the antibody 
specificity was not clearly proven. Also Mohanakumar (Mohanakumar et .1, 
1981) reported the rapid failure of two reqraft. performed with donor 
specific sensitization. Both recipients received kidney •• haring • repeat 
HLA-DR mismatch with their previous donor. and were shown by eLL reactivity 
profiles and platelet absorption studies to have immediate preqraft 
antibodies to donor HLA-DR alleles. The antibody titres in one patient rose 
form 1/6 to 1/512 twenty-one days post-tran8plant and this was a •• oci.ted 
with graft 108s. Furthermore Ahern (Ahern et al, 1982) r.port.d two c •••• 
of hyperacute rejection with a positive B cell cro.smatch cau •• d by HLA-
DR antibodies. Both patients were highly •• n.itized with 100' p.n.l 
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reactive antibodies and both received kidneys from HLA-A,-8 and -c 
identical donors having a negative T cell crossmatch. Platelet absorptions 
and absorptions using homozygous typing cells provided convincing evidence 
of the HLA-DR specificity. The titres were 1/64 and 1/32 immediately pre-
transplant and in one case the titre decreased to 1/1 twenty-four hours 
post-transplant indicating absorption onto the renal vasculature. Using a 
skin biopsy crossmatch the antibody was shown to react with donor 
endothelium in one case. 80th transplants suffered immediate histologically 
proven hyperacute rejection. These authors suggested that high titre donor 
specific HLA-DR antibodies may mediate graft destruction. 
In subsequent years many other investigators have reported poor graft 
survival associated with 8 cell alloantibodies. Noreen (Noreen et al, 1983) 
found a significantly worse prognosis in transplants with a positive 8 cell 
crossmatch regardless of the temperature of reactivity. In 48 positive 
crossmatch transplants, 67\ were successful at two years compared to 79' 
with a negative crossmatch. There was only a 43' graft survival in patients 
where autoantibodies could not be demonstrated. Posner (Posner et al, 
1984), in a retrospective study of 84 transplants found 28 had a current 
positive 8 cell crossmatch. No hyperacute rejections were seen and there 
was no difference in overall graft survival ratea. However, regrafta with 
a positive crossmatch fared slightly worse, although the difference waa 
amall. 
In addition, Marrow (MOrrowet al, 1984), in a series of S6 positive B cell 
crossmatch transplants reported a lower two year graft survival associated 
with both primary and regrafta (64' and 88\ succ.ssful with a positive and 
negative crossmatch respectively). This was true for cadaver donor and 
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single haplotype matched live related donor transplants, and was also found 
regardless of optimal thermal reactivity. Moreover, patient survival was 
significantly worse in the positive crossmatch group (80' versus 95' at two 
years). In cOlmlon with most other reports, although graft outcome was 
significantly poorer, 6o, were still successful with no incidence of 
hyperacute rejection. 
Rhodes (Rhodes et al, 1984) reported that patients with HLA-DR reactivity 
(defined as eLL positive) had poor graft outcome. They confirmed the HLA-
DR specificity following ilmlunoprecipitation of HLA-class II like molecules 
(29kD and 34kD) with patient sera. Blank and colleagues (Blank et al, 1982) 
found that a warm B cell crossmatch precedes the development of a positive 
T cell crossmatch following DST, which precludes transplantation with a 
living related donor. Vaidya (Vaidya et al, 1984) reported that in single 
haplotype matched LRD transplants who had received DST, 63' (N-16) with a 
positive B cell crossmatch had reversible acute rejection episodes compared 
to 37' with a negative crossmatch. There was however no difference in 
ultimate graft outcome. 
Nunez and co-workers (Nunez, McPhaul and Stastny, 1983) utilized the 
technique of cytotoxicity inhibition to define the specificity of 
antibodies causing a positive B cell crossmatch. Using a non-cytotoxic 
monoclonal antibody (L227) reactive with a common framework determinant on 
HLA-DR molecules and a polyreactive chicken anti-human Ia (reactive with 
HLA-DR related supertypic class II specificities), they investigated the 
panel reactivity of patient sera pre- and post-transplant. They found that 
transplants with pregraft HLA-DR antibodies rejected more often (67') than 
those without (44'). HLA-DR antibodies were present in 94' of patients who 
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lost their transplant due to rejection and were eluted from 85\ of rejected 
kidneys. These results implied a role for HLA-DR antibodies in the 
pathogenesis of graft destruction although 55' of transplants had good 
function. 
Fauchet and colleagues (Fauchet et al, 1985) prospectively examined the 
role of B warm and cold antibodies in allosensitized recipients in response 
to blood transfusions. In 90 transplants, 16\ had B cold and 17\ had B warm 
positive crossmatches. They found no difference in the incidence of acute 
rejection episodes or with graft outcome. However, presensitization to HLA-
DR was considered a contra-indication and such transplants were 
prospectively avoided. 
Salvatierra (Salvatierra et al, 1985) published their experience of 239 
live related transplants following DST. Zero and one haplotype matched 
transfused recipients had an equal four year graft survival to HLA 
identical patients. However, despite administration of imuran or 
cyclosporin during DST to prevent sensitization, 62 patients developed B 
warm positive crossmatches which were considered a contra-indication to 
transplantation. The crossmatches were repeated using flow cytometry 
against T cells in order to identify and exclude weak (subliminal) HLA 
class I reactivity. Of the 62 patient., 45 (73\) were negative and 
subsequently transplanted. Forty-four (all with titre. of <1/4) were 
successful. They noted that the single failure had a titre of 1/8 with 
donor B cells. 
Reekers and Fluit (Reeker. and Fluit, 1985) found no influence of • B cell 
crossmatch due to alloantibodies (defined •• autoantibody negative) in 
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primary transplants (80% successful at one year, N-32) but reported poor 
regraft survival with 6/14 successful at one year compared to 70' with a 
negative crossmatch. Russ and colleagues (Russ et al, 1987) reported 32 
positive B cell crossmatch transplants with 48' one year graft survival 
compared to 75% with a negative crossmatch. There was a higher proportion 
of regrafts and sensitized patients (>50\ PRA) in the positive crossmatch 
group although increased rejection was found with both primary and 
regrafts. Further to this (Russ et al, 1987) they reported 47\ of the 
positive B cell group had rejection within 7 days compared to only 15\ 
without antibodies. Platelet absorption and screening with HLAtyped panels 
were used to confirm the specificity which showed HLA-D and weak HLA-A,B,C 
antibodies were associated with an increased incidence of rejection. 
Biopsies showed evidence of antibody mediated damage with polymorph and 
monocyte infiltration and early acute glomerular rejection. Noreen (Noreen 
et al, 1987) found similar results, with 62\ one year success in 81 primary 
grafts in the B cell positive group compared to 80\ with a negative 
crossmatch. 
Lazda and co-workers (Lazda et al, 1987) examined the influence of a 
current B cell positive crossmatch in the pre- and post-cyclo.porin era. 
From 1978-1983 (pre cyclosporin) 56\ and 40\ were .uccessful with a 
negative and positive B cell crossmatch respectively. Thi. detrimental 
effect was only found with regraft.. In the negative cro •• match 
transplants, poor regraft survival was associated with .ensitization, with 
44% one year graft survival in patients with >10\ PRA compared to 67\ with 
<10\ PRA. Graft survival with a positive cros.match directed at &LA cla •• 
II (not platelet absorbed) was no different to tho.e with no antibodie •• 
However, of six transplants with a current positive flow cytometry 
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crossmatch due to HLA-class I and II antibodies, only one (17\) was 
successful. With cyclosporin (post 1984) no difference in graft survival 
was seen although the positive B cell group had higher rejection rates (55\ 
versus 75%) which again correlated with levels of T cell PRA. They proposed 
that the B cell crossmatch and flow cytometry technique detected 
'subliminal' sensitization to HLA class I. 
Alarif (Alarif et al, 1987) reported no overall difference in graft outcome 
but they also found a strong correlation with previous levels of 
sensitization. Van der Berg-Loonan (Van den Berg-Loonen et al, 1987) 
reported that after blood transfusion, 53\ had B cell antibodies of which 
only half were against HLA-DR/DQ. Positive crossmatch transplants due to 
HLA antibodies were avoided and no difference in graft outcome was seen. 
Tzakis (Tzakis et al, 1988) investigated transplants performed with a 
current weak positive crossmatch in 39 sensitized patients. Primary and 
regraft survival was 80\ and 63\ respectively, indicating the existence of 
a 'therapeutic window' through which patients can be .ucce •• fully 
transplanted. These patients received intensive immunosuppression (OKT3) 
and an increased incidence of ATN was noted. Noreen (Noreen et al, 1989) 
examined the results of 49 B cell positive crossmatch transplants in 
patients treated with CyA. They found 88' one year success with a negative 
crossmatch compared to 71\ with a positive crossmatch. The difference wa. 
most apparent in diabetic patients (89\ vs 64\) and they concluded that a 
positive B cell crossmatch was predictive of poor graft outcome. 
A study by Phelan (Phelan et al, 1989b) showed that ten of 17 positive B 
cell crossmatch transplants were due to HLA cla.s I antibodies (confirmed 
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by flow cytometry). Poor graft survival (60') despite extensive 
immunosuppressive treatment was found indicating that weak HLA cla88 I 
sensitization was detrimental to graft outcome. 
In summary, a positive B cell (but negative T cell) crossmatch may be 
caused by heterogeneous antibody populations directed towards non-HLA, weak 
HLA class I, or HLA class II (HLA-DR, DQ and DP). The significance of such 
antibodies in renal transplantation remains controversial, with some 
reports suggesting immediate graft failure or poor graft survival, whereas 
others suggest that they have no influence or are associated with improved 
graft outcome. Most studies in which the specificity has been defined and 
was shown to be towards HLA-DR reported poor graft survival. A positive B 
cell crossmatch in regrafts and high titre B cell antibodies may be 
additional risk factors associated with poor graft survival. It is 
therefore important to distinguish between B cell antibody specificities 
to determine which, if any, are prognostic of graft failure. Because the 
early studies showed that graft survival in B cell positive crossmatch 
transplants was similar to, or even better than grafts with a negative 
crossmatch, many transplant units do not perform B cell crossmatches. On 
the other hand some centres avoid altogether transplanting any B cell 
positive crossmatch donors. 
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1.6 Peak po.itive - current negative cro .... tch transplants 
Traditionally, both historical and current sera have been used for 
crossmatching. This was based on the rational that due to immunological 
memory, an anamnestic response would result if a transplant was performed 
using a donor to which the recipient was previously sensitized. This would 
cause uncontrolled acute or accelerated rejection. 
Due to the accumulation of highly sensitized patients awaiting a negative 
crossmatch donor and following the introduction of more powerful 
immunosuppressive agents, pioneering work by Cardella and Falk (Cardella 
et al, 1982) questioned the role of non-current donor specific HLA 
antibodies. They performed 15 transplants in patients who had lost their 
antibodies during the course of time. These patients had a positive T and 
B cell crossmatch using sera taken in the past (ranging from 2 months to 
3 years) but were negative on the day of the transplant. All were 
autoantibody negative. Of the 15 transplants, 9 were successful at one year 
which was not significantly different to the negative crossmatch 
transplants performed during the same period (75' successful at one year). 
They concluded that only the current antibody status is relevant when 
selecting a suitable donor and that immunological memory is not a 
precluding factor with the use of modern day immunosuppres.ion. However, 
only six of the fifteen patients in this group were highly sensitized (>90' 
PRA). Graft rejection was treated with intensive immunosuppressive regimes 
of plasma exchange and rabbit anti-thymocyte sera which was associated with 
notable infectious morbidity. 
Following this lead, many investigators drew similar conclusions. Laupacis 
(Laupacis et al, 1983) reported 3 of 4 transplants successful (3/3 first 
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and 0/1 regrafts). Matas (Matas et al, 1984) found 3 of 5 successful (2/2 
first and 1/3 regrafts). All patients in this study were previously highly 
sensitized but had a current negative crossmatch for at least 18 months 
prior to the operation. Fuller and colleagues (Fuller, Forbes and 
Delmonico, 1985) reported 4 of 8 transplants negative for greater than 4 
months were successful and Rosenthal (Rosenthal et al, 1985) found 10 of 
12 transplants successful at one year. In a study by Norman and co-workers 
(Norman, Barry and Wetzsteon, 1985) all six transplants reported were 
successful. In this study, all were first grafts in patients sensitized 
through blood transfusion and in most cases the antibodies had a low titre. 
These and other authors drew the conclusion that the memory B cell response 
was short lived and secondary responses could be controlled by the use of 
cyclosporin. subsequently, the policy of crossmatching only current sera 
was widely adopted enabling transplantation of many highly sensitized 
patients. However despite these advances many transplants still underwent 
acute irreversible rejection. 
In subsequent studies several risk factor. which could identify tho.e 
patients' at higher risk of loosing their graft were reported. The.e were 
i) whether the transplant was a first or a regraft, ii) unresponsiveness 
to donor alloantigens induced by anti-idiotypic antibodies and iii) the 
immunoglobulin class and specificity of the T cell crossmatch. 
1.6.1 Primary and reqrafts: Several reports indicated that graft survival 
in the presence of a peak positive but current negative crosamatch was 
acceptable in primary transplant. but was a.sociated with poor regraft 
survival. Kerman (Kerman et al, 1985) reported 12 of 14 (86') first graft. 
36 
successful but none of 4 regrafts successful at one year. This compared to 
81% and 74% successful for first and regrafts respectively, performed with 
a negative crossmatch. Cardella (Cardella et al, 1985) also found a poor 
regraft survival but this was no different to their regrafts carried out 
with a negative crossmatch. In a series of 61 T and B cell positive 
crossmatch transplants they found high risk patients (defined as rejection 
of a previous transplant in less than one year) had 41% success with a 
positive crossmatch compared to 46' with a negative crossmatch. 
Goeken (Goeken and And the Clinical Affairs Committee, 1985) reported on 
the ASHI survey conducted by the clinical affairs committee. Of 216 
historical positive crossmatch transplants from 27 reporting centres, 69' 
of first grafts (N-I09) and 53' of second or subsequent transplant. (N-107) 
were successful at one year. No other factor such a. the time period 
between the positive crossmatch and transplantation, the level of peak PRA 
or whether the antibody was reactive with donor T and B cells or B cells 
only were significant. Hodge (Hodge et al, 1987) also found good primary 
(87') but poor regraft survival (56'). The mean panel reactivity of this 
group was 66\ (N-26). 
Johnson (Johnson et al, 1987), examined 162 transplants with a negative T 
cell crossmatch using serum taken up to six months prior to 
transplantation. Using the more sensitive antiqlobulin-augmentad crossmatch 
test they found 17 were positive. This was associated with an increa.ed 
incidence of accelerated rejection (p <0.01) and increased los. of reqraft. 
(p <0.02) but not first grafts. Their data indicated that when 
crossmatching current serum only, it may be important to use the extra-
sensitivity of the antiglobulin-auqmented test. This detect •• ublytic 
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levels of donor reactive antibodies which are not seen in the conventional 
crossmatch. 
Falk (Falk et al, 1987) re-examined the Canadian data and confirmed th.ir 
previous finding that the timing of the first graft loss was the only 
factor which influenced regraft outcome. One year graft survival was 50\ 
(N=lll) in patients who had rejected a previous transplant in 1 ••• than one 
year compared to 80\ (N=93) in patients whose transplants failed beyond one 
year. No correlation was found with a positive crossmatch using non-
current sera. 
In contrast, Turka (Turka et al, 1989) found an adver ••• ffect of a 
historical positive crossmatch in both first and regrafts. Primary graft 
survival at one year was 68% (N-41) with a positive cros.match compared to 
86\ with a negative crossmatch. For second and subsequent transplants, 51\ 
(N=29) of positive and 79\ of negative crossmatch transplants were 
successful. Although a historical positive crossmatch was not an absolute 
contra-indication these authors considered it a 'relative increased risk' 
when selecting suitable donor and recipient pairs. 
1.6.2 Anti-idiotypic antibodies: In 1980, Kiyajima (Kiyajima et al, 1980) 
described the presence of serum factors which caused MLR inhibition in a 
recipient of a successful transplant from a &LA mismatched cadaver donor 
on minimal immunosuppression. The donor spacific inhibition was due to IgG 
antibodies reactive with responder cells and was postulated to block the 
antigen binding site of the T cell receptor on autologous cells. They 
proposed a mechanism of anti-idiotypic antibodies playing a central role 
in the immunoregulatory system, sustaining graft protection. Takeuchi 
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(Takeuchi et al, 1985) reported similar findings in patients following DST. 
They described MLR suppression of autologous responder cells with IgG 
purified from sera following blood transfusion. This correlated with a 
lower incidence of acute rejection. They advanced the idea that anti-
idiotypic antibodies performed an important role in the prolongation of 
graft survival. Similar findings were also reported by others (Suzuki et 
al, 1985). However Daniel (Daniel, Wendler and Opelz, 1987) found non-
specific inhibition of the primary KLR, in-vitro stimulated donor specific 
T cell blasts and PHA blasts using both patient and negative control sera. 
Toma and colleagues (Toma et al, 1985) used the Lymphocytotoxic Inhibition 
Test (LIT) for the detection of anti-idiotypic antibodies. This involved 
pre-incubation of current and non-current serum (1:1) overnight at 4°C, 
followed by a cytotoxicity test. Inhibition of cytotoxicity (compared to 
an RPM I treated control) was interpreted to contain anti-idiotypic 
antibodies. The anti-anti-HLA specificity (Ab2) was confirmed by blocking 
reactivity of specific HLA antisera (Abl). Thirteen patients sensitized 
through DST, who had subsequently become negative were transplanted and 11 
(85%) were successful. They investigated one such successful transplant and 
corralated the appearance of Ab2 with MLR suppression and specificity to 
a mismatched donor antigen (HLA-Bw59). However in a follow-up study (Toma 
et al, 1987), no overall correlation with graft survival was found. 
Using a similar technique, Phelan (Phalan at al, 1985) found cytotoxic 
inhibition of control HLA antisera using both whole serum, purified IgG and 
F(ab')2. They interpreted >50\ lysis inhibition in diluted .ara as being 
Ab2 positive. Burlingham (Burlingham et al, 1988) al.o found !'(ab')2 of IgG 
contained inhibitory activity specific for donor antigens following CST 
39 
although only 2 of 12 patients studied were positive. 
Barkley and co-workers (Barkley et al, 1987) developed a solid phase enzyme 
immunoassay to define blocking antibodies. They examined the ability of 
post transfusion sera to block both polymorphic and monomorphic monoclonal 
anti-HLA antibody binding to trays coated with gluteraldehyde fixed 
platelets. Binding was detected using horseradish peroxidase conjugated 
anti-human or mouse IgG in an ELISA technique. They found 8 of 16 post 
transfusion patients showed anti-idiotypic activity which resided in the 
F(ab')2 of IgG. Furthermore, binding was directed at anti-HLA IqG (Abl) 
F(ab')2. Cytotoxicity inhibition of control HLA antibodies using F(ab')2 
fragments of IgG was also reported by MacLeod (MacLeod et al, 1989). They 
proposed that this was a possible mechanism of allograft enhancement 
following blood transfusion. 
Reed (Reed et al, 1987) tested 20 patients transplanted with a positive 
crossmatch using non-current sera using the cytotoxicity inhibition test. 
Donor specific anti-HLA sensitization in these patients was demonstrated 
by panel screening with a correlation coefficient of r->0.7 with mismatched 
donor antigens. Only sera from the last six months were prospectively 
crossmatched, without regard to previous sensitization history. The 
presence of Ab2 in current sera was found in 9 of the 10 successful 
transplants. None of the 10 failed transplant patients had Ab2 and 9 had 
potentiating antibodies (AbJ). The potentiating antibodies were postulated 
to be anti-anti-anti-HLA antibodies. They concluded that a historical 
positive crossmatch could only be ignored if the current serum contained 
anti-idiotypic HLA antibodies. 
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A paper from Michelle Jeannet's group in Geneva (Hann et al, 1988) used the 
same technique to identify inhibitory factors which blocked HLA class II 
antisera. They monitored 44 patients for anti-idiotypic antibodies 
following blood transfusion and their correlation with transplant outcome. 
Mean cytotoxic inhibition of HLA class II sera was significantly higher in 
patients with successful transplants compared to those that failed. Lack 
of inhibition was associated with irreversible rejection in patients 
treated with conventional immunosuppressive therapy (azathioprine and 
prednisolone) and with cyclosporin. However due to the inherent variability 
of the test, standard deviations were high. They noted variability with 
negative control sera, some of which also caused inhibition. There was no 
relationship of their appearance with pregraft blood transfusions, nor 
previous pregnancies. The lack of a correlation to HLA sensitization and 
therefore the production of HLA antibodies (Ab1) must bring into doubt the 
anti-idiotypic nature of these factors. In addition, cytotoxic inhibition 
was associated with the presence of immune complexes (determined by 1251 
C1q binding) found in patients with systemic disease. One explanation was 
that these represent Ab1/Ab2 complexes which block Fc receptors causing 
suppression. Inhibitory factors which block the formation of EA rosettes 
with Fc receptors on donor B cells following blood transfusion are also 
associated with good renal allograft outcome (Macleod et al, 1982). One 
year graft survival of 85\ with EA rosette inhibiting 190 antibodies was 
reported, compared to only 30\ when absent. These findings however have not 
been confirmed by others (Soulillou, Peyrat and Guenal, 1978, Soulillou and 
Peyrat, 1979; Suthanthiran et al, 1978; Suthanthiran et al, 1977). 
Phelan (Phelan, Rodey and Anderson, 1989a) investigated the occurrence of 
Ab2 in 16 patients following OST under the cover of azathioprine. Post 
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transfusion sera inhibited HLA-A,B,C,CR and CQ sera with no predilection 
for any particular locus. They appeared immediately after the first 
transfusion although some were found prior to transfusion (thought to be 
a consequence of previous transfusions). All 16 patients were successfully 
transplanted (13 LRD and 3 cadaver). 
Similar results were reported by Al-Huzairai (Al-Huzairai et aI, 1989). CST 
was administered with or without cyclosporin to 50 patients. Whilst the 
degree of sensitization was similar in both groups, those who received CyA 
quickly lost their antibodies. This was associated with the development of 
inhibiting Ab2 which was increased in the cyclosporin group (10/14 with CyA 
compared to 4/17 without CyA). All these patients were successfully 
transplanted. They concluded that persistent sensitization was prevented 
and Ab2 production was augmented by cyclosporin. They also found six 
patients who developed potentiating antibodies which were negative by the 
anti-humAn-globulin complement dependent cytotoxicity (AHG-CDC) test and 
cellular ELISA (for non-complement fixing antibodies). Unlike the 
experience of Reed, five of the six were transplanted, all of which were 
successful. 
Garovoy' s group (Pohanka et al, 1989) examined the disappearance of 
sensitization following CST in 9 transiently sensitized recipients. Four 
of 12 sera studied showed inhibition whereas six were enhancing (Ab3). 
However of the four patients with Ab2, three had been previously transfused 
and the fourth was unknown. Hone of the four previously non-transfused 
patients developed Ab2. Flow cytomatry demonstrated subliminal Abl binding 
in the six sera with enhanCing antibodies. This was not detected by the 
anti-globulin augmented cytotoxicity test. They correlated the appearance 
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of Ab2 with the duration of Abl (mean 2.5 months) whereas when enhancement 
occurred, Abl lasted significantly longer (mean 7.5 months). These results 
indicate that Ab3 is not an anti-anti-anti-HLA antibody as suggested by 
Reed, but they represent residual sublytic levels of Abl. 
Further reports of HLA anti-idiotypic antibodies correlating with graft 
protection came from Braun (Braun et al, 1988) following cardiac 
transplantation (specificity was not proven) and Rodey (Rodey and Phelan, 
1989). The later paper documented a patient who had suffered hyperacute 
rejection of a previous transplant subsequently lost the antibody with the 
emergence of a transient specific Ab2. The patient then received a .econd 
successful transplant carrying the same repeat mismatched antigen. 
Using the EBV technique, Singal (Singal et al, 1988, Singal et al, 1989a) 
produced and characterised an antiidiotypic antibody in vitro. CUlture 
supernatants contained IgM which specifically blocked HLA-B8,BS and DR3 
alloantisera. This coincided with the mismatched antigen (HLA-B8) of a 
successful transplant performed 10 years earlier. In addition, supernatant. 
caused MLR inhibition of responder/stimulator combinations .haring HLA-B 
and DR antigens with the donor and recipient. Ab.orption .tudie. indicated 
that cytotoxiCity inhibition and MLR suppression were independent, cau.ed 
by distinct antibodies. 
Following this, singal and colleagues (Singal et al, 1989b) produced and 
characterised two further human monoclonal antibodies (on. IgM and one 190) 
which suppressed specific MLR response.. A. previou81y de.cribed, the •• 
same antibodies did not block HLA alloantis.ra, confirming that di.tinct 
antibody populations were responsible for MLR suppression and cytotoxicity 
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inhibition. Immunochemical analysis, following precipitation of 358 
methionine labelled cell lysate derived from activated responder T cells, 
revealed 43kD and SlkD bands. No bands were found using activated T cells 
from irrelevant responder/stimulator combinations. The function of these 
idiotypic receptors was not def ined but an immunoregulatory role in 
alloantigen recognition was clearly implicated. 
To avoid the problems of multiple antibodies in HLA alloantisera, Pistillo 
(Pistillo et al, 1989) looked for putative anti-idiotypic inhibition using 
human HLA MAbs. Sera from patients previously sensitized to HLA-B7 
following blood transfusion (N=9), a failed transplant (N-2), or mismatched 
for B7 with no antibody production, were used to block cytotoxicity of a 
HLA-B7 MAb and two irrelevant HLA MAbs. Four patients had Ab2 activity; two 
following graft rejection (8 to 10 years previously), one following 
rejection with no detectable HLA B7 antibody production and one following 
DST. 
In conclusion anti-idiotypic antibodies have been shown to be present 
following third party and donor specific transfusions, and also after both 
failed and successful transplants. Their activity may be one mechanism of 
the transfusion effect associated with enhanced graft survival. They may 
also playa regulatory role leading to transplantation tolerance. They can 
block alloreactive T cell recognition or antibody binding, or act as a 
marker for other regulatory events. However, definitive confirmation of 
their existence is still lacking. 
1.6.3 Antibody class and specificity; Ayoub, Terasaki and Tonai (Ayoub, 
Terasaki and Tonai, 1983), on examination of the UCLA international 
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registry, demonstrated that patients who once had high antibody levels but 
whose sensitization decreased before transplantation had higher failure 
rates. This was particularly apparent in regrafts. However the effect was 
not seen in their own data. They postulated that the reason for the 
difference was their policy of crosBmatching both the highest and most 
recent serum samples, thus avoiding an anamnestic response due to 
immunological memory. The crossmatches were repeated using all available 
sera and stored donor cells and 19 were found to be positive with donor T 
cells. These had a 40\ success rate compared to 51\ (N-61) with a negative 
crossmatch (not significant). The crossmatches were retested in the 
presence of 2-mercaptoethanol which preferentially destroys the 
cytotoxicity of IgM but not 190. Of 18 positive crossmatch transplants 
tested, six were reduced indicating an IgM antibody, all of which were 
successful. However twelve were not reduced indicating an IgG antibody and 
only two were successful. Whilst this data supported the Toronto experience 
that historical positive crossmatch transplants can be successful, many 
'false positives' could be distinguished using this technique. 
Support for this hypothesis came from our own data (Chapman et al, 1986a) 
in which the reducing agent dithiothreitol (DTT) was used to distinguish 
IgM and IgG antibodies causing a positive crossmatch. Cytotoxicity 
inhibition using a non-cytotoxic mouse monoclonal anti-HLA class 1 was used 
in conjunction with DTT to define the antibody class and specificity of a 
series of positive T cell crossmatch transplants. 19M non-HLA (mainly 
autoreactive) antibodies were found in 26 cases with 72' successful at 
three months. However none of the seven transplants cau.ed by IgG HLA-
class I, and 4 of 7 due to IgM HLA class 1 antibodies were .ucce •• ful. 
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Taken together, these preliminary studies indicated that not all peak 
reactive sera can be safely ignored and that there is a high probability 
of failure if the historical crossmatch is due to an IgG antibody. 
Following these observations and also some of the work presented in this 
thesis, the benign coarse of peak reactive IgM antibodies defined by the 
OTT technique has been established (Barger et al, 1989, Royet al, 1990). 
Some apparently highly sensitized patient. have high levels of IgM 
antibodies (Rudy and Opelz, 1987; Vaidya and Ruth, 1989) and thus can be 
successfully transplanted. However there is little information confirming 
the detrimental effect of peak reactive IgG HLA antibodies, nor concerning 
the class and specificity of antibodies causing a positive B cell 
crossmatch. The significance of the non current crossmatch is still an open 
question awaiting further clarification. 
1.7 The objective. of thi. the.i. 
The aims were two-fold. Firstly to characterise the nature and molecular 
specificity of human lymphocytotoxic autoantibodies. This was attempted by 
the production human monoclonal lymphocytotoxic autoantibodies from a renal 
dialysis patient using the mouse/human heterohybridoma technique. These 
have the advantage of unlimited supply, monoclonal, and clones with a 
higher affinity can be selected. The resulting antibodies were then applied 
to determine if the multiple reactivity profiles seen with patient Sera 
represented one, or many different autoantibody populations. In addition 
immunochemical analysis was performed to identify their molecular target. 
These goals have not previously been possible as only patient sera have 
been available, with limited supply usually having low antibody titre and 
affinity. 
46 
Secondly, discrepancies in the literature concerning the clinical relevance 
of the positive crossmatch to graft outcome may be due to the poor 
definition of the antibody specificities. In the majority of studies the 
precise specificity of antibodies causing a positive crossmatch has been 
poorly defined. The aim of this project was to develop an in vitro assay 
which could reliably define the specificity of donor reactive antibodies 
in highly sensitized patients. The technique of cytotoxicity inhibition of 
the T cell crossmatch using non-cytotoxic monomorphic anti-HLA class I NAb 
was extended to define the specificity of the B cell crossmatch. This 
involved the identification of suitable monomorphic anti-HLA class I, DR 
and DQ locus specific NAbs and the development of a blocking a.say which 
could distinguish multiple antibody populations within the same serum. In 
combination with dithiothreitol (to reduce IgM) the techniques were applied 
to define the immunoglobulin class and antibody specificity of a series of 
positive crossmatch transplants. A correlation with graft outcome was then 
sought. 
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Chapter 2. Haterial. and Method. 
2.1 Microlyaphocvtotoxicitv a •• av. 
2.1.1 Reagents and buffers 
a) Physiological saline 
b) Phosphate buffered saline (PBS-DAB) 
c) Neuraminidase treated sheep red blood calls 
d) Polybrene 
a) Gidion Goldstein lysis buffer 
f) Rabbit complement 
g) Eosin staining solution 
h) Formal salina fixativa 
i) Dithiothreitol 
j) Cystine 
k) Sodium hydroxide 
2.1.2 Cell separation methods 
a) Preparation of peripheral blood lymphocytes 
b) Preparation of lymph node and spleen lymphocytas 
c) Separation of T and B lymphocytes 
d) Removal of monocytes from B cells 
2.1.3 Cytotoxicity assays 
a) Cytotoxicity inhibition assay to define tha antibody 
specificity 
b) Microlymphocytotoxicity as.ay 
c) Immunoglobulin class determination (OTT reduction) 
2.2 Ti •• ue cultur. technique. 
2.2.1 Strategy for monoclonal lymphocytotoxic autoantibody production 
2.2.2 Reagents 
a) Growth medium 
b) Selection medium 
c) Fusion medium 
d) Mouse spleen feedar calls 
2.2.3 Methods 
a) Generation of B-LCL 
b) Production of heterohybridoma 
c) Cloning. i. Clona picking, ii. Limiting dilution 
d) preparation of cell line. for cytotoxicity a.say. 
a) Assassment of haterohybridoma growth charact.ristic. 
f) DNA contant analy.i. of hat.rohybridoma 
g) Determination of monoclonal antibody cla •• 
h) Mixed lymphocyte reaction inhibition 
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2.3 Bindinq a •• ay. 
a) Cytotoxicity binding assay to select higher affinity clones 
b) Fluorescence binding assay 
c) Enzyme cleavage of cell surface molecules 
d) Autoantibody binding inhibition assay 
e) Biotin/avidin binding assay 
f) Competitive inhibition binding assay; 
i) Autoreactive monoclonal antibodies 
ii) Patient sera and serum proteins 
g) Lectin inhibition of autoantibody binding; 
i) Using fluorescence binding assay 
ii) Red blood cell agglutination 
iii) Red blood cell agglutination inhibition 
iv) Lectin/RBe cytotoxicity 
h) Sialic acid inhibition of autoantibody binding; 
i) Cytofluorograph analysis 
ii) Cytotoxicity test 
I) Effect of pH on autoantibody binding 
2.4 Immunoche.ical technique. 
2.4.1 Strategy for batch purification of IgM from tissue culture 
supernatant 
2.4.2 Reagents 
a) MES buffer, pH 5·5 
b) Sodium acetate buffer, pH 6·S 
c) Ammonium sulphate (200mK) 
d) MES buffer, pH<4·0 
e) Sodium azide (10') 
2.4.3 Methods 
a) Preconditioning of ion exchange resin 
b) Batch purification of IgM 
c) Purification of IgM by gel filtration; 
i) Column preparation 
ii) COlumn calibration 
iii) Sample application 
2.5 Determination of IqM purity by SDS-PAGE 
2.5.1 Reagents 
a) Acrylamide solution 
b) Separation gel buffer 
c) Stacking gel buffer 
d) Sodium-dodecyl sulphate (10') 
e) Ammonium persulphate 
f) Running buffer 
g) Sample buffer 
h) Running gel 
i) Stacking gel 
j) Bromo-phenol blue 
k) Coomassie blue stain 
1) Destain 
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m) Sample preparation reagents; 
i) lodo-acetamide (40mM) 
ii) Dithiothreitol (40mM) 
iii) lodo-acetamide (O·665M) 
Table 2.5.1 Running gel concentrations 
2.5.2 Method 
a) Non-reduced sample preparation 
b) Reduced sample preparation 
c) Calibration standard preparation 
d) Gel preparation 
e) Sample application 
f) Gel drying 
2.6 Biotinylation of purified IqM 
2.6.1 Reagents 
a) Sodium hydrogen carbonate buffer 
b) Biotin solution 
2.6.2 Method 
2.7 Immunoprecipitation 
2.7.1 Lactoperoxidase catalysed cell surface iodination 
a) Reagents 
b) Method 
2.7.2 Preparation of solubilized antigen 
a) Reagents 
b) Method 
2.7.3 Immunoprecipitation 
a) Reagents 
b) Method 
2.7.4 Autoradiography 
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2.1 Microlyaphocytotoxicity •••• y. 
2.1.1 aeagept. apd buffer. 
a) Physiological saline: 
9·0g of sodium chloride (NaCl, Sigma Chemical Company Ltd, Poole, Dorset) 
was dissolved in 1 litre of deionised water (dH20). 
b) Dulbecco A and B solution (PBS-DAB), 
10 phosphate buffered saline (PBS) tablet. (Dulbecco A, Oxoid Ltd, 
Basingstoke) were dissolved in 1 litre of dH20 followed by the addition of 
one vial (Sml) of mineral salts (Dulbecco B, Oxoid). The .olution waf 
passed through a grade 1 filter paper (Whatman Labsales Ltd, Maidstone, 
Kent) before use. 
c) Neuraminidase treated sheep red blood cells (N-SRBC), 
10ml of sheep blood in Alsever'. solution, (Becton Dickin.on UK Ltd, 
Oxford) was washed 3 times in PBS-DAB by centrifugation for 5 minute •• t 
'OOG. On each occaaion the white blood cell buffy coat wa. removed from the 
red cell aurface. 0'6ml of packed sheep red blood cell. were re.u.pended 
in lOml of PBS-DAB, with the addition of 300~l of neuraminida.e (Type V, 
Sigma), at a concentration of 1 unit/ml in PBS-DAB, (.tored in aliquot. at 
-80°C). Red cell. were incubated at 37°C for 30 minutes, washed x3 in PBS-
DAB and finally resuspended in SOml of PBS-DAB. Neuraminidase treated .heep 
red blood cells were stored at 4°C for up to one week before u.e. 
d) polybrene 5' wIve 
A stock solution of 5' polybrene (Sigma) w •• prepared by di •• olving 5'09 
in 100ml of dH20. This was di.pen.ed into 20ml univer.al container. 
(Sterilin Ltd, Hounalow, Middlesex) and .tored at 4°C. For u.e, the .tock 
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solution of polybrene was diluted 1/30 (100~1 in 3ml) with PBS-DAB and used 
immediately. 
e) Gidion Goldstein lysis buffer IGLB): 
8·29g of ammonium chloride (NH,Cl, Sigma) , 37mg of EDTA 
(ethylenediaminetetraacetic acid, disodium salt, Sigma) and 19 of potassium 
hydrogen carbonate (KHC03 , Sigma) were dissolved in 1 litre of dH20. The 
pH of the solution was adjusted to 7·3 with the addition of 1M NaOH added 
drop-wise with continuous mixing. The pH of the lysis buffer is not stable 
when open to air, therefore 20ml volumes were dispensed into universal 
tubes (Sterilin) and the lids sealed. 
f) Rabbit complement: 
Fresh rabbit serum was used as a source of complement for cytotoxicity 
tests. This was prepared as a routine procedure in the Tissue Typing 
Laboratory. Ten litres of fresh rabbit blood (obtained from a local farm) 
was allowed to clot at 4°C overnight. The serum was poured from the clotted 
blood and residual cells were removed following centrifugation in 1 litre 
volumes at 2000G for 10 minutes (Beckman 6L, Beckman Instruments Ltd) at 
4°C. The rabbit serum was stored on ice and dispensed in 2·Sml and Sml 
volumes. The aliquots were frozen and stored at -SooC. For use, aliquots 
were thawed and used immediately. 
g) Eosin staining solution: 
A 5·0% w/v solution of eosin was prepared by dissolving 25·09 of eosin Y 
(Sigma) in a final volume of SOOml dH20. The solution was then filtered 
through a grade 1 filter paper (Whatman). 
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h) FOrmal-saline fixative: 
200ml of 40% w/v formaldehyde (BOH, Atherstone) wa. mixed with 300ml of 
saline. A few drops of 5% phenol red (Sigma) in dH20 wa. added a. a pH 
indicator. 
i) Oithiothreitol (OTT) O·OlM: 
lS·4mg of OTT (molecular weight 154·2, Sigma) was dis.olved in 10ml of PBS-
DAB. The stock solution of OTT was dispen.ed in 300~1 aliquots and stored 
at -SooC and used immediately after thawing. 
j) Cystine 20mM: 
A stock solution (xlO concentrated) of L-cystine (molecular weight 240·8, 
Sigma) was prepared by dissolving 48mg in 10ml of dH20 and stored at 4°C 
until use. The cystine is not completely soluble at this concentration and 
should therefore be mixed before use. 
k) Sodium bydroxide 1·0M: 
MaOH (Sigma), Molecular weight 40·0. 
4·0g of MaOH was dissolved in 100ml dH20. 
2.1.2 Cell Separation Method. 
a) Preparation of peripheral blood lymphocytes: 
Peripheral blood lymphocytes (PBL) ware separated from anticoagulated 
(heparin or trisodium citrate) blood by den.ity gradient centrifugation. 
Blood was diluted with an equal volume of PBS-DAB and 7ml volumes were 
underlayed with 3ml of lymphocyte separation .... dium (Mycomed UK Ltd, 
Birmingham) in 10ml tubes (16x10Omm, L.I.P. Ltd, Shipley, We.t Yorkshire). 
The samples were centrifuged at 700G for 20 minutes, the mononuclear cells 
53 
at the interface were aspirated using a Pasteur pipette and transferred to 
a 10m1 tube. The lymphocyte suspensions were diluted with an equal volume 
of PBS-DAB and centrifuged for seven minutes at 5000. Platelets were 
removed by differential centrifugation with three washes in PBS-DAB for 
five minute. at 3500. PBL's were stored at a concentration of 2-3x10' in 
Terasaki Park medium (Gibco, Paisley) at 4°C. 
b) Preparation of lymph node and spleen lymphocytes: 
Lymphocytes from cadaver organ donor lymph node and .pleen were purified 
by repeatedly perfusing the tissue with 20ml volumes of Terasaki Park 
medium (Gibco) using a 20ml syringe and 19 gauge needle (Konoject). 
Polymorphonuclear neutrophils were removed from spleen cells by the 
addition of a microspatular of carbonyl iron (Sigma) and incubating for 20 
minutes at 37°C with periodic mixing. Phagocytes which had ingested the 
iron and any remaining free iron particle. were then separated by placing 
a magnet on the side of the tube and pouring the free cell suspension into 
a new tube. Red cells were removed by density gradient centrifugation as 
above. 
c) separation of T and B lymphocytes: 
T and B cells were separated using N-SRBC rosetting. Lymphocytes were 
suspended at 2-6xlO' cells/ml and 5m1 volumes were transferred to 50.1 
round bottom tubes (Philip Harris Scientific, London). An equal volume of 
N-SRBC's and 100~1 of freshly diluted polybrene was added. The tubes were 
centrifuged at 100G for 5 minutes, and the cell. resuspended by gently 
rotating the tubes at an angle, allowing the meniscus to pass though the 
cell pellet. The suspensions were gently transferred to 10ml tubes and 
underlayed with lymphocyte separation medium and centrifuged at 5000 for 
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15 minutes. B cells were aspirated from the interface and transferred to 
4ml tubes (LP4, Luckham Ltd, Burgess Hill), diluted with an equal volume 
of Terasaki Park medium and centrifuged. The T cell/N-SRBC rosette pellets 
and the T cell depleted (B cell enriched) fractions were resuspended in 2ml 
of GLB for 5 minutes, to lyse the red cells by hypotonic shock. Equal 
volumes of medium were added and the tubes centrifuged. The cell pellets 
were resuspended and counted under a haamocytometer using a phase contrast 
microscope (Leitz, Luton). The lymphocyte concentrations were adjusted to 
2-3xl0'/ml in Terasaki Park medium. 
d) Removal of monocytes from B cells: 
Where necessary monocytes were removed from B cells by adherence of 
monocytes to plastic. The B cell enriched suspensions, in 2ml volumes, ware 
transferred to 60mm petri dishes (Falcon Plastics, Becton Dickinson UK Ltd, 
Oxford) and incubated at 37°C for 30 minutes. Non-adherent B lymphocytes 
were removed from the plastic by gently washing the surface with two 
volumes of 2ml of medium using a Pasteur pipette, and transferred into 4ml 
tubes. B cells were then examined under a haemocytomater and suspended at 
a concentration of 2-3xl0'/ml. 
Routinely T and B cell purity was >90\ as assessed by an anti-HLA-clas. II 
MAb in a cytotoxicity assay. Lymphocytes from patient. with CLL were 
selected to have >90\ B cell purity without the need to purify the 
lymphocytes further. 
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2.1.3 Cytotoxicity ••• ay. 
a) Cytotoxic inhibition asslY to define the antibody specificity: 
The monoclonal antibodies selected for cytotoxicity inhibition .tudie. were 
PA2.6 (mouse monomorphic IgG HLA class II Prof A.McMichael, I.M.M., 
Oxford), NDS-22 (mouse monomorphic IgG HLA-DR; Fuggle, N.D.S., Oxford) and 
LEU-10 (mouse IgG HLA-DQ; Becton Dickinson). Donor T and B cell. were 
suspended at a concentration of 3x10'/ml in Terasaki Park medium (Gibco) 
and divided into three and seven aliquots respectively. One aliquot of T 
and B cells remained untreated to act as a control, whilst the remainder 
were centrifuged, the supernatants removed and cells resuspended in 
equivalent volumes of appropriate monoclonal antibody at saturating 
concentration. Two aliquots of T and B cells were resuspended with PA2.6, 
two aliquots of B cells with NDS-22 and two with LBU-10. Following 
incubation at 4°C for one hour, one aliquot of each pair was washed in 
medium and resuspended with a non-cytotoxic affinity purified F(ab')2 
fragment of goat anti-mouse IgG light and heavy chain (Northeast Biomedical 
Laboratories, Uxbridge) at a predetermined dilution (batch dependant 
variation of 1/100 to 1/200). After a final incubation at 4°C for one hour, 
these aliquots were washed and the cell. resuspended in an equivalent 
volume of cold medium. 
Treated and untreated donor cells were then crossmatched against the 
recipient sera in the microcytotoxicity assay. To each serum dilution, 1ul 
volumes of untreated cells, cells incubated with the appropriate NAb alone 
or cells treated with both the MAb and the F(ab')2 goat anti-mouse antibody 
were added. All tests were carried out in duplicate. In addition each 
aliquot of cells was tested with an appropriate anti-HLA-ABC, DR or DO 
serum, to confirm locus specific inhibition of cytotoxicity. With one 
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exception locus specific inhibition was demonstrated for all the 
serologically defined HLA-ABC, DR and DQ antigens tested. The exception was 
that LEU-10 does not bind to HLA-DQw2 and does not inhibit alloantisera 
with specificity for this antigen. A reduction of cytotoxicity by at least 
one doubling dilution was interpreted as a positive result. 
b) Microlymphocytotoxicity assay: 
The cytotoxicity tests were carried out using the standard NIH 
microlymphocytotoxicity test with an extended two hour post complement 
incubation (Terasaki PI, 1980). One microlitre volumes of tis.ue culture 
supernatant or sera were dispensed in duplicate, at doubling dilutions into 
a 60 well microtest tray (HLA S plate, Gibco), under liquid paraffin oil 
(BDH, Atherstone). To these, 1~1 volumes of cell suspension at 2xlO'/ml 
were added. The trays were incubated at 22°C for 30 minutes followed by the 
addition of 5~1 of rabbit complement and a further 2 hour incubation at 
22°C. Viability was assessed after staining and fixation, with the addition 
of 3~1 of eosin followed by 3~1 of formalin. Wells were covered with a 3x2" 
coverslip (A.R.Horwell, London) and examined using an inverted phase 
contrast microscope (Diavert, Leitz, Luton). A positive result was 
interpreted as at least 20% cell lysis above background in duplicate wells. 
c) Immunoglobulin class determination (DTT reduction), 
The antibody class was determined using DTT reduction of IgM in the 
cytotoxicity assay. l~l volumes of tissue culture supernatant or test serum 
were dispensed across six wells of a microtest tray under liquid paraffin 
oil. Two wells remained untreated as normal controls, two wells were 
inoculated with l~l of 10mM DTT in PBS-DAB, and two wells received l~l of 
PBS-DAB as diluent controls. The trays were incubated at 37°C for 30 
57 
minutes. Cells were tested in an extended microcytotoxicity test, with the 
addition of lOO~l/ml of 20mM cystine to the rabbit complement, giving a 
final concentration of 2.0mM cystine. A negative cytotoxicity reaction with 
neat serum or supernatant after OTT reduction was considered to indicate 
19M antibody only, whereas a positive reaction despite OTT treatment 
indicated an 19G antibody. A cytotoxic 19G monoclonal antibody and an 19M 
control was included for each test to confirm specific DTT reduction of 19M 
antibodies. 
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2.2 ~i •• ue Culture Technique. 
2.2.1 strategy a 
The strategy for the production of a human monoclonal lymphocytotoxic 
autoantibodies is shown in Figures 2.2.1 and 2.2.2. Initially, renal 
dialysis patients with lymphocytotoxic autoantibodies were identified. 
Lymphocytes from these patients were immortalised with Epstein Barr viru. 
(EBV), and lymphocytotoxic autoantibody producing B-LCL's were identified 
by cytotoxicity screening of tissue culture supernatants. These were fused 
with the mouse fusion partner X63-Ag8.653 (a non-secreting HAT sensitive 
mouse myeloma cell line) to produce a mouse/human heterohybridoma (Fig 
2.2.2). Lymphocytotoxic autoantibody producing clones were isolated and 
tissue culture supernatants were harvested for autoantibody and/or antigen 
characterization. 
Fig 2.2.1 In Vitro Productiop of a Mogoclopal Rumap 
Lymphocytotoxic Autoantibody 
Identify lymphocytotoxic autoantibody positive dialysis patient 
I 
Immortalise antibody producinq cells by EBV 
transformation (establish B-LCL) 
I 
Screen 
(cytotoxicity) 
I 
Select and expand autoantibody positive B-LeL's 
I I 
Expand polyclonal B-LCL 
(harvest supernatants) 
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Fig 2.2.2 Production of aqu •• /huaap h.t'rohybrido .. 
Antibody producing B-LCL 
(HAT resistant, 
Ouabain sensitive) 
(PEG 
(HAT and 
Plate out 
X63-Ag8.653 mouse fusion 
partner, (HAT sensitive 
Ouabain resistant) 
DMSO) 
Ouabain selection) 
I 
Screen 
(identify human autoantibody positive wells) 
I 
Clone 
I 
Select high affinity lymphocytotoxic 
monoclonal autoantibodies 
All the following procedures were carried out using as.ptic t.chnique, 
performed in a class II tissue culture cabinet (MHO Microflow Pathfind.r). 
2.2.2 Reagent. 
a) Growth medium: 
RPMI 1640 supplemented with 10\ heat inactivated foetal calf •• rum (81-
FCS, treated at 56°C for 20 minutes), 2mM L-Glutamine and 100 unit'/ml of 
Penicillin and streptomycin (Gibco). 
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b) 2x Concentrated selection medium: 
2ml of x100 concentrated HAT medium (0·08g hypoxanthine, 0·012g thymidine, 
0·3g glycine, 0·002g aminopterin in 100ml of PBS-DAB) was added to 100ml 
of growth medium supplemented with 2ml of O·lmM ouabain (Sigma, 7·29mg in 
100ml PBS-DAB), giving 2x concentrated HAT and ouabain. 
C) Fusion medium: 
5ml of polyethylene glycol (PEG 4000, autoclaved for 15 minutes at 15 PSI, 
Merck) was mixed with 5ml of 2x concentrated RPMI 1640 supplemented with 
10\ Dimethyl Sulfoxide (DMSO, Sigma), 4·0mM L-Glutamine and 200 units/ml 
Penicillin and Streptomycin. 
d) Mouse spleen feeder cells: 
Freshly killed Balb-C mice, between 8 and 13 weeks old, were immersed in 
70\ alcohol for 1 minute, transferred to sterile 10cm petri dishes 
(Sterilin), and excess alcohol removed with sterile gauze swabs. To a 
second petri dish, 10ml of growth medium was added, ready to receive the 
spleen. An incision was made along the mid line of the abdomen, through the 
skin without penetrating the muscle layer. The skin was then parted and a 
second incision made through the muscle layer entering the abdomen, cutting 
up to the chest. The abdomen waa opened and the spleen located (under rib 
cage on right aide), removed (taking care not to rupture the gut wall), and 
transferred to the second petri dish. 
The apleen waa transversely disaected, each half was held at the tail, and 
using curved forceps the apleen cella were teased out by gently stroking 
towards the open end. Clumps of cells were diaperaed by passage through a 
fine needle (21 gauge) and transferred to l5ml conical tubes (Falcon 
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plastics, Becton Dickinson) and washed twice in medium. The cell pellets 
were resuspended in 10ml of growth medium and the white cell population 
counted. The cells were irradiated with 2000 rads (500 rads/minute for 4 
minutes, Gammacell 1000, Atomic Energy of Canada Ltd), centrifuged and 
resuspended at a concentration of 3xlO' white cells/ml in growth medium. 
Mouse spleen feeder cells were kept at 37°C for up to one week before use. 
The white cell yields were between 0'6xlO' and 1.OxlO' per spleen. 
2.2.3 Methods 
a) Generation of EBV transformed lymphoblastoid cell lines: 
Peripheral blood lymphocytes were prepared from 20ml of heparinized blood 
by density gradient centrifugation as above. 
PBL's were counted and then centrifuged in a 15ml conical tube. The 
lymphocyte pellet was resuspended in Iml of tissue culture supernatant 
containing EBV (derived from EBV secreting marmoset cell line B95-8), and 
incubated for one hour at 37°C. The volume was made up to give a final 
concentration of lxlO' cellslml using growth medium supplemented with 
phytohaemagglutinin (PHA, HA-15, Wellcome Diagnostics, Dartford, 
reconstituted with 5ml dH20) at a dilution of 1/200. 1ml volumes of cell 
suspension were dispensed into the wells of a 24 well tissue culture tray 
(Nunc, Gibco). The trays were placed in a 37°C incubator with a humidified, 
5' CO2 atmosphere. The B-LCL's were fed after five days, then as necessary 
thereafter, replacing half the volume with fresh growth medium. When the 
cells reached >75' confluence they were transferred to 50ml and 
subsequently 250ml flasks and maintained at a concentration of 5xl05 to 
lxlO'/ml. 
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b) Production of heterohybridoma: 
Fusion of the B-LCL with the mouse myeloma cell line X63-Ag8.653 (a kind 
gift from K.M.Thompson, MRC Unit, Cambridge) was carried out according to 
the method of Thompson (Thompson et al, 1986). Heterohybridoma selection 
was carried out in Hypoxanthine, Aminopterin, Thymidine (HAT) and OUabain. 
Both cell populations were subcultured for two consecutive days prior to 
fusion to obtain logarithmic growth. Equal numbers (lx107) of X63-Ag8.6S3 
and B-LCL were pooled and centrifuged in a SOml tube (Falcon). The cell 
pellet was loosened by gentle flicking and 1ml of fusion medium at 37°C was 
added drop-wi.e over a 60 second period with continuous agitation. The 
cells were placed in a 37°C waterbath for 90 seconds followed by the 
addition of 10ml of RPMI 1640 containing 2SroM HEPES (Gibco) at 37°C, also 
added drop-wise over a 90 second period with continuous agitation. The 
suspension was then centrifuged at 340G for 5 minutes at 22°C and the cell 
pellet resuspended in 62ml of growth medium containing 1x10'/ml irradiated 
mouse spleen feeder cells, to give a final concentration of l'Sx105 of 
fused cells/ml. 1ml volumes were dispensed into the wells of 24 well trays 
(Nunc) which were incubated as above. After 24 hours, 1ml of 2x 
concentrated selection medium wa. added to each well. Cells were maintained 
in selection medium for two weeks post fusion, after which growth medium 
was used. 
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c) Cloning of heterohybridoma: 
i) Clone picking: Macroscopically vi.ible cell clu.ter. were 
identified by viewing the trays next to a bright light sourc. and their 
positions indicated by marking the underside of the trays with a marker 
pen. Individual clusters were carefully drawn up using a long form Pasteur 
pipette and transferred to individual well. of a 96 well tray. 50~1 of lx 
concentrated selection medium was added and after a 24 hour incubation 
lOO~l of growth medium containing 3xl05 irradiated mou.. spleen feed.r 
cells was added. Picked clones were expanded into 24 well trays and 
subsequently into 50ml flasks. 
ii) Limiting dilution: Hybridoma cell. were cloned at a concentration 
of one cell per well in lOO~l volumes of growth medium into flat bottomed 
96 well tissue culture trays (NunC), containing 3x105 irradiated mou •• 
spleen feeder cells. The trays were incubated as above for .even day., 
after which cells were fed initially with growth medium containing 3x10'/ml 
irradiated mouse spleen feeder cells, and .ubsequently with growth medium 
alone. When the hybridoma cells reached >75' confluence they were 
transferred into 24 well tray. (Nunc) and .ub •• quently into 5Cml and 250ml 
tissue culture flasks (Nunc). Hybridoma cell. were maintained at a 
concentration of between 1xl05 and lxlO'/ml. 
d) Preparation of cell lines for cytotoxicity assays: 
Cell lines were suspended at 5x105/ml in 250ml tis.u. culture fla.k. 
(Falcon, Secton Dickinson, Oxford) in growth medium and incubated a. abov., 
being fed for two consecutive days before u •• , to obtain logarithmic growth 
phase. Cells were centrifuged, resuspended in 10ml of Tera.aki Park medium 
and layered onto 4ml of lymphocyte separation medium in 15ml conical tube. 
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(Falcon) and centrifuged for 15 minutes at SOOG. B-LeL's were aspirated 
from the interface and waBhed in Terasaki Park medium, then resuspended at 
a concentration of 1-2x10'/ml for cytotoxicity screening. 
e) ABBessment of growth characteristics of heterohybridoma clones 
Hybridoma cell lines (in growth phase) were counted, centrifuged and 
resuspended in fresh growth medium at a concentration of 5xlO'/ml. Bach 
cell line was then dispenBed in triplicate, in 1ml volumes, into 24 well 
culture trays (Nunc). A small aliquot (20~l) of each cell population was 
removed daily for five consecutive days and the number of viable cells was 
assessed by counting (in duplicate) on a haamocytometer, using a phase 
contrast microscope. A growth curve was then plotted for each cell line. 
To aBBeSB the antibody production relative to cell growth, supernatants 
from the triplicate Bamples were pooled and screened in duplicate, at 
doubling dilutions in the cytotoxicity assay. 
f) DNA content analysis of heterohybridomasl 
To confirm that the cell lines generated represented stable 
heterohybridomas and not out-growth of surviving parent cell line., the DNA 
content of the parent cell lines (X63-Ag8. 653 and B-LCL) and 
heterohybridomas were measured. 
Reagents 
i) Alcohol fixative: 
70mls of ethanol (BDH) was mixed with 30ml dH20. 
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ii) RNAse enzyme solution: 
A 10\ RNAse (Sigma) stock solution was prepared by dissolving 100mg in 1ml 
of Terasaki Park medium and stored at -BODC. This was diluted 1/10 (0·5ml 
+ 4·5ml) with medium before use. 
iii) Staining solution: 
2·5mg of propidium iodide (Sigma) was dis.olved in lOml of Terasaki Park 
medium. 
Method 
Cell lines were prepared as for the cytotoxicity method and re.uspended at 
2x10'/ml in Terasaki Park medium. Duplicate 250~1 aliquots of each cell 
population were centrifuged, the pellets resuspended in ice cold alcohol 
fixative, and incubated for 15 minutes. The samples were then washed three 
times in 4ml volumes of Terasaki Park medium, by centrifuging at 4000 for 
5 minutes and resuspended in 200~1 of medium. To this, 200~1 of 1\ RNAs. 
solution and 100~1 of staining solution was added, and the cells incubated 
at 37°C for 20 minute.. DNA content was then analyzed on an Ortho 
Cytofluorograph. 
g) Determination of monoclonal antibody claaal 
Single radial immunodiffuaion was used to define the immunoglobulin cla •• 
and light chain isotype of the monoclonal antibodies. Well. of 'low level' 
anti-human IgO, IgM, kappa and lambda light chain single radial 
immunodiffusion platea (LC-Partigen, Hoechst UK Ltd, Houn.low, Kiddle.ex) 
were inoculated with 20~l (for 19O and IgM) and S~l (for kappa and lambda) 
of tiasue culture supernatant or control .era at the appropriate dilutions. 
Por quantitative evaluation of IgM levela, dilutions of protein .tandard 
66 
serum (LC-A, human) in PBS-DAB was used. For the measurement of IgG levels, 
protein standard serum (LC-V, human) was used, and for kappa and lambda 
light chain determination standard human serum (Hoechst) was used. The 
dilutions of protein standards used were batch dependant and are 9iven in 
the results. Trays were placed in a moist chamber at 22°C for 72 hours. 
Precipitation bands were intensified by the addition of lOml of O·lM DL-
DOPA (Sigma) in PBS-DAB for 24 hours and differentiated with multiple 
washes of dH20, after which the ring diameters were measured with an 
accuracy of O·Olmm using a micrometer. Quantitative immunoglobulin levels 
were determined from a standard curve, after plotting the square of the 
ring diameter (mm2 , Y axis) against the standard protein concentration 
(~g/ml, X axis). For the kappa and lambda light chain determination it was 
necessary to concentrate the supernatants xS in a 815 Minicon ultra 
filtration concentrator (Amicon Ltd, Stonehouse, Gloucestershire). 
h) Mixed lymphocyte reaction (MLR) inhibition: 
PBL'. were prepared from defibrinated blood as above with the omission of 
platelet washes. Lymphocytes were suspended in 10ml of RPMI with 2SmM HEPBS 
(Gibco) in conical lSml tubes (Falcon) and counted on a haemocytometer. 
Bach sample was then divided into two 5ml aliquots and lymphocytes counted 
a second time. The tubes were centrifuged at 3400 for 5 minutes and the 
lymphocytes resuspended at lxlO'/ml (calculated from the mean of the two 
cell counts) in growth medium supplemented with 15' heat inactivated human 
serum (pooled from 5 blood group A8 untransfu.ed male.) in place of the 10' 
HI-FCS. One tube of each pair was irradiated with 2000 rads (500 rad. per 
minute for 4 minute. on a Gammacell 1000) to u.e a •• t~ulators, whilst the 
second tube of each pair remained untreated, a. a re.ponder cell 
population. Cells were dispensed in SO~l volumes, in quadruplicate., into 
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U bottomed 96 well trays (Sterilin), using a format testing all responder 
and stimulator combinations thr.e tim.s. To the first set of trays 10~1 
PBS-DAB was added, to the second and third set of trays, 10~1 of purified 
IgM at l·Omg/ml from two autoantibody clones (F15-DD5-26 and F36-CBIO-18) 
in PBS-DAB was added. 
Th. trays were incubated for five days at 37°C in a humidified 5' CO2 
atmosphere, then each well was inoculated with l~l of tritiated thymidine 
(methyle 3H, ImCi/ml, NEN, Du-Pont, Luton, Bedfordshire). The trays were 
incubated for a further 18 hours, after which DNA was harvested onto glass 
fibre filter disks (Whatman), following cell lysis with dH20, using a cell 
harvester (Skatron, Norway). The disks were air dried and transferred into 
5ml scintillation vials (Sterilin), and 2ml of scintillation fluid 
(EcOnofluor-2, NEN) was added. Counts per minute (CPM) were measured on an 
LKB Rackbeta 1280 B counter (Pharmacia-LKB, Milton Keynes). Mean and median 
values of the quadruplicate CPK were calculated, and responses of each 
group with MAD treatment were compared to that of the control •• 
2.3 Binding A.says 
a) Cytotoxicity binding assay to select higher affinity clone.: 
To identify strong binding (higher affinity) antibodies, a .ingle and 
double wash step was introduced in the cytotoxicity te.t, between 
incubation with MAD and the addition of complement. Purified T and B 
lymphocytes at a concentration of 2-3xlO'/ml were divided into 250~l 
aliquots. Tubes were centrifuged and the cell pellet. re.u.pended in an 
equivalent volume of the appropriate MAD at dilution. of 1/2 or 1/10. Tube. 
were incubated at 22°C for 30 minutes and a .mall aliquot (50~l) wa. 
removed from each sample and stored at 22°C (no wa.he.). The remaining 
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cells were diluted with 4ml of Terasaki Park medium and centrifuged. The 
cell pellets were resuspended in 200~1 of medium and a further SO~l aliquot 
was removed (one wash). Cells were washed a second time aa above, and the 
cell pellets resuspended in lS0~1 of medium (two washes). 
The above cell aliquots (having undergone no washes, one wash and two 
washes after antibody treatment) were then tested in a cytotoxicity assay. 
Duplicate volumes (1~1) of each cell suspension were added to the wells of 
a microtest tray (Nunc), under liquid paraffin oil (BDH), and 5~1 of rabbit 
complement was added. The trays were incubated for two hours at 22°C 
followed by staining with eosin and fixation with formalin. Viability was 
assessed as for the cytotoxicity test. 
b) Fluorescence binding assay: 
Reagents 
Fixation buffer: 
A solution of 0·5% bovine serum albumin (BSA) and 1·5% formalin in PBS-
DAB was prepared by dissolving O·Sg BSA (Sigma) in 10ml of PBS-DAB. This 
was mixed with SS·Sml of PBS-DAB and 1·5ml of 40\ w/v formaldehyde (BDH). 
Method 
Separated T and B lymphocytes were suspended at 2xl0'/ml in Tera.aki Park 
medium and divided into 100~1 duplicate aliquot. in LP4 tube. (Luckham Ltd, 
Burgess Hill). One pair of each cell population remained •• an untreated 
control, whilst the other aliquots were centrifuged, the supernatants 
removed and cells resuspended in 100~1 of NAb supernatant at the 
appropriate dilution in Terasaki Park medium. All aliquot. were incubated 
on ice for 1 hour, washed once in 4ml volumes of cold PBS-DAB and 
69 
subsequently resuspended in 100/oJl of F1TC conjugated second layer antibody. 
F1TC-goat-anti-human 19M (Incstar Ltd, Winnersh, Berkshire), /oJ chain 
specific, at a predetermined dilution (1/50 in Terasaki Park medium) was 
used for human IgMMAbs. FITC-goat-anti-mouse IgG (Sigma, diluted 1/20 with 
Terasaki Park medium supplemented with 25' heat inactivated pooled human 
blood group AB serum), was used for mouse IgG MAbs. Tubes were incubated 
on ice for a second 1 hour period, washed once in cold PBS-DAB, and the 
cell pellets resuspended in 100/oJl of fixation buffer. Fixed sample. were 
stored in the dark at 4°C for up to one month before fluore.cence profile. 
were assesBed on a FAScan (logarithmic profiles) or an Ortho 
Cytofluorograph (linear profiles) (Becton Dickinson). 
c) Enzyme cleavage of lymphocyte cell surface molecules: 
Purified T and B lymphocytes were treated with a serie. of enzymes to 
remove antigenB from their cell surface, in order to identify the 
biochemical nature of the molecule(s) to which the autoantibodies bind. 
i) Enzyme preparation: 
1. Neuraminidase (Sigma), type V from Clostridium perfringens. 
Ten units of neuraminidase were dissolved in 10ml of PBS-DAB to give a 
concentration of 1 unit/ml and stored at -30°C. 
2. Papain (P4762, Sigma). 
Papain was dissolved in PBS-DAB to give a concentration of 4mg/ml 
(saturating concentration, not completely soluble). To this an equal volume 
of L-cysteine (free base, Sigma) at 4mg/ml in PBS-DAB was added, giving a 
final concentration of 2mg/ml of papain and cysteine. This wa •• tored at -
30°C until use. 
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l. Peptidase (Sigma). 
Peptidase was dissolved in PBS-DAB to give a concentration of 2mg/ml and 
stored in at -lOoC until use. 
4. Trypsin (Sigma), type XIII from bovine pancreas. 
A stock solution of trypsin was prepared by dissolving 100mg in Sml of PBS-
DAB to give a concentration of 20mg/ml. This .tock solution was stored at -
SOoC. For use the stock solution was diluted l/S in PBS-DAB to give a final 
concentration of 2·Smg/ml (30,000 units/ml). 
5. Lipase (Sigma), type I from wheat germ. 
Lipase was dissolved at a concentration of 2mg/ml in PBS-DAB (lS·S 
units/ml) and stored at -lOoC. 
6. a-Amylase (Sigma), type I-A from porcine pancreas. 
2Smg of amylase was made up to 4ml in PBS-DAB to give a concentration of 
6·2Smg/ml and stored at -lOoC. For use, this was diluted 1/l·1 to give a 
final concentration of 2mg/ml. 
Method 
Aliquots ( 1· Sml ) of separated T and B lymphocytes were suspended at a 
concentration of 2xl0'/ml in Terasaki Park medium. Cells were centrifuged 
and cell pellets resuspended in an equivalent volume of the appropriate 
enzyme, or PBS-DAB as a negative control, and incubated for 1 hour at l7·C. 
Enzyme treated cells were washed twice in PBS-DAB at 4·C, the pellets 
resuspended in cold FCS and incubated for 20 minutes on ice. The cells were 
washed in PBS-DAB at 4°C, resuspended in the original volume of cold 
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Terasaki Park medium and kept on ice. Cells were dispensed in 100,.,1 
a1iquots and analyzed for antibody binding properties in a fluorescence 
binding assay. 
d) Autoantibody binding inhibition assaysa 
Lymphocytes, at a concentration of 2x10' /m1 were divided into 1· Sml 
aliquots in LP4 tubes (Luckham Ltd). Cells were centrifuged and the pellets 
resuspended in 1·5ml volumes of blocking agent. The inhibition agents used 
were; PBS-DAB (negative control); human IgG (Sigma) O·Smg/ml in PBS-DAB; 
human IgM (Dako) 0·Smg/m1 in PBS-DAB; lipid A (Sigma) 0·2mg/m1 in PBS-
DAB; or phosphatidy1cho1ine (ptC, Sigma) prepared by warming PtC to 37·C 
and adding 1·0g to 10m1 of pre-warmed PBS-DAB and vortexing to an emulsion. 
Cells, suspended in the appropriate inhibition t.st reagents were dispensed 
in 100,.,1 volumes in LP4 tubes. Autoantibody binding inhibition was analyzed 
in a fluorescence binding assay as above. 
e) Biotin/rITC-avidin binding assay: 
Biotin-avidin binding assays were performed a. above using directly 
biotiny1ated primary KAbs, with the addition of 50111 of rITC-avidin (Sigma) 
at a predetermined dilution (1/20 in Terasaki Park medium), a. the .econd 
layer reagent. 
To confirm successful biotiny1ation, without the loss of antibody binding 
activity, biotiny1ated antibodies also were tested by conventional 
cytotoxicity, and by binding assay using rITC-goat-anti-human IgM .econd 
layer antibody, as previously described. 
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f) Competitive inhibition binding assays 
i) Inhibition by autoreactive MAbss 
PBL at a concentration of 2xlO'ml were dispensed in 20 duplicate 100#Jl 
aliquots in LP4 tubes (Luckham Ltd). Tubes were centrifuged, and the cell 
pellets resuspended in 100#Jl volumes of the appropriate blocking agent 
according to the protocol (Table 2.3.1). Five pairs were suspended in PBS-
DAB; five pairs in F36-CB10-1S purified IgM (0·05mg/ml in PBS-DAB); five 
in F15-DD5-26 purified IgM (0·05mg/ml in PBS-DAB) and five in FOM-A (human 
IgM anti-RhD) neat supernatant (0·05mg/ml). Cell. were incubated for one 
hour on ice followed by the addition of 100#Jl of second antibody (F36-
CBlO-1S IgM biotinylated at 0·1mg/ml and 0·05mg/ml, or F15-DD5-26 IgM 
biotinylated at O·1mg/ml and 0·05mg/ml) (Table 2·3.1). Negative control 
samples remained in PBS-DAB. Following a further one hour incubation on 
ice, cells were centrifuged, washed twice in 4ml volumes of cold PBS-DAB 
and cell pellets resuspended in 50#Jl of FITC-avidin (Sigma), diluted 1/20 
with Terasaki Park medium. Cells were then washed twice, and cell pellet. 
fixed in 100#Jl volumes of fixation buffer. 
Inhibition result. were expressed as percent binding of the te.t re.ult 
(biotinylated KAb in the presence of inhibiting IgM) compared to the 
untreated control (PBS-DAB alone). 
MCF of test - MCF background 
, binding - x100 
Mcr of control (PBS-DAB) - Mcr background 
MCF -mean channel fluorescence 
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Table 2.3.1 
Protocol for cross inhibition of biotinylated MAbS 
Tube No. Inhibiting antibody 2nd incubation 
1 & 2 PBS-OAB -
3 & 4 PBS-OAB CB10-18 IgK biotin O.lmg/ml 
5 & 6 PBS-OAB CB10-18 IgK biotin 0.05mg/ml 
7 & 8 PBS-OAB 005-26 IgK biotin O.lmg/ml 
9 & 10 PBS-OAB 005-26 IgK biotin 0.05mg/ml 
11 & 12 CB10-18 IgK 0.05mg/ml -
13 & 14 CB10-18 IgK 0.05mg/ml CB10-18 IgK biotin O.lmg/ml 
15 & 16 CB10-18 IgK 0.05mg/ml CB10-18 IgK biotin 0.05mg/ml 
17 & 18 CB10-18 IgK 0.05mg/ml 005-26 IgK biotin O.lmg/ml 
19 & 20 CB10-18 IgK 0.05mg/ml 005-26 IgK biotin 0.05mg/ml 
21 & 22 005-26 IgK 0.05mg/ml -
23 & 24 OD5-26 IgK 0.05mg/ml CB10-18 IgK biotin O.lmg/ml 
25 & 26 D05-26 IgK 0.05mg/ml CB10-18 IgK biotin 0.05mg/ml 
27 & 28 OD5-26 IgK 0.05mg/ml 005-26 IgK biotin O.lmg/ml 
29 & 30 005-26 IgK 0.05mg/ml 00S-26 IgK biotin O.OSmg/ml 
31 & 32 FOK-A spnt neat -
33 & 34 FOK-A spnt neat CB10-18 IgK biotin O.lmg/ml 
35 & 36 FOK-A spnt neat CB10-18 IgK biotin 0.05mg/ml 
37 & 38 FOK-A spnt neat 005-26 IgK biotin O.lmg/ml 
39 & 40 FOK-A spnt neat 005-26 IgK biotin 0.05mg/ml 
ii) Inhibition of autoreactive monoclonal antibodie. by patient .erum and 
serum proteins: 
The ability of autoantibodies from renal dialy.is patient serum and other 
serum proteins, to inhibit monoclonal autoantibody binding was a.sessed 
using binding inhibition of biotinylated autoreactive HAb., te.ted again.t 
T and B cells according to the protocol in Tables 2.3.2 and 2.3.3. 
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Table 2.3.2 
Protocol for inhibition of biotinylated MAbS by patients' sera 
Tube No. Inhibiting antibody 2nd incubation 
1 & 2 PBS-OAB -
3 & 4 PBS-OAB CB10-18 IgM biotin O.lmg/ml 
5 & 6 PBS-OAB CB10-18 IgM biotin 0.05mg/ml 
7 & 8 PBS-OAB 005-26 IgM biotin O.lmg/ml 
9 & 10 PBS-OAB 005-26 19M biotin 0.05mg/ml 
11 & 12 AB serum -
13 & 14 AB serum CB10-18 19M biotin O.lmg/ml 
15 & 16 AB serum CB10-18 19M biotin 0.05mg/ml 
17 & 18 AB serum 005-26 19M biotin 0.1m9/ml 
19 & 20 AB serum 005-26 19M biotin 0.05mg/ml 
21 & 22 Patient serum (OV) -
23 & 24 Patient serum (OV) CB10-18 19M biotin 0. lm9/ml 
25 & 26 Patient serum (OV) CBI0-18 19M biotin 0. 05m9/ml 
27 & 28 Patient serum (OV) 005-26 IgM biotin 0. 1m9/ml 
29 & 30 Patient serum (OV) 005-26 19M biotin 0. 05m9/ml 
31 & 32 Patient serum (EW) -
33 & 34 Patient serum (EW) CB10-18 IgM biotin O.lmg/ml 
35 & 36 Patient serum (EW) CB10-18 19M biotin 0.05mg/ml 
37 & 38 Patient serum (EW) 005-26 IgM biotin 0. 1m9/ml 
39 & 40 Patient serum (EW) 005-26 19M biotin 0.05mg/ml 
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Table 2.3.3 
Protocol for inhibition of biotinvlated MAb' bv 
human .erum proteins 
Tube No. Inhibiting antibody 2nd incubation 
1 & 2 PBS-DAB -
3 & 4 PBS-DAB CB10-18 IgM biotin O.lmg/ml 
5 & 6 PBS-DAB CB10-18 IgM biotin 0.05mg/ml 
7 & 8 PBS-DAB DD5-26 IgM biotin O.lmg/ml 
9 & 10 PBS-DAB DD5-26 IgM biotin 0.05mg/ml 
11 & 12 Albumin 60mg/ml -
13 & 14 Albumin 60mg/ml CBlO-18 IgM biotin O.lmg/ml 
15 & 16 Albumin 60mg/ml CB10-18 IgM biotin 0.05mg/ml 
17 & 18 Albumin 60mg/ml DD5-26 IgM biotin O.lmg/ml 
19 & 20 Albumin 60mg/ml DD5-26 IgM biotin 0.05mg/ml 
21 & 22 Albumin 40mg/ml -
23 & 24 Albumin 40mg/ml CB10-18 IgM biotin O.lmg/ml 
25 & 26 Albumin 40mg/ml CB10-18 IgM biotin 0.05mg/ml 
27 & 28 Albumin 40mg/ml DD5-26 IgM biotin O.lmg/ml 
29 & 30 Albumin 40mg/ml DD5-26 IgM biotin 0.05mg/ml 
31 & 32 Human IgK 1. Omg/ml -
33 & 34 Human IgK 1.0mg/ml CB10-18 IgM biotin O.lmg/ml 
35 & 36 Human IgM 1.0mg/ml CB10-18 IgM biotin 0.05mg/ml 
37 & 38 Human IgK 1.0mg/ml DD5-26 IgM biotin O.lmg/ml 
39 & 40 Human IgK 1.0mg/ml DD5-26 IgM biotin 0.05mg/ml 
41 & 42 Human IgG 13mg/ml -
43 & 44 Human IgG 13mg/ml CB10-18 IgM biotin O.lmg/ml 
45 & 46 Human IgG 13mg/ml CB10-18 IgM biotin 0.05mg/ml 
47 & 48 Human IgG 13mg/ml DD5-26 IgM biotin O.lmg/ml 
49 & 50 Human IgG 13mg/ml DD5-26 IgM biotin 0.05mg/ml 
g) Lectin inhibition of autoantibodv binding: 
i) Using fluorescence binding a •• av: Purified T and B lymphocyte. at 
a concentration of 2x10'/ml were di.penaed in 1'5ml aliquot. into LP4 tube. 
(Luckham Ltd). Tubes were centrifuged and the cell pellets re.u.pended in 
the appropriate lectin (0'2mg/ml in PBS-DAB), and one aliquot in PBS-DAB 
aa an untreated control. Cella were incubated at 22°C for one hour and 
wa.hed twice in 4ml volume. of PBS-DAB. Cell pellet. were re.u.pended in 
1· Sml of Teraaaki Park medium (clump' were disper.ed on • vortex) .nd 
dispensed in 100~1 aliquot. into LP4 tube •• Duplicate .ample. were te.ted 
for inhibition of autoantibody binding in a fluore.cence binding •••• y •• 
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above. The lectins used in thia study are ahown in Table 2.3.4. 
Table 2.3.4 Lectin Blocking 
Lectin Specificity Blood Mitogen 
Group 
Triticum vulgaris Neu NAc, NAc-D-Glc A + 
Mycoplasma gallisepticum Glycophorin 0 
Ptilota plumosa a-D-gal B 
Sophora japonica 8-D-gal NAc A,B 
Vicia faba D-man, D-glc 0 + 
Ulex europaeus a-L-fuc 0 + 
Euronymus europaeus a-D-gal(1-3)-D-gal H,B + 
Concanavalin A a-D-man, a-D-glc A + 
Lens culinaris a-D-man A + 
Phaseolus vulgaris Oligosaccharide. A + 
Dolichos biflorus a-D-gal NAc Al 
Arachis hypogaea 8-D-gal(1-3)-D-gal NAc 0 + 
Helix pornatia D-gal NAc A 
ii) Red blood cell agglutination aa.ay: Sml volume. of hepariniz.d 
blood were dilute with equal volumes of PBS-DAB and c.ntrifuged at 600G 
for S minutes. The plasma and buffy coat. were removed and the red cell. 
waBhed twice, aa above. A 2' RBC au.penaion was prepar.d by diluting 1ml 
of packed RBC's with SOml of PBS-DAB. 
Serial dilutions of the MAbs (SO~l volume. diluted in PBS-DAB) w.r. 
prepared in duplicat. along the 12 row. of U bottomed 96 w.ll tray. (Nunc, 
Gibco), from neat to 1/2048 dilution. SO~l volume. of PBS-DAB were u •• d a. 
a negative control. Equal volumes of 2' RBC'. were added .nd the c.ll. 
incubated at 22°C for 1 hour, after which e.ch well was ••••••• d for RBC 
agglutination. Agglutination (positive) was a.en a. an even layer of RBC'. 
covering the bottom of the well. No agglutination (n.gativ.) was ••• n •• 
a central "Bpot" of RBC'B. 
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iii) Inhibition of lectin agglutination of RBC by autoantibodies: 
Lectins were diluted to a concentration of 50~g/ml with PBS-DAB (1/4 from 
stock solution), and SO~l volumes were added to serial dilutions of MAbs 
prepared as above, in 96 well U bottomed trays. Trays were incubated for 
1 hour at 22°C followed by the addition of 50~1 of 2\ RBO solution of the 
appropriate blood group. Trays were incubated for a further 1 hour at 22°C 
after which each well was examined for RBC agglutination as above. 
iv) Detection of autoantibody binding to lectin coated RaO by 
cytotoxicity: 50~1 volumes of 2\ RBC in PBS-DAB, were dispensed into 96 
well trays. Equal volumes of the appropriate lectins (O·OSmg/ml in PBS-
DAB) were added and the RBC's were allowed to agglutinate. Following an 
incubation of 1 hour at 22°C, 50~1 volumes of MAbs at the appropriate 
dilution were added to duplicate wells. MAbs, titred at doubling dilution 
in PBS-DAB from neat to 1/2048 were used with PBS-DAB as a negative 
control. The trays were incubated at 22°C for one hour followed by the 
addition of 100~1 of rabbit complement and a further incubation for 1 hour 
at 22°0. Positive cell lysis was assessed as no visible RBC's, whereas 
negative wells were seen as agglutinated RBC's. Additional controls with 
MAbs tested as above with the addition of 50~1 of PBS-DAB in place of the 
lectin were included. 
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h) Sialic acid inhibition of autoantibody binding: 
i) Cytofluorograph analysis; Sialic acid (N-Acetyl Neuramic acid 
(NANA) , Sigma, type IV) was dissolved in Terasaki Park medium at 
concentration of 25·0 and 12·5mg/ml. The pH waa measured and found to be 
4·0. For comparison as an untreated control, the pH of Terasaki Park medium 
was adjuated to pH4·0 by the addition of 2~1 of 2·5M HCl to 5ml of medium. 
The monoclonal antibodies at neat and 1/5 dilution (100~1 volumes) were 
mixed with an equal volume of sialic acid at 25·0 and 12·5mg/ml, giving MAb 
dilutions 1/2 and 1/10. Duplicate samples of each combination were tested 
against T and B cells for inhibition of autoantibody binding in a 
fluorescence binding assay as above. 
ii) Cytotoxicity; 1~1 volumes of aialic acid at the appropriate 
concentrations were added to 1~1 of MAbs at serial dilutions from neat to 
1/128 in the wells of a microtest tray. Following incubation for one hour 
at 22°C, l~l of T or B cells were added in a standard 
microlymphocytotoxicity test. As an untreated control, 1~1 of Terasaki Park 
medium at pH4·0 (aa above) and pH7·2 were added. Cytotoxicity titre. were 
compared to the untreated controls. 
I) Effect of pH on autoantibogy binding: 
Purified T lymphocytes at 2x105 cells per tube were tested in a 
fluorescence binding assay aa above, u.ing 100~1 volumes of F15-DDS-26 and 
F36-CB10-18 at doubling dilutions from 1/2 to 1/256, diluted in buffered 
saline at pH4·0 (18ml of 0·2M sodium acetate mixed with 82ml of O·2M acetic 
acid), pH7·2 (PBS-DAB) and pH9·6 (45m1 of 0·1M sodium carbonate mixed with 
55ml of 0·1M aodium bicarbonate). 
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2.4 Immunocheaical Techpique. 
2.4.1 strategy for batch purificatiop of IgM fro. ti •• ue culture 
,upematapt. 
Low concentrations of IgM (SOmg/l) were to be purified from large volume. 
of tissue culture supernatant. In the absence of preparative scale HPLC 
equipment, ion exchange chromatography u.ing Bakerbond ABx 40~m ion 
exchange resin was selected. The manufactures claimed batch purification 
of IgM could be achieved using a slurry technique, giving 80 to 9S' 
immunoglobulin yield and 97' purity. This method required no specialised 
equipment and as the ion exchange resin was reusable the technique waf 
relatively cheap. However, application of the technique required adaptation 
of the manufacturers original specifications and the addition of a gel 
filtration step to obtain acceptable IgM purity. 
2.4.2 Reagept,. 
a) 25mK (2[N-MQrpholinQlethane-sulphQnic acid (MES) pHSoS. 
MES (Sigma, Poole), free acid, molecular weight 195·9. 
A stock solution of O·lM MES was made by dissQlving 9 079Sg in SOOrnl Qf 
dH20. 
2SmM MES pHSoS was prepared by mixing 2S0ml Qf 001M .tQck MBS with 745ml 
of dH20. The sQlution waf adjusted tQ pHSoS by adding 1
00M NaOH drQP-wi.e 
with cQntinuQus mixing (apprQximately 3ml) and the final VQlume waf made 
up to 1 litre with dH20. The pH was checked and adju.ted apprQpriately 
immediately priQr tQ use. 
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b) 20mM sodium acetate in SOOmM ammonium sulphate. pH6·8: 
Sodium acetate (CH3COO Na, BDH Analar) molecular weight 82·03. Ammonium 
sulphate ([NH,J 2so" BDH Analar) molecular weight 132·1l. 
66·06g of (NH')2S0, was dissolved in glOml dH20. To this, 1·64g of CH3COO 
Na was added. The volume was adjusted to 1 litre with dH20. About 0·2ml of 
1·0M NaOH was added orop-wise with continuous stirring to give pH 6·8. 
c) 200mM Ammonium sulphate: 
ll·21lg of (NH')2S0, was dissolved in a final volume of SOOml dH20. 
d) 2SmM MES pH<4·0: 
100ml of O·lM stock MES was made up to 400ml with dH20 (pH-l·6). 
e) 10\ Sodium azide: 
Sodium azide (NaN3 , Sigma). 109 of sodium azide was dissolved in a final 
volume of 100ml of PBS-DAB. This was diluted 1/100 (0·1\ final 
concentration) for use. (Caution; extremely toxic). 
2.4.l Method. 
a) Preconditioning of Bakerbond hBx 40um ion exchange resin: 
The method was adapted for use from that described by the manufacturer •• 
The volumes given for IgM purification are for 10ml of lOx concentrated 
tissue culture supernatant. Where different volumes of .upernatant were 
used, the amount of resin and reagents were adjusted proportionately_ 
i) 4-0g of Bakerbond ABx40~ ion exchange resin (Technicol, Stockport) wa. 
equilibrated in 20ml of 2SmMMES pHS-S (solution A) in a SOml tube (Falcon) 
81 
with continuous mixing, for five minutes. 
ii) 2·0ml of heat inactivated foetal calf serum (HI-FeS, Gibco) was added 
and mixed for a further five minutes. The resin was allowed to settle and 
the supernatant decanted and discarded. The hydrated volume of ABx40IJm 
resin was measured for future re-use (1·0g of equilibrated ABx40IJm -2·8ml). 
iii) The resin was washed in 40ml of 2SmM XES pHS·S (solution A) and mixed 
for two minutes. The resin was then allowed to settle and the supernatant 
discarded. 
iv) 40ml of 20mM sodium acetate in SOOmM ammonium sulphate pH6·8 (solution 
B) was added with continuous mixing for two minutes in a 2S0ml flask. 40ml 
of dH20 was added, the resin mixed, allowed to settle, and the supernatant 
discarded. 
v) 80ml of 2SmM MES pH<4·0 (solution D) was added and mixed for two 
minutes. The resin was allowed to settle and the supernatant discarded. 
vi) The resin was washed in 80ml of 2SmM XES pHS·S (solution A), mixed for 
two minutes, allowed to settle and the supernatant decanted. The pH of the 
supernatant was checked and found to be 5·5. The resin was stored in 2SmM 
XES pHS·S with 0·1, sodium azide until use. 
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b) Batch purification of 19M from tissue culture ,ypernatant: 
i) 10ml of lOx concentrated tissue culture ,upernatant wa. mixed with 
30ml of 25mM MES pH<4·0 (solution D) in a 250ml fla.k, giving pH-6·0. To 
this, 4Sml of 2SmM MES pHS·S (solution A) wa. added, giving pHS·S. 
ii) The diluted supernatant was mixed with 4·0g of equilibrated Bakerbond 
ABx40~m ion exchange resin. 1Sml of 200mM ammonium sulphate (.olution C) 
was added, giving a final concentration of 30mM ammonium .ulphate. Thi. wa. 
mixed continuously for 10 minutes and the resin allowed to settl. for 10 
minutes. 
iii) The immunoglobulin depleted supernatant was decanted and the resin wa. 
washed, with the addition of 80ml of 2SmM MES pHS·S (.olution A). Th. re.in 
was allowed to settle and the supernatant discarded. 
iv) 40ml of 20mM sodium acetate in SOOmM ammonium .ulphat. pH6·8 (solution 
B) was added and mixed for 10 minutes. The resin was allowed to .ettl. and 
the immunoglobulin containing fraction wa. decanted and .tored. This .t.p 
was repeated a second time to en sur. complete elution of immunoglobulin 
from the resin. 
v) The immunoglobulin containing fraction wa. then concentrated through a 
YM10 ultrafiltration membrane (Amicon) with positive pres.ur., to a volume 
of 4ml. 
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c) Purification of IgM by gel filtration chromatography: 
i) Column preparation: 
200ml of pre-swollen Sephacryl S300 (High resolution, Pharmacia-LKB, Milton 
Keynes) was washed in 400ml of buffer (PBS-DAB pH7·2) and allowed to .ettle 
(gel volume -150ml). The excess buffer was decanted and the gel 
equilibrated in PBS-DAB by washing twice more, as above. The gel was 
resuspended in 150ml of buffer and degassed under a vacuum in a Buchner 
flask for five minutes. 
A 94x2cm chromatography column (Pharmacia-LKB) was mounted vertically and 
the lower bed support secured about 3cm from the base. The lower flow 
outlet was turned off and 1Sml of buffer was poured into the column 
ensuring the release of air bubbles. The gel was gently mixed and using a 
glass rod the slurry was poured down the inner wall of the column, ensuring 
that no air was introduced. The gel was allowed to settle under gravity at 
room temperature, collecting excess buffer through the lower outlet. The 
gel was packed to about 4cm from the top of the column, ensuring the gel 
did not dry. The upper bed support was inserted, level with the gel bed, 
ensuring no air was trapped in the column. 
The gel filtration column was run in an ascending direction, with the lower 
outlet tube placed in a reservoir containing buffer placed above the top 
of the column, and the upper outlet tube placed in an eluent reservoir 
positioned below the column. A syphoning action was started by gently 
drawing buffer through the upper outlet using a 10ml syringe to apply a 
vacuum. To equilibrate the column, buffer was allowed to flow through the 
column for 24 hours. The flow rate was measured at about 15ml per hour. The 
elution tube was then plugged until the column was ready for use. 
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ii) Column calibration: 
High molecular weight protein standards thyroglobulin, ferritin, catalase 
and aldolase (Pharmacia-LKB, ART No. 17-0441-01) were dissolved in PBS-
DAB at a concentration of 5mg/ml (with the exception of ferritin at 1mg/ml) 
and allowed to stand for 10 minutes. 3ml of thyroglobulin was applied to 
the column through the lower bed support tube (positioned above the column) 
ensuring that no air was introduced. The upper outlet tube was connected 
to a fraction collector (Redirac 2112, LKB-Pharmacia) preset at 80 drops 
per tube (-4ml per fraction). When the protein solution had been applied, 
the lower bed support tube was placed in a PBS-DAB reservoir placed above 
the column. Elution of the protein standard was monitored by determining 
the absorbance of the each fraction at 280nm on a spectrophotometer (LKB 
Pharmacia Ltd). The protein elution profile was then calculated by plotting 
the absorbance of each fraction against the accumulative elution volume. 
Each protein standard was applied in turn, as above. Following use, the 
column was flushed with 200ml of PBS-DAB containing 0·1, sodium azide to 
prevent microbial growth. Before subsequent use the column was flushed 
over-night with PBS-DAB to remove residual sodium azide. 
iii) Sample application: 
4ml of the partially purified immunoglobulin fraction (following ion 
exchange extraction using the Bakerbond ABx 40~m) was applied to the column 
as above. The elution profile was monitored as for the protein standards. 
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2.5 Determination of IgM purity u.ipg Sodiua Podecyl Sulphate 
Polyacrylamide Oel Electrophore.i. (SDS-PAQI) 
2.5.1 Reagent. 
a) Solution A. Acrylamide solution: 
30\ acrylamide with O·S\ bis-acrylamide. Acrylamide (BOH, No.44299). NN'-
Methylene-bis Acrylamide (Sigma, M-7256). 
150g of acrylamide and 4·0g of bia-acrylamide were di •• olved in 300ml of 
dH20 and the volume made up to 500ml. The .olution wa. filtered (Whatman, 
grade 1) and stored in the dark at 4°C. 
b) Solution B. Separation gel buffer: 
0·75M Tris buffer pHS·S. Trizma base, molecular weight 121·1 (Sigma, T-
1503). 
45·413g of Trizma base was dissolved in 400ml of dH20 and then made up to 
a final volume of 500ml. The .olution adjusted to pHS·a with the addition 
of concentrated HCl added drop-wise with continuous .tirring. 
c) Solution C. Stacking gel buffer: 
1·00M Tris pH6·8. 
60.55g of Trizma base was dissolved in a final volume of 500ml of dH20. The 
pH was adjusted to 6·S with the addition of concentrated HCl added drop-
wise with continuous stirring. 
d) Solution D. 10\ Sodium-dodecyl sulphate: 
Sodium-dodecyl Sulphate (SOS, Lauryl sulphate, sodium .alt, Sigma, L-
4509). 50g of SOS was dissolved in a final volume of SOOml of dH20. 
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e) Solution E. 1\ Ammonium peraulphate: 
19 of ammonium peraulphate (BOH, N044307) was dissolved in a final volume 
of lOOml of dH20. This reagent oxidises and was therefore prepared fresh, 
immediately before use. 
f) Running buffer. Tria-glycine pHS·3 (X10 concentrated): 
Glycine (Sigma, G-7126). Ten times concentrated running buffer was prepared 
by dissolving 60·6g of Trizma base and 28S·0g of glycine in a final volume 
of two litres dH20 giving pH 8·3. For use, SOOml of x10 concentrated 
running buffer was diluted with 4·5 litres of dH20, with the addition of 
S·Og (0·1\) of SOS. 
g) Sample buffer: 
0·2M Tris, S·OM Urea and 2\ SOS pHS·O. Urea (Sigma, U-12S0) molecular 
weight 60·06. 
4.8449 of Trizma base, 96.0969 of Urea and 4·09 of SOS were dissolved in 
a final volume of 200ml of dH20 with continuous stirring on a warm plate. 
h) Running gel: 
A 10\ running gel was made up according to the volume. given in Table 
2.5.1. 
i) stacking gel: 
A 3\ stacking gel was made up according to the volume. given in Table 
2.5.1. 
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j) Bromo-phenol blue: 
Bromophenol blue (BDH, No.44305). A microspatular of bromophenol blue was 
dissolved in 10ml of sample buffer. 
k) Cogmassie blue stain: 
Brilliant blue R (Sigma, B-0630). Methanol (BDH, No.10158). Acetic acid 
(BDH, No.27013). (Detects -l~g ml-1 protein). 1·0g of Brilliant blue R was 
dissolved in 364ml of dH20. To this, 73·6ml of acetic acid and 364ml of 
methanol was added and the solution passed through a filter (Whatman, grade 
1, medium fast). 
1) Destain: 
5' methanol, 7·5' acetic acid. 150ml of acetic acid and 100ml of methanol 
was mixed with 1750ml of dH20. (The gel may be stored in 7' acetic acid). 
m) sample Preparation Reagents 
i) 40mK iodo-acetamide (IAA): 
lAA (Sigma, 1-6125) molecular weight 185. 
37mg of lAA was dissolved in 5ml of sample buffer. 
ii) 40mK DL-dithiothreitol: 
DTT (Sigma, D-0632) molecular weight 154·2. 
31mg of DTT was dissolved in 5ml of sample buffer. 
iii) 0·66SM lAA: 
123mg of lAA was dissolved in 1ml of dH20. 
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Table 2.5.1. Recipes for Running Gel Concentrations 
Percentage Gel Concentration 
Solution 5' 7·5' 10' 12·5' 15' 20' 3' 
A 10.0* 15.0 20.0 25.0 30.0 40.0 1.8 
B 30.0 30.0 30.0 30.0 26.4 9.0$ -
C - - - - - - 2.0 
D 0.6 0.6 0.6 0.6 0.6 0.6 0.16 
E 3.0 3.0 3.0 3.0 3.0 3.0 0.8 
dH20 16.4 11.4 6.4 1.4 - 10.0 11.0 
TEMED 40.0 40.0 40.0 40.0 40.0 40.0 30.0 
~ volumes are in millilitres except TEMED for which the volumes are in 
microlitres (~l). The volumes given are those required for each gel and 
should be mixed in order as above. 
TEMEDi NNN'N' Tetramethylethylene diamine (Sigma). 
t 2.5M Tris pHS·S. 
For proteins of molecular weights 10,000 to 100,000 use a 10' or 12·5' gel. 
For peptides a 20' gel is recommended. The 3' gel i. used •• a stacking 
gel. 
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2.5.2 Method 
a) Non-reduced sample preparation: 
lOO~l of 40mM IAA was mixed with an equal volume of test sample in 1·5ml 
eppendorf tubes (Beckman). The tops were sealed and a small hole pierced 
through each lid. The tubes were placed in a boiling water bath for two 
minutes. 
b) Reduced samples preparations 
100~1 of test sample was mixed with an equal volume of 40mM OTT and boiled 
as above for two minutes. 10~1 of O·665M lAA was added and the tub •• were 
placed in a boiling water bath for a further two minutes. 
c) Calibration standard preparation: 
Electrophoresis calibration kit, ART No.17-0446-01, Pharmacia-LXB. 
Low molecular weight .tandards were dissolved in 100~1 of 40mM OTT and 
boiled as above, for two minutes. 10~1 of O·665M lAA was added and the 
sample boiled for a further two minutes. 
All sample. were coloured by the addition of 1~1 of bromophenol blue to 
each tube, to enable visualisation of the running front during 
electrophoresis. 
d) Gel preparation: 
The 14x16cm vertical slab gel electrophoresis apparatus (Biotech 
Instrument. LTD, Luton, S1600) was assembled according to the manufacture. 
instructions. Before use the apparatus was washed in 70\ alcohol and rinsed 
in dH20. Gloves were worn at all stage •• 
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i) The 10\ SDS running gel (Table 2.5.1), prepared immediately prior to 
use, was poured evenly between the glass plates to a depth of 3cm below the 
height of the combs. Air bubbles were removed by running a 190 (1·5 inch) 
needle through the gel surface. 
ii) Using a Pasteur pipette, dH20 was gently layered onto the gel to a 
depth of 2mm to ensure gel had a flat surface. The gel was allowed to 
polymerise for about 15 minutes. 
iii) After polymerisation, a 3\ stacking gel was prepared immediately prior 
to use (Table 2.5.1). Water was blotted from the running gel using an 
absorbent towel, taking care not to disturb the gel surface. The stacking 
gel was poured to a depth of 3cm and air bubbles were released as above. 
iv) The combs were inserted, ensuring no air bubbles were introduced and 
the gel was left to polymerise for about 15 minutes. 
v) Five litres of running buffer containing 0·1\ SDS was prepared from the 
xlO concentrated stock solution, and poured into the electrophoresis tank 
to three quarters full. The combs were removed from the stacking gel and 
air bubbles floated out using running buffer. The gel plates were located 
in the top gel reservoir and locked into position. The base supports were 
removed and the apparatus was inserted into the electrophoresis tank. The 
top reservoir was half filled with running buffer. Air bubbles were removed 
from the bottom of the plates by gently "swilling" with a Sml pipette. 
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e) Sample APplication: 
Between lO~l and lOO~l of non-reduced or reduced sample (2-20~g of protein 
per band) was added to each alternate lane using a 100~1 Hamilton .yringe. 
When possible the two outer lanes (1 and 15) were left empty and 10~l of 
low molecular weight calibration markers were added to lanes 2 and 14. 
The lid of the electrophoresis tank was .ecured and the electrode. 
connected. The gels were run at 3SmA (constant current) per gel, with 
continuous water cooling, until the bromophenol blue dye front was 1-2cm 
from the end of the gel (about 4 hours). 
The current was switched off and the electrodes and water cooling 
disconnected. The slab gel plate. were dismantled and the gel floated off 
the glass plates into a large flat dish containing Coomassie blue staining 
solution. After 18 hours the gel was placed in destain, with three changes, 
until the protein bands were clearly differentiated. The gels were then 
photographed and dried. 
f) Gel drying: 
Gels were place onto chromatography card (Whatman) and covered with clear 
film (Saran Dow, Genetic Research Ltd, Pelstead). They were placed onto a 
slab gel dryer (Sic-Rad Laboratories), the rubber mat placed over the gels 
and a vacuum applied. Gels were dried at 80°C for 2 hours. 
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2.6 Biotinylatiop of purifi.d IqMa 
The method for biotinylation of 19M antibodi •• wa. carried out a. d •• crib.d 
by Gretch (Gretch, Suter and Stinski, 1987) for IgG antibodies. NHS-LC-
Biotin was used to label 19M purified from autoreactive MAbs F1S-DDS-26 and 
F36-CB10-18. NHS-LC-Biotin contains an extended spacer arm approximately 
221 in length. This spacer arm reduc.. .t.ric hind.ranc. cau •• d by 
glycosylat.d residues and certain amino acids with subsequ.nt improvement 
in the biotin/avidin association. 
At alkaline pH the N-Hydroxysulfosuccinimide ester (NHS) r.acts with 
primary amine groups (NH2 ) such as lysine residues on the ~unoglobulin 
molecule. This results in amid. bond formation b.tween the biotin .ster and 
the immunoglobulin, with the release of N-Hydroxysulfosuccinimid •• 
2.6.1 R.ag.nt. 
a) Sodium hydrogen carbonate buffer: 
NaHC03 , molecular weight 84·01 (Sigma). 4·2g of NaHC03 wa. di •• olved in 
SOOml of dH20 to give a O·lM solution, pH8·3. 
b) Biotin solution: 
1·63mg of NHS-LC-Biotin (Pearce, Life Science Laboratorie. Ltd, Luton) was 
dissolved in 1ml of DMSO. Biotin is readily hydroly.ed, therefor. to avoid 
condensation the biotin bottle was allowed to r.ach room temperature b.for. 
opening and the solution was made up immediat.ly before u ••• 
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2.6.2 Method 
The volume of purified 19M in PBS-DAB containing 1mg of protein (a. 
determined by optical density, assuming that 1mg/ml of protein gives an 
absorbance of 1·4 at 280nm) at approximately 1mg/ml was dialys.d against 
the NaBC03 pHS· 3 buffer in a Centricon-30 microconcentrator (Amicon) 
according to the manufactures instructions. Microconcentrator8 containing 
the PBS-DAB/1gM solution were centrifuged at 6000 rpm at 4°C in an MSE High 
Spin centrifuge fitted with a SxSOml fixed angle rotor. 1ml of NaBC03 
buffer was added and the process repeated three times to ensure complete 
removal of all the PBS-DAB. 
Following the final dialysis, 1ml of NaBC03 was added and the optical 
density measured as above. The volume of NHS-LC-Biotin ester required to 
give a concentration of 30~1 per mg of protein was calculated (87·9mM) and 
added to the NAb and incubated at room temperature for 1 hour. 
The samples were then dialysed x3 against PBS-DAB in a Centricon-30 
microconcentrator as above, to remove all unbound biotin, and finally 
resuspended in PBS-DAB with 0·1\ NaN3 , at 1mg/ml. The antibodies were 
stored at 4°C and tested for F1TC-avidin binding on a FACScan (logarithmic 
profiles) or an Ortho Cytofluorograph (linear profiles). 
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2.7 I"uDoprecipitatioD 
2.7.1 Lactoperoxidase catalysed cell surface iodination 
a) Reagents 
1. Glucose 18mg/ml (Sigma); 1·8g of glucose was dissolved in 100ml of PBS-
DAB. 
2. Glucose oxidase (Sigma, type V from Aspergillus niger) 21 units/ml, 
100~1 of stock (1000 units/ml) was diluted with 4·7ml of PBS-DAB. 
3. Lactoperoxidase (Sigma, from bovine milk) 0·2mq/mll A stock solution was 
prepared by dissolving 5mg in 1ml of PBS-DAB. For use 100~1 of stock 
solution was made up to 2·5ml in PBS-DAB. 
b) Method; The autoantibody sensitive cell lin. K562 (logarithmic growth 
phase) was layered over lymphoprep and centrifuged as previously described. 
The cells were washed and lxl07 cells suspended in 100~1 of PBS-DAB in a 
1·5ml microcentifuge tube. To this the following reagents were added, 10~1 
of 1 125 (1 mCi, danger extremely volatile), 30~1 of glucose (18mg/ml), 30~1 
of glucose oxidase (21 unita/ml) and 30~1 of lactoperoxidase (0·2mg/ml). 
The prossess was performed in a fume hood designated for us. with radio 
active isotopes. The tubes were incubated at room temperature for 15 
minutes and then washed three times in cold PBS-DAB at 4°C, centrifuging 
for 1 minute at 13,000g. 
2.7.2 preparation of solubilized antigen 
a) Reagent. 
Lysis Buffer; l' NP-40 (Sigma, lml stock) 
10mK Tria (Sigma, 0·2422g in 190ml H20) 
150mK NaCl (Sigma 1·,532g in 200ml H20) 
5mM EDTA (Sigma, 0·3722g in 100ml H20) 
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0·5% BSA (Sigma, 0·59 in 100ml) 
Added fresh 1mM PMSF, smM IAA (x100 -0·092s/ml H20) 
b) Method; The I 125 labelled cells were centrifuged and the pellets 
resuspended in 1ml of lysis buffer and incubated on ice for 30 minutes. The 
nucleii were removed by centrifuging at 13,000g in a microcentrifuge for 
5 minutes at 4°C. The supernatant was transfered into a fresh tube. 
2.7.3 Immunoprecipitation 
a) Reagents 
i) Immune precipitation Buffer 
7sml of PBS-DAB pH7·s was supplemented with the followings 
0·1% SDS, (lml from 10% stock solution in PBS), 
1·0\ NP-40, (BDH, 1ml stock), 
0·5\ DOC, (Sodium deoxycholate acetone purified, 0·5g), 
0·02\ NaN3 , (0·2ml of 10\ stock solution in PBS), 
100pg/ml PMSF, (Phenylmethylsulphonyl fluoride, 1ml of 100x 
concentrated stock solution, 10mg/ml freshly dissolved in isopropanol). 
The volume was made up to 100ml with PBS-DAB. 
ii) Washina Buffer 
100ml of PBS-DAB pH7·s was supplemented with the followings 
0·1% NP-40, (100pl stock), 
100ug/ml PMSF, (lml from 100x concentrated stock .s above). 
iii) Elution Buffer; O·lM Glycine-HCl pH2·2. 
A stock solution of 0·4M glycine (Sigma) was prepared by di.solving 3·0g 
in 100ml of H20. A 0·4M solution of HCl was prepared by diluting 2m1 of 
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concentrated Hel (BDH) in "·6ml of H20. To 25ml of O·4M glycine, 
approximately 25ml of O·4M Hel was added dropwise with continuous mixing 
to give pH2·2. The volume was then made up to 100ml with H20. 
b) Method; Solubilized antigen was divided into two aliquots. To the first 
aliquot 20~1 of biotinylated F1S-DDS-26 (lmg/ml) was added and to the 
second aliquot 20~l of biotinylated F36-CB10-18 (lmg/ml) was added. Tubes 
were incubated overnight on ice followed by the addition of 200~l of 
Streptavidin-agarose. The tubes were mixed well for one hour at 4°C. The 
agarose bound immune complexes were washed three times using lml volume. 
of washing buffer, until no counts could be detected in the eluted washing 
buffer, followed by one wash with dH20. 
O·5ml of elution buffer was added and tubes were rotated for 1 hour at 4°C. 
The agarose was then centrifuged and the supernatants removed. The eluted 
supernatant was neutralised with 50~1 of 1·0M NaOH. Few count. were 
detectable in the supernatant, therefore the agarose was .equentially 
treated with O·Sml of glycine BCL at 56°C for 15 minute., and also boiled 
in DTT as previously described. 
2.7.4 Autoradiography 
Eluted fractions were run on an SDS-PAGE gel. The gels were .tainad for 
protein, destained and dried as previously described. Autoradiography was 
performed by exposing the dried gel to X-ray film (Sigma, XAR 5) placed in 
a cassette (Genetic Research Instrumentation Ltd, Bishop. Stortford) at -
80°C for seven days before developing. 
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3.1 Oeneration of • lymphocytotoxic autoaptibody producipg B-LCL 
3.1.1 Patient details: 
Patient BN was placed on the renal transplant waiting list following end 
stage renal failure in 1984. He became sensitised, with the production of 
lymphocytotoxic autoantibodies and anti-HLA antibodies following multiple 
blood transfusions (15 units) and a failed renal allograft. An HLA-DR 
matched kidney became available in October 1986, which was found to have 
a current positive crossmatch with the donor B lymphocytes. The crossmatch 
was negative following OTT treatment, and was not blocked by monomorphic 
anti-HLA-ABC, DR, or DQ antibodies indicating an IgM non-HLA antibody. In 
addition the patients sera demonstrated cytotoxicity with autOlogous B 
lymphocytes. On the basis that this represented a non damaging 
lymphocytotoxic autoantibody the patient was transplanted. The post 
transplant course was uneventful and the patient has a serum creatinine of 
164~M/l, 3 years post transplant. 
In an attempt to produce a monoclonal lymphocytotoxic autoantibody this 
patients PBL' s were EBV transformed to produce a B-lymphoblastoid cell line 
(B-LCL). Tissue culture supernatants were then tested for the presence of 
lymphocytotoxic autoantibody production. 
3.1.2 Cytotoxicity screening of B-LCL (BN) ,upernatant.: 
EBV treated PBL' s (BN) at a concentration of 1x10'/ml were initially 
dispensed into seven wells of a 24 well tissue culture tray. Screening of 
culture supernatants, harvested three week. po.t tran.formation was 
performed using the microlymphocytotoxicity technique against a .mall panel 
of T cells, B cells and CLL cells. The re.ults demonstrated typical 
lymphocytotoxic autoantibody profile. previou.ly ob.erved in renal dialy.l. 
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patient serum (Fig 3.1.1). 
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Figure 3.1.1 Cytotoxicity profiles of tissue culture supernatants derived 
from B-LCL (BB) harvested three weeks post transformation tested at neat, 
1/2 and 1/4 dilutions against a panel of; 
o = B cells, C and R =selected autoantibody sensitive CLL cells, 
x = T cells, K -K562 autoantibody sensitive cell line, 
+ a eLL cells Ta-autologous T cells, 
Ba=autologous B-LCL. 
Supernatants gave strongest cytotoxic reactivity when tested against 8 
cells, with weaker reactivity against T cells and CLL cells. In addition, 
the supernatants reacted with two selected autoantibody sensitive CLL cells 
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(Cx and Rs), and B2 and B4 were weakly reactive with the cell line KS62. 
Although screening was negative with the patients autologous T lymphocytes 
(Ta), B2, B4 and BS had strong reactivity with the autologous B-LCL (BN). 
Of the seven wells, four supernatants (B2,B4,BS,C4) had lymphocytotoxic 
autoantibody reactivity with titres greater than 1/4 and were selected for 
expansion. 
Antibody production was monitored by cytotoxicity, with positive flasks 
being subcultured twice weekly. Flasks were terminated following two 
consecutive negative screening results. Antibody production from wells B2 
and C4 ceased after six weeks, B4 after two months, whereas BS continued 
for three months. A total of 1· 2 and 3·5 litres of supernatant were 
harvested from B4 and BS respectively. OVer the course of 3 months the 
initial broad panel reactivity was slowly lost. In each case, CLL and T 
cell reactivity was lost first, whereas B cell reactivity was maintained 
longest. 
The cytotoxicity profiles were found to be dependant on antibody 
concentration. Supernatants pooled from B5 had only weak reactivity with 
B cells, Cx and Rs, whereas B4 was negative with all cell types. However 
on concentrating the supernatants 9 fold and 6 fold respectively (YM10 
ultrafiltration membrane, Amicon) broad panel reactivity was obtained. 
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3.1.3 Determination of antibody class: 
Tissue culture supernatants from wells 82, 84, 85 and C4, harvested at 4 
and 6 weeks post transformation were tested by cytotoxicity against two 
autoantibody sensitive CLL cells (Cx and Rs), with the reducing agent DTT. 
Cytotoxic antibody reactivity was completely removed following DTT 
treatment, under conditions which reduce IgM. In control tests, reactivity 
of the MAb NDS-22 (IgG anti-HLA-DR, SV.Fuggle, NOS) at a dilution of 1/100 
was not destroyed by DTT. 
For quantitative determination of immunoglobulin levels, supernatants from 
exhausted cultures harvested at four weeks post transformation were tested 
using low level single radial immunodiffusion plates. For the determination 
of IgM levels, wells one, two and three were inoculated with 20~1 of human 
standard protein (LC-A, IgM level 0·148g/1) at neat, and dilutions of 1/2 
and 1/4 respectively (Fig 3.1.2). Duplicate wells (4 to 11) were inoculated 
with 20~1 of neat tissue culture supernatant, and well 12 with fresh growth 
medium as a negative control. Immunoprecipitation ring diameters were 
measured, and the square of the ring diameters (mm2 ) were plotted against 
the protein standard concentrations. Immunoglobulin levels of tissue 
culture supernatants were then determined from the calibration graph. 
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Quantitative Determination of Human IgM 
in B-LCL (BN) Culture Supernatant 
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Figure 3.1.2 Quantitative determination of human IgH levels in B-LCL (BN) 
tissue culture supernatant harvested four weeJcs post transformation, 
measured by single radial immunodiffusion. 
The results indicated total IgM levels of 40~g/ml for supernatants 82, 84, 
and C4 (ring diameters Smm), and SS~g/ml (ring diameter S·Smm) for 85. No 
precipitation rings were detectable in well 12 containing growth medium 
alone, nor in the teat wella on the IgG plate, which was .enaitive to 
levels of 8~g/ml. 
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3.2 Generation of lymphocytotoxic autoantibody producing heterohybridomas 
3.2.1 Heterohybridoma fusion and DNA content analysis: 
Antibody producing 8-LCL (8N) cells pooled from wells 82,84,85 and C4 were 
fused four weeks post E8V transformation. The fused cells were dispensed 
into 63 wells. To establish that the cells derived represented hybridoma 
cells and not continued growth of parental cell lines, cells were analyzed 
for DNA content by flow cytometry. DNA histograms for each parental cell, 
fused cell lines and control cells were obtained. 
Figure 3.2.1 demonstrates the DNA profile of the cell line K562. The first 
peak (left) represents fluorescence intensity of cells in GO and G1 
(resting) phase of the cell cycle. The second peak (right) indicates cells 
in G2 and M (mitosis) phase and the central area are cells in S (synthesis) 
phase. 
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compared to the parent cell lines X63.AgB-653 and B-LCL BN. 
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Figure 3.2.2 shows the DNA profiles of the parental cell lines (X63.Ag8-
653 and B-LCL BN) with two heterohybridoma cell lines, F15 (panel a) and 
F36 (panel b). Peak channel fluorescence of X63.Ag8-653 was 205 and B-LCL 
BN was 159, giving a total of 364. The peak channel fluorescence of F15 and 
F36 were 351 and 350 respectively. Therefore the heterohybridoma cells 
derived in HAT and Ouabain selection medium demonstrated approximately the 
sum DNA content of the two parental cell lines (peak channel fluorescence 
of 364 compared to 350). No DNA peaks representing either of the parental 
cells alone were seen following hybridoma selection. This indicates that 
parental cell lines X63.Ag8-653 and B-LCL (BN) had not survived 
heterohybridoma selection. 
3.2.2 Heterohybridoma cloning: 
supernatants were screened 14 days post fusion when an average of 5 
macroscopically visible clones could be seen in each well. Clone picking 
was performed three weeks post fusion. Fifty-five clones were transferred 
into 96 well trays, of which 35 were successfully expanded (Table 3.2.1). 
Table 3.2.1 Heterohybridoma cloning and antibody screening results 
Clone No. of Wells with Wells No. antibody Ab 
wells growth expanded positive Class 
Fusion (bulk) 63 5/well all 15 19M 
Picked clones 55 35 35 11 (31%) 19M 
F15(1) 90 0 - - -
F15(2) 110 3 2 2 (100%) 19M 
F15-005 110 24 24 24 (100%) 19M 
F36(1) 90 8 6 5 (83%) 19M 
F36(2) 110 27 14 12 (86%) 19M 
F36-CB10 110 22 15 15 (100%) 19M 
F36-AF8 110 23 14 8 (57%) 19M 
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On the basis of initial cytotoxicity profilea, two cell population. (1'15 
and 1'36) were selected for recloning. Initially culture. gave poor 
viability, despite attempts to maintain optimal growth condition •• 1'15 and 
1'36 were cloned at one cell per well, each into 90 wella (Table 3.2.1). No 
clones were successfully derived from P1S and only 8 clone. were derived 
from 1'36. Of the 8 1'36 clones, .ix were .ucces.fully expanded, with two 
dying at an early stage. The poor cloning efficiency poasibly reflect. 
instability of the mouse/human heterohybridoma. 
A second attempt at cloning into 110 well. produced 3 and 27 clone. from 
1'15 and F36 respectively (Table 3.2.1). However only 2/3 PlS clone. and 
14/27 P36 clones were successfully expanded. 
F1S-DDS, F36-CB10 and F36-AF8 were recloned into 110 wall. giving 24, 22 
and 23 subclones respectively (Table 3.2.1). Of the.e, all 24 P1S-DDS 
clones were successfully expanded and 15/22 and 14/23 clone. were derived 
from F36-CB10 and F36-AF8 respectively. 
The improved cloning efficiency of 1'15 probably reflect. the derivation of 
stable cella following the first cloning atep. Initial cloning of 1'15 
produced only 2 atable clones but on recloning 24 .ubclone. ware derived, 
all being atable. However, initial cloning of P36(1) and 1'36(2) produced 
a total of 20 .table clones, and recloning generated 22 1'36-CB10 and 23 
1'36-AF8 aubclonea, of which only 15 (68') and 14 (61\) ware atable 
respectively. 
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3.2.3 Cytotoxicity screening of heterohybridoma supernatants: 
Following fusion, tissue culture supernatants were tested on day 14, at 
neat and 1/2 dilution. A small panel of two T and B cells, two CLL cells, 
two autoantibody sensitive CLL cells (Cx and Rs), the autologous B-LCL (BN) 
and autoantibody sensitive cell line KS62 were used for screening. Of the 
63 wells, 15 demonstrated strong positive cytotoxic antibody reactivity at 
both dilutions against B cells, B-LCL (BN), Cx and Rs and K562. All 
cytotoxicity reactivity was OTT reduced indicating IgM antibody (Table 
3.2.1). Following clone picking, F36 was positive with both T and B cells 
and FIS was positive with B cells only. Both clones were negative with CLL 
cells. 
After initial cloning, of the six stable clones derived from F36, 5 (83') 
were antibody positive. Following the second cloning attempt 2/2 (100') F1S 
clones, and 12/14 (86') F36 clones were antibody positive (Table 3.2.1). 
On recloning, 24/24 (100') F1S-DDS subclones, 15/15 (100') F36-CB10 
subclones and 8/14 (57') F36-AF8 subclones were antibody positive (Tabla 
3.2.1). The low antibody producing fraquency of F36-AF8 subclonas may 
reflect derivation from an unstabla clone or that it was not monoclonal. 
3.2.4 Cytotoxicity profiles of heterohybridoma lupernatant.: 
Several clones wera lost at a lata stage due to an incubator fault. Only 
seven clones which had been cryoprasarvad ware available for te.ting. The 
cytotoxicity profiles of positive subclone. wera testad against a panal of 
T cells, B cells and eLL cellI (Fig 3.2.3). 
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Cytotoxicity Profiles of Lymphocytotoxic 
Autoantibody Heterohybridoma Supernatant 
Cytotoxicity titre (reciprocal) 
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Figure 3.2.3 Cytotoxicity profiles of autoreactive heterohybridoma 
supernatants tested at doubling dilutions against a panel of B cells (0), 
T cells (x) and CLL cells (+). 
The cytotoxicity profiles demonstrated similar panel reactive profiles to 
the B-LCL supernatants. However, cytotoxicity titres were higher with 
cloned heterohybridoma supernatants than those of the B-LCL supernatants. 
Neat supernatants gave broad panel reactive profiles being reactive with 
all T cells, B cells and CLL cells. On dilution, first CLL reactivity and 
then the T cell reactivity were lost and B cell reactivity was maintained 
at the highest dilutions. All clones were strongly positive with the 
autoantibody sensitive cell line K562 and the autologous B-LCL (data not 
shown). On the supposition that the antibodies are monoclonal, the three 
profiles described above probably represent one type of autoantibody with 
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differing target cell sensitivity. The initial profiles of T and B cell 
reactivity, or B cell reactivity only, but negative with CLL cells was 
dependant on antibody concentration. Thi. data also confirms that CLL 
reactivity can be caused by autoreactive antibodies, although CLL cell. are 
the least sensitive target. 
3.3 Selection of clones for further study 
Selection of clones for further study waa a.ses.ed on the baai. of; i) 
growth characteristics, 
immunoglobulin isotype. 
H) antibody bindinc;r profUe., and Hi) 
3.3.1 Hybridoma growth characteristics: 
Subclones derived from F1S and F36 demonstrated differinc;r c;rrowth ratea. In 
order to identify clones with c;rood growth characteristic., cell growth was 
monitored over a five day period (Fic;r 3.3.1). 
Clones F1S-DDS, F36-AD3 and F36-DE4 demonstrated faste.t c;rrowth 
characteristics. This was also evident during maintenance of bulk culture •• 
Clones F36-BC8, F36-CB10, F36-DCS and P36-AP8 all demon.trated relatively 
slow growth characteristic •• However the.e clones approximately doubled in 
cell number between day. four and five. By de.ic;rn, cell. initially in log 
phase were suspended at a low concentration (Sx10'/ml) in fre.h c;rrowth 
medium. Growth of these cella may require a higher cell concentration and 
the presence of conditioned medium. Therefore optimal c;rrowth of the.e 
clones was only achieved by day four. 
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Heterohybridoma Growth Rates 
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Figure 3.3.1 Analysis of heterohybridoma growth rate over a five day 
period to compare cell growth characteristics with immunoglobulin 
production and cytotoxicity profiles. 
3.3.2 Antibody binding profiles: 
It may be assumed that the fastest growing cells are not necessarily the 
best antibody producers. Therefore, following five consecutive days growth 
supernatants were tested by cytotoxicity against a panel of cells to assess 
the antibody binding profiles and titres. 
Supernatants from the triplicate growth assay, harvested at five days, were 
individually screened against lymphocytes from two autoantibody sensitive 
eLL patients (ex and Rs), two eLL patients and peripheral blood T and B 
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lymphocytes from three normal individuals. In addition, supernatants were 
also screened with K562 and the autologous B-LCL (BN). All tests were 
performed in duplicate. The mean of the end pOint titre (last dilution with 
positive cytotoxicity) for each cell type is shown in figure 3.3.2. 
Cytotoxicity Profiles of Heterohybridoma 
Supernatants 
Mean cytotoxicity titre (reciprocal) 
120~----------------------------------------~ 
100~'-------'--'-----------------------
80 
60 
40 
20 
o 
Auto Cll 
• F1~-DD~ 
ffiillil F36-BCB 
Cll cells T cells 
Target cell type 
• F36-AD3 
o F36-AFB 
Em F36-DE4 
• F36-DC5 
8 cells 
,. F30-CB10 
m F1~ 
Figure 3.3.2 Cytotoxicity profiles of heterohybridoma supernatants derived 
from five day old cultures to compare cell growth characteristics with 
antibody production and cytotoxicity profiles. The clones are ranked in 
descending order of cell growth rate from left to right. 
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The cytotoxicity titres showed some correl.tion with cell growth r.te when 
tested .g.inst B cells .nd the .uto.ntibody .en.itive CLL cell. (Cx .nd 
Rs), with the exception of F36-DE4 .nd F36-BC8 which g.ve rel.tively low 
titres. No correl.tion of cell growth .nd .ntibody titre w •• observed for 
the eLL cells .nd the T cells. As w.. noted with the B-LCL (BN) 
.upern.t.nts, the cytotoxicity profile. were depend.nt on the .ntibody 
concentration. All cell types were positive with ne.t supern.t.nt derived 
from .11 clones. However on dilution, initi.lly CLL re.ctivity, then T cell 
reactivity w.s lost, with B lymphocytes being the mo.t .en.itiv. t.rget. 
3.3.3 Immunoglobulin cl.ss and light ch.in isotype: 
Pooled supern.t.nts from the above culture. were •••• y.d for immunoglobulin 
class and light chain isotype by single r.di.l immunodiffusion using low 
level human IgM, IgG, k.pp •• nd lambda tr.ys (Pig 3.3.3). 
All immunoglobulin production was of the IgM cl.s.. Immunoglobulin level. 
r.nged from 76~g/ml (FIS-DDS) to 12~g/ml (P36-DCS). P36-BC8 levels were 
only detectable in x5 concentrated supern.t.nt and w •• 9·8~g/ml (dat. not 
shown). No IgG w.s detected using ne.t or xS concentrated supernatant 
(sensitive to 9·O~g/ml). 
concentrated supernatants (xS) from antibody producing clones were analyzed 
for immunoglobulin light ch.in i.otypes k.pp •• nd lambda (Table 3.3.1). The 
p.rent cell population P1S, .nd its subclone P1S-DDS produced kappa light 
ch.in., where.s P36 and all P36 .ubclones produced lambda light chain. 
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Quantitative Determination of Human IgM 
in Heterohybridoma Supernatants 
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Figure 3.3.3 Quantitative determination of human IgM in heterohybridoma 
supernatants derived from five day old cultures to compare cell growth 
characteristics with immunoglobulin production and cytotoxicity profile •• 
3.3.4 Selection of higher affinity clones: 
We have previously found that lymphocytotoxic autoantibodies in renal 
patient serum react weakly or are negative in fluorescence binding assays. 
This is probably due to low antibody binding affinity. To identify higher 
affinity clones, a single and double wash step was introduced to the 
cytotoxicity test between incubation with MAD and the addition of 
complement. MADs at dilutions of 1/2 and 1/10 were each tested against T 
cells and B cells from an individual donor (Table 3.3.1). Most clones were 
weak or negative with T cells following one and two washes with MAbs 
diluted 1/2 and 1/10, with the exception of F36-CBIO which was still 
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positive after two washes at 1/10 dilution. Binding to B cell. was positive 
with all clones at both dilutions following one wash, and with F36-CB10, 
F36-AD3 and F36-AF8 following two washes at a dilution of 1/10. Thi. 
indicates that B cells constitute a higher affinity target. 
Table 3.3.1 Heterohybridoroa immunoglobulin class. light chain 
isotype and antibody binding affinity result. 
Clone 19M 180type Growth No. washes (affinity)@ 
ug/ml k 1 rate 1 2 112 
xlO-S T cell B cell 
Dilution (reciprocal) 
2 10 2 10 2 10 2 10 
F15 38 + - 0.2 - - - - + (+) (+) -
F1S-DDS 76 + - 2.8 (+) - - - + + + -
F36* 26 - + NT + - + - + + (+) (+) 
F36-CB10 52 - + 1.0 + (+) (+) (+) + + + + 
F36-AD3 39 - + 1.6 (+) - (+) - + + + + 
F36-AF8 39 - + 0.7 (+) - (+) - + + + + 
F36-DE4 28 - + 1.35 - - - - + + + -
F36-DC5 12 - + 0.63 (+) - - - + + + -
F36-BC8 10 - - 0.92 (+) - - - + + + (+) 
* F36 supernatant was obtained from an exhausted 5 day old culture. 
, Number of washes between the addition of NAb (at dilutions of 1/2 and 
1/10) and the addition of rabbit complement. + - strong positive (BO' to 
100\ cell lysis), (+) - positive (21\ to 79\ cell ly.i.), - - negative 
«20\ cell lysis). NT Not tested. 
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3.4 aecloninq of .elected auto.ntibodY produciRq h.t.robybri40 .. , 
3.4.1 Third cloning 
From the above d.t., 1"15-005 demon.trated the highe.t growth rate and 
immunoglobulin production, where.s 1"36-CB10 and 1"36-Al"8 had the be.t 
.ntibody binding .ffinities. In .ddition, 1"15-005 .ecreted IgM with the 
k.ppa light ch.in iaotype where.s F36-CB10 .nd 1"36-Al"8 produced 1ambd. 
light chains. This indicates that the clones had origin.ted from cell. 
secreting immunoglobulin with different .pecificitie.. These cell. ware 
selected for further study and recloned (Table 3.2.1). 
3.4.2 Selection of higher affinity clones 
Following the third cloning, supernatant. from 7 1"36-AF8, 12 1"36-CB10 and 
5 1"15-005 subclones were tested using the cytotoxicity binding •••• y, u.ing 
two low affinity target cell type. (peripher.l blood T c.1l. from on. pan.l 
member and lymphocytes from one CLL pati.nt). The re.ult. are .hown in 
Table 3.4.1. 
All of the 1"36-CB10 .nd F36-Al"8 subclones te.ted demon.trated higher 
affinity binding to T cells a. as.essed by po.itive cytotoxicity at a 
dilution of 1/2 and 1/10 following two washes. Cytotoxicity with CLL cell. 
at a MAb dilution of 1/2 following both one and two w.she. w.re po.itive. 
However most clones were either weak or negative with CLL c.ll. at a 
dilution of 1/10 following only one wash. The re.ult. show that 
supernatants derived from F36-CB10 and 1"36-Al"8 .ubc1one. bind to thi. CLL 
cell with lower affinity than T cell •• All five of the 1"15-005 .ubclone. 
tested had low affinity binding with both T c.ll. and CLL c.ll., b.ing weak 
or negative at both dilutions following one and two w •• h •• (Tabl. 3.4.1). 
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Table 3.4.1 Analysis of the binding affinity of heterohybridoma subclone, 
[15-005, [36-C810 and r36-Ar8 to T cell, and CLL cell, 
T 
Target rell type 
cell CLL cell 
I 
MAb* No. of washes 
Subclone oil 0 1 2 0 1 2 
F36-AF8-1 1/2 + + + + + + 
1/10 + + (+) (+) (+) -
-3 1/2 + (+) (+) + + + 
1/10 + + + (+) - -
-4 1/2 + + + + + + 
1/10 + + + + - -
-7 1/2 + + + + + + 
1/10 + + + + - -
-11 1/2 + + + + + + 
1/10 + (+) (+) (+) - -
-12 1/2 + (+) + + + + 
1/10 + (+) (+) + - -
-15 1/2 + + + + + + 
1/10 + (+) (+) + - -
-
F36-CB10-2 1/2 + + + + + + 
1/10 + + + + - -
-3 1/2 + + + + + + 
1/10 + (+) (+) + (+) -
-4 1/2 + + + + + + 
1/10 + + (+) + - -
-5 1/2 + + + + + + 
1/10 + + (+) (+) - -
-10 1/2 + (+) (+) + + (+) 
1/10 + (+) (+) (+) - -
-11 1/2 + + + + + (+) 
1/10 + + (+) (+) - -
-12 1/2 + + + + + + 
1/10 + + (+) + - -
-13 1/2 + + (+) + + + 
1/10 + (+) (+) + (+) -
-14 1/2 + + + + + + 
1/10 + (+) (+) + (+) -
-15 1/2 + + + + + + 
1/10 + (+) (+) + + (+) 
-16 1/2 + + (+) + + + 
1/10 + (+) (+) + (+) -
-18 1/2 + + + + + + 
1/10 + + + + + (+) 
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Table 3.4.1 continued 
T 
Target rell type 
cell eLL cell 
I 
MAb No. of washes 
Subclone oil 0 1 2 0 1 2 
F1S-00S-23 1/2 + (+) - + - -
1/10 + - - (+) - -
-24 1/2 + - - + - -
1/10 + - - - - -
-26 1/2 + - - + - -
1/10 + - - (+) - -
-39 1/2 + (+) - + - -
1/10 + - - (+) - -
-43 1/2 + - - + - -
1/10 + - - + - -
* Supernatants from P15-DD5, P36-CB10 and F36-AP8 subclone. were harve.ted 
from exhausted cultures. 
+ -strong positive cytotoxicity (>80' cell lysis), 
(+) -positive cytotoxicity (20-79' cell ly.is), 
- -negative cytotoxicity «20' cell lysis). 
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3.5 Characterisation of .onoclonal lymphocytotoxic autoaptibody bindipg 
by cytotoxicity 
3.5.1 Comparison of target cell sensitivities: 
The relative sensitivity of different t.rget cell types w ••••••••• d u.ing 
subclones derived from F1S-DDS (N-24), F36-CB10 (N-13) .nd F36-AF8 (N-8). 
Tissue culture supern.t.nts from e.ch subclone were individu.lly te.t.d .t 
doubling dilutions by cytotoxicity .g.inst • p.nel of T .nd B cells d.rived 
from five cadaver donor spleen or lymph nodes .nd 12 r.ndom CLL p.ti.nt •• 
In .ddition the .uto.ntibody sensitive c.ll line KS62, .nd the .utologous 
B-LCL (BN) were used. The me.n of the end point of cytotoxicity w.s 
calcul.ted for e.ch family of subclone •• g.in.t •• ch c.ll type (Fig 3.5.1). 
The results indic.te th.t T cells, B-LCL .nd KS62 h.ve simil.r 
sensitivities, where.s CLL cells re.ct .t .n .ver.ge of one to two doubling 
dilutions below T cells. B cells constitute the .trongest t.rget, .lthough 
the sensitivity .bove T cells was not .ssessed .s most NAbs titred beyond 
1/128. NAb cytotoxicity titre •• g.inst CLL c.ll targ.ts w.re variable, with 
some we.kly re.ctive (positive .t ne.t .nd 1/2 dilution) .nd some strongly 
re.ctive (positive .t 1/128 dilution). Re.ctivity with T .nd B cells was 
less variable with NAb cytotoxicity titres between 1/4 and 1/64 for T cells 
.nd 1/32 to 1/128 for B cells. 
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Relative Sensitivities of Target Cells 
to Lymphocytotoxic Autoantibodies 
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Figure 3.5.1 Comparison of the relative sensitiviti •• of ~ c.ll., B c.ll., 
CLL cells, K562 and B-LCL (BN) to cytotoxicity by lymphocytotoxic 
autoantibodie •• 
3.5.2 Comparison of lymphocvtotoxic autoantibody binding profile, with 
other human IgM monoclonal antibodies: 
To determine if the cytotoxicity profile. were unique to lymphocytotoxic 
autoantibodies or a common feature of many human 19M antibodi •• , the 
cytotoxicity profile, of the monoclonal lymphocytotoxic autoantibodie. were 
compared to five other human 19M MAb., FOM-A, FOM-1 and HAD (all anti-
RhO), BIO-4F11 (anti-tetanu, toxoid) (all a kind gift from Dr Hugh-Jone. 
group, Babraham, Cambridge) and RFAR (rheumatoid factor, a kind gift from 
Dr M.Steinitz, Hadaasah Medical School, Jerusalem) (Fig 3.5.2). 
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Figure 3.5.2 Comparison of cytotoxicity profiles of control human Iglf 
heterohybridoma lfAbs of defined specificities, with autoreactive monoclonal 
antibodies tested at doubling dilutions against a panel of B cell. (0), ~ 
cells (x) and CLL cells (+). 
The results showed similar cytotoxicity profiles between the anti-RhO NAbs 
(FOM-A, FOM-1 and MAO) and the autoantibodies. No difference was observed 
whether the target cells were derived from rhesus positive or negative 
donors. The anti-tetanus toxoid (B10-4Fll) and anti-rheumatoid factor 
(RFAN) antibodies were negative against all target cell.. Th •• e data 
demonstrated that well characterised RhO human 19M NAbs can give "non 
specific" cytotoxicity which mimic lymphocytotoxic autoantibody reactivity 
profiles. 
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3.S.3 Correlation of human IgM monoclonal antibody Cytotoxicity profiles 
with immunoglobulin levels 
To determine if the cytotoxicity profiles of the human IgM monoclonal 
antibodies were a reflection of the antibody specificity or mer.ly 
dependant on IgM levels, the immunoglobulin concentration of .ach 
monoclonal antibody was measured (Fig 3.S.3). 
The results show that cytotoxicity profiles were independent of 
immunoglobulin levels (the monoclonal antibodies in figure 3.5.2 ara shown 
in descending order of IgM levels from left to right). The lowest IgM 
concentration of 18~g/ml was found in FOM-1 which was positiva by 
cytotoxicity, whereas B10-4F11 and RFAR with lavels of 34~g/ml and 22~g/ml 
respectively, were both negative. In addition, positive cytotoxicity had 
previously been found with F36-BC8 with 19M levels of <10~g/ml. Therefore 
cytotoxicity was a results of the antibody specificity and not solely the 
immunoglobulin concentration. 
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Quantitative Determination of Human IgM 
in Heterohybridoma Supernatants 
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Figure 3.5.3 Immunoglobulin concentrations of human IgN monoclonal 
antibodies determined by single radial immunodiffusion. The calculated IgN 
levels for each monoclonal antibody are pre.ented in descending order of 
antibody concentration given below. 
MAD (anti-RhO) >70~g/ml; FOM-A (anti-RhO) 5B~g/ml, F36-CBIO-IB 
(autoreactive) 42~g/ml; BIO-4Fll (anti-Tetanus toxoid) 34~g/ml, RFAN (anti 
rheumatoid factor) 22~g/mll FON-l (anti-RhO) IB~g/ml. 
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3.6 Dilcu"iop 
Lymphocytotoxic autoantibodies in renal dialysis patient. have been 
recognised for more than 14 years, but the nature of their specificity has 
not been fully defined. These antibodies have been shown to react with 
normal B cells alone (Ettenger et al, 1976), normal T and B cell. (Ting and 
Korris, 1983) and with T, Band CLL cells (Ting and Korris, 1978). The 
different reactivity profiles suggest that the autoantibodies may represent 
multiple antibody populations or one population but with different 
sensitivities against different targets. The difficulty in reliably 
distinguishing autoreactive from alloreactive antibodies in the cro •• match 
test for kidney transplantation has lead to many patient. being denied a 
kidney transplant, often due to a false positive crossmatch (Taylor et al, 
1989) • 
In an attempt to resolve these question. we have generated human monoclonal 
lymphocytotoxic autoantibodies, to define their target cell .pecificity and 
develop a technique to distinguish autoreactive from alloreactive 
antibodies in highly .ensiti.ed patients. 
The monoclonal antibodies generated in this .tudy gave identical 
cytotoxicity profile. to autoantibodies found in the .era of renal dialy.i. 
patients. However the multiple profiles seen with .era from different renal 
patients could all be reproduced by .ingle monoclonal antibodies at 
different dilutions. Cytotoxicity testing .howed a progres.ive 
susceptibility of different cell type. to lYBie by the autoreacti"e 
monoclonal antibodies. B cell. were strongly reacti"e, whereas T cell. and 
CLL cells were less sensitive. This finding i •• imilar to that of Ozturk 
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(Ozturk and Terasaki, 1979) who reported a marked difference in the 
susceptibility to lysis of B cells compared to T cells using cytotoxic .era 
from normal individuals and from patients with various disease.. It i. 
therefore possible that these antibodies do not repre.ent di.tinct 
specificities, but reflect differing target cell .en.itivitie., which i. 
dependent on antibody concentration. 
The finding of "autoantibody profiles" with well-characteri.ed human IgM 
monoclonal antibodies to RhD suggests that binding is non-specific and that 
many IgM antibodies may result in apparent autoreactivity in-vitro. Red 
cell agglutination and fluorescence binding studies confirmed that the.e 
antibodies are reactive with RhD positive cells to dilutions of 1/1000, 
whereas the autoreactive monoclonal antibodies 1'15-005-26 and F36-CBI0-
18 do not bind red cells (see later). The finding i. not related to IgM 
concentration as cytotoxicity was found in .ome monoclonal antibodies with 
IgM levels well below the two negative monoclonal antibodies (BI0-4Fll and 
RFAN) • 
polyreactive antibodies capable of binding multiple type. of antigen. have 
been described (Casali and Notkins, 1989). Polyreactive antibodies can 
recognise a variety of self and exogenous antigens, and bind with low 
intrinsic affinity (Nakamura et al, 1988). They are .ecreted by CD5 
positive B cells (20' of PB-B cells in adults) and are thought to 
constitute the natural antibodies of serum giving a first line of defence. 
They use 80me conserved (germ line) V gene segments coding for .equenee. 
postulated to have large binding site., capable of accommodating multiple 
antigens (Sanz et al, 1989, Pennell et al, 1988). Many polyre.etive 
antibodies with low affinity for ssONA, rheumatoid factor (IgG Pc) , 
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thyroglobulin, insulin, Tetanus toxoid, bacterial lipopolysaccharides 
(lipid A), saccharides and phospholipids (phosphatidylcholine) have been 
characterised (Casali and Botkins, 1989, Van Rooijen, 1989). Their 
production is enhanced by exogenous antigen (Tetanu. toxoid, bacterial 
lipopolysaccharides, viral, bacterial and parasitic infection), which is 
consistent with the association of their appearance with viral infection 
in renal transplant patients (Jeannet, Benzonana and Arni, 1981, Cross, 
Greiner and whittier, 1976; Kacleod et al, 1987). However, because of their 
low affinity their presence does not predispose to the pathogenesis of the 
autoimmune disease. This would be consistent with the lack of clinical 
evidence for lymphocyte related autoimmune diseases in renal dialy.i. 
patients. 
Comparisons of the characteristics of polyreactive antibodies with 
lymphocytotoxic autoantibodies are consistent with the hypothe.i. that 
autoantibodies in renal dialysis patients are polyreactive and that they 
may represent a similar group of antibodies. The antibodies are low 
affinity (therefore of no clinical relevance), bind more strongly at 4°C, 
are easily washed off and react with self (autologous lymphocytes) in 
cytotoxicity assays. 
The method employed for the production of the monoclonal autoantibodies in 
this study was through EBV transformation of B lymphocyte.. It is now 
recognised that EBV activates CDS positive B cell. and .timulate. 
polyclonal IgK production with polyreactivity (Ca.ali and Botkin., 1989). 
This would explain the high frequency of autoantibody production from this 
and other B-LeLs (data not shown) and the correlation of .uch antibodies 
with lymphocytotoxic autoantibody profile •• Therefore, we would po.tulate 
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that there is no unique priming antigenic stimulus for the appearance of 
lymphocytotoxic autoantibodies and that they may result from polyclonal B 
cell activation by a variety of stimuli. 
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Chapter 4. 
Characteri.atioD of autoreactiva aoDocloDal aDtibody biDdiDg 
profile. aDd .pacificity 
4.1 Analysis of MAb binding profiles by fluorescence binding assay. 
4.1.1 FACScan analysis of autoreactive and anti-RhO NAb binding profil •• 
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profiles 
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dilutions 
4.1.4 Fluorescence binding profile. of autoreactiv. and anti-RhO NAba 
against a panel of T and B cella 
4.1.5 Effect of temperature on autoantibody binding 
4.1.6 Discussion 
4.2 Autoantibody binding inhibition studies 
4.2.1 Binding inhibition using lipid-A and pho.phatidylcholine 
4.2.2 Binding inhibition using human IgG and IgM 
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4.1.1 FACScan analysis of autoreactive and anti-RhO MAb binding profile.1 
Fluorescence binding profiles with spleen T and B cell. were analyzed u.ing 
MAbs F15-005-26, F36-CB10-18 (autoreactive) and MAD (anti-RhO) at 1/2 and 
1/10 dilutions on a FACScan (Fig 4.1.1). Similar T cell binding profile. 
were seen for each antibody, although MAD binding was weak. F36-CBI0-18, 
which was selected for improved T cell binding affinity reacted the 
strongest, being positive with 82\ of T cells at 1/2 dilution (Fig 4.1.1A, 
panel b). Lower mean channel fluorescence values were found at 1/10 
dilution. 
Binding profiles for B cells with FITC-goat-anti-human IgM alone (Fig 
4.1.1B) demonstrated two peaks, the left peak representing surface IgM 
negative B cells, and the right peak indicating surface IgM positive B 
cells. Following the addition of the autoreactive (1'15-005-26 and 1'36-
CB10-18) and anti-RhO (MAD) MAbs, both cell populations were po.itive, a. 
indicated by a shift of both peaks to the right. Due to the .hape of the 
profiles it was not possible to determine the percentage of B cell. 
positive as the weakly positive B cell peak overlapped with the IgM 
positive B cells in the negative control. 
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Figure 4.1.1 FACScan binding profiles of autoreactive (F15-DD5-26 and F36-
CBI0-18) and anti-RhO (NAD) human IgN NAbs with T cells (panel a) and B 
cells (panel b) at dilutions of 1/2 and 1/10. 
-FITC-goat-anti-human-IgN alone, 
-NAb dilution 1/2, 
-- -- -NAb dilution 1/10. 
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4.1.2 Cytofluorograph analysis of autoreactive and anti-RhD NAb binding 
profiles 
The use of logarithmic profilea by FACScan analysia waa not routinely 
available, therefore an Ortho Cytofluorograph (linear profilea) was used. 
On each occasion the cytofluorograph was calibrated using fluorotrol 
standards (Becton Dickinson), to enaure consistent fluorescent values, 
allowing comparisons of results on a day to day basis. Test were performed 
in duplicate. The mean difference of 50 consecutive T cell duplicates was 
4.6\ and 50 B cell duplicates was 1.9\ (data not shown). 
Linear profiles derived from the autoreactive (F15-DD5-26 and F36-CB10-
18) and anti-RhD (MAO) MAbs tested against spleen T and B cells are shown 
in Figures 4.1.2 and 4.1.3. 
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Figure 4.1.2 Cytorluorograph proriles or F15-DD5-26, F36-CB10-1B and HAD 
binding at 1/2 and 1/10 dilutions to T cells. 
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Figure 4.1.3 Cytofluorograph profiles of F15-DD5-26, F36-CBI0-1B and NAD 
binding at 1/2 and 1/10 dilutions to B cells. 
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T cell binding was relatively weak for each antibody at 1/2 dilution and 
was further reduced at 1/10 dilution as indicated by movement of the peaks 
to the left (Fig 4.1.2). F36-CB10-18 gave highest mean channel fluorescence 
confirming improved T cell binding affinity. MAD (anti-RhO) gave weakest 
binding, having been selected for RhO binding by independent criteria. 
By electronically subtracting the background fluorescence (FITC-anti-
human-IgM alone) the percentage of T cells positive was determined (Fig 
4.1.4). F15-005-26 was positive with 62~ and 36' of T cells at 1/2 and 1/10 
dilutions respectively. F36-CB10-18 was positive with 68' and 63\ at 
dilutions 1/2 and 1/10 respectively. On comparison of F36-CB10-18 (lgM 
concentration 42J,Jg/ml) and F15-DD5-26 (lgM concentration 68J,Jg/ml), the 
higher binding reactivity of F36-CB10-18 at 1/10 dilution, despite lower 
IgM levels confirms improved binding affinity to T cells. 
B cell binding with FITC anti-human-IgM alone (negative control) gave a 
negative peak and a positive 'tail', indicating cell surface IgM negative 
and positive B cells respectively. The two distinct B cell subpopulations 
could not be distinguished using linear profiles as was seen on the 
FACScan. Binding of the autoreactive MAbs showed no discrete peak of 
positive cells (Fig 4.1.3). The graphs demonstrated long flat profiles, 
ranging from weakly positive cells (left) to intensely positive B cells 
(right). Approximately 25' of B cells gave maxilllum fluorescence in channels 
999-1000. This was true for both the autoreactive and anti-RhO KAbs. 
On lowering the fluorescence intensity 'gain' (Pig 4.1.S), the intensely 
positive cells formed a broad peak, and the weakly positive cell. entered 
channell (negative). As with the logarithmic profile. on the FACScan, it 
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was not possible to determine the percentage of B cells positive, as the 
weakly positive cells overlapped with the cell surface IgM positive B cells 
in the negative control. Therefore in all subsequent fluorescence binding 
data, . mean channel fluorescence values have been calculated following 
subtraction of the appropriate negative control (FITc-anti-human-IgM 
alone) • 
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Figure 4.1.4 Cytofluorograph analysis of F15-DD5-26 and F36-CBI0-IB 
binding at 1/2 and 1/10 dilutions to T cells. The negative control (FITC 
alone) has been electronically subtracted, allowing calculation of the 
percentage cell positive at each dilution. 
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Figure 4.1.5 Cytofluorograph profiles of F15-DD5-26, F36-CBI0-1B and HAD 
binding at 1/2 and 1/10 dilutions to B cells. The fluore.cence 'gain' has 
been reduced to enable improved visualisation of the binding profile. 
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4.1.3 Binding profiles of autoreactive and anti-RhO MAb' at .erial 
dilutions 
MAbs F15-DD5-26 and F36-CB10-18 were te.ted at doubling dilution. again.t 
T and B cell. on a cytofluorograph (Fig 4.1.6). The profile. demon.trated 
high mean channel fluorescence values with B cell. at all dilution •• A mean 
of 21\ and 28\ of B cells were in channel. 999-1000 for F1S-00S-26 and F36-
CB10-18 respectively. This remained conatant to a dilution of 1/64 and 
dropped to 9\ at a dilution of 1/128. T cell profiles demonatrated 
relatively low mean channel fluorescence values which dropped on dilution. 
F36-CB10-18, which was selected for improved T cell binding affinity gav. 
higher mean channel fluoresc.nce at a dilution of 1/2. Thia fell .harply 
through dilutions 1/4, 1/8 and 1/16. 
Fluorescence binding profiles of the lymphocytotoxic autoantibodie. F1S-
005-26 and F36-CB10-18 were compared to FOM-A (anti-RhO), by te.ting at 
doubling dilutions against spleen T and B cell. from a RhD negative donor 
(Fig 4.1. 7a and b). Little diff.rence in binding profile. wa. ob.erved 
between the autoreactive MAb. and FOM-A (anti-RhO). Thi. wa. true for RhO 
positive and RhO negative donor. (data not shown). The re.ult. .how 
relatively high binding to B cell. to 1/32 dilution, wherea. T cell. gave 
lower mean channel fluor.scence. The level of binding to T cell. wa •• till 
further reduced on dilution. These resulta, and tho.e of Fig 4.1.6 indicate 
that the weaker binding profiles with T cell. i. not a re.ult of antibody 
concentration, but that they constitute lower affinity target •• 
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Figure 4.1.6 Cytofluorograph analysis of F15-DDS-26 and F36-CB10-1B 
binding to T and B cells at serial dilutions from 1/2 to 1/128. All mean 
channel fluorescence values in this and subsequent figures have had the 
appropriate negative control values (FITC-goat-anti-human IgM alone) 
subtracted. 
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Figure 4.1.7 Comparison of cytofluorograph binding profile. of human IgN 
autoreactive (F15-DD5-26 and F36-CBIO-18) and anti-RhO (FON-A) NAb. te.ted 
at doubling dilutions using spleen T cells (panel a) and B cell. (panel b) 
from a RhO negative donor. 
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4.1.4 Fluorescence binding profiles of autoreactive and anti-RhD MAP' 
against a panel of T and B cells 
To confirm this observation, F15-DD5-26, F36-CBI0-18 and FOM-A were te.ted 
at dilutions of 1/2 and 1/10 against a panel of donor lymph node and .pleen 
T and B cell. (Fig 4.1.8). B cell binding profile, revealed a relatively 
high mean channel fluorescence, whichwaa not significantly changed between 
the dilutions 1/2 and 1/10 (366 ±26 and 330 ±23 respectively). A mean of 
31\ and 25\ of B cells gave maximum fluorescence value' at channels 999-
1000 at dilution. 1/2 and 1/10 respectively. The binding profile. of T 
cells revealed a relatively low mean channel fluorescence at 1/2 dilution 
(172 ±11), which was further reduced at 1/10 (92 ±9). Thi. data confirms 
that the lower sensitivity of T cells relative to B cell targets is not due 
to antibody concentration but is a result of low antigen den,ity and/or low 
antibody binding affinity. The data al.o confirm. higher T cell binding 
affinity by F36-CB10-18, and that high binding to B cells was con,i,tent 
regardless of the selection of high affinity antibodies. 
(Data comparing the mean channel fluorescence and standard errors are given 
numerically in Table 4.1.1) 
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Figure 4.1.8 CytoLluorograph binding proLiles oL autoreactive (F15-DD5-
26 and F36-CBI0-1B) and anti-RhO (FOil-A) human IgllllAbs t.sted at dilutions 
1/2 and 1/10 against a panel oL lymph node and spl.en !' and B cells. The 
number oL panel cells used Lor each IIAb are: 
F15-DD5-26 -16 T cells and 12 B cells, 
F36-CBI0-18 -17 T cells and 13 B cells, 
FOIl-A -10 T cells and 11 B cells. 
Table 4.1.1 Standard Error of the Mean (SEM) 
Cell type T cells B cells 
Ab dilution 1/2 1/10 1/2 1/10 
mean ± SEM mean ± SEM mean ± SEM mean ± SEM 
F15-DD5-26 158.3 ± 11.2 86.9 ± 7.7 369.8 ± 29.6 337.6 ± 24.3 
F36-CB10-18 265.3 ± 13.7 131.5 ± 10.1 377.7 ± 27.4 358.0 :I: 21.8 
FOM-A 92.0 ± 8.1 56.4 ± 8.8 351.1 :I: 20.6 294.1 :I: 23.4 
Mean 172 :I: 11 92 :I: 9 366 :I: 26 330 ± 23 
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4.1.5 Effect of temperature on autoantibody binding 
Varying the precomplement incubation temperature in cytotoxicity •••• y. h •• 
been used to distinguish lymphocytotoxic .utoantibodies from HLA 
.ntibodies. Autoantibodies h.ve been reported to react more strongly .t low 
temperatures (4°C) whereas anti-HLA antibodies react more strongly .t w.rm 
temperatures (37°C). This test h.s been utilised in the cro •• m.tch te.t to 
distinguish damaging and non-damaging antibodies in ren.l transplantation. 
Binding profiles of the autoreactive MAb. P15-DDS-26 and P36-CBIO-18 at xlO 
concentrated, neat and 1/10 dilution were asses.ed using low affinity T 
cell and CLL cell targets, tested .t 4°C, 22°C .nd 37°C. 
Binding of Pl5-DD5-26 to CLL cells and T cells showed no influence of 
temperature (Fig 4.1.9 •• nd b). F36-CBIO-18 demonstrated a weak trend 
towards higher affinity binding to T cells .t 4°C comp.red to 37°C, but no 
influence was observed with CLL cell binding (Pig 4.1.9c and d). Therefore 
the results do not demonstrate improved binding affinity to T cell. and CLL 
cells at low incubation temperature •• 
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Figure 4.1.9 Cytofluorograph analysis of the effect of temperature on F15-
DD5-26 and F36-CBI0-IB binding (at ,,10 concentrated, neat and 1/10 
dilution) to low affinity CLL cell and T cell targets. 
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4.1.6 Discussion 
Fluorescent binding assays demonstrate that B cell. constitute high 
affinity targets, whereas T cell. and CLL cells are low affinity target •• 
Reliable absorption of B cell autoantibodies has only been achieved u.ing 
autologous B-LCL's (Deierhoi, Ting and Morris, 1985; Nicholls and RUs., 
1989) or extremely high concentrations of autologous PBL'. (zttenger and 
Robertson, 1987). Although these observation. have indicated the exi.tence 
of multiple autoantibody populations, the results are consistent with the 
view that they represent only one antibody population with differing target 
cell sensitivities. As B cells are the mo.t .ensitive target, autoantibody 
reactivity is only efficiently removed following absorption with high 
affinity targets such as B cell lines. T cell and CLL cell reactivity is 
more easily removed, as they represent low sensitivity target •• 
FACScan binding profiles demonstrate that both .urface IgM positive and IgM 
negative B cells are reactive with lymphocytotoxic autoantibodie.. Thi. 
suggests that these particular antibodies are not the IgM-anti-IgM type 
described by Cicciarelli and others (Ozturk and Terasaki, 1980; Takaha.hi 
et al, 1980; Cicciarelli et al, 1980; Ayoub at al, 1980). 
Binding to low affinity targets .uch as T celh and CLL cell. wa. not 
Significantly improved at low incubation temperature. (4°C) compared to 
warm temperatures (37°C). Varying the pre-complement incubation temperature 
has been used to distinguish damaging (HLA antibodies) from non-damaging 
(non-HLA) antibodies in the cro •• match test (Revillard, Rivera and Robert, 
1980; Lobo, Sturgill and Bolton, 1984; Iwaki et al, 1979). Poor graft 
survival has been reported in transplant. performed with a warm reactive 
positive crossmatch compared to improved graft .urvival with a po.itive 
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crossmatch due to cold reactive antibodiea. However thia method of defining 
damaging and non-damaging antibodiea is not reliable as many aucceasful 
transplants have been performed in the pre.ence of warm reactive poaitive 
crossmatches (Oeierhoi, Ting and Morri., 1983). 
The differential autoantibody binding to T and B cell. indicate. that the 
nature of the auto-antigen varies on cells of different lineage. 
difference in cell surface expression may be due to post translational 
modification of the autoantigen, which may be different on T cella and B 
cells. Examples of such post translational modificationa of one antigen 
present on cells of different lineage have been described (Barclay, 
Letarte-Muirhead and Williams, 1976; Standring et al, 1978). Alternatively, 
higher binding to B cells may be explained on the basis of difference. in 
cell surface electrostatic charge. B cells adhere to tissue culture plastic 
and nylon wool with higher affinity than T cells. These properties have 
been used to separate T and B cells in vitro. In addition B cella have been 
shown to adsorb the blood group antigen 'Lewis' onto its cell surface, 
whereas T cells do not express Lewis (Park et al, 1979). An electroatatic 
interaction may enable stronger binding of polyreactive IgM antibodiea to 
B cells relative to T cells. This may offer an explanation for the broad 
range of B cell binding, from weakly reactive to strongly reactive, seen 
on the linear cytofluorograph profiles. 
Similar binding profiles were observed for T and B cell. when comparing the 
autoreactive and the anti-RhO MAbs. Thia is conaiatent with the 
cytotoxicity profiles previously described (Chapter 3). Similarities 
between binding of the human IgM autoreactive antibodies and tho.e of KAbs 
of defined specificities (anti-RhO) indicate. that binding to T and B cell. 
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may be non-specific. The results are in accordance with the proposal that 
lymphocytotoxic autoantibodies in renal dialysis patients share many of the 
characteristics described for polyreactive 19M antibodies. The data 
demonstrates that they represent a similar group of antibodies, which can 
bind multiple antigens which may vary on T cells, B cells and eLL cell •• 
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4.2 Autoantibody binding iphibition .tudia. 
Reports on the specificities of lymphocytotoxic autoantibodie. in renal 
dialysis patients have shown IgM and 19O Fc (rheumatoid factor.) to ba 
possible target molecules (Cicciarelli et al, 1980; Ozturk and Terasaki, 
1980; Takahashi et al, 1980; Ayoub et al, 1980). Polyreactive antibodie. 
may al.o react with IgM and IgO Fc and in addition with molecule. .uch a. 
lipid-A and phosphatidylcholina (PtC) (Schru.ter et al, 1979; Mercolino at 
al, 1988; Nakamura et al, 1988; Van Rooijen, 1989). 
As possible candidates for the .pecificitie. of the autoreactive 
(polyreactive) antibodies generated in this study, binding inhibition 
studies were performed using IgM, IgO, lipid-A and phosphatidylcholine to 
inhibit binding of the monoclonal autoantibodies to T and B lymphocyta •• 
4.2.1 Binding inhibition using lipid-A and PtC: 
Autoreactive MAbs (F1S-DDS-26 and F36-CBI0-18) and anti-RhO MAb (roM-A) at 
dilution. 1/2 and 1/10, were incubated with T and B cell. in tha presenca 
of lipid-A (0·2mg/ml) or phosphatidylcholine (100mg/ml), and mean channel 
fluorescence values were compared to untreated control.. PtC at thi. 
concentration produced an emulsion, most of which wa. washed away during 
the binding assay. The remaining Ptc contaminants gave broad 
cytofluorograph scatter profiles, above which a di.tinct population of 
lymphocytes were gated. 
No binding inhibition wa. found with lipid-A again.t T or B call targat. 
(Fig 4.2.1a and b) nor with Ptc against T or B cell target. (Fig 4.2.2. and 
b). 
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Figure 4.2. J Binding inhibition of autoreactive (FJ5-DD5-26 and F36-CBJO-
J8) and anti-RhD (FOM-A) human IgM MAbs tested at J/2 and 1/10 dilutions 
against T cells (panel a) and B cells (panel b) by lipid-A. 
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Figure 4.2.2 Binding inhibition of autoreactive (F15-DD5-26 and F36-CBI0-
18) and anti-RhD (FOM-A) human IgM MAbs tested at 1/2 and 1/10 dilutions 
against T cells (panel a) and B cells (panel b) by pho.phatidylcholine. 
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4.2.2 Binding inhibition using human IgG and IgK: 
Autoreactive and anti-RhD KAbs were tested as above for binding inhibition 
using human IgG and IgK. No binding inhibition was found for IgG against 
T or B cell targets (Fig 4.2.3a and b). The purified polyclonal IgM alone 
(negative control) gave strong background binding (Fig 4.2.4a and b) (no 
background values have been deducted from this data). The non-specific 
background binding was stronger with B cells than T cells, as has been 
noted for the autoreactive antibody binding. Despite the negative control 
binding, the addition of the autoreactive KAbs (F1S-DDS-26 and F36-CB10-
18) gave an increased mean channel fluorescence compared to the negative 
control (lgM alone). The increase in mean channel fluorescence shifts above 
background values was similar to those seen in normal binding assays using 
F1S-DDS-26 and F36-CB10-18 alone. Therefore the results indicate normal 
binding profiles of the monoclonal autoantibodies to both T cells and B 
cells, in the presence of free and cell bound human IgM. In view of the 
relative concentration of IgM present (OoSmg/ml for polyclonal IgM, 
compared to between 6-30~g/ml for the autoreactive KAbs), there was no 
evidence of binding inhibition to T or B cells. The non-specific IgM 
binding in the 'negative controls' also supports the observation that many 
different human IgM antibodies may be polyreactive, capable of binding 
strongly to B cells and less strongly with T cella, resulting in apparent 
lymphocytotoxic autoantibody profiles. 
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Figure 4.2.3 Binding inhibition of autoreactive (F15-DD5-26 and F36-CBIO-
18) and anti-RhO (FOM-A) human IgM MAbs tested at 1/2 and 1/10 dilutions 
against T cells (panel a) and B cells (panel b) by human IgG. 
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Figure 4.2.4 Binding inhibition of autoreactive (F15-DD5-26 and F36-CB10-
18) and anti-RhO (FON-A) human IgN NAbs tested at 1/2 and 1/10 dilutions 
against T cells (panel a) and B cells (panel b) by human IgN. 
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4.2.3 Discussiop 
Van Rooijen has described naturally occurring autoantibodies reactive with 
phospholipids in human and rabbit .era (Van Rooijen, 1989). The.e 
antibodies are postulated to arise from exposure to endotoxin. 
(lipopolysaccharide) or their lipid containing fractions. Lipid. derived 
from the endotoxins of Gram negative bacteria are absorbed onto the ho.t 
cell membrane. This stimulates autoreactive IgM antibodies which bind to 
phospholipid. on the cell surface. Antibody reactivity i. thought to be 
directed at the polar heads of phospholipid. found in the membrane of all 
cells (Mercolino et al, 1988). Phosphatidylcholine alone is non-immunogenic 
but lipid A (endotoxin fragment) insertion into the cell membrane can serve 
as a hapten/carrier, facilitating the generation of autoantibodies reactive 
with lipid A and with phosphatidylcholine (Schruster et al, 1979). Lipid 
A is an endotoxin from Gram negative bacteria and can absorb to the cell 
membrane of lymphocytes which may trigger autoreactive anti-phospholipid 
lymphocytotoxic antibodies. Endotoxins from Gram negative bacteria are 
widely found in the environment and are absorbed through the gut. They are 
also found in high concentrations in vaccine •• Therefore normal individuals 
are exposed to endotoxin. throughout their life. Lipopolysaccharide (LPS) 
and its lipid A fragment. are thymu. independent antigen. which do not 
require T cell help. Therefore the antibodies produced are IgM, and there 
is no immunological memory to this response. Anti-pho.pholipid antibodies 
are produced by the CDS positive subset of B cell. which appear to have a 
limited repertoire of specificities and share common idiotypic determinants 
(Mercolino et al, 1988). 
Casali and Botkins have described polyreactive IgM a. natural antibodies 
of the serum, giving the first line of defence (Casali and Botkin., 1989). 
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The broad binding reactivity of these antibodies, although inefficient in 
the destruction of invading pathogens, may allow the vital time required 
for the induction of a more specific and effective secondary response. It 
is unclear whether the same CDS positive B cells producing polyreactive IgM 
undergo antibody class switch and somatic mutation to produce specific high 
affinity IgG antibodies, or if these arise from a separate lineage of CDS 
negative B cells. 
CDS positive B cells are increased in patients with rheumatoid arthritis 
(27-52%) compared to normal controls (20%). Polyreactiva antibodies have 
also been identified in these patient •• This correlate. with the finding. 
of Ozturke who reported a high incidence of lymphocytotoxic autoantibodies 
in patients with rheumatoid arthritis (Ozturk and Tera.aki, 1979). Ozturke 
also found a marked difference in the susceptibility to lysis of B cells 
compared to T cells using cytotoxic eera from normal individuals and from 
patients with various diseases. In addition, Park (Park, Terasaki and 
Bernoco, 1977) reported lymphocytotoxic autoantibodies in 20\ of normal 
healthy adults. The appearance of the autoantibodies has been correlated 
with infections and vaccination. (Jeannet, Benzonana and Arni, 1981, Cros., 
Greiner and Whittier, 1976, Macleod et al, 1987). 
Lymphocytotoxic autoantibodies have also been reported in patient. with 
Systemic Lupus Erythematosus (SLE). However unlike the autoantibodies 
previously described, these are often IgG and are equally reactive with T 
and B cells. Therefore it is possible that the autoantibodies in SLB 
patients represent a different type to those de.cribed in RA and renal 
dialysis patients. Alternatively, the .ame polyreactive autoantibody 
producing B cell in SLE patients clone. may differentiate into CD5 negative 
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B cells, undergoing somatic mutation with the production of high affinity 
IgG which react equally with T cells and B cells. 
However, despite observations correlating similaritias between 
lymphocytotoxic autoantibodies and polyreactive IgM binding 
characteristics, inhibition data using lipid-A and ptC indicate that 
binding of the monoclonal autoantibodies, and the non-specific binding of 
anti-RhO MAD to T and B cells is not directed at a lipid component of the 
lymphocyte cell membrane. Although the non-specific binding of the anti-
RhO MADs to lymphocytes and the monoclonal autoantibody profiles indicate 
that binding may be due to polyreactivity, the target molecula in this case 
does not appear to be PtC as has been found for many naturally occurring 
and induced polyreactive antibodies in humans and rabbits (Van Rooijan, 
1989) • 
Furthermore, these monoclonal autoantibodies were not inhibited by axcess 
concentrations of human IgG or IgM. This indicates that the MADs used in 
this study are not rheumatoid factors (lgM-anti-lgG) or react iva with IgM 
on the B cell surface (lgM-anti-lgM) as suggested by Cicciarelli. Two 
separate observations support this data. Firstly, cytotoxicity assays 
indicate that the monoclonal autoantibodies are reactive with both T and 
B cells, and that the different binding profiles are due to the target cell 
binding affinity. As T cells do not express cell surface immunoglobulin, 
and only a portion of adult spleen and lymph node B cell. expre •• IgM, the 
reactivity of lymphocytotoxic autoantibodies with all T and B calls 
indicate that cell surface I9K is an unlikely target. Furthermore, the 
FACScan profiles demonstrated autoantibody binding to both cell .urface IgM 
positive and negative B cells. Secondly, the lack of reactivity of tha 
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human 19M anti-rheumatoid factor MAb (RFAN) with T and B cells in 
cytotoxicity assays indicate that rheumatoid factor. par •• do not give 
rise to autoantibody profiles in cytotoxicity assays. 
These data indicate that 19G, 19M, lipid-A and pte are not the primary 
target molecules for lymphocytotoxic autoantibody reactivity. 
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autoantibody binding 
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Group 2. Lectins which caused increased autoantibody binding 
Group 3. Lectins which inhibited autoantibody binding 
5.2.2 Lectin inhibition of autoantibody binding in cytotoxicity testa 
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5.3 Sialic acid inhibition of autoantibody bipdipg 
5.3.1 Cytofluoroqraph analysis of sialic acid inhibition of autoantibody 
bindinq 
5.3.2 Cytotoxicity analysis of sialic acid inhibition of autoantibody 
bindinq 
5.4 Bffect of pIon autoantibody binding 
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5.1 Epzy.e digestion of lymphocyte cell .urfac. aptigep. 
Enzyme cleavage of cell surface molecules from lymphocytes was used to 
determine the biochemical nature of the autoantigen. The effect of 
proteolytic, glycosidic and liposidic enzyme digestion of antigenic 
determinants on lymphocyte membranes was investigated. Subsequent binding 
of ALA' s was analyzed to examine the protein, carbohydrate and lipid 
contributions to the antigenicity of the target molecule. The enzymes 
selected for this study were neuraminidase and amylase for carbohydrate 
analysis; papain, trypsin and peptidase for protein analysis and lipase for 
lipid and phospholipid analysis. 
5.1.1 Effect of Xeura.ipida.e dig •• tiop op ALA NAb bipdipga 
Neuraminidase (sialidase) was used to cleave N-acetyl neuramic acid (NANA) 
determinants from the cell surface of lymphocyte •• 
a) Specificity controls 
Positive and negative specificity control. were .elected to demonstrate the 
specific cleavage of sialic acid residues from the lymphocyte cell surface 
by neuraminidase. The mouse IgG MAb, W6/32, which binds a protein defined 
monomorphic determinant on HLA class I molecule. was used a. a negative 
control. Reactivity of W6/32 with HLA class I is resi.tant to neuraminidase 
treatment. Cytofluorograph analy.i. showed binding of W6/32 at 1/10 
dilution to T and B cells was increased following enzyme digestion (rig 
5.1.1). This suggests that sialic acid cleavage from HLA clas. I molecules 
allows increased binding of W6/32. 
MAb DF-Tl (a kind gift from D.J. Flavell, Oxford [stross et al, 1989a) 
which binds a neuraminidase sensitive .pitope on CD43 molecule. pr.s.nt on 
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T cells (Stross et al, 1989b) was selected as a positive specificity 
control. Enzyme treated cells were tested for CD43 binding using DF-T1 at 
1/2 and 1/10 dilutions (Fig 5.1.2). CD43 binding was completely removed at 
neuraminidase concentrations of 2'0 U/ml down to 0'25 U/ml, demonstrating 
specific activity of neuraminidase treatment. 
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Enzyme Treatment 
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mEl Neuram 0.4 U/ml • Neuram 0.8 U/ml 
Figure 5.1.1 Cytofluorograph analysis of W6/32 (mouse IgG anti-HLA-class 
I) binding at lIla dilution to ~ and B cells following neuraminidase 
treatment using O'S, 0'4 and 0·2 Ulml. 
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Figure 5.1.2 Cytofluorograph analysis of DF-Tl (mou •• IgG anti-CD43) 
binding at 1/2 and 1/10 dilutions to T c.ll. following n.urutinid ••• 
treatment using 2·0, 1·0, 0·5, and 0·25 U/ml. 
b) Cytotoxicity analysis of neuraminidase dige.tion on ALA MAb binding 
Neuraminidase treated T and B lymphocyte. were te.ted for ALA binding u.ing 
F1S-DDS-26 and F36-CBIO-1S MAb. by cytotoxicity. Following enzyme 
treatment, the cell. were >90' viable a. a •••••• d by eo.in dye exclu.ion. 
However 100' background ly.is was ob.erved following cytotoxicity te.t. 
using .nzyme concentrations down to 0·03 U/ml. Neuraminida.e at 0·015 U/ml 
gave no background cell lysis, however there was no reduction in the titre 
of the autoantibodies using this enzyme concentration (data not .hown). 
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The non-specific cell lYBie was found to be due to complement toxicity •• 
it did not occur in the absence of complement, or with heat inactivated 
complement. This finding ia in accordance with reports that cleavage of 
sialic acid from the cell surface result. in non-.pecific activation of the 
alternative complement pathway (Dr K.Wood, NOS, Oxford, personal 
communication). However, the test does demonstrate the cleavage of aialic 
acid residues from the cell surface using neuraminidase at concentration. 
of 0·03 U/ml. 
c) Cytofluorograph analyais of neuraminida.e digestion on ALA MAP binding: 
Neuraminidaae treated CLL cella, T cells and B cella were tested for 
inhibition of monoclonal autoantibody binding in fluoreacence binding 
aaaaya. Cytofluorograph profile. of enzyme treated and untreated cella were 
compared. 
i) CLL cella; CLL cella were tested for autoantibody binding with F15-
005-26 and F36-CB10-18 at 1/2 and 1/10 dilutions following neuraminida.e 
treatment uaing 0'1 U/ml and 0'05 U/ml (Fioa 5.1.3. and 5.1.3b). The 
cytofluorograph profiles show that the autoantibody binding to CLL cell. 
was markedly reduced following treatment at both enzyme concentrationa. 
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Figure 5.1.3a cytofluorograph binding profiles of F15-DD5-26 at 1/2 and 
1/10 dilutions to CLL cells following neuraminidase treatment at 0'1 and 
0'05 U/ml. 
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Figure 5.1.3b Cytofluorograph binding profiles of F36-CBI0-18 at 1/2 and 
1/10 dilutions to CLL cells following neuraminidase treatment at 0'1 and 
0-05 U/ml. 
164 
Figure 5.1.4 shows the mean channel fluorescence value. for F15-005-26 and 
F36-CB10-18 binding to CLL cell.. Following enzyme treatment, near 
background binding levels were found, demonstrating complete removal of the 
autoantigenic epitope by neuraminidase. 
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I'igure 5.1.4 
binding at 1/2 and 1/10 dilution. to eLL cell. following neurUlinid •• e 
treatment at 0·1 and 0·05 U/ml. 
ii) T And B cella1 MonoclonAl AutOAntibody binding to T cell. wa. not 
consistently removed At these enzyme concentration. and B cell binding wa. 
unaffected (datA not .hown). Neuraminida.e concentration. of 0·1 and 0·2 
U/ml reduced r15-DD5-26 binding at 1/2 dilution to T cell. by 19' and 28' 
re.pectively (Fig 5.l.5a). F36-CB10-18 binding at 1/2 dilution .howed a 46' 
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Neuraminidase Digestion 
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Figure 5.1.5 Cytofluorograph analy.i. of F15-DD5-26 and F36-CB10-lB 
binding at 1/2 and 1/10 dilution. to ~ cell. (panel a) and B cell. (panel 
b) following neuraminidase treatment at 0·1 and 0·2 U/_l. 
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and 53% reduction in mean channel fluore.cence (Fig 5.1.5a). The.e enzyme 
concentrations produced no effect on ALA binding to B cell. (Fig 5.1.5b). 
The effect of neuraminidase treatment on autoantibody binding to T cells 
was variable. One experiment, using F36-CB10-18 at 1/2 and 1/10 dilutions 
showed a marked reduction in autoantibody binding uaing neuraminidaae at 
0·8, 0·4 and 0·2 U/ml (Fig 5.1.6a). Again, B cell binding was unaffected 
at these concentrations (Fig 5.1.6b). Although the B cell profilea ahowed 
some shift to the left with F36-CB10-18 at 1/2 dilution, there waa no 
overall reduction in mean channel fluorescence at 1/2 or 1/10 dilutiona. 
These results indicate the involvement of a carbohydrate reaidue (aialic 
acid) in autoantibody binding to CLL and T cella, but not to B cella. The 
resistance of the B cell autoantigen to cleavage by neuraminidaae may be 
caused by differing degrees of sensitivity, or be due to a diatinct 
neuraminidase insensitive epitope. To inveatigate thia further, T and B 
cells were tested using an increased enzyme concentration of 1·0 U/ml (Fig 
5.1.7). As previously found, T cella ahowed a marked inhibition in 
autoantibody binding, with a mean reduction of 68' in mean channel 
fluorescence (Fig 5.1.7a). B cell binding showed a mean reduction of 35' 
following neuraminidase treatment at 1·0 U/ml (Fig 5.1.7b). Binding of the 
anti-RhO MAb, FOM-A, at 1/10 dilution waa reduced following neuraminidaae 
treatment using 1·0 U/ml for both T cells (Fig 5.l.7a) and B cella (Fig 
5.l.7b), although little effect was found at 1/2 dilution. 
The results suggest that autoantibody binding to CLL cells and T cella i. 
dependant on a sialic acid defined epitope, whereaa B cell binding ia only 
partially dependant on this molecule. 
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Figure 5.1.6a Cytofluorograph binding profiles of F36-CBI0-18 binding at 
1/2 and 1/10 dilutions to T cells following neuraminidase treatment at 0'8, 
0·4 and 0·2 U/ml. 
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Figure 5.1.6b Cytofluorograph binding profiles of F36-CB10-1S binding at 
1/2 and 1/10 dilutions to B cells following neuraminidase treatment at O·S, 
0·4 and 0·2 U/ml. 
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Figure 5.1.7 Cytofluorograph analysis of r15-DD5-26, r36-CBIO-IB and IOK-
A binding at 1/2 and 1/10 dilutions to T cells (panel a) and B cells (panel 
b) following neuraminidase treatment at 1·0 U/ml. 
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5.1.2 Effect of P.p.iR dige.tiop on ALA NAb bipdipg' 
.) Control .tudie. 
i) Cytotoxicity. Papain i. a proteolytic enzyme which cleave. HLA cla •• I 
molecule. from the cell .urface (Chapal and Weleh, 1972). The effect of 
papain treatment on T and B celle w.e te.ted ueing an HLA cl... I 
alloanti.era epacific for HLA-Bw6 by cytotoxicity. papain at concentration. 
of 2·0mg/ml down to 0·125mg/ml produced high background lyei. in the 
cytotoxicity a.say (data not .hown). Concentration. below 0·125mq/ml 
produced no reduction in titre with the HLA-cla.. I .lloantieera nor with 
the ALA MAD. (data not .hown). Therefore the cytotoxicity method could not 
be u.ed to determine the effect of papain on autoantibody binding. 
ii) Fluorescence binding assay. The mou.e IqG MAb W6/32, which recogni.e. 
a monomorphic protein defined determinant on all HLA cla •• I molecule. wa. 
u.ed •• a po.itive control in a fluore.cence binding •••• y. T cell. tre.ted 
with papain at 4·0mg/ml down to 0·25mg/ml were an.lyzed for W6/32 binding 
(Fig 5.1.8). Enzyme concentratione of O·S and 0·25mg/ml had little effect 
on HLA class I binding. At 1·0mg/ml a 35\ reduction in mean channel 
fluorescence was observed, and at 2·0 and 4-0mg/ml an 82\ and 93\ reduction 
in binding were found reepectively. Papain at 2·Omg/ml gave good 
cytofluorograph .catter profiles and at 4-Omg/ml had acceptable .catter 
profile •• Therefore the.e enzyme concentration. were .elected for analy.i. 
of ALA binding. 
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Figure 5.1.8 Cy~ofluorograph analysis of papain cleavage of HLA cla.s I 
molecules from T cells using enzyme concen~ration. of 4 - O.gl_l down ~o 
0·25mglml with W6132 (mouse IgG anti-HLA class I) at 1110 dilution_ 
b) Cytofluorograph analysis of papain treatment on ALA bindings 
Treatment of lymphocytes with papain at 2-0 and 4-Omg/ml wa. found to cau •• 
high non-specific background binding of the PITC-goat-anti-human-IgM alone 
( Fig 5 _ 1. 9 ) _ 
Attempts were made to block this non-specific s.cond layer binding with 
foetal calf serum (PCS) and human blood group AB •• ra (AB)_ rollowing 
enzyme treatment using papain at 2-0 and 4-Omq/ml, the c.lls were incubated 
with neat rcs or human AB serum, on ic. for 20 minutes, a. d •• cribed in 
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Materials and Methods (Chapter 2.3c). Non-specific background binding of 
FITC-rabbit-anti-mouse-IgG (RaM) and FITC-goat-anti-human-IgM (GaB) w.re 
measured (Fig 5.1.10). 
The results showed that there was no background binding to papain tr.ated 
cells when using RaM-IgG. However, the high background binding .een with 
GaB-IgM wa. completely blocked following incubation in foetal calf •• rum. 
Blocking with human blood group AD •• rum only .erved to increa.ed the 
background binding. 
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Figure 5.1.9 
background binding, F15-DD5-26 and F36-CBIO-IB binding to T cell. ~ollo"ing 
papain treatment at 2·0 and '·Omg/ml. 
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Cytofluorograph analysis of foetal calf •• Z'WI ('CB) and 
human AB serum (AB) blocking on background binding of 'ITC-rabbit-anti-
mouse-IgG and FITC-goat-anti-human-IgN to T c.lls following papain 
digestion at 2·0 and 4·0mg/ml. 
Blocking with FCS enabled analysis of the effect of papain digestion on 
monoclonal autoantibody binding to lymphocytes to be determined. ALA 
binding following treatment of T cells with papain at 2·Omg/ml, and with 
B cells using papain at 2·0 and 4·Omg/ml war. tested using F1S-DDS-26, FJ6-
CBIO-1S, and FOM-A (anti-RhO), at 1/2 and 1/10 dilutions (Fig 5.1.11). 
ALA binding to T cells was partially removed following treatment with 
papain, with a reduction in mean channel fluorescence of 32' and 37' for 
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F15-DD5-26 and F36-CB10-18 respectively (Fig 5.1.11a). No effect of papain 
digestion was found for FOM-A binding to T cella. In parallel control 
studies, reactivity of PA2.6 (mouse IgG anti-HLA class I) was reduced by 
7S', demonstrating papain activity. 
Binding inhibition to B cells was only found at 1/10 dilution, with 35' and 
46' reduction in F15-DDS-26 and F36-CB10-1S binding respectively (Fig 
5.1.11b). There was also a 70' reduction in FOM-A binding to B cella at 
1/10 dilution. Reactivity of the control antibody, PA2.6 (mouse IgG anti-
HLA class I), was completely removed following papain digestion. 
The results suggest that the autoantibody target antigen is possibly a 
glycoprotein molecule. However the effect of papain was les. than that for 
neuraminidase. 
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Figure 5.1.11 Cyto:fluorograph analysis of P15-DD5-26, P36-CBIO-IB Md POII-
A binding at 1/2 and 1110 dilutions and PA2.' (lMJuse IgG Mti-HLA-class I 
control) to 2' cells (panel a) and B cells (pMel b) :following papain 
digestion at 2·0 and 4·01llglal. (Background binding of PITC-goat-Mti-
human-Iglf in this and all subsequent en.yme digestion e"perilMtnts have been 
blocked with FCS as previously described). 
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5.1.3 'ff.ct of '.ptida •• dig •• tioR op ALA lAb bipdipg: 
Th. .ff.ct of peptidase digestion on autoantibody binding to T and B c.ll 
targets waf performed u.ing F15-DD5-26 and F36-CB10-18 at 1/2 dilution. 
(Fig 5.1.12). The results show peptida •• at 2·Omq/ml produced no 
significant change in mean channel fluor •• cenc •• 
Peptidase Digestion 
Target cells: T and 8 Lymphocytes 
Mean channel fluorescence 
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Enzyme treatment 
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Figure 5.1.12 Cytofluorograph analysis of 1'15-DD5-26 and I'J6-CB10-lB 
binding at 1/2 dilution to 2' and B c.ll targ.t. following p.ptida •• 
dig.stion at 2·0mg/ml. 
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5.1.4 Effect of Lip •• e dige.tiop oR ALA NAb bipdipg: 
Lipase digestion at enzyme concentrations of 2·0 and 4·0mg/ml was tested 
against T and B cell targets using F15-DD5-26 and F36-CB10-18 at 1/2 and 
1/10 dilutions (Fig 5.1.13). 
F15-DD5-26 and F36-CB10-18 binding to T cells at 1/2 dilution. was slightly 
increased following lipase digestion at 2·0 and 4 0 0mg/ml (Pig 5.1.13a). At 
1/10 dilution, no change in mean channel fluorescence values were found 
using lipase at 4'Omg/ml, and binding wa. increased with lipase at 
2·0mg/ml. 
Lipase digestion of B cell targets produced a small decrea.e in P15-DD5-
26 and F36-CB10-18 binding at 1/2 dilution (Fig 5.1.13b), and further 
inhibition of binding at 1/10 dilution. To confirm this ob.ervation, a 
second experiment was performed using lipase at 2'Omg/ml using T and B cell 
targets with F15-DD5-26, F36-CB10-18 and FOM-A at 1/2 and 1/10 dilutions 
(Fig 5.1.14). No consistent inhibition of NAb binding wa •• een in this 
experiment with either T cell. (Pig 5.1.14a) or B cell. (Pig 5.1.14b). 
The discrepancy of B cell binding between the.e experiment. remain. 
unresolved. There was no evidence of binding inhibition following lipase 
digestion of T cell targets in either experiment, and only a .mall 
reduction in ALA binding to B cells in one experiment. Therefore there i. 
insufficient evidence to support cleavage of the autoantigenic epitope from 
T or B cells by lipa.e. Clearly, the experiments lack appropriate control. 
to demonstrate enzyme cleavage of lipid molecule. from the cell aurface. 
This was due to difficulty in locating MAba known to bind a lipid defined 
antigenic determinant found on the cell .urface of human lymphocyte •• 
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Pigure 5.1.13 Cytofluorograph analysis o~ I'15-DD5-26 and P36-CB10-18 
binding at 1/2 and 1/10 dilutions to T cells (panel a) and B cells (panel 
b) following lipa.e treatment at 2·0 and '·Oag/al. 
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Figure 5.1.14 Cytofluorograph analysis of F15-DD5-26, 1'36-CBIO-lB and 1'011-
A binding at 1/2 and 1/10 dilutions to T cella (panel a) and B cella (panel 
b) following lipase treatment at 2·0mg/ml. 
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5.1.5 Effect of Aay1ase digestiop on ALA NAb bindipg: 
Amylase digestion of T and B cell targets was tested using enzyme 
concentrations of 2'0 and 6'25mg/ml using autoreactive MAbs (F15-DD5-26 and 
F36-CB10-18) and anti-RhD MAb (FOM-A) at 1/2 and 1/10 dilutions (Fig 
5.1.15) • 
A small reduction in mean channel fluorescence was observed for T cells 
using amylase at 2'Omg/ml (Fig 5.1.15a). There was no change in mean 
channel fluorescence values for T cells using amylase at 6'25mg/ml, 
although the cytofluorograph scatter profiles were poor (data not shown). 
There was no inhibition of autoantibody binding to B cell targets following 
amylase digestion at 2'Omg/ml (Figs 5.1.15b). As was seen for T cells, B 
cell targets treated with amylase at 6'25mg/ml had poor cytofluorograph 
scatter profiles. At 1/2 dilution there was increased B cell binding of 
F15-DD5-26 and F36-CB10-18 compared to the untreated controls (data not 
shown). However, at 1/10 dilution there was no change in binding levels. 
As for the lipase digestion, no suitable control MAbs which bind an amylase 
sensitive carbohydrate epitope on the lymphocyt. cell surface was found. 
Therefore amylase activity was not confirmed. However increased .nzyme 
concentrations above 2'Omg/ml resulted in a poor cytofluorograph scatter 
profiles which could not be assessed. 
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Figure 5.1.15 Cytofluorograph analyaia of P1S-DDS-26, P36-CB10-IB and FOII-
A binding at 1/2 and 1/10 dilutions to T cella (panel a) and B cella (panel 
b) following amylase treatment at 2·0mg/ml. 
182 
5.1.6 Effect of ~rypsin digestion OD ALA NAb binding: 
Trypsin digestion of T and B cell targets at a concentration of 2·Smg/ml 
was tested using F15-005-26, F36-CB10-18 and FOM-A at 1/2 and 1/10 dilution 
(Fig 5.1.16). 
T cell binding was marginally reduced for F15-005-26 and F36-CB10-18 at 1/2 
dilution, but not at 1/10 (Fig 5.1.16a). Binding of FOM-A (anti-RhO) to T 
cells was increased following trypsin digestion. 
Trypsin digestion of B cell targets produced no significant change in mean 
channel fluorescence for F15-005-26, F36-CB10-18 or FOM-A at either 1/2 or 
1/10 dilution (Fig 5.1.16b). 
In parallel assays, binding of PA2·6 (mouse IgG anti-HLA cla •• I) was 
reduced by only 10\ following trypsin digestion. Increased trypsin 
concentrations produced poor cytofluorograph scatter profiles which could 
not be analyzed (data not shown). 
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Pigure 5.1.16 CytoLluorograph analy.i. oL P15-DD5-26, P36-CB10-lB and POII-
A binding at 1/2 and 1/10 dilution. to 2' cell. (panel a) and B cell. (panel 
b) following trYP8in treatment at 2' 51ag/al. 
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5.1.7 Pi.cu •• iop 
The molecular nature of the epitopes recognised by ALA was inve.tigated by 
enzymatic cleavage of cell surface molecule.. The involvement of 
carbohydrate, protein and lipid residue. in ALA binding were d.termin.d. 
The results showed that ALA binding to low affinity T and eLL c.ll target. 
was dependant on N-acetyl-neuramic acid (.ialic acid), whereas high 
affinity binding to B cells was only partially d.pendant on this molecule. 
This indicates that the molecular natura of the autoantig.n may vary on 
cells of different lineage. There appear. to be a diff.rent distribution 
of autoantigenic epitopes on T and B cell. giving ri.e to the different 
binding profiles. Therefore, the difference. in T and B c.ll binding 
affinity found in cytotoxicity and binding as.ays may b •• xplained by 
differing carbohydrate composition of the autoantigen. 
Heterogeneity of carbohydrate residue. on identical protein mol.cul •• 
present on cells of different lineage have been report.d. Barclay et al 
have reported differential glycosylation of the Thy-1 mol.cule .xpr •••• d 
on rat thymocyt •• and the brain (Barclay, L.tart.-Muirhead and William., 
1976). In addition they identifi.d two type. of Thy-1 molecule on 
thymocytes according to their ability to bind lentil l.ctin, which th.y 
termed Thy-1L+ and Thy-1L-. In both example., Thy-l mol.cule. on thymocyt •• 
and brain had similar amino acid composition, but marked diff.r.nce. in 
carbohydrate compo.itions. In particular, .ialic acid r •• idu •• were found 
in .mall amount. on brain Thy-1 and in incr.a.ed amount. on thymocyte Thy-
lL+ and Thy-1L- molecule •• 
Differences in glycosylation of glycoprotein. on rat T and B cell. have 
also be.n report.d (Standring et al, 1978). The leucocyte common antigen 
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(LCA) on rat thymocytes, T cells and B cells were found to have molecular 
weights of 150,000, 170,000 and 200,000 kD respectively. These differences 
were due to differential glycosylation of LCA. Again, sialic acid was 
identified as an abundant membrane molecule associated with differential 
glycosylation. 
Moreover, evidence for the differential glycosylation of HLA-DR molecules 
has been found on cells of different lineage. Cowing (Cowing and 
Chapdelaine, 1983) demonstrated that HLA-DR molecules on normal resting B 
cells are unable to stimulate alloreactive T cells in a primary MLR, 
whereas HLA-DR on dendritic cells act as very potent stimulator of the MLR 
response. However, cleavage of sialic acid from the HLA class II molecules 
with neuraminidase restored the ability of B cells to stimulate a primary 
alloreactive response. 
The digestion of T and B cell targets with papain alao reduced ALA binding. 
These results, and those using neuraminidase, indicate the possibility of 
a glycoprotein molecule as the target molecule. The involvement of cell 
surface protein molecules could not be confirmed using peptidase or trypsin 
digestion. 
Lipase digestion of lymphocyte cell surface molecule. also produced no 
consistent difference in autoantibody binding. This support. the earlier 
findings where ALA binding was not inhibited by pte or lipid-A. The lipase 
results add further evidence to exclude the involvement of lipid 
determinants as the lymphocytotoxic autoantibody target molecule. 
The lack of suitable controls to demonstrate specific enzyme cleavage of 
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cell surface molecules in some experiments means that some results should 
be interpreted with caution. The methods used for these experiments were 
based on published data examining carbohydrate and protein contributions 
to various antigenic epitopes on HLA molecules (Sparrow, V.ugh.n .nd 
McKenzi., 1986). These reports .lso l.ck.d .ppropri.t. control. to confirm 
.pecific enzyme activity. Attempt. to incr ••••• nzyme conc.ntr.tion. from 
those used result.d in poor cytofluorogr.ph .c.tt.r profile. which could 
not be analyzed. Therefore the maximum enzyme concentr.tions possible for 
the.. experiments were used indicating th.t l.ck of .nzyme .ctivity w.s 
unlikely. 
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5.2 Lectip Inhibitiop Studi •• to D.t'raiD' ALA Specificiti •• 
Enzyme cleavage of lymphocyte cell surface molecule. indicated that a 
sialic acid defined epitope is involved in autoantibody binding. 
Corroborative evidence for this was sought by binding inhibition studi.s 
using lectins to block carbohydrate determinants. Lectins are proteins or 
glycoproteins of non-immune origin which can bind and precipitate complex 
carbohydrates. The lectins used, their carbohydrate specificities, blood 
group specificities and mitogenic properties are shown in Materials and 
Methods (Table 2.3.4). 
Purified T and B lymphocytes were pre-incubated with the appropriate 
lectin, then washed and tested for lymphocytotoxic autoantibody binding 
inhibition. The concentration of lectin used for thi. study (O·2mg/ml) wa. 
chosen to be about ten to twenty times that required in RBC agglutination 
assays, given by the manufacture. 
5.2.1 Cytofluorograph analysis of lectin inhibition of autoantibody binding 
Following lectin treatment of T and B cell target., three different 
patterns of lymphocytotoxic autoantibody binding reactivity were found 
( summar ised in Table 5.2. 1). The first group produced no change in 
autoantibody binding, the second produced increased autoantibody binding 
and the third produced inhibition of autoantibody binding. 
Group 1. Lectins which gave no change in autoantibody bindingl 
Ptilota plumasa, Sophora japonica, Ulex europaeus, Dolichos bifloru., 
Arachis hypogaea and Helix pomatia gave no change in lymphocytotoxic 
autoantibody binding after lectin treatment of T and B cell target. (rig' 
5.2.1-5.2.6). 
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Table S.2.1 Lectin Inhibition Results 
Lectin Inhibition re.ult. 
T cella 3 B cella 
DDS Ca10 FOM DDS Ca10 POM 
Group 1. 
Ptilota plumosa(Red marine algae) - - - - - -
Sophora japonica(Japanese pagoda) - - - - - -
U1ex europaeus (Gorse) - - - - - -
Dolichos biflorus (Horse gram) - - - - - -
Arachis hypogaea (peanut) - - - - - -
Helix pomatia(Roman edible anail) - - - - - -
Group 2. 
Vicia faba (Fava bean) * * * * * * 
Phaseolus vulgaris (Kidney bean) * * * (*) (* ) * 
Lena culinaria (Lentil) * * - - - -
Euronymua europaeua(Spindle tree) - * - - (*) -
Concanavalin A (Jack bean) NA * * - - * 
Group 3. 
Triticum vulgaris (Wheat germ) + + + + + + 
Mycoplasma gallisepticum + + + - - -
No change in autoantibody binding following lectin treatment. 
+ Inhibition of autoantibody binding following lectin treatment. 
* Increased autoantibody binding following lectin treatment 
(*) weak increase. 
NA Not assessed. 
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Figure 5.2.1 Cytofluorograph analysis of r15-DD5-26, r36-CB10-11 and 108-
A binding at 1/2 and 1/10 dilutions to T cells (panel a) and B cells (panel 
b) following Ptilota plumosa lectin treat.ent at 0·2ag/~. 
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Figure 5.2.2 Cytofluorograph analysis of F15-DD5-26, r36-CB10-l' and 10«-
A binding at 1/2 and 1/10 dilutions to 2' cells (panel a) and B cells (panel 
b) following Sophora japonica lectin treatment at 0·2~/.l. 
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Figure 5.2.3 Cytofluorograph analy.i. of F15-DD5-26, F36-CBIO-IB and FQN-
A binding at 1/2 and 1/10 dilution. to T cell. (panel a) and B cell. (panel 
b) following Ulex europaeu. lectin treatment at O·2ag/_l. 
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Figure 5.2.4 Cytofluorograph analy.i. of F15-DD5-26, F36-CB10-1B and FON-
A binding at 1/2 and 1/10 dilution. to ~ cell. (panel a) and B cell. (panel 
b) following Dolicho. bifloru. lectin treat.ent at 0·2~/.1. 
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Figure 5.2.5 Cytofluorograph analysis of FIS-DDS-26, FJ6-CBIO-l' and 10«-
A binding at 112 and 1110 dilutions to r cell. (panel a) and B cell. (panel 
b) following Arachis hypogaea lectin treae.ent at Oo2-v/.J. 
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rigure 5.2.6 Cytofluorograph analy.i. of r15-DD5-21, rJI-CBIO-l' and ~-
A binding at 112 and 1110 dilution. to r cell. (panel a) and • cell. ("anel 
b) following Helix po.atia lectin treac.ent at O·2~/.l. 
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Group 2. Lectins which caused increased aytoantibody binding: 
The following lectins resulted in increased lymphocytotoxic autoantibody 
binding to T and/or B cells. Vicia faba and Phaaeolus vulgaris produced 
increased binding to both T and B cells (Figs 5.2.7 and 5.2.8). Lens 
culinaris produced increased autoantibody binding to T cells alone (Fig 
5.2.9), and Euronymus europaeus produced increased T cell binding (and 
marginal increased B cell binding) for F36-CB10-18 only (Fig 5.2.10). 
Concanavalin A produced poor T cell profiles, with greatly increased 
autoantibody binding (Fig 5.2.11a, F15-DD5-26 binding profiles were not 
assessable), and a small increase in autoantibody binding to B cells (Fig 
5.2 .11b) • 
196 
Vicia faba Lectin Blocking 
Target cell: T lymphocytes 
Mean channel fluorescence 
500.------------------------------------------. 
400 
300 
200 
100 
o 
005 1/2 005 1110 C810 112 C8101l10 FOM-A 1I2FOM-A 1110 
Vicia faba Lectin Blocking 
Target cell: B lymphocytes 
Mean channel fluorescence 
500.------------------------------------------. 
400 
300 
200 
100 
o 
005 112 005 1/10 C8101l2 C8101l10 FOM-A 1I2FOM-A 1110 
Monoclonal antibody dilution 
Cell treatment 
_ Untreated _ Lectin 0.2mg/ml 
Figure 5.2.7 CytoLluorograph analy.i. oL 'J5-DD5-21, ,3I-c1JO-J' and 1Oa-
A binding at 1/2 and 1110 dilut.l.on. to r cell. (panel a) and • cell. (panel 
b) following Vicia Lava lectin treat.ent at O·2~/~. 
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Pigure 5.2.8 Cytofluorograph analy.i. of P15-DD5-21, 'JI-cBIO-l. and ~-
A binding at 112 and 1110 dilution. to 'r cell. (panel a) and • cell. ("anel 
b) following Pha.eolu. vulgari. lectin treac.ent at O·2~/~. 
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Figure 5.2.9 Cytotluorograph analy.i. ot '15-DD5-2f, 'Jf-c810-1' and ~-
A binding at 1/2 and 1/10 dilution. to r cell. (panel a) and • cell. (panel 
b) following Len. culinari. lectin treat.ent at 0·2~/~. 
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Figure 5.2.10 Cytofluorograph analyaia of '15-DD5-2f, 'Jf-c.10-l' anel I'0Il-
A binding at 112 and 1110 dilutiona to ~ cella (lJanel a) anel. cella (lJanel 
b) following Euronymua europ.eua lectin treat.ent at O·2~/~. 
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Figure 5.2.11 Cytofluorograph analy.i. of I"lS-DD5-26, "36-CBlO-l B and I'0Il-
A binding at 1/2 and 1/10 dilution. to 2' cell. (panel aJ and B cell. (panel 
bJ following Concanavalin A lectin treatment at 0·2~/.1. 
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Group 3. Lectins which inhibited autoantibody binding: 
The lectin from Triticum vulgaris (wheat germ), which binds sialic acid, 
strongly inhibited autoantibody reactivity against both T and B cell 
targets (Fig 5.2.12). A mean inhibition of 53\ and 72\ was found for 
autoantibody binding to T cells (low affinity target) and B cella (high 
affinity target) respectively. Binding of FOM-A (anti-RhD) to T and B cells 
was also inhibited. To confirm this observation, in a second independent 
experiment, a mean T cell binding inhibition of 35\ and B cell binding 
inhibition of 69\ was seen for F15-DD5-26, F36-CB10-18, and MAD (anti-
RhD) (data not shown). 
Mycoplasma gallisepticum produced 59\ inhibition of autoantibody binding 
to T cell targets, but no inhibition with B cell targets (Fig 5.2.13). 
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Figure 5.2.12 Cytofluorograph analy.i. of r15-DD5-26, r36-CB10-1B and roII-
A binding at 1/2 and 1/10 dilution. to T cell. (panel a) and B cell. (panel 
b) following Triticum vulgari. lectin treae.ent at O·2~/.l. 
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Figure 5.2.13 Cytofluorograph analysis of '15-DD5-26, '36-CBI0-IB and rcJII-
A binding at 1/2 and 1/10 dilutions to 2' cells (panel a) and B cells (panel 
b) following Mycoplasma gallisepticua lectin treatment at 0·2ag/al. 
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5.2.2 Lectin inhibition of autoantibody binding in cytotoxicity teltl 
Cytofluorograph binding inhibition studiel indicated that pretreatment of 
T and B cells with lectin from Triticum vulgaril blocked monoclonal 
lymphocytotoxic autoantibody binding. In an attempt to apply thi. finding 
to block autoantibodies in the crossmatch test, reactivity wa. allessed 
following lectin treatment of cell. in the cytotoxicity allay. 
T and B lymphocyte I were pretreated with different concentration. (.erial 
dilutionl from 10mg/ml to O'015mg/ml) of lectin from Triticum vulgari •• The 
cellI were then tested by cytotoxicity uling autoreactive and anti-HLA 
antibodie. and the titrea were compared to untreated control •• Monoclonal 
lymphocytotoxic autoantibodiel (P1S-00S-26, P36-CB10-18), anti-RhO (MAD), 
anti-HLA-A2 alloserum and a T and B cell lymphocytotoxic autoantibody from 
a renal dialYlis patient (OV) were te.ted. volume. of 1~1 of each reagent 
were dispensed at lerial dilutions from neat to 1/128 into the well. of 
microtest trays. Each serum dilution was tested with lectin treated and 
untreated T and B cells for cytotoxicity inhibition. 
No change in cytotoxicity titres were found for any combination of lectin 
and antibody concentration with either T or B cells (data not shown). 
S.2.3 Autoantibody binding to lectins 
Cytofluorograph binding .tudie. demon.trated increa.ed binding of 
monoclonal autoantibodiea to T and B cell. coated with lectin from Vicia 
fava and Phaaeolul vulgari.. Thi. indicated that the polyreactive 
antibodies could bind the lectin on the cell Burface. An alternative 
posaibility is that the lectin is polyvalent, being able to bind both the 
cell membrane and IgM carbohydrate determinant.. To inve.tigate thi. 
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further, two teata were performed to analyze the nature of the lectin 
binding. 
i) Lyaia of lectin coated red blood cella by 1ymphocytotoxic autoantibodiel 
and complement. 
The method was followed aa described in Material. and Methods (2.3 g-iv). 
Red blood cells were coated with lectin and allowed to agglutinate in 96 
well microtitre plate.. Thi. was followed by the addition of 
lymphocytotoxic autoantibodies (1"15-005-26 and F36-CB10-18) and anti-RhO 
(POM-1) MAbs at doubling dilutions from 1/2 to 1/2048. To detect binding 
of the antibodies to lectin coated red cells, rabbit complement was added 
and following incubation the well. were examined for cell lysi, (Table 
5.3.1). 
The results show that red blood cells coated with lectin from Phaseolus 
vulgaris were lysed in the pre.ence of the autoreactive MAbs and rabbit 
complement (Table 5.3.1 panel a). 1"15-005-26 gave 100~ lysis at 1/2 
dilution and 1"36-CB10-18 to 1/8 dilution. No lysis was seen with 1"OM-1 nor 
in the PBS controls. 
Blood group B RhO negative red cell' coated with lectin from Buronymul 
europaeus were also lysed by 1"15-005-26 and 1"36-CBIO-18 to 1/8 and 1/32 
dilutions re'pectively (Table 5.3.1 B). Thil lectin produced increa,ed 
binding of 1"36-CB10-18 to lymphocyte. in cytofluorograph analYlil. AI the 
IgM levels of 1"15-005-26 (67~g/ml) are higher than 1"36-CB10-18 (42~g/m1), 
the increased titre of 1"36-CB10-18 can not be due higher to immunoglobulin 
levels. Therefore the result. are more likely to relate to the antibody 
specificity, with the autoantibodies binding to the lectin. However, the 
206 
possibility of the lectin binding the IgM can not be ruled out. 
Additional controls, consisting of untreated red celle with antibody plus 
complement (in the absence of lectin), and also red cells coated with 
lectin from Triticum vulgaris (which caused inhibition of autoantibody 
binding) resulted in weak red cell lysis at MAb dilutions of 1/2 for P15-
005-26 and 1/4 with F36-CB10-18 (data not shown). The difference in red 
cell lysis between the controls and the presence of lectin from Phaseolus 
vulgaris and Euronymus europaeus were marked. Although the weak lysis of 
untreated red cells by autoreactive MAbs and complement indicated some 
binding, fluorescence binding assays analyzed on a cytofluorograph were 
completely negative (data not shown). In control studies, FOH-1 (anti-
RhO) was found to bind specifically to RhO positive but not RhO negative 
red blood cells. The results may indicate weak low affinity binding of the 
autoreactive MAbs to red blood cells which is only detected in cytotoxicity 
assays as no washing steps are involved. This would be compatible with the 
hypothesis that the antibodies are polyreactive and bind with low affinity 
to multiple antigenic targets. 
The results indicate that the antibodies can bind lectin coated red blood 
cells and support the cytofluorograph analysis data which showed increased 
binding of autoreactive MAbs to lectin coated lymphocytes. The higher 
titres of F36-CB10-18 de.pite lower immunoglobulin levels argue against the 
possibility that the lectin i8 binding 19M directly. However due to the 
weak background lysis in the negative controls, the result. should be 
interpreted with caution. 
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Monoclonal antibody dilution (reciprocal) 
2 4 8 16 32 64 128 256 512 1024 2048 
005-26 + (+) - - - - - - - - -
+ (+ ) - - - - - - - - -
CB10-18 + + + (+) - - - - - - -
+ + + (+) - - - - - - -
FOM-1 - - - - - - - - - - -
- - - - - - - - - - -
PBS - - - - - - - - - - -- - - - - - - - - - -
(A) Lysis of blood group A RhO nega~ive red cells coa~ed wi~h 
lectin from Phaseolus vulgaris. 
Monoclonal antibody dilution (reciprocal) 
2 4 8 16 32 64 128 256 512 1024 2048 
005-26 + + + (+) - - - - - - -
+ + + (+) - - - - - - -
CBlO-l8 + + + + + (+) - - - - -
+ + + + + (+) - - - - -
FOM-1 - - - - - - - - - - -- - - - - - - - - - -
PBS - - - - - - - - - - -- - - - - - - - - - -
(B) Lysis of blood group B RhO nega~ive red cells coated wi~h 
lectin for Euronymus europaeus. 
Table 5.3.1 Au~oantibody and complement mediated lysis of Phaseolus 
vulgaris (A) and Euronymus europaeus (B) coated red blood cells from blood 
group A and B RhD negative donors respectively. (+. cell lysis, -. no 
cell lysis). 
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ii) Inhibition of lectin agglutination of red blood cells by 
lymphocytotoxic autoantibodies. 
To confirm the formation of lectin/IgM complexes, the ability of the 
lymphocytotoxic autoantibodies to inhibit lectin agglutination of red blood 
cells was determined. The method was followed as described in Materials and 
Methods (Chapter 2.3-g-iii). Autoreactive MAbs (F1S-DDS-26 and F36-CB10-
lS) and anti-RhD MAb (FOM-1) at serial dilutions from neat to 1/1024 were 
incubated with the appropriate lectin at O·2mg/ml for one hour at 22°C, 
followed by the addition of 100~1 of a 2\ red blood cell suspension. The 
lectins selected for study were Phaseolua vulgaris, Ulex europaeus, 
Euronymus europaeus and Triticum vulgaris. 
The results (Table 5.3.2) show inhibition of Phaseolus vulgari8 lectin 
agglutination of red blood cells by F1S-DDS-26 and F36-CB10-1S to dilution8 
of 1/8. FOM-1 gave no agglutination inhibition in this experiment but gave 
weak inhibition at neat only in 8ubsequent te.t. (data not shown). 
Incubation of Phaseolus vulgaris in PBS-DAB alone gave no inhibition. 
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Monoclonal antibody dilution (reciprocal) 
N 2 4 8 16 32 64 128 256 512 1024 
DD5-26 - - - (-) (+) + + + + + + 
- - (-) (+) + + + + + + 
CB10-18 - - - (+) (+) + + + + + + - - - (-) (+) + + + + + + 
FOM-1 (-) + + + + + + + + + + 
(-) + + + + + + + + + + 
PBS + + + + + + + + + + + 
+ + + + + + + + + + + 
Table 5.3.2 Inhibition of red blood cell agglutination by lectin frollt 
Phaseolus vulgaris at 0'2~g/ml by autoreactive (FI5-DD5-26 and F36-CB10-
18) and anti-RhO (FON-I) NAbs at dilutions neat to 1/1024 (+ -
agglutination, - - no agglutination). 
The lectins from Triticum vulgaris and Ulex europaeu. (which cau.ed no 
increase in MAb binding to lymphocytes) gave no inhibition of red cell 
agglutination (data not shown). However the lectin from Euronymu. europaeu. 
(which caused increased MAb binding to lymphocyte. and MAb ly.i. of lectin 
coated red cells) also gave no inhibition of agglutination. Thi. 
observation is not consistent with the interpretation of the previous 
results indicating the formation of MAb/lectin complexes u.ing lectin from 
Euronymus europaeus. It is however pos.ible that the formation of MAb 
complexes with this lectin does not block it. ability to agglutinate red 
blood cells. 
The data indicates the presence of Ph.seolu. vulgari./MAb complexes which 
block the ability of the lectin to bind red blood cell.. The re.ult. 
further support the suggestion that the autoantibodies bind the lectin from 
Phaaeolus vulgaris on the cell surface. 
210 
iii) Lectin inhibition of autoantibody binding in the lymphocytotoxicity 
test 
The above data indicates that the autoantibodies can bind some lectin. on 
the cell surface of lymphocytes and red blood cells. In addition, 
inhibition of red cell agglutination .howed that the autoantibodies form 
MAb/lectin complexes which block lectin activity. It is therefore possible 
that the formation of MAb/lectin complexes may also block lymphocytotoxic 
autoantibody reactivity. 
Attempts were made to utilise the formation of MAb/ lectin complexes through 
inhibition of autoantibody reactivity in the cytotoxicity test. F15-DD5-
26, F36-CB10-18, FOM-1, anti-HLA-A2 alloaerum, anti-HLA-Bw6 alloaerum and 
serum from a patient with T and B cell lymphocytotoxic autoantibodies (DV) 
were tested at serial dilutions from neat to 1/128. The reagents ware 
incubated with lectin from Phaseolu. vulgaris, Triticum vulgari., Ulex 
europaeus and Vicia fava at concentrations of 50 and 25~g/ml in PBS-DAB. 
As untreated control. MAbs were incubated with PBS-DAB alone. Volume. of 
1~1 were then dispensed into a microtest tray under paraffin oil and tested 
against T cell targets in a standard cytotoxicity assay. Cytotoxicity 
titres of the lectin treated and untreated antibodies were compared. 
No inhibition of MAb cytotoxicity was found (data not shown). Additional 
experiments were performed using Vicia fava at serial dilutions from 
500~g/ml to 3·8~g/ml with the above reagents using T cell targets. These 
also produced no cytotoxicity inhibition (data not shown). 
The above results using cytofluorograph analysis, lectin coated red blood 
cell cytotoxicity and monoclonal autoantibody inhibition of lectin/red 
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blood cell agglutination all indicated the formation of lectin/NAb 
complexes. These complexes were able to inhibit lectin binding to red blood 
cells, however no inhibition of monoclonal autoantibody reactivity was 
observed in cytotoxicity tests. It is possible that the lectin formed 
complexes with the IgK antibodies by binding carbohydrate determinant. 
without inhibiting the antibody binding site and/or blocking it. ability 
to activate complement. Therefore these findings were not helpful for the 
differentiation of autoreactive antibodies and HLA antibodies in the 
crossmatch test using a cytotoxicity assay. 
The dichotomy of effective blocking of autoantibody binding by lectin from 
Triticum vulgaris in cytofluorograph assay. but not in cytotoxicity te.t. 
is also difficult to resolve. Result. of both test. were reproducible, and 
yet the use of lectin inhibition to distingui.h autoantibodies from 
alloantibodies by cytotoxicity does not work. 
5.3 Sialic acid inhibitiop of autoantibody bipdipg 
The results of neuraminidase treatment of eLL cell., T and B cell. and the 
inhibition of autoantibody binding by the lectin Triticum vulgaris are both 
consistent with the view that autoantibody binding is dependant on a .ialic 
acid defined epitope. Therefore attempt. were made to block autoantibody 
binding to T and B cells using sialic acid in cytofluorograph binding and 
cytotoxicity assays. 
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5.3.1 Cytofluorograph analysis of sialic acid inhibition of autoantibody 
binding 
Fluorescence binding assays were performed with T and B cell targets using 
autoreactive MAns (F15-DD5-26 and F36-CB10-18) and anti-RhO MAb (MAO) at 
1/2 and 1/10 dilutions in the pr.s.nc. of sialic acid at 25 and 12·Smg/ml. 
Due to the low pH of the sialic acid (pH4·0), the untr.at.d controls war. 
also adjusted to pH4'0 accordingly (Fig 5.3.1). 
The results show increased autoantibody binding to both T and B c.lls 
targets in the presence of sialic acid compar.d to the untr.at.d controls. 
This indicates that there was no blocking of autoantibody binding in the 
presence of free sialic acid. However, unlike in previous obs.rvations, T 
cell binding at pH4'0 (negative control) showed higher autoantibody binding 
at 1/10 than at 1/2 dilution. This contrasts with the consist.nt 
observation of reduced binding to low affinity T c.ll targ.t. following 
autoantibody dilution at pH7' 2 (Chapter 4). Viability t.sts using .osin dye 
exclusion demonstrated that both the sialic acid tr •• t.d and untr.at.d 
cells were >95' viable (d.ta not shown), th.r.for •• xcluding the 
possibility of non-specific binding to dead c.ll •• 
The lack of inhibition by free (synthetic) sialic acid may b. due to 
different conformations of sialic acid dependant .pitopa. pre •• nt on 
membrane bound glycoprotein molecules comp.red to free .ialic .cid in 
solution. However the results indicate incr •••• d MAb binding to low 
affinity T cell targets at low pH. It i. po •• ibl. that .utor •• ctiv. 
antibodies may bind negatively charged c.ll surface molecul •• , shOWing 
increased affinity at low pH due to the pr ••• nce of th ••• mol.cul •• in 
ionised form. 
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Figure 5.3.1 cytofluorograph analysis of FI5-DD5-2f, FJf-CB10-1B and NAD 
binding at 1/2 and 1/10 dilutions to T cells (panel aJ and B cells (panel 
b) in the presence of free sialic acid at 12·5 and 25·0ag/_l. 
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5.3.2 Cytotoxicity analysis of sialic acid inhibition of autoantibody 
binding 
MAbs were incubated with an equal volume of sialic acid at 8~g/ml in PBS-
DAB or with PBS-DAB alone for 1 hour at 4°C. Volume. of l~l were dispensed 
into the well. of a microtest tray and screened in a standard 
microlymphocytotoxicity test. Initial studies were performed using MAbs 
F15-DD5-26, F36-CB10-18 and MAD at 1/2 and 1/10 dilutions against a panel 
of four T and B cell targets. Cytotoxicity reactivity of treated and 
untreated MAbs were compared (Table 5.3.3). 
MAb F15-DD5-26 F36-CB10-18 MAD 
dilution normal sialic normal sialic normal sialic 
acid acid acid 
T cells 
1/2 4/4* 4/4 4/4 4/4 4/4 4/4 
1/10 4/4 0/4 4/4 2/4 4/4 0/4 
B cells I 
1/2 4/4 4/4 4/4 4/4 4/4 4/4 
1/10 4/4 1/4 4/4 4/4 4/4 2/4 
Table 5.3.3 Cytotoxic inhibition of autoreactive (1'15-DD5-26 and 1'36-
CBI0-18) and anti-RhO (NAD) NAbs at 1/2 and 1/10 dilutions treated with 
sialic acid at Bmg/ml compared to untreated controls (* No. of cells 
positive / No. of cells tested). 
No inhibition of cytotoxicity was found against T or B cell targets at 1/2 
dilution. However at 1/10 dilution, all P15-DD5-26 and MAD reactivity and 
2 of 4 tests using F36-CB10-18 were blocked against T cell targets. In 
addition, 3 of 4 tests using P1S-DDS-26 and 2 of 4 teata uaing MAD were 
blocked against B cell targets. No B cell inhibition was found using P36-
CBlO-lS. 
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Further tests were performed comparing titres of the above MAbs (sialic 
acid treated and untreated) at doubling dilutions from neat to 1/128 
against a T and B cell target. Controls studies were performed using 
Terasaki Park medium at pH4 and pH7·2. No difference in cytotoxicity titres 
of the MAbs at pH4 and pH7·2 was found in the untreated controls. There was 
a mean reduction of between 2 and 3 doubling dilutions with sialic acid at 
8~g/ml against both T and B cell targets (data not shown). 
These results indicated that sialic acid could partially block MAb 
reactivity in the cytotoxicity test. Low affinity T cell targets were more 
effectively blocked than high affinity B cell targets. Furthermore, 
blocking of the lower affinity MAbs, F1S-DDS-26 and MAD, was greater than 
that for the higher affinity MAb, F36-CB10-18. 
In an attempt to optimise the sialic acid blocking, cytotoxicity titres of 
MAbs and alloantisera treated with different concentrations of sialic acid 
were compared. MAbs F1S-DDS-26, F36-CB10-18, two anti-HLA alloantisera 
(Orford HLA-A2 and Clark HLA-B12) and serum from a patient with T and B 
cell autoantibodies (DV) were tested. The reagents were titrated at 
doubling dilutions from neat to 1/128 in duplicate. Bach sample was treated 
with an equal volume of sialic acid at concentrations of 50mg/ml down to 
1·S6mg/ml at pH4 and pH7. Cytotoxicity titres against one T cell target 
were compared to the untreated controls (Table 5.3.4). 
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Sialic acid F36-CB10-18 dilution (reciprocal) 
concentration N 2 4 8 16 32 64 128 
50mg/ml (pH4) - - - - - - - -
25 - - - - - - - -
12.5 + (+) - - - - - -
6.25 + + + + (+) - - -
3.125 + + + + + - - -
1.56 + + + + (+) - - -
0 + + + + (+) - - -
50mg/ml(pH7.2) + + + + - - - -
25 + + + + (+) - - -
12.5 + + + (+) - - - -
6.25 + + + + + - - -
3.125 + + + + (+) - - -
1.56 + + + (+) (+) - - -
0 + + + + (+) - - -
Sialic acid F15-DD5-26 dilution (reciprocal) 
concentration N 2 4 8 16 32 64 128 
50mg/ml (pH4) - - - - - - - -
25 - - - - - - - -
12.5 + (+) - - - - - -
6.25 + + + + (+) - - -
3.125 + + + + (+) - - -
1.56 + + + + - - - -
0 + + + + (+) - - -
50mg/ml(pH7.2) + + + + (+) - - -
25 + + + + + - - -
12.5 + + + (+) (+) - - -
6.25 + + + + + - - -
3.125 + + + + + - - -
1.56 + + + + (+) - - -
0 + + + + (+) - - -
Table 5.3.4 Cytotoxicity titre. of autoreactive NAbs F36-CBIO-18 and F15-
DD5-26 at doubling dilutions from neat to 1/128 against a T cell target, 
following pretreatment with .ialic acid at pH4 and pH7·2 using 
concentrations of 50mg/ml to 1·56mg/ml, compared to untreated controls. 
+ -80-100\ lysis, (+) -20-79\ lysis, - -negative, NT -not te.ted. 
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a) 
Sialic acid Serum DV dilution (reciprocal) 
concentration N 2 4 8 16 32 64 128 
50mg/ml (pH4) - - - - - - - -
25 + - - - - - - -
12.5 + (+) - - - - - -
6.25 + (+) - - - - - -
3.125 + + (+) - - - - -
1.56 + + (+) - - - - -
0 + + (+) - - - - -
50mg/ml(pH7.2) + (+) (+) - - - - -
25 + + (+) - - - - -
12.5 + (+) - - - - - -
0 + + + + (+) - - -
b) 
Sialic acid Clark (812) dilution (reciprocal) 
concentration N 2 4 8 16 32 64 128 
50mg/ml (pH4) - - - - - - - -
25 + - - - - - - -
12.5 + + + (+) - - - -
6.25 + + + + - - - -
3.125 + + + + (+) - - -
1.56 + + + + (+) - - -
0 + + + + (+) - - -
50mg/ml(pH7.2) + + NT NT NT NT NT NT 
25 + + + + - - - -
12.5 + + + + - - - -
6.25 + + + - - - - -
3.125 + + + + (+) - - -
1.56 + + + + - - - -
0 + + + + - - - -
Table 5.3.5 Cytotoxicity titres of a T and B cell lymphocytotoxic 
autoantibody (DV, panel a) and a HLA-B12 alloantiserum (Clark, panel b) at 
doubling dilutions from neat to 1/128 against a T cell target, following 
pretreatment with sialic acid at pH4 and pH7·2 using concentrations of 
SOmg/ml to 1·S6mg/ml, compared to untre.ted controls. 
+ -80-100% lysis, 
(+) -20-79% lysis, 
- =negative, NT -not tested. 
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c) 
Sialic acid Orford (A2) dilution (reciprocal) 
concentration N 2 4 8 16 32 64 128 
50mq/ml (pH4) - - - - - - - -
25 - - - - - - - -
12.5 + + - - - - - -
6.25 + + + + - - - -
3.125 + + + + - - - -
0 + + + + - - - -
50mq/ml(pH7.2) + + + (+) - - - -
25 + + + (+) - - - -
12.5 + + + (+) - - - -
6.25 + + + (+) - - - -
3.125 + + + (+) - - - -
0 + + + (+) - - - -
Table 5.3.5c Cytotoxicity titres of anti-HLA-A2 alloserum (Orford) tested 
at doubling dilutions from neat to 1/128 against a T cell target, following 
pretreatment with sialic acid at pH4 and pH7·2 using concentrations of 
50mg/ml to 1·56mg/ml, compared to untreated controls. 
The results show that sialic acid concentrations of 50mq/ml at pH4 caused 
complete inhibition of cytotoxicity with both the autoreactive NAbs (F15-
005-26 and F36-CB10-18), patient serum lymphocytotoxic autoantibody (OV), 
and the anti HLA-A2 (Orford) and B12 (Clark) alloantisera. At a sialic acid 
concentration of 25mq/ml reactivity of F15-0D5-26, F36-CB10-18 and Orford 
(HLA-A2) was completely removed, and residual activity with neat serum 
only was seen with OV (T and B auto) and Clark (HLA-B12). Usinq sialic acid 
concentrations of 12·5mq/ml, the titre of each reagent was blocked by two 
doublinq dilutions. Sialic acid concentration. of 6 0 25mq/ml and below gave 
no chanqe in cytotoxicity titres compared to the untreated control. No 
cytotoxicity inhibition usinq any concentration of sialic acid wa •• een at 
pH7-2. 
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The results indicated that sialic acid could inhibit cytotoxicity of both 
the monoclonal autoantibodies and the lymphocytotoxic autoantibodies in 
patient serum. However the effect was not specific to autoantibodies as 
inhibition of cytotoxic HLA class I alloantisera was also found. It was 
possible that the non-specific inhibition was due to blocking of complement 
activity. 
To investigate this further a standard cytotoxicity test was performed 
using F36-CB10-18 at doubling dilutions against a T cell target, with the 
addition sialic acid added directly to the rabbit complement ~diately 
before use. The equivalent of l~l of sialic acid (at each of the above 
concentrations, pH4 and pH7'2) per 5~1 of complement was used (Table 
5.3.6). 
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Sialic acid F36-CB10-18 dilution (reciprocal) 
concentration N 2 4 8 16 32 64 128 
5Omg/ml (pH4) - - - - - - - -
25 + + + + + (+) - -
12.5 + + + + + (+) (+) -
6.25 + + + + + + (+) -
3.125 + + + + + + (+) -
0 + + + + + + (+) -
50mg/ml(pH7.2) + + + + (+) (+) - -
25 + + + + (+) (+) - -
12.5 + + + + + (+) (+) -
6.25 + + + + + (+) (+) -
3.125 + + + + + (+) (+) -
0 + + + + + (+) (+) -
Table 5.3.6 Cytotoxicity titre of F36-CB10-18 at doubling dilutiona fro. 
neat to 1/128 against a T cell target, with the addition of aialic acid 
(pH4 and pH7·2) from 50mg/ml to 3·125mg/ml added directly to the rabbit 
complement. The equivalent of 1,.,1 of aialic acid per 5,.,1 of rabbit 
complement was used. 
The results show complete inhibition of cytotoxicity using sialic acid at 
concentrations of SOmg/ml at pH4, wh.n added directly to the rabbit 
complement. No difference in cytotoxicity titres was s.en for the other 
sialic acid concentrations at pH4 and no inhibition was found using sialic 
acid at any concentration at pH7. The results therefore indicate that the 
cytotoxicity inhibition may be at tha laval of the complement and may not 
be due to antibody binding inhibition. It is therefore not possible to 
interpret lymphocytotoxic autoantibody binding inhibition results using 
sialic acid in cytotoxicity aaaays. 
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5.4 Effect of pH op autoantibody bipdipq 
Although neuraminidase cleavage of cell surface molecules and blocking with 
lectin from Triticum vulgaris indicated that autoantibody binding was to 
a sialic acid defined epitope, binding inhibition studies using free sialic 
acid gave increased autoantibody binding. Also increased binding to low 
affinity T cell targets was found in the low pH controls. 
This suggests an alternative possibility, that polyreactivity of the.e 
antibodies are dependent on antigenic charge, specifically against 
negatively charged cell surface molecules. To investigate this possibility 
the influence of pH on MAb binding to low affinity T cell targets was 
examined. The fluorescence binding assay was used with F15-DD5-26 and F36-
CB10-18 at doubling dilutions from 1/2 to 1/256, diluted in buffered saline 
at pH 4·0 (18ml of 0·2M sodium acetate mixed with 82ml of 0·2M acetic 
acid), pH ,·2 (PBS-DAB), and pH 9·6 (45ml of 0·1M sodium carbonate mixed 
with 5Sml of 0·1M sodium bicarbonate) (Fig 5.4.1). 
The results show a rapid fall in MAb titre at pH '·2 and 9·6. However the 
low affinity T cell binding was rever.ed at pH 4·0 with both MAbs reactive 
to 1/32 dilution. Theae results confirm that low pH increase. the MAb 
binding affinity to T cell targets, suggesting that binding may be to 
multiple negatively charged cell surface molecule. in ioni.ed form. 
222 
Effect of pH on F15-DD5-26 
Binding to T cells 
Mean channel fluorescence 
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Figure 5.4.1 Cytofluorograph analysis of the effect of pH on r15-DD5-26 
(panel a) and F36-CB10-1B (panel b) binding to low affinity r cell targets 
using NAbs at doubling dilutions (1/2 to 1/256) at pH4·0, 7·2 and 9·6. 
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DiscUlliop 
The lectin from Triticum vulgaris (wheat germ) bind. N-acetyl-neuramic acid 
and N-acetyl-O-glucosamine. Pre-treatment of both T and B cell. with 
Triticum vulgaris lectin strongly inhibited autoantibody and non-.pecific 
anti-RhO binding to lymphocytes in the fluorescence binding as.ay. 
Moreover, binding to high affinity B cell target. was inhibited by 70'. 
Lectin from Mycoplasma gallisepticum, .pecific for glycophorin, al.o 
inhibited T cell but not B cell ALA binding. No other lectin te.ted 
inhibited autoantibody binding. Glycophorin i. a carbohydrate determinant 
on group 0 red blood cells. Red cell agglutination and cytofluorograph 
binding studies have shown that the autoantibodies produced in this .tudy 
do not bind red cells of any major blood group. Therefore glycophorin alone 
is unlikely to constitute the autoantigen. 
The binding inhibition by Triticum vulgaris i. con.i.tent with the 
neuraminidase sensitivity, as both technique. are .pecific for N-acetyl-
neuramic acid. The results .uggest that autoreactive antibodies bind a 
sialic acid dependent epitope. An alternative hypothe.i. i. the 
polyreactivity of the autoantibodies i. dependent on antigenic charge. 
Lymphocytotoxic autoantibodies may be capable of binding many negatively 
charged cell surface molecules. This view is supported by the finding that 
incubation of T cells with the autoantibodies at low pH alters the binding 
profile from low affinity to high affinity target.. Charge dependent 
polyreactive IgM antibodies with specificity for anionic phospholipid. have 
been described (Mackworth-Young, 1990). Th. high binding to B cells and 
partial cleavage by papain are all consistent with the view that thes. are 
polyreactive antibodies, capable of binding multiple negatively charged 
antigens with no unique antigenic priming .timulus or specificity. 
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Other lectins, particularly lectin from Vicia fava and Phaaeolu. vulgaria 
caused an increase in ALA binding. Thia waa not due to low pH aa all 
lectina had neutral pH at O·2mg/ml in PBS-DAB. It therefore appear. that 
the autoantibodies bound some lectin. attached to the cell aurface. Thi. 
finding is consistent with the view that lymphocytotoxic autoantibodies are 
capable of binding multiple types of molecules, due to their 
polyreactivity. Alternatively it is posaible that the lectin. are 
polyvalent and bind IgM directly. However the increa.ed titre of F36-CB10-
18 in lectin/red blood cell lysis and agglutination inhibition experiment. 
compared to F15-DD5-26, despite lower immunoglobulin level., argue. again.t 
this. 
We conclude that the characterisation of autoantibodies in renal dialy.i. 
patients, and comparison of the.e finding. with de.cription. of 
polyreactive IgM antibodies, demon.trate that they repre.ent a .imilar 
group of antibodies. Low affinity binding of lymphocytotoxic autoantibodies 
may be associated with sialic acid dependant epitope. on T cell. and CLL 
cells, and other negatively charged molecule. found on different cell 
types. 
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6.1 In-vivo production of lyaphocytotoxic autoaptibodi •• i8 DUd. aic. 
To produce high concentrations of human IgM, the in-vivo growth of 
heterohybridomas in ascites fluid of nude mice waf attempted. 
Twenty pristane treated eight week old HPl nude mic. were inoculat.d by an 
intraperitoneal injection of heterohybridoma c.lls. T.n mic. each rec.ived 
1'5 x10' F15-DD5-26 cells and ten mice r.ceived 1·5 x10' F36-CB10-18 cell •• 
After one month, no mice injected with F36-CB10-18 .howed .ign. of a.cite. 
production. However four of the ten mice inoculat.d with P15-DD5-26 had 
ascites production. A total of 39ml of a.cite. fluid waf harv •• t.d from 
these mice. Ascites fluids were individually scr •• ned by cytotoxicity 
against a panel of 6 T cells, 5 B cell. and 4 CLL c.lla at doubling 
dilutions from neat to 1/128. All gave po.itive cytotoxicity with each c.ll 
type, although the strength of reactivity and the pan.l r.activ. profil •• 
were only equal to those found with ti.su. culture ,upernatant •• Th. median 
cytotoxicity titres were 1/12 for T c.lls and CLL c.ll. and 1/128 for B 
cells (data not shown). It was ther.for. f.lt that the a.cit.. fluid 
offered no advantage compared to tissue cultur. ,upernatant. a. a .ourc. 
of IgM. 
At the time of harvesting, heterohybridoma c.lls d.rived from two a.cit •• 
fluid. were returned to tissue cultur. in-vitro. Both clon •• continued to 
grow well, although one gave only weak cytotoxiC B c.ll r.activity. It 
therefore appeared that soma hybridoma cell. had become un.tabl. wh.n grown 
in-vivo and had either failed to grow or lo.t antibody production. Thi. 
finding may explain the unexpectedly low lymphocytotoxic autoantibody 
titr.. of the a.cite. fluid. Th. .ucc ••• ful growth of .ome of the r15-
DD5-26 clones compared to no growth of r36-CB10-18 clon •• probably r.fl.ct. 
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the faster growth rate and ~proved stability of F1S-DDS-26. 
It was recognised that the surviving F1S-DDS-26 antibody producing 
heterohybridoma8 may have adapted for in-vivo growth in nude mice. However, 
sub8equent inoculation of nude mice with the8e cells, with the expectancy 
of improved results was not attempted. 
6.2 IaN purificatioD froM tis.ue culture ,upemataat 
Human IgM waf present in F1S-DDS-26 and F36-CB10-18 ti •• ue culture 
8upernatant at levels of between 40-70~g/ml. In the absence of equipment 
for preparative HPLC or affinity chromatography, a method for purification 
of IgM from large quantitie8 of ti8sue culture supernatant was developed 
by combining ion exchange chromatography and molecular exclusion gel 
filtration. This enabled bulk extraction of immunoglobulin pre.ent at low 
levels in tis8ue culture supernatant. SDS-PAGE analysis and cytotoxicity 
testing of the purified immunoglobulin indicated that acceptable IgMyields 
and purity could be obtained. 
6.2.1 Ion exchange chromatography 
Bakerbond ABx 40~ i8 an ion exchange resin which exhibits high affinity 
for all immunoglobulin classes. The manufacturers .pecifications indicate 
that the resin does not bind the major contaminating proteins, albumin and 
transferrin, and other serum proteins found in tissue culture supernatants 
or ascites fluid. The resin is a silica ba.ed porous material with weakly 
anionic and cationic functional groups. The binding and elution of the 
immunoglobulin is based on manipulation of the pH and ionic strength of the 
buffers. The manufactures describe a one step purification procedure of 
immunoglobulin with an 80-99\ purity from tissue culture media and ascites 
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fluid, with a 97' immunoglobulin recov.ry. Thi. procedure may b. performed 
using a solid phase 'slurry' techniqu" without the n.ed for chromatography 
equipment for batch purification of immunoglobulin from ti •• u. cultur • 
• upernatant. 
a) IgM purification using ABx 40um ion exchange resina 
Manufactures specifications indicated l'Og of ABx 40~m r.sin would bind 
lS0mg of IgG. No information on the binding capacity of IgM wa. availabl •• 
It was estimated that 1m1 of ten time. concentrat.d ti •• ue cultur. 
supernatant would contain O'Smg of IgM, therefor. 3'Omg of resin would have 
sufficient binding capacity for O'Smg of immunoglobulin. On the as.umption 
that the resin binding capacity for IgM, b.ing a larger molecule than IgG, 
may be lower, initial tests using SOmg of resin per 1ml of x10 conc.ntrat.d 
tissue culture supernatant were used. 
Immunoglobulin positive and negative fraction. were s'parated from F1S-
DOS-26 ascites, F1S-DDS-26 supernatant and F36-CB10-18 .upernatant 
according to the protocol in materials and method.. Th. fraction. w.r. 
dialysed with PBS-DAB and concentrated to their original volume. (lml) and 
then tested by cytotoxicity for lymphocytotoxic autoantibody r.activity 
against a panel of 3 T cells, 3 B c.lls and 1 CLL c.ll (Tabl. 6.2.1). 
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Median cytotoxicit titre (reciprocal) 
Target IgM positive fraction IgM negative fraction 
cell DD5asc DD5spt CB10spt DD5aac DD5.pt CB10.pt 
O.D. 0.597 0.501 0.701 3.44 3.30 3.36 
T 16 32 8 32 64 64 
B >128 >128 32 >128 >128 >128 
CLL 16 16 4 64 128 32 
O.D. - optical density (absorbance at 280nm). 
Table 6.2.1 Cytotoxicity titres of IgN positivI and negative fractions 
separated from Iml of xl0 concentrated tissul culture supernatant (spt) or 
neat ascites fluid (asc) using 50mg of ABx 40~ ion exchange resin. 
Cytotoxicity results show that autoantibody titrea were higher in IgM 
negative fractions than the IgM positive fractions for each cIll te.ted. 
This indicates that the separation of IgM wa. incomplete. A.cite. fluid wa. 
noted to produced a cloudy precipitatIon dilution with NBS buffer, with 
protein precipitating out of solution. 
b) Determination of IgM binding capacity of ABX 40um ion .xchange re.in 
To determine the optimal quantity of ABx 40~m re.in required to bind all 
the IgM present in tissue culture supernatant, 1ml volume. of x10 
concentrated '15-D05-26 supernatant wal absorbed with 200, 400 and 800mg/ml 
of ABx 40~ ion exchange resin. The eluted IgM containing and IgM depleted 
fractions were dialysed in PBS-DAB, concentrat.d to 1ml final volume and 
tested by cytotoxicity against 3 T cellI, 3 B cell. and 1 CLL cell (Tabl. 
6.2.2) • 
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ABx40pm Target Median cytotoxicity titre (reciprocal) 
(mg) cell IgM +'ve (0.0.) IgM - eve (0.0.) 
200 T 16 (2.20) 0 (3.34) 
B >128 8 
CLL 8 0 
400 T 16 (3.05 ) 4 (3.23) 
B >128 32 
CLL 16 2 
800 T 16 (2.45) 0 (3.23) 
B >128 8 
eLL 16 0 
O.D.- optical density (absorbance at 2BOnm). 
Table 6.2.2 Determination oL the optimal quantity oL ABx 40~m ion exchange 
resin required Lor the separation oL IgN from Iml of xl0 concentrated '15-
DD5-26 tissue culture supernatant. 
The cytotoxicity results using T cell. and the eLL cell target. .howed 
complete absorbtion of reactivity from the IgM depleted fraction. u.ing 200 
and 800mg/ml of resin. The residual T cell and CLL cell reactivity in the 
IgM depleted fraction using 40Omg/ml was not in accordance with the result. 
using lower and higher resin concentrations and r ..... in. unexplained. 
Residual B cell reactivity was found at all re.in concentration •• This 
reflects the high 8ensitivity of B cell targets in cytotoxicity teets. The 
low B cell titres in IgM depleted fraction. is probably a result of very 
low concentrations of residual 19M. The.e results demonstrated that most 
IgM contained in the tissue culture supernatant had been eluted in the 
~unoglobulin positive fractions. 
c) SDS-PAGE analyeie of lqM purity: 
The high optical densities of the 19M positive fractions (Table 6.2.2) 
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indicated protein concentrations of between 1· 6 and 2· 2mg/ml. This was 
higher than expected for IgK alone and therefore suggested contamination 
with other proteins. To determine the immunoglobulin purity, IgK positive 
and negative fractions from F1S-00S-26 supernatant, separated using 
200mg/ml ABx 40~m, were analyzed by SOS-PAGE under non-reduced and reduced 
conditions (Plate 6.2.1). 
Lane 2, using 20~g of commercially purified IgK (non-reduced, Northeast 
Biomedical, Uxbridge), demonstrated pentameric IgK (molecular weight 
900,000) which does not migrate into a 10' acrylamide gel, with several 
lower molecular weight contaminating protein bands. On reduction (lane 3), 
IgK heavy chains at molecular weight 70,000 ( indicated) and several 
contaminating protein bands were found. The non-reduced IgM positive 
fraction from F1S-OOS-26 (lanes 4 and 7) show high molecular weight IgM 
with three major contaminating protein bands between molecular weights 
43,000 and 67,000. The reduced samples ( lanes 5 and 8) show two maj or 
contaminating bands at molecular weights 67,000, with only weak IgM heavy 
chain bands (indicated). IgK light chains (molecular weight 23,000) have 
migrated off the lower end of these gels. The non-reduced and reduced IgM 
negative fraction (lanes 9 and 10) demonstrate the mass of contaminating 
protein depleted from the IgM positive fraction. 
These results demonstrate that there were major contaminating protein bands 
present in both the commercial and F1S-00S-26 purified IgK preparations. 
The contaminating protein in F1S-DOS-26 was of low molecular weight 
(between molecular weights 43,000 and 67,000) compared to the non-reduced 
pentameric IgM (molecular weight 900,000). 
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Plate 6.2.1 
SOS-PAGE analysis of purified 19M from '15-005-26 tillue culture 
supernatant usin9 200mg/ml of ABx 40um ion exchange resin 
Lane 1, low molecular weight marker. (94k, 67k, 43k). 
Lane 2, commercial IgM (20~g of protein), non-reduced. 
Lane 3, commercial IgM (20~g of protein), reduced. 
Lane 4, IgM positive fraction (30~g of protein), non-reduced. 
Lane 5, IgM positive fraction (30~g of protein), reduced. 
Lane 6, low molecular weight marker •• 
Lane 7, IgM positive fraction (60~g of protein), non-reduced. 
Lane 8, IgM positive fraction (60~g of protein), reduced. 
Lane 9, IgM negative fraction, non-reduced. 
Lane 10, IgM negative fraction, reduced. 
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d) Further purification of IgM by ion exchange chromatography 
The F15-DD5-26 IgM positive fractions pooled from 200, 400 and 800mg/ml of 
ABx 40~m ion exchange preparations were purified a second time by the same 
procedure. Re-purified I9M positive and negative fractions were analyzed 
by SDS-PAGE (Plate 6.2.2). Lanes 2 (non-reduced) and 3 (reduced) show the 
single step IgM purification of F15-DD5-26 used as a starting material. 
Lanes 4 (non-reduced) and 5 (reduced) show the repeated ion exchange 
purification step gave near pure IgM with only minor contaminating protein 
banda. Lanes 6 (non-reduced) and 7 (reduced) show the contaminating 
proteins were eluted in the 19M negative fraction. 
This indicated that near pure 19M could be prepared from tissue culture 
supernatants using this method. However, the x2 purified IgM fraction 
contained only 120~9 of protein, indicating a 24' immunoglobulin yield. 
Cytotoxicity screening using 3 CLL cells, 3 T cell. and 3 B cell targets 
gave weak reactivity, with mean titre. of 1/2, 1/4 and 1/16 re.pectively 
(data not shown). This confirmed that the 19M yield was very low. The x2 
purified 19M negative fraction was completely negative in cytotoxicity 
tests against all cell types. 
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Plate 6.2.2 
SOS-PAGE analysis of F15-005-26 19M positive fractions purified x2 using 
ABx 40um ion exchange resin 
Lane 1, low molecular weight markers (94k, 67k, 43k) • 
Lane 2, purified xl, 19M positive fraction, non-reduced. 
Lane 3, purified xl, 19M positive fraction, reduced. 
Lane 4, purified x2, 19M positive fraction, non-reduced. 
Lane 5, purified x2, 19M positive fraction, reduced. 
Lane 6, purified x2, IgM negative fraction, non-reduced. 
Lane 7, purified x2, 19M negative fraction, reduced. 
(Protein bands between lanes on this gel were due to inadvertent 
overloading of lane 2). 
--
-- --
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6.3 Purification of IgN by gel filtratiop 
Preparative IgM purification from tissue culture supernatant using single 
step ion exchange chromatography with AS x 40~m resin gave good IgM 
recovery although two major contaminating protein bands were found on SDS-
PAGE analysis. These bands were of low molecular weight compared to 
pentameric IgM. Therefore further IgM purification was obtained by 
molecular exclusion chromatography using Sephacryl S300 High Resolution gel 
filtration. 
6.3.1 Column calibration 
High molecular weight calibration markers, thyroglobulin (molecular weight 
669,000), ferritin (molecular weight 440,000), catalase (molecular weight 
232,000) and aldolase (molecular weight 158,000) were applied to a 
Sephacryl S300 gel filtration column to ensure appropriate separation of 
these molecules. Their elution profiles are shown in Figure 6.3.1. 
The results demonstrate sequential elution of the calibration markers in 
descending order of molecular weight. The column gave complete separation 
of thyroglobulin from catalase and aldolase. This indicates that ascending 
gel filtration was successful at separating the calibration markers between 
molecular weights 669,000 and 232,000 and would therefore be appropriate 
for the separation of IgM (molecular weight 900,000) from the low molecular 
weight contaminating proteins (molecular weights between 43,000 and 
67,000). 
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8ephacryl 8300 Gel Filtration 
Column Calibration 
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Figure 6.3.1 Calibration of Sephacryl 8300 gel filtration coluan. 
6.3.2 purification of r15-DD5-26 laM by gel filtrltion 
The technique WI. then Ipplied to the IgM positive frictions partillly 
purified from F15-005-26 using ABx 40~ ion exchlnge chromatogrlphy. 19M 
in I finll volume of 10ml PBS-DAB WIS prepared frOil 10.1 of xlO 
concentrated F15-D05-26 tissue culture supernatant by ion exchange 
chromatography (aa above), giving I totll protein yield of 8·36mg. Half of 
this (5ml) WI. 10lded onto the Sephlcryl S300 gel filtrltion colu.n. The 
elution profile (indicated by absorbance at 280nm) is shown in Figure 
6.3.2. 
Three peaka were seen, the firat pelk being high molecular weight 
pentamaric IgM and the subsequant peaks being the lower molecular weight 
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contaminating proteina. The total protein content in the 19M fraction. 
(peak 1) was 1·12mg, indicating an overall 45' ~unoqlobulin yield from 
the original lOOml of tissue culture supernatant (containing about Smg of 
IgM) • 
Elution Profile of F15-DD5-26 IgM Using 
Sephacryl 8300 Gel Filtration 
Absorbance (280nm) 0,5,..---------------------, 
0,4 ,,--.----- --- ._._-4\-._----_._----1 
0,3 ---.--.--------------,~+---------_I 
0,2+----· 
0,1 
25 45 85 85 105 125 145 185 185 
Elution volume (mil 
Figure 6.3.2 sephacryl S300 gel ~iltration elution profile of elle IglI 
positive fraction from 10ml of x10 concentrated r15-DD5-26 tissue culture 
supernatant, initially purified using ABx 40,. ion exchange clJrolNtography. 
~he hatched area denotes the fractions with lyaphocytotoxic autoantibody 
reactivity. 
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6.3.3 SOS-PAGE analysis of F15-005-26 IgM fraction. purified u.ing ABx 40um 
ion exchange chromatography and molecular excluaion gel filtration 
To confirm the purity of the IgM, fraction. from th. thre. peak. w.re 
analyzed by SOS-PAGE (Plate 6.3.3). Commercially purifi.d IgM .how. a large 
number of contaminating protein band. when non-reduced (lan. 2) and r.duc.d 
(lane 3) aa previously described. IgM h.avy chain. (mol.cular w.ight 
70,000) and light chain. (molecular weight 23,000) can be ••• n in lane 3 
(reduced) • 
As previously seen, IgM positive fraction. purifi.d from F15-005-26 
supernatant by ion exchange chromatography, contain. a numb.r of 
contaminating protein bands when non-reduc.d (lan. 4) and r.duc.d (lan. 5). 
However following further purification by q.l filtration, IgM harv •• t.d 
from peak 1 (fractions 19-22) ahow. no contaminating band. wh.n non-
r.duced (lane 7). F15-D05-26 IgM heavy and light chain. are ••• n in lane 
6 (reduced) with a minor contaminating band (mol.cular w.ight approximat.ly 
67,000) located below the IgM heavy chain. Thi. prot.in band wa. 
predominantly eluted in fraction 23, betw.en peaks 1 and 2 a •••• n in lan. 
8 (reduced). The major contaminatinq prot. in band. w.re proqr ••• iv.ly 
eluted in fractions 25 (lanea 14 and 15) and fraction 27 (lan •• 16 and 17) 
which correspond to the second peak, and fractione 35-40 (lan •• 18 and 19) 
from the third peak. 
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Plate 6.3.3 
SDS-PAGE analysis of lqM purified from 100ml of '15-PD5-26 tia,u. 
culture supernatant by ion exchange chromatography and gel 
filtration 
Lane 1, low molecular weight mark.ra (94k, 67k, 43k, 30k, 20k) • 
Lane 2, commercially purified IgM, non-reduced. 
Lan. 3, commercially purifi.d IgM, reduc.d. 
Lane 4, purified IgM (xl ABx 40,nn) , non-reduced. 
Lane 5, purified IgM (xl ABx 40,nn) , reduc.d. 
Lane 6, gel filtration fractiona 19-22 (peak 1), r.duc.d. 
Lane 7, gel filtration fractions 19-22 (peak 1), non-reduced. 
Lane 8, gel filtration fraction 23 (between peaka 1 Ii 2),reduc.d. 
Lane 9, gel filtration fraction 23 (between peaka 1 Ii 2) , 
non-reduced. 
Lane 10, low molecular weight marker. (94k, 67k, 43k, 30k, 20k). 
Lane 11, low molecular weight marker. (94k, 67k, 43k, 30k, 20k). 
Lane 12, commercially purified IgM, non-reduced. 
Lane 13, commercially purified IgM, reduced. 
Lane 14, gel filtration fraction 25 (early peak 2), r.duced. 
Lane 15, gel filtration fraction 25 (early peak 2), non-reduc.d. 
Lane 16, gel filtration fraction 27 (peak 2), r.duced. 
Lane 17, gel filtration fraction 27 (peak 2), non-reduced. 
Lane 18, gel filtration fraction, 35-40 (peak 3), reduc.d. 
Lane 19, gel filtration fractions 35-40 (peak 3), non-r.duced. 
Lane 20, low molecular weight markera (94k, 67k, 43k, 30k, 20k). 
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6.3.4 Cytotoxicity screening of IgH purified from r15-D05-26 
The cytotoxicity titres of the original x10 concentrated tis.ue culture 
supernatants, the IgM positive and negative fractions purified using ABx 
40~m ion exchange chromatography and the gel filtration fractions from the 
three peaks were screened by cytotoxicity using 5 T cells, 3 B cells and 
1 CLL cell (Table 6.3.1). 
• I I I I I 
Med1an cytotoxicity titre reciprocal) 
Target x10 cone ABx 40 ABx 40 F19-22 F25-29 F35-40 
cell T.C spnt I9M + I9M - peak 1 peak 2 peak 3 
T cell 128 32 16 16 0 0 
B cell 1024 >128 >128 64 2 0 
CLL cell 64 8 2 8 0 0 
Table 6.3.1 Cytotoxicity titres of Iglf purified from 10.1 of xl0 
concentrated F15-DD5-26 tissue culture supernatant by ion exchange 
chromatography and gel filtration. 
The results show strong cytotoxic reactivity in the ABx 40~ IgM positive 
fraction. However strong residual reactivity was found in the IgM negative 
fraction indicating incomplete separation of IgM. Following gel filtration 
all the IgK cytotoxic reactivity was found in the first peak (fractions 19-
22), with only very weak B cell reactivity in the second peak (fraction. 
25-29) and no reactivity in the third peak (fraction. 35-40). 
The results confirm that near pure IgM, with acceptable immunoglobulin 
yields could be purified from tis.ue culture supernatant u.ing combined ion 
exchange chromatography and molecular exclusion gel filtration. Moreover, 
lymphocytotoxic autoantibody reactivity was i.olated only in the purified 
IgK containing fractions. This confirm. that autoantibody reactivity i. due 
to IgK antibodies. 
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6.4 Purification of laM froa r36-CBIQ-18 ti.,u. cul\ur. 'MP'ma\an\ 
The above procedure, combining ion exchange chromatography and mol.cular 
exclusion gel filtration was then applied for the purification of IgM from 
F36-CBI0-18 tissue culture supernatant. 
6.4.1 Purification of IgM from F36-CBI0-l8 u.ing combin.d ion .xchang. 
chromatogrAphy and molecular .xclu.ion g.l filtration 
IgM purified from 10ml of xl0 concentrat.d r36-CB10-18 ti •• u. cultur. 
,upernatant using 400mg/ml of ABx40~m ion .xchang. r •• in wa. dialy •• d into 
a final volume of 10ml in PBS-DAB. Sml of the IgM po.itiv. fraction wa. 
applied to a Sephacryl S300 g.l filtration column a. pr.viou.ly d •• cribed. 
Two protein peaks were eluted from the column (Figur. 6.4.1). 
The first peak (fractions 17-21) contained high mol.cular weight pent_ric 
IgM with 0·61mg of protein. This indicat.d a total IgM yi.ld of l o 22mq from 
100ml of supernatant which repre.ent. about a 30' r.cov.ry (a •• uming an 
original IgM concentration of 40~g/ml in 100ml of ti •• u. cultur. 
supernatant). 
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Elution Profile of F36-CB10-18 IgM Using 
8ephacryl 8300 Gel Filtration 
Absorbance (280nm) 
0,7 r-----------------------. 
0,5 .--.... -.".--.-.. "" .. --" .. - .. --.---+-+-----
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Figure 6.4.1 Sephacryl S300 gel L il eration e1 ution profile of ehe IglI 
p08itive fraction from 10ml of x10 concentraeed F36-CB10-1B ti •• ue culture 
8upernatant, initially purified u.ing ABx 40,.,. ion exchange chrolNtography. 
The hatched area denote. fraction. wieh lpphocytotoxic autoaneibody 
reactivity. 
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6.4.2 SDS-PAGE analysis of laK purified from [36-C810-18 
IgK positive and negative fractions purified using 400mq/ml of ABx 40~m ion 
exchange resin and selected gel filtration fractions were analyzed by SDS-
PAGE (Plate 6.4.1). As previously described, lanes 2 and 3 (non-reduced and 
reduced) show commercially purified IgK, with heavy and light chains 
visible in lane 3 (reduced). Lanes 4 and 5 (non-reduced and reduced) show 
the IgK positive fraction purified using ABx 40~ ion exchange 
chromatography, with IgK heavy and light chains indicated (lane 5, 
reduced). Gel filtration fractions 17,18 and 21 from peak 1 (lanes 6,8 and 
10, non-reduced) all demonstrated pentameric IgK which does not migrate 
into the 10' acrylamide gel, with little evidence of other contaminating 
protein bands. When reduced (lanes 7,9 and 11) IgK heavy chains (molecular 
weight 70,000) and light chains (molecular weight 23,000) ware pre.ent. In 
addition a minor contaminating protein band was found at molecular weight 
67,000, as was seen with [15-DD5-26 IgK purification. Again this 
contaminating protein band was predominantly eluted after the IgM, in 
fraction 25 (lanes 15 and 16) and fraction 26 (lanes 17 and 18). The major 
low molecular weight contaminating proteins from the ion exchange .tep were 
progressively eluted in the second peak (fractions 28-30, lanes 19-24). 
These results show that F36-C810-18 gel filtration fractions eluted in peak 
1 contained IgK, with no major contaminating proteins. 
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Plate 6.4.1 
SDS-PAGE analysis of laM purified from 10ml of 110 conc.ntrated rl6-CBI0-
18 tissue culture supernatant by ion ex chang. chromatography and gel 
filtration 
Lan. 1, low molecular w.ight mark.r. (94k, 67k, 4lk, lOk, 20k). 
Lane 2, commercially purified IgM, non-reduc.d. 
Lane l, commercially purified IgM, reduced. 
Lane 4, purified IgM (xl Alx 40llm) , non-reduced. 
Lane 5, purified IgM (xl Alx 40llm) , reduced. 
Lane 6, gel filtration fraction 17 (peak 1) , non-r.duced. 
Lane 7, gel filtration fraction 17 (peak 1) , reduc.d. 
Lane 8, gel filtration fraction 18 (peak 1) , non-r.duc.d. 
Lan. 9, gel filtration fraction 18 (peak 1) , reduc.d. 
Lan. 10, gel filtration fraction 21 (peak 1), non-reduced. 
Lane 11, gel filtration fraction 21 (peak 1), reduced. 
Lane 12, low molecular weight mark.r. (94k, 67k, 4lk, lOk, 20k) • 
Lane ll, low molecular weight marker. (94k, 67k, 4lk, lOk, 20k) • 
Lane 14, Low molecular weight marker. (94k, 67k, 4lk, lOk, 20k). 
Lane 15, gel filtration fraction 25, non-reduc.d. 
Lane 16, gel filtration fraction 25, reduced. 
Lane 17, gel filtration fraction 26 (peak 2), non-reduced. 
Lan. 18, gel filtration fraction 26 (peak 2), reduced. 
Lane 19, gel filtration fraction 28 (peak 2), non-reduc.d. 
Lana 20, gel filtration fraction 28 (peak 2) , reduced. 
Lana 21, gel filtration fraction 29 (peak 2) , non-reduced. 
Lana 22, gel filtration fraction 29 (peak 2) , reduced. 
Lana 23, gel filtration fraction 30 (peak 2) , non-reduc.d. 
Lan. 24, gal filtration fraction lO (peak 2), reduced. 
Lana 25, low molecular weight markar. (94k, 67k, 4lk, 30k, 20k) • 
Lan. 26, low mol.cular weight mark.r •• 
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6.4.3 Cytotoxicity screening of 1qM purified from r36-C810-18 
19M positive and negative fractions following purification from r36-C810-
18 tissue culture supernatant using 400mg/ml of ABx 40~m ion exchange re.in 
and pooled fractions from the two gel filtration peak. (fraction. 17-21 and 
26-30) were tested by cytotoxicity using 3 T cell., 2 8 cell. and 1 CLL 
cell (Table 6.4.1). 
d' I t iii ,I I Target Me 1an cyto ox c ty t1tre (reciprocal) 
cell x10 cone ABx 40um ABx 40um F11-21 F26-30 
TCS 19M + 19M - peak 1 peak 2 
T cell 256 >128 8 128 0 
B cell 168 >128 32 >128 2 
CLL cell 64 64 2 128 0 
2'able 6.4.1 Cytotoxicity titre. of Iglf fractions purified frOla 10,u of x10 
concentrated F36-CBIO-IB tissue culture supernatant by ion exchange 
chromatography and gel filtration. 
The results show strong cytotoxicity in the 19Mpo.itive fraction follOWing 
purification using 40Omg/ml of ABx 40,.,... re.in, with relatively weak 
re.idual cytotoxicity in the 19M depleted fraction. Lymphocytotoxic 
autoantibody reactivity was eluted in the fir.t gel filtration peak 
(fractions 17-21) containing the 19M. No T c.ll and CLL cell, and only weak 
8 cell reactivity was found in the .econd peak (fraction. 26-30). The.e 
data .how good 19M purity and cytotoxic r.activity of r36-C810-18 .eparated 
u.ing combined ion exchange chromatography and gel filtration although the 
overall immunoglobulin yield was low (31'). 
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6.5 lulk Purification of IQN fro- r15-DD5-at and r36-CI10-18 tiltu. cultur. 
,upematant 
The use of Bakerbond ABx 40#Jm ion exchange r •• in combined with g.l 
filtration on a Sephacryl S300 column damon.trat.d that milligram 
quantities of IgM could be separated from ti.su. cultur. .uptrnatant with 
good immunoglobulin purity and an acc.ptabl. yi.ld. Th. method w.. th.n 
.caled up for the separation of IgM from 1 litre qu.ntiti.. of r15-DD5-
26 and F36-CBI0-18. The cytotoxicity titr •• , immunoglobulin yi.ld .nd 
purity were analyzed. 
6.5.1 Bulk purification of laM from one litre volume' of F15-DD5-26 .nd 
F36-CBIO-1S tissue culture supernatants 
On. litre volumes of medium harvested from .xh.u.ted F15-DD5-26 .nd r36-
CBI0-18 cultures were concentrated to 100ml through. YMI0 ultra filtr.tion 
membrane by positive pressure at 15 P.S.I. P.rti.lly purified 19M w •• 
pr.pared, as above, using 40g of ABx 40#Jm ion .xchang. r •• in .nd di.ly.ed 
in PBS-DAB to a final volume of 9ml. IgM po.itiv. fr.ction. Wlr. p •••• d 
through a Sephacryl S300 gel filtration column in thr ••• t.p. of 3ml 
volumes. 
6.5.2 Sephacryl S300 Gel filtration profil •• 
Th. gel filtration elution profile. ware ,imilar to tho •• pr.viou.ly found 
for each antibody (Figure 6.5.1). 
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Bulk Purification of F15-DD5-25 IgM 
Using 8ephacryl 8300 Gel Filtration 
Absorbance (280nm) 
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Bulk Purification of F36-CB10-18 IgM 
Using 8ephacryl 8300 Gel Filtration 
Absorbance (280nm) 
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rlgure 6.5.1 Sephacryl s300 gel flltratlon elutJ.on profi-le of the IglI 
fraction from 100ml of xl0 concentrated r15-DD5-26 (panel a) and r36-c810-
18 (panel b) tissue culture supernatant, J.nJ..tJ..ally purJ..fJ..ed usJ..ng ABz 40",. 
ion exchange chromatography. The hatched area denotes fractiOlls wi-th 
lymphocytotoxic autoantibody reactivity. 
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6.5.3 SOS-PAGE analysis of purified 19M 
The final purity of 19M (gel filtration fraction. pooled from peak 1) of 
F15-005-26 and F36-C810-18 were analyzed using SOS-PAGE (Plate 6.5.1). 
Lan •• 2 and 6 (non-reduced) show pentameric 19M from F15-005-26 and F35-
C810-18 respectively, which does not migrate into the 10\ acrylamide gel. 
Mo contaminating protein bands were s.en. Lanes 3 and 8 (reduced) show 
bands at molecular weights 70,000 and 23,000 corre.ponding to the 19M heavy 
and light chains for F15-005-26 and F36-0810-18 re.pectively. Again, no 
major contaminating protein bands were pre.ent. The total purified 19M 
recovered (indicated by absorbance at 280nm) was 22·6mg for '15-005-26 and 
17·14mg for '36-C810-18, representing an approximate 34\ and 41\ yield for 
each antibody respectively. Thi. indicated that the .caled up method for 
bulk purification of human 19M from tis.ue culture .upernatant gave near 
pur. immunoglobulin with an acceptable yield. 
252 
Plate 6.5.1 
SDS-PAGE analysis of bulk purification of IgM from 100ml of xlO 
concentrated F15-DD5-26 and F36-CB10-18 tissue culture supernatant by ion 
exchange chromatography and gel filtration. 
Lane 1, Low molecular weight markers (94k, 67k, 43k, 30k, 20k) • 
Lane 2, F15-DD5-26 purified IgM, non-reduced. 
Lane 3, F15-DD5-26 purified IgM, reduced. 
Lane 4, F15-DD5-26 purified IgM, biotinylated, non-reduced. 
Lane 5, F15-DD5-26 purified IgM, biotinylated, reduced. 
Lane 6, F36-CB10-18 purified IgM, non-reduced. 
Lane 7, F36-CB1O-18 purified IgM, reduced. 
Lane 8, F36-CB10-18 purified IgM, biotinylated, non-reduced. 
Lane 9, F36-CB10-18 purified IgM, biotinylated, reduced. 
Lane 10, Low molecular weight markers (94k, 67k, 43k, 30k, 20k) • 
(, ...., 10 
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6.5.4 Cytotoxicity screening of purified IgM 
Fractions corresponding to each peak for each antibody were pool.d and 
t.st.d for lymphocytotoxic autoantibody reactivity against one T cell, one 
B c.ll and one eLL cell (Table 6.5.1). Th. r.sults r.v.al.d that strong 
lymphocytotoxic autoantibody r.activity was eluted in the IqM positive 
fractions following purification with ABx 40IJm ion .xchang. chromatoqraphy, 
with only weak residual B c.ll r.activity in the IgM depl.ted fraction. 
Following further purification by g.l filtration, lymphocytotoxic 
autoantibody reactivity was eluted in peak 1, with w.ak.r r.sidual B c.ll 
reactivity in the IgM depleted fraction. (peaks 2 and 3). 
Monoclonal antibody ! 
I 
Cytotoxicity titre (reciprocal) 
T cell B cell eLL cell 
F15-DD5-26 
ABx 40 I9M +'ve >256 >256 128 
ABx 40 I9M -eve 0 8 0 
Peak 1 (I9M) 32 >256 16 
Between peaks 1 & 2 4 32 4 
Peak 2 0 0 0 
Peak 3 0 0 0 
F36-CB10-18 
ABx 40",m I9M +'ve >256 >256 >256 
ABx 40",m I9M -eve 0 32 0 
Peak 1 (I9M) >256 >256 >256 
Between peaks 1 & 2 2 32 4 
Peak 2 0 16 0 
~able 6.5.1 Cytotoxicity titre. of IgN fractions purifi.d fro. on. litre 
volume. of F15-DD5-26 and F36-CB10-1B tissue cultur. sup.rnatant. 
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6.6 liotipylatioD of purified IgH 
Img quantities of purified IgK from FI5-0D5-26 .nd 1'36-CII0-18 ware 
directly biotinylated according to the method of Gretch (Gretch, Suter and 
Stinski, 1987). To confirm successful biotinylation without 10 •• of 
antibody reactivity, binding of labelled and unlabelled NAb, were compared 
by a) cytotoxicity and conventional binding •••• y. u.ing FITC-anti-human-
IgM, and b) biotin/FITC-avidin binding ."ay" again,t T and 1 cell 
targets. 
6.6.1 Cytotoxicity and binding assay re,ult'l 
A .mall reduction in cytotoxicity titre (one doubling dilution) wa, found 
with the biotinylated NAbs compared to the origin.l unlabelled IgK (data 
not shown). A corresponding drop in me.n ch.nnel fluore.cence of 25' wa. 
found on cytofluorograph analy.i, u,ing I'ITC-anti-human-IgK (data not 
shown). These data showed that the biotinylation procedure h.d not re.ulted 
in substantial loss of cytotoxicity and binding re.ctivity of the 
.utoantibodies. 
6.6.2 linding profiles of biotinylated monoclonal antibodie,. 
FACScan profiles (logarithmic ,cale) of biotinylated NAb" 1'15-D05-26 and 
F36-CII0-18 tested at 1/10 and 1/20 dilution, ag.in,t T and 8 cell. are 
.hown Figure 6.6.1. 
T cell binding profile, (panel a) ,how ,ucce"ful biotinylation of both 
r15-D05-26 and F36-CII0-18, with both antibodie. giving .imilar profile. 
to those .een with FITC-anti-human-IgM. NAb 1'15-005-26 gave .. an channel 
fluore.cence values of 88 (76' po.itive) and 49 (54' po'itive) .t 1/10 and 
1/20 dilution. respectively. r36-CIIO-18 g.ve higher binding with .. an 
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channel fluorescence values of 227 (88' positive) and 178 (87' positive) 
at 1/10 and 1/20 dilutions respectively (background .. an channel 
fluorescence value. of 10 with 10' positive have been deducted fro. this 
data) • 
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B cell binding profiles (panel b) ahow higher mean ch.nnel fluoreacence 
values of 295 (72' positive) and 199 (62' poaitive) for P15-DD5-26 .t 1/10 
.nd 1/20 dilutiona respectively. P36-CB10-18 g.ve v.lue. of 518 (79' 
positive) and 339 (75' positive) at 1/10 and 1/20 dilutiona re.pectively 
(background values of 61 with 12' poaitive have been deducted from thia 
data) • 
The stronger binding of P36-CB10-18 compared to P15-DDS-26 may reflect more 
efficient biotin labelling of P36-CB10-l8, or altern.tively be due to it. 
increased binding affinity. The result. u.ing directly biotinylated MAh. 
are in accordance with the cytotoxicity and cytofluorograph binding • •••• y. 
which demonstrated low binding to T cells which waa atill further reduced 
at dilution, at antibody concentrations which give higher _an channel 
fluorescence with B cell target •• However a reduction in _.n ch.nne1 
fluorescence using B cell target a was .een between 1/10 and 1/20 dilution., 
indicating that the antibodies were not .aturating. 
PACScan binding profiles for B lymphocyte. u.ing PITC-anti-human-IgM 
demon.trated two cell populations, .urface 19K poaitive .nd .urface 19M 
negative B cells (see Chapter 4). Binding of the .utoreactive MAb. 
indicated that both cell population. were po.itive, with a .hift of both 
peaks to the right. The PACScan profile. u.ing directly biotinylated MAb. 
also correlate with these finding •• Only one a cell peak wa .... n u8ing 
P1TC-avidin alone. This peak .hifted to the right with the addition of the 
biotinylated MAbs. The positive a cell population wa .... n a. a .ingle 
peak, indicating that there i. no di.crete B cell .ubpopulation to which 
the autoantibodies are binding. However a '.houlder' wa .... n with the P36-
CalO-18 binding to B cells at 1/10 dilution, indicating .ome degr.. of 
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differential binding to B cell populations. This profile wa. not apparent 
for 1'15-005-26. The results are consistent with the view that 
autoantibodies bind both surface IgM positive and IgM negative B cell •• 
6.7 Cqapetitiye inbibitiop of IJWRhocytotolic autoaptibody bipdipal 
Characterisation of the lymphocytotoxic autoantibodies thus far ha. 
indicated that they may be polyreactive, with broad .pecificitie.. The 
result. have sugge.ted that the autoreactive antibodies are capable of 
binding many negatively charged molecule. on the cell .urface. To 
investigate if the monoclonal lymphocytotoxic autoantibodies bind .imilar 
or di.tinct cell surface molecules, unlabelled IgM purified from F15-005-
26 and F36-CB10-18, and I'OM-A tissue culture .upernatant were u.ed to 
inhibit the binding of directly biotinylated MAb •• The experimental de.ign 
i. shown in Materials and Methods (Table 2.3.1). 
The percentage binding of biotinylated HAb in the pre.ence of each 
unlabelled inhibiting antibody were compared to the normal control. (PBS-
OAB alone). Biotinylated F15-005-26 was .trongly inhibited by unlabelled 
IgM purified from P15-DD5-26 (Fig 6.7.1 panel a). Equal inhibition wa. 
found using both O'1mg/ml and O'05mg/ml of biotinylated IgK with 24' and 
27' binding of controls respectively. Inhibition of biotinylated r15-0D5-
26 at O'1mg/ml and Oo05mg/ml by F36-CB10-11 19K gave 71' and 73' binding 
of controls respectively, indicating a degr .. of cOllllDOn .pecificity. 
However little inhibition was found with FOH-A ti •• ue culture .upernatant 
(approximately OoOSmg/ml) using biotinylated r15-D05-26 at OOlmg/lll or 
O'OSmg/ml (77' and 91' binding re.pectively)o 
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Inhibition of Biotinylated F15-DD5-26 
Binding 
Percentage binding of controls 
120~------------------------------~ 
None 0810 1 0810 6 DDS 1 DD6 6 FOM-A 1 FOM-A 6 
Inhibiting antibody 
Inhibition of Biotinylated F36-CB10-18 
Binding 
Percentage binding of oontrols 
120~------------------------------~ 
None 0810 1 0910 6 DD5 1 DD5 5 FOM-A 1 FOM-A 5 
Inhibiting antibody 
a) and F36-CBIO-IB Iglf (panel bJ at 0-1 and 0-05aglllJ., u.J.ng ualabellecf ZgII 
purified ~ro. PI5-DD5-26 and PJ6-CBJO-J', and ~-A ti •• ue cultu~ 
.upernatant. 
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Similar results were found with inhibition of biotinylated P36-CB10-18 
binding (Fig 6.7.1 panel b). Directly biotinylated F36-CB10-18 at O·lmq/ml 
and 0·05 mg/ml was strongly inhibited by it.elf with 26' and 22' binding 
of controls respectively. A 68' and 76' binding inhibition was found using 
unlabelled F1S-DDS-26 IgM and no inhibition wa. found u.ing POM-A ti •• ue 
culture supernatant. 
These results indicate that F1S-DDS-26 and F36-CB10-18 give weak mutual 
inhibition, demonstrating that they share some degree of common binding 
.pecificity. However the strong 'auto-inhibition' by them.elve. (mean 75' 
inhibition) compared to the weaker 'cro •• -inhibition' (mean 26' inhibition) 
.hows that they also bind distinct antigenic epitopes. F1S-DDS-26 and P36-
CalO-18 were selected as having different immunoglobulin light chain u.age 
(lambda and kappa respectively) and therefore the difference. in binding 
.pecificity are not surprising. However the cro •• inhibition of each other 
are consistent with them sharing some collective binding feature •• The lack 
of binding inhibition by FOM-A tissue culture .upernatant may indicate that 
the non-specific binding i. too distinct structure. to those of P1S-DDS-
26 and F36-CB10-18. Alternatively, the lack of inhibition may be due to the 
lower binding affinity of FOM-A compared to the autoreactive MAb.. Thi. 
latter view gains support from the .mall degr.. of inhibition of P1S-DD5-
26 which has low affinity compared to no inhibition of P36-CB10-18 which 
was selected for improved binding affinity. POK-A ti.sue culture 
.upernatant was used in this te.t a. insufficient antibody was available 
for purification of 19M. However equivalent concentration. of IgM 
(approximately O·OSmg/ml) were used. It i. therefore unlikely that the lack 
of inhibition by FOM-A was due to this factor. 
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6.8 Iphibition of biotinylat.d aut0aDtibodi •• by pati'At .eryaa 
The a •• umption that the monoclonal lymphocytotoxic autoantibodie. 1'15-
DD5-26 and F36-CBIO-18 are the same a. tho.. found in the .erum of renal 
dialy,is patient, hal thu, far been founded on correlation. of the 
cytotoxicity profiles found using patient. serum and the monoclonal 
antibodie,. The monoclonal antibodies produced in thi' .tudy have identical 
reactivity patterns to those in patient.' .ara. 
The availability of biotinylated primary antibodie. allow. direct 
comparison of the specificity of autoantibodie. in patient.' .era and the 
autoreactive MADs. Binding inhibition of biotin labelled monoclonal 
antibodies was tested with T and B cell. u.ing .erum from, 1) normal 
individuals (blood group AB .erum pooled from five untran.fu.ed male.), 2) 
dialysis patient DV, with 100\ T, Band CLL cell panel reactivity due 
.olely to IgM lymphocytotoxic autoantibodie., and 3) dialy.i. patient IW, 
with 100\ B cell panel reactivity due to IgK autoreactive antibodie •• 
6.8.1 Inhibition of autoantibody binding to T cell. by patient .eraa 
Tha ra,ult. 'how that T cell binding waf .trongly inhibited by normal AS 
.erum (mean binding 44\) aa well a. that of .erum DV (mean binding 52\) 
(Fig 6.8.1). Leaa binding inhibition waf found with .erum IW containing 
autoreactive B cell antibodie. (mean binding 71\). The.e re.ult. indicate 
that lymphocytotoxic autoantibody binding to low affinity T cell target. 
could be blocked by normal ,erum a. well a. tho.e with lymphocytotoxic 
autoantibodiea. 
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Inhibition of Autoantibody Binding to 
T cells by Autolymphocytotoxic Sera 
Percentage binding of controls 
120r-------------------------------------~ 
60 
40 
20 
o 
ooe-280.1mg/ml ooe-280.oemg/ml 0810-180.1mg/ml 0810-180.oemo/ml 
Monoclonal antibody 
Inhibiting .. rum 
• PBS 1\1 Normal human .. rum 
mm T and B autoantibody • BOlli autoantibOdy 
ligure 6.8.1 Percentage binding inhibition of biotinylated I15-DD5-~6 and 
136-CSIO-18 IglI binding at 0·1 and 0·051MJ11IJ., to r cell. by a) nOrJlal hUIIaIJ 
.erulll, b) patient DV with r, • and CLL cell l)WIJIJocytotoxic autoantibocUe. 
and cJ patient Btl with. cell lYl'l'hocytotoxic autoantibocUe. only. 
'1'0 inve.tigate thb further, the ability of purified eerua protein. to 
inhibit autoreactive monoclonal antibody bindill9 va. t •• ted. IIWIan albwain 
at 4Omg/ml (normal phy.iolQ9ical concentration of _rua albuain), and 
6Omg/ml (total .erum protein level), and huaan 19K at l·o.g/al and loG at 
5.0119/1111 (within normal phy.iolQ9ical range) _re \I" to 1Dbibit Db 
binding (Fig 6.8.2). 
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Inhibition of Autoantibody Binding to 
T cells by Human Albumin 
Percentage binding of control 
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Inhibition of Autoantibody Binding to 
T cells by Human IgM and IgG 
Percentage binding of control 
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• PBS • Human IgM 1.0mg/ml ., Human IgG 6,Omg/ml 
rigure 6.B.2 Co.petitive inhibition ot biotinylated r15-DD5-21 zga and 
rJ6-CBIO-ZB IglI at 0·1 and 0·05tag/1d again.t 2' cell target., u.ing lJuau 
albWl1n at 40 and 60~/1d (panel a) and lJuaan Zg. OeDag/Id) and ZgG 
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, 
T cell binding of F15-005-26 was inhibited by human .erum albumin at both 
40mg/ml and 60mg/ml with mean 77' and 83' binding respectively. Thia 
confirms that the low affinity T cell binding inhibition wa. non-.pecific. 
19M and IgG also gave binding inhibition, with mean binding of 70' and 89' 
compared to the normal control. (PBS-DAB alone). F36-CB10-18 wa •• imilarly 
blocked by human albumin at 4Omg/ml and 6Omg/ml (mean 66' and 67' binding 
respectively) and by IgM and IqG (mean 66' and 83' binding re.pectively). 
6.8.2 Inhibition of autoantibody binding to B cell. by patient •• eral 
The same experiment. were performed using high affinity B cell target. 
(Figure 6.8.3). In these tests only .erum DV, with strong T and B cell 
lymphocytotoxic autoantibodies caused inhibition of MAb binding, with 50' 
and 62' binding for F15-005-26 and r36-CB10-18 re.pectively. The higher 
binding of F36-CB10-18 compared to F15-D05-26 again correlate. it. higher 
binding affinity. No inhibition wa. found u.ing normal AS .erum (mean 102' 
binding), and weak inhibition was .een with .erum •• (B cell 
autoantibodies), with 82' and 85' binding for F15-DD5-26 and r36-CBIO-18 
respectively. 
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Inhibition of Autoantibody Binding to 
B cells by Autolymphocytotoxic sera 
Percent binding Of control 
120r--=~--------------------------------~ 
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40 
20 
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DD6-2e 0,1mg/ml DD6-2e 0,06mg/ml 0910-1e O,1mg/ml 0910-16 0,06mg/ml 
Monoclonal antibody 
Inhibiting reagent 
• P9S • Normal human serum 
IZZl T and B autoantibody • B oell autoantl body 
Figure 6.8.3 Percentage binding inhibition o~ biotinylated F15-DD5-26 and 
F36-CBIO-18 Iglf binding at 0·1 and 0·05mg/1IIl, to B cells by a) normal human 
.erum, b) patient DV with 100\ T, B and eLL cell lymphocytotoJlic 
autoantibodies and c) pat.ient. EfI with B cell lymphocytotoxic autoantibodi •• 
only. 
No significant B cell binding inhibition was found with human albumin at 
40mg/ml or 60mg/ml (mean 92\ and 95\ binding respectively) (Figure 6.8.4), 
nor with purified human IgM or IgG (mean 90\ and 98' binding respectively). 
These results demonstrate that the monoclonal lymphocytotoxic autoantibody 
binding to B cells were only inhibited by alloanti.era containing strong 
lymphocytotoxic autoantibodies. 
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Inhibition of Autoantibody Binding to 
B cells by Human Albumin 
Percent binding Of contrOl 
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Inhibition of Autoantibody Binding to 
B cells by Human IgG and IgM 
Percent binding of control 
120~------------------------------~ 
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OOG-20 O,1mg/ml OOG-2e O,OGmg/ml CB10-180,1mg/ml 0810-180,oemg,ml 
Monoclonal antibody 
Inhibiting reagent 
• PBS • Human IgM 1.0mg/ml • Human IgG 6,Omg/ml 
,igure 6.B.4 Ctwpetitive inhibition oL biotiIJ),latecl 'U-DD5-ll ZgII and 
albuatn at 40 and 60~/tV. (panel a) and hUIIU Zgll O-Oag/lIl) ud ZgG 
(5·0~/tV.) (panel b). 
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6.9 Discussion 
The results show that low affinity T cell bindinq can be non-.pecifically 
blocked using physioloqical concentration. of normal human .erum and 
purified protein. (albumin, IqK and IqG). The apparent non-.pecific 
blockinq by unlabelled human 1qK u.inq T cell tarqet. may explain the 
discrepancy with Cicciarelli (Cicciarelli et al, 1980) who concluded that 
the autoantibodies are IgK-anti-IqK. However hiqh affinity B cell bindinq 
i. not inhibited by normal human .erum, nor by purified human albumin or 
IgK and IqG at physioloqical concentration.. B cell bindinq was only 
inhibited by serum DV. Thi. patient wa. .elected to have .tronq (hiqh 
titre) IgM lymphocytotoxic autoantibodies reactive with all T, Band CLL 
cell targets. The cro •• inhibition by autoantibodies from this patient • 
•• rum indicate. that they .hare a common .pecificity. 
There was only weak binding inhibition with .erum &W, containinq only B 
cell lymphocytotoxic autoantibodie.. The cytotoxicity of this .erum with 
B cell. alone i. probably due to low antibody titre and affinity, being 
reactive with only high affinity B cell target., but not low affinity T and 
CLL cell targets. Therefore EW was le •• able to block the .tronger binding 
of the KAb •• 
The data therefore .upport. the view that the human monoclonal 
autoantibodies produced in this .tudy are the .... a. the autoantibodies 
found in renal dialysis patient.' .erum. 
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6.10 ImmUDoprecipitation 
Attempts to immunoprecipitate the autoantigenic target molecule from the 
cell surface of the cell line KS62 ware unsuccessful (data not shown). 
Immunoprecipitation using IgM is known to be difficult. Therefore to 
improve the chances of success, affinity chromatography using the avidin-
biotin technique was used (Wilchek and Bayer, 1988). High affinity 
interactions between these molecules (1015 M-1 ) and the ability to 
introduce 'spacers' onto the biotin molecule to avoid steric hinderance, 
enables increased efficiency for antigen purification compared to 
conventional MAb-agarose affinity columns (Updyke, Nicolsen and A, 1984). 
Gretch (Gretch, Suter and Stinski, 1987) estimated that the u.e of the 
avidin/biotin based immunoaffinity system was 20-50 times more efficient 
at isolating antigen than the use of antibody linked to cyanogen-bromide 
activated sepharose. 
Autoradiography revealed no immunoprecipitation bands from detergent 
solubilised K562 cell membrane antigen.. However, binding of biotin 
labelled IgM to the avidin-agarose matrix was confirmed as immunoglobulin 
light and heavy chains were eluted and identified following protein 
staining of the gel. This indicate. that the method worked appropriately. 
One possible reason for the absence of an immunoprecipitation product may 
have been the susceptibility of the glycoprotein to acid hydrolysis 
following elution at low pH. 
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6.11 Iphibition of the aixed 1ymphocyt. r.action CHLR) 
Reports have postulated that lymphocytotoxic autoantibodi.. have an 
immunoregulatory role associated with enhanc.d graft .urvival (s •• Chapt.r 
1). Some investigators have found that serum from pati.nt. with 
autoantibodies block MLR reactivity (Esqu.nazi .t al, 1983, Spitalnik .t 
al, 1984). To investigate if the monoclonal lymphocytotoxic autoantibodi.s 
cause inhibition of MLR responses, prolif.ration of allor.activ. T c.lls 
were assessed with and without the addition of the MAb •• 
MLR inhibition studies were initially perform.d using FlS-DDS-26 and F36-
CB10-1S tissue cultur. supernatant. Th.s. gave gr.atly .nhanc.d 
proliferative responses in both the allor.active and autologous 
combinations (data not shown). Th. incr.a •• d prolif.ration was lik.ly to 
b. due to the presence of non-specific growth factor. in the condition.d 
media. 
The assays were repeated using IgM purifi.d from tis.u. cultur. 
supernatant. Initially, 10~1 of IgM at O·Smq/ml in PBS-DAB wa. added to an 
MLR with four respond.r and .ix .timulator c.ll combination.. Untr.at.d 
controls received 10~1 of PBS-DAB alon.. Median count. per minute of 
quadruplicate tests were calculated for .ach r.spond.r and stimulat.r 
combination following background (autologous control) subtraction. Th. 
l.v.ls of stimulation of MAb treat.d combinations wer. compared to the 
untreated controls. Th. r.sults showed no con.ist.nt tr.nd of inhibition 
or stimulation and th.refor. the data is summaris.d as the .. an r.spons. 
of .ach cell against the six stimulator c.lls (Pig 6.11.1). Th.r. was no 
overall inhibitory or stimulatory .ff.ct of NAb tr.atment wh.n compar.d to 
the normal untreat.d controls. 
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MLR Inhibition Using IgM Purified 
from F15-DD5-26 and F36-CB10-18 
Oounts per minute (thousands) 
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MLR Inhibition Using IgM Purified 
from F15-DD5-26 and F36-CB10-18 
Oounts per minute (thousands) 
" .. pond"1 " .. pond" I " .. pond" • " .. pond" , 
If'HI 
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Figure 6.11.1 The effect of IgH purified from F15-DD5-26 and '36-CBJO-
18 at a final concentration of O·05mg/ml on HLR re.ponses of four normal 
individuals. Panel 'a' shows the mean counts for the four responders and 
panel 'b' shows the individual counts of each r.spond.r/st~lator 
combination. 
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Further combinations were tested, aa above, using increased 19M 
concentrations (10~1 at 1·0mg/ml) in an MLR with four responder and four 
.timulator cell combinations. Cells were derived from three normal 
individuals (GF, CT, MW) and one patient with X-linked hypogammaglobulin 
anaemia (RR) (Fig 6.11.2). Comparisons of re.ponse. of the three normal 
individuals (panel a) showed no effect of MAb treatment compared to the 
untreated controls. However both the respon.e and stimulation values of the 
patient R.R. were markedly inhibited following MAb treatment. There wa. an 
82' and 99\ suppression of response (panel a) and 83' and 98' 8uppre •• ion 
of stimulation values (panel b) for F1S-DDS-26 and F36-CB10-18 
respectively. Although this patient had normal MLR re.pon.es in the 
untreated controls, he was found to have a deficient T cell respon.e to PHA 
which was only 11\ relative to the healthy controls (GF,CT,MW) (data not 
shown) • 
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MLR Inhibition by Using IgM 
Purified from F16-DD6-26 and F36-CB10-18 
Oounts per minute [thousands) 
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rigure 6.11.2 ~he effect 01 IgN purified fro. 'J5-DD5-26 and ,3.-c8JO-
ZB at a linal concentration of O·l.g/Ill on the IILR re.fIOlJ ••• (JMlJ.l a) and 
.tiaulation (panel b) of three nomal individual. (GI, cr and _) and 011. 
p.tient with X-linked hypog .... globulin an.e.i. (AR). 
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A third MLR was carried out to investigate if the monoclonal autoantibodiea 
caused inhibition of weak MLR combinations, but not atrong alloreactive 
responsea. An MLR with four reaponder and four atLmulator cell combinationa 
was carried out with the inclusion of a one haplotype matched aibling pair 
(AC and RC) (Fig 6.11.3). The double normaliaed relative reaponse of thia 
pair was 49' compared to a mean of 94' for the mismatched controls (data 
not shown). The addition of the NAba gave only a small auppresaive effect 
with both the weaker aibling pair combination and the atrong mismatched 
unrelated control •• 
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MLR Inhibition Using IgM Purified 
IgM from F15-DD5-26 and F36-CB10-18 
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MLR Inhibition Using IgM Purified 
from F15-DD5-26 and F36-CB10-18 
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Figure 6.11.3 The effect of autoreactive (F15-DD5-26 and F36-CB10-1B) 
human IgM MAbs on MLR responses of two unrelated individuals (OF, SL) and 
a one haplotype matched sibling pair (AC, RC). Panel 'a' shows the mean 
counts of the four responders and panel 'b' shows the individual counts of 
each responder/stimulator combination. 
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6. 12 Di.cuuion 
Several reports have shown HLR inhibition caused by lymphocytotoxic 
antibodies in serum from renal dialysis patients (Sengar, Rashid and 
Barris, 1975; Miller et al, 1975). Bowever, these studies are subject to 
question as the results may be explained by factors other than the presence 
of autoantibodies. For example HLA class II antibodies (Bttenger et al, 
1978) and antiidiotypic antibodies induced following blood transfusion 
(Nagarkatti, Joseph and Singal, 1983, Baisa et al, 1989) inhibit HLR 
respon.e •• Mat.umoto demon.trated inhibition of HLR. and mitogen stimulated 
lymphocytes aSBociated with sera containing cold 8-cell cytotoxin. 
(Matsumoto et al, 1983). Inhibition was strongest when the sera were 
lymphocytotoxic against both the responder and stimulator cells. They also 
demonstrated that inhibitory reactivity could be absorbed with spleen cells 
and wa. present in the IgM but not IgG and IgA fractions. 
Primary alloreactive MLR respon.e. are mediated through CD4 positive T cell 
recognition of HLA-DR, and -DQ (and -DP?) molecules on the stimulator cell 
surface. Many patient. with autoantibodies also have additional HLA 
antibodies, which may be the true source of HLR inhibition. Furthermore, 
severe uraemia causes an immuno.uppressive effect. This may act as an 
inherent source of error in the studies performed using serum .nd cells 
from renal dialysis patients. Post tr.nspl.nt serum m.y cont.in 
immunosuppressive drugs such as cyclosporine which would .lso non-
specifically cause HLR suppression. 
This study utilised purified IgM fro. lymphocytotoxic monoclon.l 
autoantibodies. This has the advantage of being able to .... ur. the effect 
of the autoantibodies without being influenced by oth.r .xtr.neou. f.ctor •• 
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The results showed no conaistent effect of the lymphocytotoxic 
autoantibodies on MLR reactivity of normal cell •• Thi. wa. true for both 
weak and strong alloreactive combination •• We therefore conclude that I9M 
lymphocytotoxic autoantibodies do not cau.e MLR .uppre •• ion and it i. 
unlikely that they perform an aaaociated immunoregulatory role in-vivo. 
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Chapter 7 
D.t.raination of the ieeUAOalObuliA cIa.. apd .ptcificity 
of aptibodi.. cau.ipa a po.itiy. crP"aatch 
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7.1.1 Background studies 
7.1.2 Positive Crossmatch Transplant. 
7.1.3 Selection of serum sample. for cro •• matching 
7.1.4 Immunosuppression 
7.2 R •• ult. of coptrol .tudi •• 
7.2.1 HLA Class I 
7.2.2 HLA-DR 
7.2.3 HLA-DQ 
7.3 Po.itiv. cro .... tch trap.plapt. 
T and B cell positive crossmatch transplant. 
7.3.1 IgM non-HLA antibodie. 
a) Live related donor.; 
b) Cadaver donor tran.plant., fir.t graft. 
c) Cadaver donor transplant., r.graft. 
7.3.2 T and B cell positive cros.match transplant. cau •• d by IgM HLA 
cIa.. I antibodie. 
7.3.3 T and B cell positive cro •• match tran.plant. cau •• d by 190 HLA 
class 1 antibodie. 
7.4 B c.ll po.itiv. cro •••• tch traplplapt. 
7.4.1 IgM non-HLA antibodie. 
a) Living related donor. 
b) Cadaver donor transpl.nt., first graft. 
c) C.daver donor tran.plant., r.graft. 
7.4.2 positive B cell cro.ematch tran.plant. cau •• d by IgM HLA antibodi •• 
7.4.3 B cell positive crossmatch tran.plant. cau.ed by 190 HLA antibodi •• 
7.4.4 Analysis of a positive Beall cro.amatch cau.ed by HLA antibodi •• 
in primary and regraft. 
7.4.5 Discussion 
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7.5 ca'. Pre •• ntation: A politive B cIll cro .... tch due to IgG 
anti-BLA-po antibody prelept at the tiae of 
tran'plantation in a IUCCI.lful renal allograft 
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7.1 Introduction 
It is well established that a positive crossmatch c.u.ed by lymphocytotoxic 
autoantibodies are not associated with e.rly graft failure. However the 
clinic.l relevance of a po.itive cro .... tch in the ab.ence of 
.utoantibodies is less clear. In highly .en.itized p.tient., who may h.ve 
multiple antibody population., the preci.e .pecificity of the po.itive 
crossmatch against a particul.r donor i. difficult to determine. It i. 
pos.ible that reports of varied tr.nsplant outcome when performed with • 
positive crossmatch may be due to different antibody .pecificitie. c.u.ing 
the positive crossmatch. 
The aim of this chapter was to develop .n in-vitro •••• y which could 
reliably define the specificity of donor re.ctive .ntibodie. in highly 
.en.itized patients with multiple .ntibody popul.tion. .nd in combination 
with the use of dithiothreitol (to reduce IgM), to define the .ntibody 
cla.s and specificity in a s.ri.s of po.itive cro .... tch tr.n.pl.nt •• 
7.1.1 Background studies 
Previous studies had established that pre-incub.tion of T lymphocyte. with 
allele specific non-cytotoxic mouse monoclonal antibodies directed .g.in.t 
HLA class I antigens could specifically inhibit anti-HLA alloantibodie. of 
the .ame specificity (Elli., Taylor .nd McMichael, 1982). It wa. al.o 
established that broadly reactive NAb. (locu •• pecific) could .pecific.lly 
inhibit alloantibodi.s without interfering with antibodies directed at 
unrelated determinants (Ellis et .1, 1985). 
Studies using HLA-Class I specific monoc1on.1 antibodies directed .gain.t 
monomorphic determinants demonstr.ted locu. .pecific cytotoxicity 
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inhibition of alloantisera. This method has been utili.ed to determine the 
antibody specificity of a aerie. of tran.plant. performed with a po.itive 
T and B cell croasmatch (Chapman et al, 1986a). 
In this study, the technique of cytotoxicity inhibition of the T cell 
cro.smatch uaing monomorphic anti-HLA cla.. I monoclonal antibodies ha. 
been extended to define the .pecificity of the B cell crosamatch. This 
involved the identification of .uitable non-cytotoxic monomorphic anti-
HLA claaa I, DR and DQ locus specific MAbs and the development of a 
cytotoxicity inhibition assay which could define the .pecificity of the B 
cell croaamatch. Preliminary .tudie. identified three .uitable MAb. which 
under optimal conditions gave locus apecific inhibition of a number of wall 
characterised anti-HLA alloantisera. It wa. al.o e.tabli.hed that the 
technique could distinguish multiple antibody population. pre.ent in many 
dialysis patients. 
The technique of cytotoxicity inhibition, in combination with the u.e of 
dithiothreitol reduction was then applied to define the immunoglobulin 
class and specificity of donor reactive antibodies in 152 renal tran.plant. 
performed with a positive crossmatch. A correlation wa. then .ought with 
graft outcome to investigate the clinical relevance of the different 
antibody types. 
7.1.2 Positive erossmatch Tran,pllnt. 
Between 1978 and 1990, 232 renal tran.plant. were performed with a po.itive 
cro.smatch. This represent. about 25' of all tran'plante carried out in 
oxford (Figure 7.1.1). Actuarial one year graft eurvival of fir.t graft. 
(panel a) was 73' (N-115) which was identical to traneplant. performed with 
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a negative crossmatch (N-SSS). Of 176 regrafts, approximately 2/3 (N-111) 
have been performed with a positive crossmatch (panel b). One year 
actuarial regraft survival was 6S\ for those with a positive crossmatch 
compared to 81\ with a negative crossmatch. This demonstrated a higher 
initial loss although there was no difference in reqraft survival at ten 
years. 
Crossmatching: All Immunosuppression 
(1st Cadaver Grafts) 
Crossmatching: All Immunosuppression 
(Cadaver Regrafta) - . 
..---~~-.+ .. -.... 
eo ..... - ... -_ .. _.--_. --. ... ;;:-===*'''''.,,:t;-;:::-.--.-.. -------... 
. _ ... +--+ .. _+ .. 
20 - ... -.- .. -. 
o~~~_+~~~~J-+-~r-~~_+~~~~ 0~~~~~-r~~J-+-4-r-~~~~-+-L­
o 2 3 4 6 7 8 9 10 o 2 3 7 8 11 
~ars "'ar. 
I - -XM (566) -+-- + XM (115) I I - -XM (84) ........ + XM (118) I 
Oxford Transplant Cantre Oxford Transplant Centra 
rig 7.1.1 Actuarial graLt survival oL all renal transplants perLorrHd with 
a positive T and/or B cell crosamatch compared to tho.e with a negative 
crossmatch in primary graLts (panel a) and regraLt. (panel b). 
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Donor T and/or B cells and the appropriate recipient sera were available 
in 152 cases to determine the immunoglobulin class and specificity of the 
antibody causing the positive crosamatch. For the early transplants this 
was performed retrospectively using cryopre.erved donor lymphocytes and 
stored recipient sera. Kore recently the study has been carried out 
prospectively using fresh donor cells. 
7.1.3 Selection of serum samples for crolsmatching 
Serum lamples were collected from patients at monthly intervals after 
acceptance on to the transplant waiting list, with additional samples taken 
14 days following any blood transfusions. After transplantation, serua 
samples were collected daily for the first week and then at weekly 
intervals for three months, and monthly thereafter. The samples were .tored 
at -30°C until testing using a selected panel of 40 peripheral blood 
lymphocytes and 30 B cell. from patient. with chronic lymphatic leukaemia 
(CLL), covering all the accepted HLA-ABC, DR and DQ alleles. Sera with the 
highest panel reactivity, representing different period. of .ensiti.ation 
("peak") and the most recent sample available ("current") were .elected for 
crossmatching. 
7.1.4 Immunosuppression 
During the period of this .tudy a number of different po.t tran.plant 
immunosuppression protocols were used. Between 1978 and 1985 patient. 
received azathioprine in combination with low doee .teroid. (23 patients) 
or high dose steroids (one patient) (KOrris et al, 1982). Between 1982 and 
1985, 34 patients received cyclo.porin, either alone or in combination with 
prednisolone (Korrie et al, 1987), and from 1985 94 patient. received 
triple therapy (Jones et al, 1988). Highly .en.iti.ed patient. were given 
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prophylactic intravenous methylpredni.olone at SOOmq daily for the fir.t 
three days. Subsequent rejection epi.ode. were treated with a three day 
cour.e of methylprednisolone at SOOmq daily. More recently anti-thymocyte 
globulin (ATG) ha. been used and wa. admini.tered in 22 patient. and OXTl 
in 3 patients. All patient. in this .tudy with a po.itive T cell cro .... tch 
cau.ed by HLA antibodies received cyclo.porin with one exception who 
received azathioprine and low dose .teroid •• 
7.2 Result. of control studies 
7.2.1 HLA Class I 
Twenty HLA-cla.. I typing reagent. were te.ted again.t 60 B cell donor. 
(Table 7.2.1). Fifty-nine of the 60 te.t. were blocked by one or more 
doubling dilution with PA2.6 alone, with 12 te.t. completely blocked. The 
average reduction in titre was 2.2 doubling dilution •• Blocking wa. further 
improved by the addition of the F(ab l )2 .econd layer antibody, with all 60 
test. blocked by one or more doubling dilution, and 26 completely blocked. 
The average reduction in titre wa. 3.2 doubling dilution •• 
7.2.2 HLA-DR 
A total of 23 HLA-DR typing reagent. were te.ted again.t 66 B cell. (Table 
7.2.1). Of the 66 tests, 41 were blocked by NDS-22 alone and 9 ware 
completely blocked. The average reduction in titre wa. one doubling 
dilution. With the addition of the F(ab l )2 .econd layer antibody 64 B cell. 
were tested. Blocking was improved, with all 64 te.t. blocked by one or 
more doubling dilutions and 33 completely blocked. The average reduction 
in titre was 3 doubling dilution •• 
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7.2.3 BLA-OO 
Pifteen HLA-OQ typing reagents were tested against 65 B cell. (Table 
7.2.1). Of S3 B cells tested using alloanti.era specific for HLA-DOw1 
(including the splits OQw5 and 6) and DQw3 (including the splits DOw7, w8 
and w9), 50 were blocked by LEU-10 alone, and eleven tests were completely 
blocked. The mean reduction in titre was 2 doubling dilution.. With the 
addition of the J!'(ab')2 second layer antibody 59 B cells were tested. 
Blocking was only marginally improved, 55 te.t. were blocked by at least 
one doubling dilution, 21 completely blocked and an average reduction in 
titre of 2.1 doubling dilutions. None of the 6 tests, u.ing two sera with 
.pecificity for HLA-DQw2 were blocked by LEU-10 alone, nor with the 
addition of the F(ab')2 second layer antibody (Table 7.2.1). 
No. MAb No. Spec if- MAb Alone I No. MAb + P(ab')2 
sera icity cell Blockeda AveC cell Blocked CompletebAve 
20 PA2.6 HLA-ABC 60 59 (98)c:l 2.2 60 60 (100) 26 (43) 3.2 
23 NOS-22 HLA-OR 66 41 (62) 1.0 64 64 (100) 33 (52) 3.0 
13 LEU-10 HLA-DQw1,3 53 50 (94) 2.0 59 55 (93) 21 (38) 2.1 
2 LEU-10 HLA-DQw2 6 0 - 6 0 - -
A The number of tests with a reduction in titre of at least 1 doubling 
dilution. 
~ The number of tests giving total inhibition (negative in neat seru.). 
~ The average reduction in titre (number of doubling dilutions). 
4 Numbers in parentheses represent the percentage of tests blocked. 
Table 7.2.1 Cytotoxicity inhibition controls. 
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7.3 Positive crossmatch transplants 
The positive crossmatch transplant. have been .n.lyzed on the b •• i. of 
reactivity with donor T and B cell. or B cell. only. Th ••• group. war. 
further .ubdivided according to the ~unoqlobulin cl •••• nd .pecificity 
of the crossmatch and correlated with gr.ft .urviv.l .t .ix month. .nd one 
year after tran'plantation. 
T and B cell positive crossmatch transplant. 
A total of 87 transplants performed with a po.itiv. T .nd B cell cro •• match 
were analyzed for the immunoglobulin cl •••• nd 'pecificity of the .ntibody 
against donor cell •• Overall graft .urviv.l at on. ye.r w •• 69'. 
7.3.1 19M non-HLA antibodies 
a) Liye related donors; Nine tran.plant. ware performed u.ing rel.ted 
donor. (Table 7.3.1). Of the.e, 4 war. HLA identic.l .nd 5 were .ingle 
haplotype matched. All the cros.matche. ware DTT reduc.d indic.ting .n IgM 
antibody and all had a positive .utologou. cro •• match. Blocking .tudi •• 
using PA2.6 (anti- HLA class I) were performed in four c •••• which .howed 
no cytotoxicity inhibition confirming the non-HLA n.tur. of th ••• 
antibodies. Of the nine tran.pl.nt., .ight (89') were .ucc ••• ful. The 
.ingle graft loss (patient JM) was a non r'jection f.ilure following •• vere 
hypotension and sub.equent r.nal vein thrombo.i.. In •• ven c.... the 
crossmatch was positive at the time of tr.n.pl.nt.tion (curr.nt) and .11 
.even were successful. 
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Initials TpN TxDate ImSup TxN Hap PRA Curr OTT PA2.6 OUtcome 
ST 290 20. 7.81 Low 1 2 99 + Y •• No Succ ••• 
MS 389 26. 9.83 Low 1 2 100 + Y •• No Succ ••• 
SW 436 25. 6.84 Low 1 2 100 + Y •• NT Succ ••• 
AT 516 8. 7.85 Low 1 1 100 + Y •• No Succ ••• 
DO 637 16. 2.87 Trip 1 1 75 167 Y •• NT Succ ••• 
D 663 13. 7.87 Trip 1 2 85 + Y •• NT Succ ••• 
AA 707 7.12.87 Trip 1 1 + Y •• NT Succ ••• 
BP 762 26. 9.88 Trip* 1 1 70 + Y •• No Succ ••• 
JM 882 8. 1.90 Trip* 3 1 100 4738 Y •• NT NJUI' 5 
non-HLA antibodies performed using live r.lat.d donor •• 
Legend for Table 7.3.1 and subs.auent tabl ••• 
TpN -transplant number. 2'zD.t. -tran.plant dat •• 
z.sup -immunosuppres.ion protocol; Low - ••• thioprin. with low do •• 
st.roids; 
CyA -Cyclosporin A alone; CYA+S -Cyclo.porin plus low do.. .t.roid., 
Trip -triple therapy; * -ATG; A -OKT3. 
H.p -number of haplotype. match.d. 
PRA -Percentage pan.l reactive antibodi.. d.t.r.in.d u.ing • pan.l of 40 
peripheral blood lymphocyte. or purifi.d T c.ll •• 
curr -number of days from the po.itiv. cro .... tch to the tille of 
transplantation; + -curr.nt po.itiv. with the .a.t r.c.nt •• rua ... pl •• 
D.rr -dithiothr.itol r.duction; r •• -DTT r.duc.d (Ig~), No -not DTT r.duc.d 
(IgG) • 
PA2.6 -Cytotoxicity inhibition by ~Ab PA2.6 (.anOlaOrphic HLA-cla •• I), r •• 
-blocked; No -not blocked; NT -not t •• t.d. 
Outca.e -graft outcome at the pr •• ent tille, .ucc ••• ful -pati.nt fr.. fro. 
dialy.i.; Rej -graft failure due to r.j.ction or NU -non-r.j.ction failure 
(return to dialysis or pati.nt d.ath) with the nu.ber of day. to f.ilur •• 
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b) Cadaver donor transplantl. firlt graft. 
Po.itive T and B cell crossmatche. cauled by 1qM non-HLA antibodi.. were 
found with 26 fir.t cadaver transplanta (Table 7.3.2) and 22 (85') were 
.uccessful at six months. Of th ••• , 13 w.r. poaitiv. at the time ot the 
transplant and 10 (77\) were auccealful at aix montha. 
c) Cadaver donor transplanta. regrafta 
Of 22 reqrafta performed with a T and B c.ll po.itiv. cro .... tch, 20 (91') 
were successful at six month. (Table 7.3.3). ot th ••• , tour were poaitive 
at the time of transplantation and all were .ucce.aful. 
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Initiala TpN TxDate ImSup TxN PRA CUrr DTT PA2.6 OUtcome 
AW 211 11.11. 79 Low 1 100 86 Y •• Nol Succ ••• 
AS 292 30. 7.81 Low 1 100 + Y •• No NRI' 2254 
PL 318 6. 4.82 CyA 1 100 + Y •• No Succ ••• 
EW 348 22. 9.82 CyA 1 100 + Y •• No NJUP 211 
GP 368 17. 3.83 Low 1 100 + Y •• No RBJ 2335 
YO 413 8. 2.84 Low 1 95 1068 Y •• No Succ ••• 
RR 415 18. 2.84 Low 1 100 927 Ye. NO NRI' 0 
GI' 457 23. 9.84 CyA 1 63 2298 Y •• No Succ ••• 
MC 467 24.10.84 CyA 1 63 257 Y •• NO RBJ 356 
DB 474 19.11.84 Low 1 100 + Y •• Ho NJUP 71 
WS 545 5.11.85 Trip* 1 100 456 Y •• Ho RBJ 302 
DB 585 10. 6.86 Trip 1 88 799 Y •• Ho Succ ••• 
LC 607 17. 9.86 Trip 1 90 + Y •• Ho Succ ••• 
RV 627 22. 1.87 Trip 1 100 1339 Y •• Ho# Succ ••• 
AT 691 18.10.87 Trip 1 43 996 Y •• Ho Succ ••• 
RB 693 21.10.87 Trip 1 100 2282 Y •• No Succ ••• 
RA 737 19. 5.88 Trip* 1 71 + Y •• Ho Succ ••• 
n 742 18. 6.88 Trip 1 90 123 Y •• Hoi Succ ••• 
JP 749 6. 7.88 Trip 1 100 736 Y •• No Succ ••• 
n 766 26.10.88 Trip 1 98 + Y •• Ho Succ ••• 
MB 779 5.12.88 Trip* 1 100 + Y •• Ho Succ ••• 
SS 796 13. 2.89 Trip* 1 100 + Y •• NO IfJUP 0 
SO 799 14. 3.89 Trip 1 100 5136 Y •• Ro Suec ••• 
RJ 808 18. 4.89 Trip 1 100 + Y •• No NJUP 0 
SI 826 9. 6.89 Trip 1 87 + Y •• Ho Succ ••• 
ED 913 14. 5.90 Trip 1 100 + Y •• NO Succ ••• 
non-HLA antibodies performed in first cad.ver gr.fts. 
# -Al.o had a positive B cell cro •••• tch c.us.d by an Ig~ non-HLA antibody 
pre.ent at the time of tran.plant.tion (not included in the B cell 
cro.smatch analysis). 
288 
Initials TpN TxDate ImSup TxN PRA CUr DTT PA2.6 Outcome 
DP 177 2. 1. 79 Low 2 100 102 Y •• No R.j 97 
JS 241 3. 6.80 Low 2 100 1125 Y •• Ho Succ ••• 
LW 375 4. 5.83 CyA 3 100 1420 Y •• Ho R.j 691 
VB 444 11. 7.84 CyA+S 2 100 726 Y •• Ho Succ ••• 
SM 511 18. 6.85 CyA+S 2 100 2722 Y •• Ho Succ ••• 
EW 521 17. 7.85 Trip 2 100 1078 Y •• Ho HRP 1379 
KC 534 20. 9.85 Trip 2 100 1719 Y •• No Succ ••• 
JM 541 12.10.85 Trip 2 100 3230 Y •• No Raj 0 
SR 561 14. 1.86 Trip 2 100 259 Y •• No Succ ••• 
LW 568 25. 2.86 Trip 4 100 536 Y •• Ho Succ ••• 
MIt 589 26. 6.86 Trip 2 96 1296 Y •• No Succ ••• 
SG 618 20.11.86 Trip 2 23 + Y •• No Succ ••• 
D 623 26.12.86 Trip 2 100 + Y •• Ho HRP 1048 
S8 647 29. 3.87 Trip 3 88 3355 Y •• Ho Succ ••• 
ML 677 14. 8.87 Trip 2 100 2608 Y •• Ho Succ ••• 
ST 679 28. 8.87 Trip 2 83 + Y •• No Succ ••• 
PM 684 10. 9.87 Trip 2 100 203 Y •• No Succ ••• 
JR 746 25. 6.88 Trip 2 100 395 Y •• Hoi Succ ••• 
EG 798 10. 3.89 Trip 2 100 1414 Y •• No Succ ••• 
PR 851 21. 9.89 Trip* 2 65 528 Y •• Ho Succ ••• 
VA 874 5.12.89 Trip* 3 87 1804 Y •• No Succ ••• 
RR 938 16. 8.90 Trip 3 100 + Y •• Ho Succ ••• 
Table 7.3.3 T and B cell po.itiv. cro .... tch tran.plant. c.u •• d by IgN 
non-HLA antibodies performed in c.d.ver r.gr.ft •• 
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7.3.2 T and B cell positive crossmatch transplants cau.ed by 
laM HLA class I antibodies 
Donor T and B cell reactive IgM HLA claa. I antibodiea (OTT reduced and 
blocked by PA2.6) were found in 17 patienta (Table 7.3.4). Six were fir.t 
grafts and 5 (83\) were successful and 11 were regraft. and 7 (64\) were 
successful. 
Initials TpN TxOate ImSup TxN PRA Cur OTT PA2.6 OUtcome 
co SS8 10. 1. 86 Trip 1 100 1025 Yea Ye. - succe •• 
JB 674 29. 7.87 Trip 1 100 1239 Ye. Yea& Succe •• 
JW 695 3.11.87 Trip 1 63 571 y •• Ye. Succe •• 
TG 754 17. 8,88 Trip· 1 13 42 Ye. y •• Succe •• 
JW 810 20. 4.89 Trip 1 65 345 Ye. y •• Succe •• 
RH 820 26. S.89 Trip 1 93 352 Ye. y •• Rej 0 
JB 434 7. 6.84 Low 2 100 912 y •• Ye. Rej 8 
WB 438 28. 6.84 CyA+S 2 100 1828 Ye. Ye. Succe •• 
CK 439 28. 6.84 CyA+S 2 100 1190 Ye. Ye. Succe •• 
CB 445 20. 7.84 CyA+S 3 100 1060 Ye. Ye. Rej 45 
ED 449 20. 8.84 CyA+S 3 100 1000 Ye. Ye. Succe •• 
MM 506 24. 5.85 CyA+S 2 63 1228 Ye. y •• Succe •• 
TL 523 19. 7.85 Trip 2 100 2025 Ye. Ye. R.j 83 
DB 539 6.10.85 Trip 2 96 1921 Ye. Ye. Rej 4 
TM 587 24. 6.86 Trip· 2 100 3905 Ye. y •• Succ ••• 
TB 642 8. 3.87 Trip· 2 100 573 Ye. Ye. Succe •• 
KW 653 6. 6.87 Trip 2 100 1591 Y •• Y •• S Succ ••• 
Table 7.3.4 T and B cell positive crossmatch tran.plant. c.u.ed by IgN 
anti-HLA class I antibodies. 
- Also had a positive B cell cro.am.tch due to an IgG HLA-DQ antibody, 
present at the time of transplantation (.ee B cell cro .... tch an.ly.i.). 
$ Also had a peak reactive B cell cro .... tch due to an IgN HLA-DQ antibody 
(see B cell crossmatch analysi.). 
, Also had a peak reactive B cell cro •• match due to an IgM HLA-OR antibody 
(aee B cell croasmatch analy.i.). 
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7.3.3 T and B cell positive crossmatch transplants caused by IgG 
HLA class I antibodies 
Of nine T and B cell positive crossmatch transplant caused by IgG HLA cla •• 
I antibodies (blocked by PA2.6 and not reduced by DTT) only one (11') 
functioned beyond 28 days (Table 7.3.1). All gr.ft f.ilurea were due to 
rejection. In one case (RF, TP No.443) the croaamatch waa poaitive .t the 
time of transplantation using current serum. In this caae the kidney donor 
and recipient were thought to be HLA identical, however r.tro.pectiv. 
analysis demonstrated a HLA-C locus incompatibility to which the recipient 
waa sensitised. This transplant suffered • hyper.cut. rej.ction (Ch.pman 
et al, 1986c). (The patient has subsequently received. fifth tr.n.pl.nt 
using a fully HLA identical donor and this tranaplant ia aucc.aaful with 
a creatinine of 177~mol/l one and. half ye.r. poat tr.napl.nt). 
In addition there were a further four poaitiv. croaamatch tr.napl.nt. 
caused by IgG antibodies which were not block.d by PA2.6 (two c •••• ) .nd 
cytotoxicity inhibition tests were not performed (two c.aea). All four of 
these transplants failed within 3 month •• 
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Initials TpN TxData ImSup TxN PRA CUr DTT PA2.6 OUtcome 
DH 435 16. 6.84 eyA+S 1 100 2950 No No NRI' 44 
AL 463 12.10.84 CyA+S 1 100 1920 No No NRI' 24 
BB 491 23. 3.85 eyA+S 1 69 3283 No Ye. Rej 7 
RF 388 14. 7.83 eyA 3 100 720 No NT Rej 0 
RF 443 10. 7.84 eyA+S 4 100 + No Ye. Rej 0 
GH 446 1. 8.84 eyA+S 2 100 1035 No Ye. Rej 0 
RI 447 1. 8.84 eyA+S 2 94 830 No NT Rej 9 
MD 448 6. 8.84 eyA+S 2 35 1410 No Ye. Rej 28 
BH 464 21.10.84 eyA+S 3 100 1760 No Ye. Rej 9 
BX 552 20.12.85 Trip 3 100 3089 No Ye.£ Rej 0 
MB 592 17. 7.86 Trip· 2 100 1444 No Ye. Rej 28 
MJ 615 10.10.86 Trip* 2 100 311 No Ye.' Rej 8 
EH 643 9. 3.87 Trip* 2 98 706 No Ye. Succe •• 
Table 7.3.1 T and B cell posi~ive cros .. a~ch transplants caused by IgQ 
antibodies. 
£ -also had a peak reactive B cell crosB1lla~ch due ~o an IgQ HLA-DR an~ibody 
(not included in ~he B cell crosB1lla~ch analysis). 
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7.4 B c.ll poaitiye cro.amatch tran.pllnt. 
A total of 65 tranaplant. performed with I po.itivI B cIll (negltivI T 
cell) croaamatch w.r. analyz.d. OVlrall onl Ylar grift .urvivil for thi. 
group waa 78\. 
7.4.1 IgM non-HLA antibodiea 
I) Living related donora 
Bight poaitive B c.ll cro •• match trln.plant. werl performed u.ing living 
related donora (Table 7.4.1). All wer •• ingll hlplotype matched Ind werl 
poaitive at the time of tran'plantltion. An lutologou. cro •• match WI. 
po.itive in each caae and III wIre cau.,d by 19M Intibodi,.. All 
trlnaplanta were aucce.aful with I follow-up ttme of betweln onl Ind fivI 
year •• 
Initiala TpN TxOate ImSup TxN Hap CUr DTT outcome 
AS 496 11. 4.85 CyA+S 1 1 + YI. SUCCI •• 
SA 498 15. 4.85 CyA+S 1 1 + YI. SUCCI •• 
FA 583 9. 6.86 Trip 1 1 + YI. SUCCI •• 
OA 621 8.12.86 Trip 1 1 + YI. SUCCI •• 
AM 628 26. 1.87 Trip 1 1 + YI. SUCCI •• 
AS 710 11. 1.88 Trip 1 1 + YI. SUCCI •• 
F 717 8. 2.88 Trip 1 1 + YI. SUCCI •• 
8M 836 24. 7.89 Trip 1 1 + r,. SUCCI •• 
Table 7.4.1 Positive B cell crosam.tch transplants causld by IgN non-HLA 
antibodies using live relatld donors. 
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b) Cadaver donor tranaplanta, first graft a 
Of 17 primary transp1anta performed with a po.itiv. B c.ll cro ..... tch 
caused by IgK non-HLA antibodi.a 13 (76') w.r •• ucc ••• ful at .ix month. 
(Table 7.4.2). Of these, sev.n were positive u.ing curr.nt •• rum and .ix 
(86') were successful at six month •• 
Initials TpN TxDat. ImSup TxN PRA CUr DTT Block OUtcOlDe 
OZ 278 29. 4.81 CyA 1 13 539 Y •• No 8ucc ••• 
MH 342 4. 9.82 CyA 1 87 + Y •• No Succ ••• 
JP 354 19.10.82 Low 1 50 + Y •• No Succ ••• 
AO 364 9. 2.83 Low 1 57 303 Y •• No Raj 35 
PH 441 6. 7.84 Low 1 36 + Y •• No R.j 718 
DH 469 26.10.84 CyA 1 95 170 Y •• NT Succ ••• 
DH 597 5. 8.86 Trip 1 43 495 Y •• No Succ ••• 
AD 616 15.10.86 Trip 1 80 + Y •• No Succ ••• 
CR 626 22. 1.87 Trip 1 53 79 Y •• No NRP 44 
MS 645 26. 3.87 Trip 1 97 408 Y •• No Succ ••• 
PR 726 7. 4.88 Trip 1 50 247 Y •• No NRP 0 
EH 745 24. 6.88 Trip 1 40 + Y •• No Succ ••• 
EH 790 28.12.88 Trip 1 83 2612 Y •• No Succ ••• 
PJ 791 28.12.88 Trip 1 48 853 Y •• No Succ ••• 
PT 875 8.12.89 Trip 1 7 + Y •• No NRP 58 
KB 892 6. 2.90 Trip 1 73 + Y •• No Succ ••• 
CO 917 23. 5.90 Trip 1 51 76 Y •• No Succ ••• 
~able 7.4.2 po.itive B cell cro .... tch tran.plant. c.u.ed by Ig_ non-HLA 
antibodies in primary cad.ver grafts. (PRA -higheat percent.ge re.ctivity 
of .era tested against a panel of 40 PBL'a and 30 eLL'a). 
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c) Cadaver donor transplants. regrafts 
Of 18 regrafts performed with a positive B cell cro.smatch cau •• d by IgM 
non-HLA antibodies 16 (89\) were successful at six month. (Table 7.4.3). 
Six crossmatches were positive using current .erum taken at the time of 
transplantation and all were successful. 
Initials TpN TxOate ImSup TxN PRA Cur DTT Block OUtcome 
AA 158 29. 7.78 High 2 94 970 Ye. No NRF 2802 
HD 248 9. 7.80 Low 2 84 + Yea No Succe •• 
BP 298 27. 9.81 Low 2 100 + Ye. No Succe •• 
JK 372 4. 4.83 Low 3 100 605 Yea No Rej 41 
CO 442 6. 7.84 CyA+S 2 85 1155 Ye. No Succe •• 
OF 451 28. 8.84 CyA+S 3 96 1595 Y •• No Succe •• 
VA 462 11.10.84 CyA+S 2 100 2400 Ye. No Rej 120 
RC 468 25.10.84 CyA+S 2 100 1375 Ye. No Succe •• 
JO 520 17. 7.85 Trip 2 41 1160 Ye. No Succe •• 
BN 617 24.10.86 Trip 2 93 + Y •• No Succ ••• 
GM 750 7. 7.88 Trip 2 43 + Ye. No Succe •• 
MH 765 26.10.88 Trip· 2 97 1402 Y •• No Succe •• 
RF 834 21- 7.89 Trip· 2 57 898 Ye. No Succe •• 
AL 853 21- 9.89 Trip· 2 33 + Y •• No Succ ••• 
PW 852 21- 9.89 Trip 2 87 71 Y •• No Succe •• 
MB 854 23. 9.89 Trip 2 NT 445 Y •• No Succ ••• 
LW 865 5.11.89 Trip .... 3 97 1797 Ye. No Succe •• 
SL 883 8. 1.90 Trip· 3 53 + Y •• No Succe •• 
Table 7.4.3 Positive B cell crossmatch transplants caused by IgN non-HLA 
antibodies in cadaver regraLta. 
In addition two patients (one fir.t graft and one regraft) had a po.itive 
B c.ll crossmatch which was not reduced by OTT and not blocked for HLA 
class I, DR or OQ indicating an IgG non-HLA antibody. Both tran.plant. are 
8uccessful beyond on. year (data not .hown). 
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7.4.2 Positive B cell crossmatch transplant. caused by laM HLA antibodi •• 
Ten transplants were performed with peak positive - current negative B c.ll 
crossmatches caused by IgM HLA antibodie. of which .ix (60') wer. 
successful at six months (Table 7.4.4). Five were due to HLA cla •• I 
antibodies (reactive with B cells only becau.e of incr.a •• d antigen 
expression compared with T cell, (Coxe-Gilliand and Cro •• , 1980)) and four 
(80\) were successful. 
Only one positive B cell crossmatch wa. due to IgM HLA-DR antibodi •• 
(blocked by NDS-22) and this graft is functioning beyond on. year. Th. lack 
of positive crossmatches due to HLA-DR antibodies in thi. .tudy i. not 
unexpected because our policy has been not to tran'plant an HLA-DR 
mismatched kidney into a patient with a po.itiv. cro.amatch wh.r. 
autoantibodies could not be demonstrated. 
Four B cell positive crossmatch tran'plant. were found to be cau.ed by peak 
reactive IgM HLA-DQ antibodie, (blocked by LEU-lO). All wer. r.graft. and 
only one (25\) was succes,ful beyond one month. 
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Name TpN TxDate ImSup TxN PRA Cur DTT Block outcome 
MJ 418 28. 2.84 Low 1 75 21 Yea PA2.6 Succe •• 
JJ 644 26. 3.87 Trip 1 100 547 Ye. PA2.6 Succe •• 
ET 821 1- 6.89 Trip 1 77 360 Ye. PA2.6 Succe •• 
MB 594 27. 7.86 Trip· 2 100 1117 Ye. PA2.6 Succe •• 
8H 652 12. 5.87 Trip· 4 100 875 Ye. PA2.6 Rej 8 
JB 674 29. 7.87 Trip 1 100 1239 Ye. NDS-22' Succe •• 
GP 329 13. 6.82 Low 2 100 401 Ye. LEU-10" Rej 0 
RD 493 25. 3.85 CyA+S 2 99 2531 Ye. LEU-10 Rej 18 
S8 629 29. 1.87 Trip 2 88 3436 Ye. LBU-10@ Rej 5 
KW 653 6. 6.87 Trip 2 100 1591 Y •• LEU-10' Succe •• 
Table 7.4.4 B cell positive crossmatch transplUlts caused by Iglf HLA 
antibodies. 
, -also had a peak reactive positive T cell crossmatch due to an Iglf non-
HLA antibody (not included in the T cell Ulalysis). 
& -also had a peak reactive positive T cell cros.match due to Ul Iglf HLA-
class I antibody (see T cell crossmatch analysis). 
" -also had a current positive B cell cros .. atch due to Ul Iglf non-HLA 
antibody (not included in the analysis). 
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7.4.3 B cell positive crossmatch transplant. cau •• d by IgG HLA antibodi •• 
Ten positive crossmatch transplants were caus.d by peak r.activ. IgG HLA 
antibodies and six (60\) were successful at .ix month •• Fiv. w.r. dir.ct.d 
at HLA clasa I (blocked by PA2.6) and thr.e w.r •• ucc.s.ful at .ix month •• 
On. patient (KM, TpN 417) had poor function and the tran'plant fail.d at 
14 months due to chronic rej.ction. 
Two transplants were performed with peak r.activ. po.itiv. B c.ll 
croaamatchea cauaed by IgG HLA-DR antibodie.. In both .ituation. the 
patients were highly sensiti.ed for HLA-Cla.. I and a donor waf found with 
a negative T cell crossmatch. Patient RO al.o had a repeat HLA-DR mi.match 
with a previous donor. The clast and .pecificity of the cro •• match waf 
det.rmined prospectively and the patient. were tr.at.d prophylactically 
with a ten day course of OKT3. Pati.nt RO al.o r.c.ived con •• cutiv. 
immunosuppression with ATG. D •• pit. the •• mea.ur •• both pati.nt. .uff.r.d 
acute rejection. Patient JL failed at two month. and pati.nt RO, although 
free from dialysis at on. year hal n.v.r .njoy.d good function. Thi. 
patient haa a creatinine of 547~1/L 17 month. po.t tran.plant. 
Three transplants were performed with po.itiv. B c.ll cro.amatch.. cau •• d 
by IgG HLA-DQ antibodi ••• Two w.r. pr ••• nt in the peak r.activ ••• rum only 
and one was successful. One pati.nt (00) had a po.itiv. cro •• match u.ing 
current serum and this tran'plant wa. .ucc ••• ful. Thi. ca.. .tudy 11 
di.cussed in detail in Chapt.r 7.5. 
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Name TpN TxDate ImSup TxN PRA Cur OTT Block OUtcome 
MM 417 19. 2.84 Low 1 100 1040 No PA2.6 Rej 425 
MC 398 8.11.83 Low 2 92 575 Ho PA2.6 Rej ° GH 430 11- 4.84 CyA 2 60 2976 No PA2.6 Succ ••• 
DB 483 13. 2.85 CyA+S 3 94 3385 Ho PA2.6 Rej 28 
CP 795 10. 2.89 Trip· 2 100 1647 Ho PA2.6@ Succ ••• 
1m 822 1. 6.89 Trip'" 3 100 1401 Ho HDS-22 Succ ••• 
JL 911 9. 5.90 Trip'" 2 93 456 Ho HDS-22 Rej 65 
CO 558 10. 1.86 Trip 1 100 + Ho LEU-10& Succ ••• 
EM 582 2. 6.86 Trip 2 47 487 Ho LEU-lO NRF 0 
PP 625 31.12.86 Trip· 1 100 238 Ho LBU-10 Succe •• 
Table 7.4.5 Positive B cell croBBmatch transplants caused by IgG HLA 
antibodieB • 
... -received OKT3 immunoBuppresBive therapy (patient RD also received ATG). 
, -also had a peak reactive positive T cell cro .... tch due to an IgN non-
HLA antibody (not included in the T cell analy.i.). 
, -also had a peak reactive po.itive T cell cro .... tch due to an IgN HLA-
class I antibody (Be. T c.ll crossmatch analysis). 
7.4.4 Analysis of a positive B e.ll ero •• mlteh eau'ed by HLA antib04ie. 
in primary and regrafts 
No association was .een b.tween the ~un0910bulin ela •• of the B cell RLA 
antibody and graft outcom •• The .ix month graft .ucee •• rat •• wer. 60' for 
both 19G and 19M, although two pati.nt. with IgG antibodie. had poor 
function and on. failed ju.t beyond on. y.ar. Howev.r wh.n the data ar. 
analyz.d according to primary or regraft, all 7 priaary graft. Wlrt 
functioning b.yond on. y.ar compared to only 5/13 (38') r.graft •• 
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7.4.5 Discussion 
The interpretation of the relevance of a po.itiv. .erological cro .... tch 
to renal allograft outcome has become con.id.rably more complic.ted th.n 
previously b.lieved. It i. n.c •••• ry to con.ider the .pecificity of the 
antibody, whether the antibody i. in peak .nd current .er. or in pe.k .erwa 
only, and the immunoglobulin cl ••• of the .ntibody. The .pecificity of the 
antibody may be HLA claa. I, HLA cla •• II (HLA-DR, DO or DP), or not 
dir.cted at HLA at all, the.e l.tter antibodies being mo.tly .utore.ctive. 
The immunoglobulin cla88 of the cytotoxic .ntibody c.n be 190 or IqM. 
The favourable outcome of renal tran.plantation in p.tient. with. po.itive 
croaamatch resulting from auto.ntibodie. i. not in que.tion (Cro •• , Greiner 
and Whittier, 1976; Reekers et .1, 1977, Ting .nd Morri., 1977), .nd this 
i. true even when the current •• rum give •• po.itive cro .... tch (Ting .nd 
Korria, 1983). On the other hand the relev.nce of • po.itive cro .... tch due 
to HLA antibodi •• i. not fully under.tood. The m.in re •• on. for thiB 
controv.ray i. that the pr.ci.e .pecificity of the .ntibody c.u.ing • 
po.itive croaamatch has not be.n d.fined in mo.t .tudie., .nd in .any 
.tudie. the author. h.ve a •• umed th.t the .ntibody i. .g.in.t HLA without 
any .upporting data. For exampl., the di.tinction between HLA .nd non-HLA 
antibodies has been deduced by platelet ab.orption (Je.nnet, Ben.onana .nd 
Arni, 1981; Sirchia et al, 1979, Ru.. et .1, 1987), perforainq an 
autologoua croaamatch (Bttenqer, Jordan .nd Fine, 1983, Cro •• , Greiner .nd 
Whittier, 1976) and varying the pre-compl_nt incub.tion t.aper.ture 
(Ayoub et al, 1980, Fauchet et al, 1980, Iw.ki et al, 1979). Cold re.ctive 
or non-platelet ab.orbed .ntibodie. (pre.waecl non-HLA) have been a.aociatecl 
with good graft .urvival, where •• warm reactive or pl.telet abaorbecl 
.ntibodies (presumed HLA) h.ve been ••• oci.ted with poor qraft .urviv.l 
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(Iwaki et al, 1979; Ayoub et al, 1980; Rhodes et al, 1984; Sirchia et al, 
1979). Unfortunately, these tests do not alway. di.tingui.h non-HLA from 
&LA antibodies since many autoantibodies react at all temperature. 
(Deierhoi, Ting and Morris, 1983), platelet ab.orption doe. not di.tingui.h 
between HLA class II and non-HLA antibodies, and patient. who have 
autoantibodies may have HLA antibodies in addition. 
As a more reliable test to distinguish HLA from non-HLA antibodies the 
cytotoxicity inhibition test has been developed with MAb. again.t HLA cla •• 
I, DR, and DQ. Control studies have demonstrated locus .pecific inhibition 
of alloantisera specific for alleles of these loci (with the exception of 
HLA-DQw2), and the ability of the technique to define antibody 
specificities in highly sensiti.ed patient. that were undefined by 
conventional serology. In combination with the u.e of D'l"r, these technique. 
were applied to define the preci.e .pecificity and ~unoglobulin cla •• of 
152 positive crossmatch transplant •• 
In this study the 1 year graft survival for all po.itive T and 8 cell 
crossmatch transplants was 69', and this figure i •• imilar to other report. 
(Cardella et al, 1982; Goeken and the Clinical Affair. COmmittee, 1985). 
However, when the data are divided into tho.e cau.ed by HLA cla •• I and by 
non-HLA antibodies a different picture emerge.. The non-HLA group (mo.t 
were autoreactive) had a very high .ucce •• rate of 88' at 6 month. compared 
with only 50\ for the HLA cla •• I antibody group. Furthermore, when the HLA 
antibody group was broken down into tho.e with IgK and IqG antibodies a 
.triking difference was .een. The former group had a re.pectable .ucce •• 
rate of 71' at 6 months, but in the latter group it wa. only 8'_ The.e data 
.trongly suggests that the specificity and immunoglobulin cla •• of the peak 
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antibody that gives rise to a positive crosamatch is an important 
consideration in the decision whether or not to proceed with a transplant. 
It is not possible to make the broad generalisation that a peak positive 
T cell crossmatch can always be ignored, as some studies have suggested. 
Perhaps the early failures seen in many published studies are in patients 
with IgG HLA antibodies, and if this ia ao then a poaitive croaamatch 
caused by this type of antibody should be a contra-indication to 
transplantation. The number of patients in thia atudy ia relatively small 
and obviously an analysis of a larger number of patienta ia needed before 
one can be certain about this conclusion. 
Several studies have indicated that the proqnosis for success is lower in 
cadaver regrafts than primary grafts performed in the preaence of a 
positive crossmatch (Kerman et al, 1985, Goeken and the Clinical Affaira 
committee, 1985; Matas et al, 1984). Cardella alao reported a lower regraft 
outcome, although this was not different from their regraft aUCCeaa rate 
in transplants performed with a negative crossmatch (Cardella et al, 1985). 
OVerall the Oxford data shows a lower regraft aucceaa rate when compared 
with primary grafts. However, the resulta do not correlate with prt.ary 
grafte and regrafts per ee, but with the type of pragraft aenaitiaation. 
The cadaver regrafts have a high expectancy of aucceaa if the croaamatch 
ia due to IgM non-HLA antibody, while thoee due to IgG BLA antibodiea have 
failed whether they were primary graft a or regrafta. 
The eignificance of a positive B cell cro .... tch ia alao controveraial. 
Because the early studies ahowed that graft aurvival in B cell positive 
crossmatch transplants was aimilar to, or evan batter than, grafta with a 
negative cros.match (Fauchet et al, 1985, Kyburgh et al, 1977, Bttenger et 
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al, 1976; Ting and Morris, 1977, D'Apice and Tait, 1979), many tran.plant 
units do not perform B cell crossmatches. On the other hand .ome centre. 
avoid altogether transplanting any B cell positive cro.smatch donor •• The 
finding of an overall one year graft survival rate of 78' i. in agreement 
with other studies that have demonstrated no deleterious effect of a 
positive B cell crossmatch. However, like the T cell cro •• matche., when the 
positive B cell crossmatch transplant. are divided according to 
specificity, those due to autoantibodies have a much higher .ucce •• rate 
than those due to HLA antibodies for both primary graft. and regraft •• Thi. 
was true whether the antibody was in the peak .erum only or in the current 
serum as well. However, unlike the T cell cro.smatch data there wa. no 
correlation between the immunoglobulin cla •• of the B cell &LA antibody and 
graft outcome. The only striking correlation .een in the B cell po.itive 
crossmatch group due to HLA antibodies was with good primary graft .urvival 
(100') but poor regraft survival (38'), and the.e result. are in agreement 
with those of Reekers and Pluit (Reeker. and Fluit, 1985). When the &LA 
antibody group was divided into those due to &LA-ABC, DR, and DO antibodies 
the number of patients in each group were too amall to draw firm 
conclusions. However, it may be relevant to note that two of five graft. 
with IgG HLA class I antibodies failed within 6 months, and a third graft 
failed at 15 months due to chronic vascular rejection. 
There are few reports on the relevance of &LA-DR antibodi.s causing a 
positive crossmatch. This paucity of data may be because transplant units 
are reluctant to transplant a DR mismatched graft in the pr.s.nc. of a 
positive B cell crossmatch or, a. suggested .ome time ago, most positi.e 
B cell crossmatches are not caused by lILA-DR antibodi.s but by non-lILA 
antibodies (D'Apice and Tait, 1980). In the studi •• where &LA-DR antibodies 
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have been implicated, most have shown a deleterious effect (Rhode. et al, 
1984; Ayoub et al, 1980; Russ et al, 1987, Ting and Morri., 1981, Sirchia 
et al, 1979; Noreen et al, 1987), and in a report of hyperacute rejection 
by Ahern et al. (Ahern et al, 1982), and other .imilar report. (Dejelo and 
Williams, 1977; Hohanakumar et al, 1981; Berg and MoUer, 1981) the 
antibody was present at the time of transplantation. In this .tudy there 
were only two cases of a positive crossmatch due to 190 HLA antibodies 
present at the time of transplantation. One was an HLA-C locus antibody and 
the graft suffered hyperacute rejection (Chapman et al, 1986c). The other 
was an HLA-DQ antibody and this graft was .ucce •• ful (Taylor et al, 1987). 
In two cases a peak reactive IgG HLA-DR antibody wa. defined. De.pite 
prophylactic immunosuppression with OKT3 and ATe both kidney. .uffered 
acute rejection. One patient (JL) failed at two month. and the .econd (Re) 
has poor function at one year. In the latter case the cros.match had been 
negative for nearly four years. Although it i. dangerous to draw 
conclusions from just two example., it doe. appear that even prophylactic 
OKT3 and ATG can not control the memory re.pon.e in patient. .en.itized to 
HLA-DR. 
Another factor, the relevance of which i. not fully under.tood i. the 
interval between the last po.itive cro •• match and the tran.plant. Some 
investigators consider as little a. two mont he appropriate (Cardella et al, 
1982), whereas others require four month. (Fuller, Forbe. and Delmonico, 
1985) or six months (Norman, Barry and Wetz.teen, 1985, Reed et al, 1987) 
before transplantation. However in a report by Palmer et al. (Palmer et 
al, 1989), where the antibodies cau.ing a po.itive cro .... tch were removed 
by extracorporeal ~unoadsorption, the interval wa. only a few hour.. By 
design, in this study the interval between a po.itive T and B cell 
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crossmatch caused by HLA antibodies was greater than one year (range 1.5 
to 10 years) for all but one patient in whom it was 42 days. 
Although many advances have been made in our understanding of the 
significance of a positive crossmatch in predicting renal graft outcome 
there are still many unanswered questions. It does appear that the 
specificity and immunoglobulin class of the antibody causing the positive 
crossmatch is an important consideration. In spite of the advances, many 
more well-defined studies are needed before we can say for certain which 
positive crossmatches are clinically relevant and which can be ignored, but 
some indications are strongly suggested in this study. 
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7.5 Case Presentation: A positive B cell crossmatch due to IgG aot1-BLA-DQ 
antibody present at the time of tranlplantation 1n a 
succes.ful renal allograft 
7.5.1 Patient details 
A 25 year old woman with .nd .tag. r.nal failure due to chronic 
py.lonephritis began haemodialy.i. tr.atment in 1983. Ih. wa. nulliparou. 
and had not previou.ly b.en tran.fu.ld. Th. pati.nt fir.t r.c.ived .1.ctiVl 
platelet transfusions (3 unit.) (Chapman.t al, 1986b), and th.n clinically 
necessary blood transfusion. (16 unit.) betwe.n h.r acc.ptanc. on to the 
transplant waiting list (1983) and subs.qu.nt tran'plantation (1986). 
Figure 7.5.1 demonstrate. the evolution of h.r cytotoxic antibodi •• ov.r 
this period, and the association of th.s. antibodi •• with the tran.fu.ion •• 
The patient was highly sensitised, with 100' pan.l r.activ. antibodi •• and 
consequently had a positive crossmatch with all pot.ntial donor.. In 
January 1986 vascular acces. for haemodialy.i. wa. becoming difficult and 
peritoneal dialysis was contraindicated by pr.viou. abdominal .urg.ry. Ih. 
wa. therefore considered urgently for r.nal tran'plantation with a view to 
accepting a kidney with a positive T c.ll cro'8mltch with peak r.activ. but 
negative with current serum. A donor wa. found who fulfillld thi. crit'ria 
but in addition had a positive B cell cro'8mltch in •• rum tak.n on the day 
of transplantation. Becausa of the clinical urg.ncy the d.ci.ion wa. tak.n 
to transplant despite both the peak •• rum po.itiv. T c.ll and a curr.nt 
•• rum positive Beall crosamatch. 
lmmuno.uppres.ion after tran'plantation con.i.ted of triple th.rapy with 
cyclosporin, azathioprine and pr.dnisolon., with prophylactic u" of 
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intravenous methylprednisolone SOOmg daily for the first five d.ys .nd for 
the treatment of rejection episodes thereafter. Following tr.nspl.nt.tion 
the graft functioned immediately with the production of 3,600.1 of urine 
in the first 24 hours. Despite prophyl.ctic use of methylprednisolone the 
aerum creatinine did not fall rapidly .nd • tot.l of four grams of 
methylprednisolone were used to treat acute rejection within the first nine 
days. Renal function subsequently improved such th.t on d.y 18 post 
transplant her creatinine was 162 Ilmol/l. She h.s suffered no further 
rejection episodes the patient is currently well with • pl .... cre.tinine 
level of 1961lmol/l four years poat transplant. 
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FJ.gure 7.5.1 Panel reactJ.vJ.ty of .ez-w. ... ple. taken frota the patJ.ent 
between 1982 and 1986. Ti.llling of both platelet and blood tran.fu.J.on. are 
indJ.cated by arrows. Sera A to B have be.n .el.cted for Lurther .tudy wJ.th 
the results of the donor and autologou. T and B c.ll cro .... tch •• .JJown. 
The conclusions for the determined antJ.body cl... and .p.cJ.LJ.cJ.ty of the 
crossmatch as defind by further studJ.e. are given for each .ez-w.. 
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7.5.2 Serology 
Cytotoxicity inhibition and OTT reduction studies were performed on 
selected sera, four taken before transplantation (sara A to 0, Figure 
7.5.1), and one after transplantation (serum B, Figura 7.5.1). 
Serum A was taken before tha first transfusions and wa. autoreactive, 
lysing both autologous T and B cells (Figure 7.5.1). The donor cro •• match 
was also positive with T and B cells, but could not be inhibited by PA2.6 
(anti-HLA class I) and was entirely reduced by OTT (Table 7.5.1). 
Serum B was taken after the fir.t transfusion and wa. .elected becau.e 
autoreactivity could not be demonstrated, but the donor cro .... tch wa. 
positive with both T and 8 cell.. 80th the T and 8 cell cro .... tch was 
blocked by PA2.6 (Table 7.5.1) indicating antibody specific for donor HLA 
class I. This positive crossmatch was al.o reduced by OTT .ugge.ting an 19M 
anti-HLA class 1 antibody. 
Serum C reacted with 55' of the panel of CLL cells but only 5' of the P8L 
panel and was shown to be specific for HLA-DQw1 in panel te.t. (Chi 2 
-21.63, [p<O.001 with Yates correction), r-O.86). Panel screening 
demonstrated that this serum was not reactive with HLA-DRw13 and DRw52, 
which were the other serologically defined HLA-O region antigen. mismatched 
between donor and recipient (Table 7.5.2). Reactivity of this serum wa. 
inhibited from a titre of 1/32 to a titre of 1/4 on donor 8 lymphocytes by 
LEU-10 which is specific for HLA-DQ locus product. (Table 7.5.1). The 8 
cell crossmatch was not reduced by OTT, sugge.ting that the antibody wa. 
an 190 anti HLA-OQw1. 
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Serum D was taken on the day of transplantation and h.d • titre of 1/128 
in the standard crossmatch with donor B lymphocytes. Despite bro.d panel 
reactivity with undefinable specificity, the donor crossmatch using serum 
D was not reduced by DTT and was inhibited by LBU-10 (Table 7.5.1). The 
donor and recipient were mismatched for &LA-DOw1, DRw13 .nd DRw52 but no 
inhibition of the B cell crossmatch was ... n with HDS-22 (.pecific for 
&LA-DR) which inhibited known &LA-DR ser. in par.llel •••• y •• We therefore 
concluded that the positive B cell crossmatch using .erum t.ken on the d.y 
of transplantation was caused by .n 190 .nti &LA-DQ .ntibody. It w ••• 1.0 
possible to identify the same antibody .t .n unch.nged titre u.ing .erum 
taken five days after transplantation (Table 7.5.1, .erum B). In .ddition, 
lymph collected from the lymphocoele one month .fter tr.n.pl.nt.tion 
revealed an IgG antibody specific for &LA-DOw1 (Chi2.16.30 (PCO.001 with 
Yates correction], r-O.73), also with a titre of 1/128. 
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Serum MAb Cell Titre of cro •• match DTT Conclu.ion 
Cell treatment 
None !lAb !IAb+ 
alone P(ab' )2 
A PA2.6 T 1* 1 1 Ye. 19M autoantibody 
B PA2.6 T 16 1 neg Ye. 19M HLA cla.. 1 
PA2.6 B 64 16 4 Y •• 
NDS-22 B 32 64 64 
Leu-10 B 64 64 64 
C PA2.6 B 32 32 32 No 190 HLA-DQ 
NDS-22 B 16 16 16 
Leu-10 B 32 4 8 
D PA2.6 B 128 128 128 No 190 HLA-DQ 
NDS-22 B 128 128 128 
Leu-10 B 128 32 64 
B PA2.6 8 128 128 128 No 190 HLA-DQ 
NDS-22 8 128 128 128 
Leu-10 8 128 64 64 
Table 7.5.1 Class and specificity of the donor cro .... tch •• d..an.tr.ted 
by DTT reduction and cytotoxicity inhibition 
(* -reciprocal of titre). 
Recipient type. Donor type. 
HLA-A 1, 24(A9) 24(A9) , 25(AIO) 
B 35, 44(812) 7, 18 
Bw 4, 6 6 
Cw 4, 5 7 
DR 4, 4, !l!U (!I!§) 
DRw 53, 53, U. 
DQw 3, 3, .1 
Table 7.5.2 Serological HLA ti •• ue typing of donor and recipient. 
Donor HLA class II antigen. _i.-atched Lor the recipient are underlined. 
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7.5.3 Immunohistology 
Histopathology of the allograft (carried out by Dr M.Dunnill, 
Histopathology, John Radcliffe Hoapital) demon.trated the pre.ence of 
glomerular neutrophil polymorph. one hour after reva.culari.ation, which 
w.r. not s.en in the biop.y taken immediately before tran.plantation. Thi. 
glomerular infiltrate was a •• ociated with occa.ional foci of inter.titial 
neutrophil •• At day •• v.n occa.ional neutrophil. ware .till pre.ent within 
the glomeruli and focal adh.aion. between the glomerular tuft and Bowman'. 
capsule were .een, while the interstitial ti •• ue .howed only mild focal 
lymphocyt. infiltration. By day 19 the tubular morphology and inter.titium 
were essentially normal though the glomeruli were .till abnormal with 
capillary oblit.ration and meaangial expan.ion. The.e change. had largely 
r.gr •••• d by three month. at which time there wa. no inter.titial fibro.i. 
and only minor art.rial intimal fibro.i.. By .even month. the major 
abnormaliti •• w.re intimal fibro.i. of the arterie. with a 50' reduction 
in th.ir lumen, and moderate diffu.e int.r.titial fibro.i •• 
Immunoperoxida.e .tudie. of the early biop.ie. (carried out by Dr 
S.V.Fuggle, Nuffield Department of Surgery) revealed normal expre •• ion of 
HLA-DO antigen. b.for. tran.plantation with weak .taining of the glomerular 
endothelium and intertubular .tructure •• Thi. pattern wa. unchanqed in the 
day 7 biop.y but at day 19 a focal area of proximal tubule. were al.o 
expre •• ing HLA-DO antigen.. staininq for monomorphic lILA-DR .howed the .... 
pattern with normal .xpr ••• ion on glomerular endothelium and ... anqium, 
int.rtubular .tructur •• and proximal tubule. at day 0 and day 7, while 
there was a focal area of increa.ed expre •• ion at day 19. 
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7.5.4 Discussion 
It is generally accepted that a po.itive T and B cell cro.amatch cau.ed by 
antibodies to HLA class I antigen. and pre.ent at the t~ of 
tran.plantation would r •• ult in rapid graft failure and probably hyperacute 
rejection. The question that has been addre •• ed here i. whether or not that 
holds true for antibodies .pecific for &LA cla.. II antigen. pre.ent in 
s.rum taken on the day of the tran.plant. 
The major difficulty .ncountered in analy.i. of the po.itive 8 cell 
cro.smatch is the exact definition of the antibody .pecificity. 
Identification of antibodi.s .pecific for &LA-cla •• II antigen. ha. u.ually 
relied upon indirect technique. .uch a. .egregation with lILA-DR in 
familie., or ti •• ue typed panel. demon.trating definable lILA-DR 
polymorph isms (d'Apice & Tait 1980). However it i. not u.ually po •• ible to 
define specificities when a mixture of antibodies are pre.ent in a highly 
sensitised patient. The technique of cytotoxicity inhibition can di •• ect 
.pecificities contained within complex multi.pacific anti.era and this ha. 
enabled the preci8e identification of the .pacificity of antibodi •• cau.ing 
po.itive crossmatche. again.t this particular kidney donor. 
In this case presentation the patient had .erum .ample. which gave po.itive 
cro.amatche. cau.ed by thr_ different antibodi... Prior to h.r fir.t 
tran.fusion there was a po.itive T and 8 c.ll cro .... tch with donor 
lymphocyte. that was due to an 19K autoantibody. Following the initial 
plat.let tran.fu.ion. the patient developed an I9K anti-lILA cla.. I 
antibody that was reactive with donor T and B c.ll •• Po.itive cro .... tch •• 
cau •• d by both of the.e antibodies were a • .ociated with 900d outca.e of 
r.nal tran.plantation (Chapter 7.1 and 7.3). The third antibody r.active 
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with donor lymphocytes developed after further blood tran.fu.ion., remained 
to the day of transplantation, and was .till detectable in both .erum and 
lymph with tha functioning graft in-.itu. Thi. antibody wa. 190 and wa. 
reactive with B but not T lymphocyte. from the donor. At one point 
conventional specificity analy.i. defined an anti-IlLA-DOw1 antibody, while 
the positive B cell crosamatch wa. inhibited by a monoclonal antibody 
specific for HLA-DOw1 and DQw3 (LBU-IO). 
By analogy with the T cell cro •• match, this patient r.pr ••• nt. the mo.t 
.tringent test of the relevanca of lILA-DO specific antibodies in renal 
transplantation, since the positive crosamatch wa. pr ••• nt in •• rum taken 
at the time of operation. However the transplant did not .uff.r hyperacute 
rejection. The graft glomeruli were however infiltrated by neutrophil 
polymorphs within one hour, suggesting the pres.nce of antibody -.diated 
damage (Williams et al, 1968, Xincaid-Smith et al, 1969). Renal function 
was poor for the first week but by th.n the histology r.v.aled little 
avidence of rejection. The immune response that did occur wa •• uffici.ntly 
controlled for the graft to maintain r.a.onabl. function at thr .. y.ar •• 
study of the expression of HLA cla.s II antig.n. in this r.nal allograft, 
using monomorphic monoclonal antibodi.. confirmed the pr ••• nc. of IILA-DQ 
in a normal distribution (Fuggl. et al, 1986). Monomorphic lILA-DR 
expression was also normal in the initial biop.y but a focal incr.... in 
both HLA-DR and DO was seen in the biopsy taken on day 19. It i. th.r.for. 
unlikely that lack of antigen .xpre.sion in this particular kidn.y 
.xplained the abaence of a cata.trophic ~n. reaction. 
The experience of thia pati.nt would .ugg •• t that .ucc ••• ful ren.l 
transplantation can be performed d •• pit. the pr ••• nc. of Circulating 
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cytotoxic IgG antibodies specific for &LA-DO antigen •• xpr •••• d on the 
kidney. It is uncertain whether or not the relatively heavy triple th.rapy 
immunosuppression together with prophylactic methylpredni.olon. wa. 
relevant and it would be unwise to extrapolate from this .ingl •• xperi.nce. 
It is possible that antibodies to other &LA cla.. II antigen. could have 
different implication., particularly if antigen den.ity in the targ.t organ 
is important. It ia therefore important for th ••• que.tion. to be re.ol ved 
using technique. that defin., with r.a.onabl. c.rtainty, the antigen 
.pecificity of antibodies cau.ing po.itive B cell cro .... tch ••• 
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8.1 Strat.rqi •• for trap'plaatipg highly .ep.iti11d pa\i.P\' 
Th. cytotoxicity cro •• match t •• t, which id.ntifi •• pati.nt ••• n.itiled to 
a particular donor, ha. virtually .ltminat.d the ph.nomenon of hyperacute 
r.j.ction with immediate irr.v.r.ibl. graft 10... A po.itiv. cro .... tch 
forewarn a the transplant team of a vigourou. ~un. r •• pon.. again.t the 
graft and the transplant would ther.for. not be performed. Tran.plant. 
parformed with a negative crostmatch do not carry the ri.k of hyperacute 
r.jection. Highly .ensitiz.d patient. are tho •• who have antibocU •• 
r.acting with >85' of potential donor. (Claa., Van L .. uwen and Van Rood, 
1989; Klouda et al, 1987). It i. extremely difficult to find a .uitabl. 
cro.smatch negative donor for these pati.nt., con.equ.ntly th.y accu.ulat. 
on transplant waiting list. (LIlIIID, Mad •• n and rj.ldborg, 1987, Ptaft, 
Vaughn and sanfilippo, 1987). Th •• ucc ••• ful tran'plantation of th ••• 
patients posea a major challenge for tran'plant c.ntr ••• 
S.veral strategies have been developed to achi.v. thi. aim. Th.y con.i.t 
of two main approaches; A) to improve the chanc •• of finding a negative 
cro.amatch donor, and B) identify circum.tanc •• und.r which a po.itiv. 
cro.amatch can be .afely ignored. 
8.1.1 LocatiM a RlClatiy. crollM\ch clopor 
i) Beneficial matching: Thit .ch_, admini.t.red through the United 
Kingdom Transplant Service (UKTS), Burotran.plant (Hendrikt .t al, 1987) 
and other. (Opelz, 1987b; Carpent.r .t a1, 1989, Pfaff, Vaughn and 
Sanfilippo, 1987) ha. enabled many .ucc ••• ful tran.plant •• &LA .. tched 
donor. are .elected to mintmi.. the chane.. of the reCipient having donor 
.pacific HLA antibodi... Matching on a national and int.rnational ba.i. 
tmprov •• the chance. of finding a compatible donor. However due to the 
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extreme polymorphi .. of the hwaan HHC, the probability of finding a matched 
donor, even using national regi.trie. i •• till remote. 
ii) The SOS scheme 
To increase the likelihood of locating a negative cro .... tch donor, .era 
are .ent to all the tran.plant c.ntr.. throughout the country and 
crosamatched again.t all donor. (Klouda et al, 1987). In the event of a 
serum giving a negative cros ..... tch, the kidn.y i. d •• patched to the 
appropriate transplant centre. Nationally 83 tran.plant. were performed 
with a 57\ one year .ucce •• rat.. Similarly, Opelz (Opelz, 1988a) ha. 
reported 100 transplant. with a 71\ fir.t and 68' regraft .ucc... at one 
year. In this .tudy, empha.is for the need of miniaUID HLA matching crit.ria 
(1 HLA-A, 1 Band 1 DR match) wa. mad. with an a •• ociated 78' .ucc •••• 
iii) Acceptable mi.matche. 
Acceptable mi.matche. are id.ntified by .cr .. ning .era again.t a panel of 
•• lected individual. who diff.r from the r.cipi.nt by only one allel. 
(Claa., Van Leeuwen and Van Rood, 1989). Thi •• nabl •• the identification 
of antigen. to which the recipi.nt i. not •• n.itized. Altogether 120 
patient. have been tran.planted with a 70' four year graft survival 
(r.claa., Burotran.plant Meeting, S.pt .... r, 1990). Interestingly the 
acceptable mismatches appear to con.i.t of the non-inherited _terDal 
haplotype (NIMA) in 50\ of patients, and both antigen. in 3o, of patients 
(Claa. et al, 1988). Thi. is proposed to reflect tolerance to _terDal 
antigens acquired during foetal d.v.lopment. 
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8.1.2 Ideatificatiop of pop-f"'qipg po.iti •• cro .... \cb •• 
i) Lymphocytotoxic Autoantibodie. 
It i, well establi.hed that lymphocytotoxic autoantibodi.. ar. not 
damaging, even when pre.ent at the time of tran'plantation ( ... Chapt.r. 
1 and 7). Technique. u.ed to identify and di.tinqui.h autoantibodie. trom 
a1loantibodie. includ.: 
a) po.itive autoloqou. cro.tmltch and ab.orption with autoloqou. PaL. Or 
LCL.; 
b) weak or negative CLL reactivity; 
c) not platelet absorbed; 
d) K562 reactivity and ab.orption; 
.) low optimal reactivity temperatur., 
f) the antibody cla.s is usually IqM; and 
q) they are not inhibited by RLA monoclonal antibodie •• 
ii) Peak positive I current n.gative cro •• match •• 
MAny centre. believe that tran.plant. can be performed without regard to 
pr.vious .ensitization provided the curr.nt •• rum i. nl9ative. Craft 
.urvival equal to tho •• with a negative cro .... tch ha. been reported ( •• 
Chapt.r 1). Howev.r other. con.id.r thi. acceptable for f ir.t but not 
reqraft. and some correlate .ucc... with the pr •• ence of anti-ldlotyplc 
antibodie. in the current .erum. Studie. pre.ented ln thl. the.l. lndlcate 
that the antibody class and .peciflcity of the cro .... tch are t.portant ln 
id.ntifyinq those with a higher propen.ity to fail, whlch 1. lndependent 
of primary or reqraft .tatu •• 
The lonq time interval between the po.itiv. cro .... tch and tran'plantatlon 
in aany ca.e. rai.e. the que.tion a. to the phy.loloqlcal role of antibody 
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in the rejection process. Acute graft 10.. may be due to cellular 
mechanisms initiated by T cell. and the immunoglobulin cla •• may act a. a 
marker for senaitization at a cellular level. The production of 19K doe. 
not require T cell priming and therefore immunological meaory i. ab.ent, 
whereas IgG production i. T cell dependant and hence indicate. prior T cell 
activation. Therefore sensitization at a cellular level i. a •• ociated with 
a .econdary reaponse which can not be controlled by conventional 
immunosuppression. The a.sociation of good primary but poor regraft 
.urvival in other studies may be due to the increa.ed likelihood of T cell 
priming and IgG production following graft rejection. We have noted that 
.ensitization through blood tran.fu.ion alone in ura .. ic dialy.i. patient. 
i. frequently asaociated with only IgK production. 
The .ignificance of the B cell cro ...... tch i. still open to dabate. Data 
pre.ented here confirm that whil.t overall acceptable graft .urvival ha. 
bean achieved, weak HLA cla •• 1 and HLA cla •• II antibodies are a •• ociated 
with poor regraft .urvival. A recent publication by Xapurran, Lindho~ and 
Koller (Karuppan, Lindholm and Koller, 1990) u.ing .imilar t.chniqu •• , i. 
in clo •• accordance with the.e finding •• They found no overall diff.r.nc. 
with IgG versus IgK in 47 pati.nt. tran.planted with a curr.nt weak 
po.itive B cell crosamatch. Neverthel ••• poor graft .urvival wa. a •• ociated 
with cla •• 1 antibodies (S0' .ucce •• ful at one y.ar, .-22) .o.t of which 
were IgG. 
iii) D ••• nsitization 
There remain. a group of pati.nt. (tho •• with current anti-RLA antibocU. •• ) 
whom it i. difficult to tran.plant. Saa. c.ntre. have atta.pted 
de .. n.itization protocol. bafor. tran.plantation. Atta.pt. to d ••• n.iti •• 
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through the generation of suppressor cells following repeated leucocyte 
transfusion in conjunction with cyclosporin have proved un.ucce •• ful (Weir . 
et al, 1988). However, circulating antibodies can be removed by 
pla.maphore.i. (Fauchald et al, 1990, Backman et al, 1989) or 
extracorporeal immuno-ad.orption (Palmer et al, 1989, re~ et a1, 1990) 
in conjunction with inten.ive immuno.uppre •• ion. 
It i. interesting to compare the acceptable outcome of tran.plant. with 
donor reactive IgG antibodies converted to negative following their 
relDOval, to the unacceptable graft .urvival in patient. who have lo.t their 
antibodies naturally. Thi. paradox i. difficult to re.olve. It i. po •• ible 
that the administration of pregraft cyclopho.phamide and relatively heavy 
po.t transplant immuno.uppression in de.en.itized patient. i. a relevant 
factor. Desensitization appear. to be mo.t effective in patient. with low 
antibody titre. (Fauchald et al, 1987, a.nault et al, 1990) .a.e of whoa 
may lo.e their antibodies spontaneou.ly (Okazaki et al, 1987). Thu., tho.e 
patient. .ucce •• fully tran.planted may repre.ent a .elected group. 
Furthermore, care wa. taken to avoid the main .pecificitie. to which the 
recipient. were sen.itized (Thick, 1987, Taube et al, 1989). A ca.bination 
of the.e factor. may be .ufficient to avoid uncontrolled graft rejection. 
COncurrent u.e of prophylactic ATG in other .tudie. may also be a relevant 
factor. However this level of t..uno.uppre •• ion carrie. inherent ri.ks 
a.sociated with increa.ed morbidity and mortality. Therefore careful 
.. lection of clinically .uitable patient. i. iIIportant CPalaer et al, 
1989). Moreover, the u.e of AM (either prophylactic or to treat rejection 
epi.ode.) in our own .tudy did not re.cue the kidney fro. irrever.ible 
de.truction. 
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8.2 Crossmatch Sensitiyity 
Ther. are two school. of thought conc.rning the v.lu. of the cro .... tch 
t •• t in clinical tr.n.plant.tion. Some f .. l more •• n.itiv. t.chniqu ••• uch 
•• the AHG-CDC (John.on .t .1, 1987) .nd flow cyta.etry (T.lbot .t .1, 
1990) .r. n.c •••• ry. Improved regr.ft .urviv.l h •• been ••• oci.ted with. 
neg.tiv. cro •• match u.ing th ••• more •• n.itive •••• y. (Ker.an .t .1, 1990, 
Iw.ki .t .1, 1987). Flow cyta.etry .leo d.t.ct. non-coaapl_nt fixing 
antibody i.otypea and i. more •• n.itiv. for the d.t.ction of IILA-
.ntibodie. than AHG-CDC .nd CDC (Rod.y .t al, 1987). Howev.r few r •• ction. 
a •• oci.ted with increa.ed morbidity .r. due to the non-cytotoxic 190 4 
i.otype (Talbot et al, 1989). Th. u •• of tmmunomagn.tic be.d •• paration 
t.chniques also renders cell. more r •• pon.iv. (V.rtd.l .t .1, 1986) .nd 
increa •• s antibody titre. (Povl.en, Graug •• rd .nd Ki .... y.r-Ri.l •• n, 1988, 
Vartdal .t al, 1987). 
Howev.r increased •• n.itivity i. oft.n a •• oci.ted with d.cr ••• ed 
.pecificity r •• ulting in many f.l •• po.itiv •• (Thi.tl.thw.it •• t .1, 1987, 
Mahon.y et al, 1990). Tran.plant. which would oth.rwi •• h.ve been 
.ucc ••• ful may th.n be .xcluded. Moreover, c.ntr •• which r.port .ignific.nt 
corr.lation. with graft outcome frequ.ntly u.. only curr.nt •• r. for 
cro •• matching (John.on et al, 1987). Th. a •• ociation of .arly gr.ft f.ilur. 
with a positive flow cytometry cro •• match al.o corr.l.t •• with previous 
•• n.itiz.tion and r.graft .tatu. (Mahon.y .t .1, 1990). It i. th.r.for. 
po •• ible that the t.chniqu. d.t.ct. .ublt.in.l •• n.iti.ation which would 
normally be det.cted in peak r.activ • .. r. t •• ted in a conventional 
cytotoxicity cro .... tch. 
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8.3 Concluding remarks 
It remains impo.sible to draw a general con.en.u. on the role of donor 
.pecific .en.itization and renal tran'plant outca.e. While a current 
po.itive cytotoxicity cro .... tch due to 190 HLA-cla.. I antibodies would 
re.ult. in hyperacute rejection their .ignificance in other .ituation. i. 
uncl.ar. There are many varied cro ...... tch technique. and policies governin9 
the .election of donor and recipient pair •• However this .tudy ha. allowed 
.ome insight into the significance of preqraft antibodies by definin9 the 
preci.e specificity and correlating their pre.ence with graft outoo.e. 
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